Images	O

Figure	O
1	O

Figure	O
2	O

Figure	O
3	O

Figure	O
4	O

Results	O

Images	O

FIGURE	O
2	O
.	O

Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
processively	O

The	O
results	O
presented	O
in	O
this	O
paper	O
clearly	O
indicate	O
that	O
Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
can	O
account	O
for	O
their	O
genome	O
replication	O
without	O
the	O
assistance	O
of	O
unwinding	O
and	O
processivity	O
factors	O
,	O
in	O
contrast	O
to	O
most	O
replicative	O
DNA	O
polymerases	O
which	O
require	O
their	O
physical	O
association	O
to	O
processivity	O
factors	O
and	O
DNA	O
unwinding	O
proteins	O
(	O
1	O
,	O
70	O
)	O
.	O

Strand	O
displacement	O
capacity	O
has	O
also	O
been	O
shown	O
for	O
other	O
protein	O
-	O
primed	O
DNA	O
polymerases	O
as	O
those	O
of	O
bacteriophages	O
phi29	O
(	O
10	O
)	O
,	O
Cp	O
-	O
1	O
(	O
71	O
)	O
and	O
PRD1	O
(	O
72	O
,	O
73	O
)	O
.	O

On	O
the	O
contrary	O
,	O
adenovirus	O
DNA	O
polymerase	O
,	O
although	O
processive	O
,	O
cannot	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
,	O
requiring	O
the	O
DNA	O
unwinding	O
activity	O
of	O
the	O
adenovirus	O
DBP	O
to	O
perform	O
strand	O
displacement	O
(	O
74	O
,	O
75	O
)	O
.	O

Whereas	O
it	O
was	O
possible	O
to	O
obtain	O
GA	O
-	O
1	O
DNA	O
replication	O
by	O
using	O
exclusively	O
the	O
GA	O
-	O
1	O
TP	O
and	O
DNA	O
polymerase	O
,	O
Nf	O
DNA	O
polymerase	O
,	O
although	O
provided	O
with	O
competent	O
strand	O
displacement	O
and	O
processivity	O
features	O
,	O
required	O
the	O
presence	O
of	O
Nf	O
DBP	O
for	O
an	O
effective	O
in	O
vitro	O
replication	O
of	O
Nf	O
TP	O
-	O
DNA	O
.	O

Results	O
presented	O
here	O
show	O
that	O
Nf	O
DBP	O
strongly	O
stimulates	O
the	O
formation	O
of	O
the	O
TP	O
-	O
dAMP	O
initiation	O
complex	O
by	O
decreasing	O
the	O
Km	O
for	O
dATP	O
and	O
facilitates	O
the	O
transition	O
from	O
initiation	O
to	O
elongation	O
,	O
as	O
it	O
occurs	O
in	O
phi29	O
(	O
76	O
)	O
.	O

These	O
results	O
point	O
to	O
either	O
a	O
specific	O
and	O
direct	O
contact	O
between	O
DBP	O
and	O
DNA	O
polymerase	O
that	O
promotes	O
conformational	O
changes	O
at	O
the	O
polymerization	O
active	O
site	O
or	O
to	O
an	O
effect	O
of	O
DBP	O
in	O
conferring	O
the	O
optimal	O
template	O
structure	O
to	O
direct	O
initiating	O
nucleotide	O
insertion	O
.	O

A	O
similar	O
role	O
has	O
been	O
proposed	O
for	O
adenovirus	O
DBP	O
,	O
a	O
DNA	O
unwinding	O
protein	O
(	O
77	O
)	O
.	O

As	O
in	O
the	O
case	O
of	O
phi29	O
and	O
Nf	O
DBP	O
,	O
this	O
protein	O
stimulates	O
the	O
rate	O
of	O
initiation	O
also	O
by	O
decreasing	O
the	O
Km	O
for	O
the	O
initiating	O
nucleotide	O
(	O
74	O
)	O
.	O

The	O
fact	O
that	O
an	O
adenovirus	O
DBP	O
mutant	O
defective	O
in	O
unwinding	O
can	O
still	O
stimulate	O
initiation	O
precludes	O
the	O
unwinding	O
role	O
as	O
the	O
one	O
responsible	O
for	O
such	O
an	O
activation	O
(	O
77	O
,	O
78	O
)	O
.	O

In	O
this	O
case	O
,	O
contacts	O
between	O
DBP	O
and	O
pTP	O
/	O
DNA	O
polymerase	O
complex	O
have	O
been	O
reported	O
(	O
77	O
)	O
.	O

The	O
effect	O
of	O
Nf	O
DBP	O
in	O
promoting	O
elongation	O
of	O
the	O
initiation	O
products	O
could	O
be	O
due	O
to	O
a	O
decrease	O
of	O
the	O
Km	O
also	O
for	O
the	O
incorporation	O
of	O
the	O
dNMPs	O
during	O
the	O
transition	O
stage	O
from	O
initiation	O
to	O
elongation	O
,	O
to	O
a	O
different	O
type	O
of	O
contact	O
with	O
the	O
DNA	O
polymerase	O
that	O
helps	O
transition	O
to	O
elongation	O
,	O
or	O
both	O
.	O

The	O
similarity	O
in	O
replication	O
rates	O
when	O
comparing	O
M13	O
DNA	O
replication	O
,	O
performed	O
in	O
the	O
absence	O
of	O
DBP	O
(	O
2400	O
nt	O
/	O
min	O
)	O
,	O
with	O
Nf	O
TP	O
-	O
DNA	O
replication	O
in	O
the	O
presence	O
of	O
DBP	O
(	O
2260	O
nt	O
/	O
min	O
)	O
,	O
suggests	O
that	O
the	O
DBP	O
stimulatory	O
role	O
is	O
restricted	O
to	O
the	O
first	O
phases	O
of	O
Nf	O
TP	O
-	O
DNA	O
replication	O
.	O

2	O
-	O
Theory	O

Scanning	O
holography	O
is	O
a	O
two	O
-	O
pupil	O
interaction	O
method	O
[	O
8	O
]	O
by	O
which	O
incoherent	O
imaging	O
with	O
complex	O
point	O
-	O
spread	O
-	O
functions	O
(	O
PSF	O
)	O
is	O
possible	O
.	O

The	O
method	O
has	O
recently	O
been	O
applied	O
to	O
the	O
recording	O
of	O
high	O
resolution	O
holographic	O
images	O
of	O
incoherent	O
objects	O
and	O
fluorescent	O
biological	O
specimens	S-Tissue
[	O
6	O
,	O
7	O
]	O
.	O

A	O
single	O
-	O
sideband	O
in	O
-	O
line	O
Fresnel	O
hologram	O
is	O
obtained	O
by	O
a	O
2D	O
raster	O
scan	O
of	O
the	O
object	O
with	O
the	O
superposed	O
3D	O
diffraction	O
distributions	O
of	O
two	O
pupils	O
,	O
as	O
sketched	O
in	O
fig	O
.	O

1	O
.	O

The	O
two	O
pupil	O
distributions	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
and	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3297	O
@	O
from	O
the	O
same	O
source	O
(	O
for	O
example	O
,	O
but	O
not	O
necessarily	O
,	O
a	O
laser	O
)	O
are	O
combined	O
by	O
a	O
beam	O
splitter	O
in	O
the	O
pupil	O
plane	O
of	O
the	O
objective	O
where	O
they	O
interfere	O
,	O
forming	O
a	O
Fresnel	O
pattern	O
with	O
a	O
depth	O
-	O
dependent	O
Fresnel	O
number	O
.	O

To	O
obtain	O
the	O
conventional	O
point	O
-	O
spread	O
function	O
of	O
wide	O
field	O
imaging	O
,	O
P1	O
is	O
chosen	O
as	O
a	O
point	O
source	O
,	O
and	O
P2	O
as	O
a	O
spherical	O
wave	O
with	O
appropriate	O
curvature	O
.	O

The	O
3D	O
specimen	S-Tissue
is	O
placed	O
in	O
the	O
focal	O
region	O
of	O
the	O
objective	O
,	O
and	O
scattered	O
lights	O
(	O
transmitted	O
,	O
reflected	O
,	O
and	O
fluorescent	O
)	O
are	O
collected	O
by	O
non	O
-	O
imaging	O
detectors	O
.	O

The	O
hologram	O
data	O
can	O
be	O
obtained	O
by	O
heterodyne	O
detection	O
with	O
one	O
of	O
the	O
pupils	O
shifted	O
in	O
frequency	O
(	O
as	O
done	O
in	O
this	O
work	O
)	O
,	O
or	O
by	O
a	O
homodyne	O
method	O
requiring	O
the	O
capture	O
of	O
at	O
least	O
three	O
frames	O
with	O
different	O
relative	O
phases	O
between	O
the	O
two	O
pupils	O
[	O
9	O
]	O
.	O

The	O
amplitude	O
distribution	O
of	O
the	O
illuminating	O
beam	O
,	O
in	O
a	O
transverse	O
plane	O
at	O
an	O
axial	O
distance	O
z	O
from	O
the	O
focal	O
plane	O
of	O
the	O
objective	O
,	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
combined	O
pupil	O
distributions	O
[	O
10	O
]	O
.	O

Namely	O
:	O

Figure	O
1	O

Experimental	O
set	O
up	O
of	O
a	O
scanning	O
holographic	O
microscope	O
.	O

Sketch	O
of	O
the	O
experimental	O
setup	O
.	O

M	O
'	O
s	O
are	O
mirrors	O
,	O
BS	O
'	O
s	O
are	O
beam	O
splitters	O
,	O
EO	O
is	O
an	O
electro	O
-	O
optic	O
phase	O
modulator	O
.	O

Lens	O
L1	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
produces	O
the	O
desired	O
Fresnel	O
pattern	O
in	O
the	O
focal	O
plane	O
of	O
L2	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
.	O

L2	O
and	O
the	O
objective	O
form	O
a	O
4	O
-	O
f	O
system	O
projecting	O
a	O
reduced	O
image	O
of	O
the	O
Fresnel	O
pattern	O
onto	O
the	O
specimen	S-Tissue
.	O

L3	O
(	O
achromat	O
doublet	O
12	O
cm	O
focal	O
length	O
)	O
projects	O
the	O
images	O
of	O
the	O
pupils	O
on	O
the	O
pinhole	O
detector	O
.	O

(	O
Not	O
shown	O
are	O
the	O
beam	O
expanders	O
used	O
to	O
illuminate	O
the	O
pupils	O
)	O
.	O

S	O
(	O
r	O
-	O
-	O
>	O
,	O
z	O
)	O
=	O
F	O
-	O
1	O
{	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
+	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
(	O
-	O
iOmegat	O
]	O
}	O
,	O
(	O
1a	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
@	O
5D95	O
@	O

where	O

P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
=	O
P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
exp	O
(	O
ipilambdazrho2	O
)	O
(	O
1b	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa	O
@	O
53A8	O
@	O

are	O
the	O
generalized	O
defocused	O
pupils	O
[	O
11	O
]	O
.	O

F	O
-	O
1	O
stands	O
for	O
inverse	O
Fourier	O
transform	O
,	O
and	O
Omega	O
is	O
the	O
frequency	O
shift	O
of	O
one	O
of	O
the	O
pupils	O
.	O

The	O
transverse	O
spatial	O
frequency	O
vector	O
rho	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa	O
@	O
2E85	O
@	O
=	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
/	O
lambdaf0	O
is	O
proportional	O
to	O
the	O
real	O
space	O
coordinate	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
in	O
the	O
pupil	O
plane	O
[	O
10	O
]	O
.	O
lambda	O
is	O
the	O
wavelength	O
of	O
the	O
illumination	O
,	O
and	O
f0	O
is	O
the	O
focal	O
length	O
of	O
the	O
objective	O
.	O

The	O
two	O
pupils	O
used	O
to	O
obtain	O
an	O
in	O
-	O
line	O
Fresnel	O
hologram	O
are	O
,	O
respectively	O
,	O
a	O
spherical	O
wave	O
filling	O
the	O
pupil	O
of	O
the	O
objective	O
,	O
and	O
a	O
point	O
at	O
the	O
center	O
of	O
that	O
pupil	O
:	O

P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
=	O
exp	O
(	O
ipilambdaz0rho2	O
)	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O

P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
delta	O
(	O
rho	O
-	O
-	O
>	O
)	O
.	O

(	O
2	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa	O
@	O
3D5F	O
@	O

circ	O
(	O
x	O
)	O
is	O
a	O
disc	O
function	O
of	O
unit	O
radius	O
.	O

rhoMAX	O
=	O
sinalpha	O
/	O
lambda	O
is	O
the	O
cutoff	O
frequency	O
of	O
the	O
objective	O
,	O
where	O
sinalpha	O
=	O
NA	O
is	O
its	O
numerical	O
aperture	O
.	O

The	O
Fresnel	O
pattern	O
projected	O
on	O
the	O
object	O
is	O
the	O
interference	O
of	O
the	O
Fourier	O
transforms	O
of	O
the	O
two	O
pupils	O
,	O
namely	O
a	O
spherical	O
wave	O
and	O
a	O
plane	O
wave	O
in	O
the	O
paraxial	O
approximation	O
.	O

The	O
Fresnel	O
number	O
of	O
this	O
pattern	O
is	O
determined	O
by	O
the	O
free	O
parameter	O
z0	O
,	O
which	O
is	O
the	O
distance	O
from	O
the	O
objective	O
'	O
s	O
focal	O
plane	O
to	O
the	O
point	O
where	O
the	O
spherical	O
wave	O
comes	O
to	O
a	O
focus	O
.	O

There	O
are	O
two	O
possible	O
modes	O
of	O
operation	O
,	O
depending	O
on	O
the	O
detector	O
geometry	O
[	O
5	O
]	O
.	O

With	O
a	O
spatially	O
integrating	O
detector	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
with	O
the	O
desired	O
complex	O
PSF	O
(	O
namely	O
,	O
a	O
spherical	O
wave	O
with	O
a	O
radius	O
of	O
curvature	O
z0	O
+	O
z	O
,	O
and	O
a	O
radius	O
a	O
=	O
z0sinalpha	O
,	O
in	O
this	O
case	O
)	O
.	O

This	O
detection	O
mode	O
leads	O
to	O
a	O
hologram	O
from	O
which	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
scattering	O
intensity	O
,	O
absorption	O
,	O
and	O
fluorescence	O
intensity	O
can	O
be	O
reconstructed	O
.	O

With	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
pupil	O
plane	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
with	O
the	O
same	O
complex	O
PSF	O
.	O

The	O
reconstruction	O
of	O
this	O
hologram	O
gives	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
the	O
specimen	S-Tissue
'	O
s	O
complex	O
amplitude	O
transmittance	O
.	O

In	O
particular	O
,	O
assuming	O
that	O
multiple	O
scattering	O
can	O
be	O
ignored	O
,	O
the	O
phase	O
of	O
the	O
reconstruction	O
is	O
a	O
quantitative	O
measure	O
of	O
the	O
integrated	O
optical	O
path	O
length	O
through	O
the	O
specimen	S-Tissue
.	O

These	O
two	O
modes	O
of	O
operation	O
are	O
similar	O
to	O
the	O
usual	O
coherent	O
/	O
incoherent	O
imaging	O
modes	O
of	O
a	O
conventional	O
system	O
,	O
which	O
are	O
obtained	O
by	O
using	O
,	O
respectively	O
,	O
a	O
point	O
source	O
,	O
or	O
a	O
large	O
spatially	O
incoherent	O
source	O
.	O

In	O
scanning	O
holography	O
,	O
the	O
detector	O
size	O
plays	O
a	O
similar	O
role	O
to	O
that	O
of	O
the	O
source	O
size	O
in	O
conventional	O
imaging	O
.	O

For	O
simplicity	O
,	O
let	O
'	O
s	O
assume	O
an	O
object	O
with	O
an	O
amplitude	O
transmittance	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
.	O

Note	O
that	O
for	O
an	O
incoherent	O
or	O
fluorescent	O
object	O
,	O
the	O
phase	O
of	O
the	O
transmitted	O
field	O
is	O
a	O
random	O
variable	O
,	O
and	O
only	O
the	O
intensity	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
is	O
measurable	O
.	O

For	O
a	O
quasi	O
transparent	O
object	O
,	O
the	O
phase	O
is	O
equal	O
to	O
the	O
integrated	O
optical	O
thickness	O
of	O
the	O
object	O
:	O
Phi	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
(	O
2pi	O
/	O
lambda	O
)	O
integraldzn	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
,	O
where	O
n	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
is	O
the	O
3D	O
distribution	O
of	O
refractive	O
index	O
.	O

The	O
amplitude	O
distribution	O
after	O
the	O
object	O
is	O
written	O
as	O

A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
=	O
integraldzS	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
T	O
[	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
-	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
,	O
z	O
]	O
,	O
(	O
3	O
)	O

where	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
is	O
the	O
instantaneous	O
position	O
of	O
the	O
2D	O
raster	O
scan	O
.	O

The	O
incoherent	O
imaging	O
mode	O
is	O
obtained	O
with	O
a	O
spatially	O
integrating	O
detector	O
,	O
leading	O
to	O
a	O
temporal	O
signal	O
proportional	O
to	O
the	O
integrated	O
intensity	O
,	O
integrald2r	O
|	O
A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
|	O
2	O
,	O
which	O
is	O
stored	O
in	O
the	O
computer	O
.	O

The	O
data	O
corresponding	O
to	O
each	O
hologram	O
line	O
is	O
cut	O
from	O
the	O
signal	O
,	O
and	O
band	O
pass	O
filtered	O
to	O
extract	O
the	O
term	O
oscillating	O
at	O
Omega	O
.	O

The	O
lines	O
are	O
then	O
rearranged	O
in	O
a	O
2D	O
format	O
.	O

The	O
resulting	O
hologram	O
amplitude	O
is	O
found	O
to	O
be	O

HI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldzI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
[	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
p	O
*	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
,	O
(	O
4	O
)	O

where	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
integral	O
,	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
,	O
and	O
p1	O
,	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
are	O
the	O
inverse	O
Fourier	O
transforms	O
of	O
the	O
defocused	O
pupil	O
distributions	O
(	O
eq	O
.	O
1b	O
)	O
.	O

The	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O

The	O
hologram	O
is	O
thus	O
the	O
convolution	O
of	O
the	O
object	O
intensity	O
with	O
a	O
spherical	O
wave	O
,	O
i	O
.	O
e	O
.	O
an	O
in	O
-	O
line	O
single	O
-	O
sideband	O
Gabor	O
hologram	O
.	O

In	O
Fourier	O
space	O
,	O
the	O
hologram	O
can	O
be	O
written	O
as	O

H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
]	O
,	O
(	O
5	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa	O
@	O
58FF	O
@	O

where	O
(	O
+	O
)	O
symbolizes	O
a	O
correlation	O
integral	O
.	O

With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O
,	O
in	O
the	O
paraxial	O
approximation	O
,	O

H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
,	O
(	O
6	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab	O
=	O
b8aWjab	O
=	O
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa	O
@	O
67E3	O
@	O

which	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
.	O

The	O
coherent	O
imaging	O
mode	O
is	O
obtained	O
by	O
using	O
a	O
pinhole	O
or	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
plane	O
of	O
the	O
pupil	O
of	O
the	O
objective	O
.	O

This	O
leads	O
to	O
the	O
hologram	O
amplitude	O

HC	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldz	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
*	O
.	O

(	O
7	O
)	O

Where	O
again	O
,	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
product	O
,	O
and	O
the	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O

In	O
Fourier	O
space	O
,	O

H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
.	O

(	O
8	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa	O
@	O
5E5B	O
@	O

With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O

H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
*	O
(	O
0	O
;	O
z	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
.	O

(	O
9	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
=	O
f8aYjabc	O
+	O
caViab	O
=	O
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa	O
@	O
6F41	O
@	O

Aside	O
from	O
an	O
inconsequential	O
complex	O
constant	O
(	O
the	O
first	O
term	O
under	O
the	O
integral	O
)	O
,	O
eq	O
.	O
9	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
.	O

Thus	O
,	O
the	O
reconstruction	O
of	O
the	O
hologram	O
recorded	O
in	O
the	O
coherent	O
mode	O
carries	O
a	O
quantitative	O
measure	O
of	O
the	O
object	O
'	O
s	O
phase	O
distribution	O
.	O

Step	O
-	O
wise	O
logistic	O
regression	O
(	O
STEPLOG	O
)	O

The	O
group	O
variable	O
was	O
considered	O
as	O
an	O
ordinal	O
(	O
or	O
binary	O
)	O
dependent	O
variable	O
and	O
the	O
feature	O
vector	O
(	O
multiple	O
marker	O
IBD	O
estimates	O
and	O
covariates	O
)	O
as	O
the	O
independent	O
variables	O
.	O

A	O
nonlinear	O
relationship	O
(	O
logit	O
)	O
between	O
the	O
dependent	O
and	O
independent	O
variables	O
was	O
taken	O
.	O

For	O
binary	O
data	O
(	O
collapsing	O
concordantly	O
affected	O
or	O
unaffected	O
sib	O
pair	O
into	O
one	O
group	O
)	O
,	O
a	O
conventional	O
logistic	O
regression	O
was	O
used	O
.	O

For	O
ordinal	O
data	O
,	O
the	O
SAS	O
LOGISTIC	O
[	O
8	O
]	O
procedure	O
fits	O
a	O
parallel	O
lines	O
regression	O
model	O
based	O
on	O
the	O
cumulative	O
distribution	O
probabilities	O
of	O
response	O
categories	O
,	O
rather	O
than	O
on	O
their	O
individual	O
probabilities	O
.	O

The	O
statistical	O
P	O
-	O
value	O
for	O
each	O
(	O
selected	O
)	O
independent	O
variable	O
was	O
obtained	O
from	O
the	O
final	O
model	O
fitting	O
with	O
only	O
selected	O
variables	O
included	O
via	O
an	O
asymptotic	O
chi	O
-	O
squared	O
statistic	O
.	O

Results	O

Here	O
we	O
include	O
data	O
obtained	O
from	O
active	O
,	O
oscillatory	O
brain	B-Multi-tissue_structure
slices	E-Multi-tissue_structure
as	O
well	O
as	O
from	O
recordings	O
during	O
cortical	S-Multi-tissue_structure
slow	O
oscillations	O
in	O
anesthetized	O
animals	O
.	O

All	O
recordings	O
included	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
visual	B-Multi-tissue_structure
cortex	E-Multi-tissue_structure
of	O
the	O
ferret	O
(	O
in	O
vitro	O
)	O
,	O
cat	O
(	O
in	O
vivo	O
)	O
and	O
from	O
barrel	B-Multi-tissue_structure
cortex	E-Multi-tissue_structure
of	O
the	O
rat	O
(	O
in	O
vivo	O
)	O
.	O

Twenty	O
-	O
nine	O
neurons	S-Cell
recorded	O
from	O
ferret	O
cortical	B-Multi-tissue_structure
slices	E-Multi-tissue_structure
are	O
included	O
in	O
this	O
study	O
(	O
22	O
regular	O
spiking	O
(	O
RS	O
)	O
;	O
5	O
chattering	O
(	O
CH	O
)	O
and	O
2	O
intrinsic	O
bursting	O
(	O
IB	O
)	O
)	O
,	O
27	O
neurons	S-Cell
from	O
cat	O
visual	B-Multi-tissue_structure
cortex	E-Multi-tissue_structure
in	O
vivo	O
(	O
14	O
RS	O
;	O
5	O
CH	O
;	O
2	O
IB	O
;	O
3	O
fast	O
spiking	O
(	O
FS	O
)	O
;	O
plus	O
3	O
non	O
classified	O
)	O
and	O
14	O
neurons	S-Cell
from	O
rat	O
barrel	B-Multi-tissue_structure
cortex	E-Multi-tissue_structure
in	O
vivo	O
(	O
12	O
RS	O
;	O
1	O
CH	O
;	O
1	O
IB	O
)	O
.	O

Synaptic	S-Cellular_component
potentials	O
were	O
evoked	O
by	O
electric	O
shocks	O
(	O
intracortical	S-Immaterial_anatomical_entity
or	O
thalamocortical	S-Cellular_component
connections	O
)	O
or	O
by	O
means	O
of	O
sensory	O
(	O
visual	O
or	O
whisker	S-Organism_subdivision
)	O
stimulation	O
.	O

The	O
main	O
results	O
are	O
:	O
1	O
)	O
Synaptic	S-Cellular_component
potentials	O
show	O
more	O
paired	O
pulsed	O
facilitation	O
and	O
synaptic	S-Cellular_component
augmentation	O
in	O
active	O
than	O
in	O
silent	O
cortical	B-Multi-tissue_structure
networks	E-Multi-tissue_structure
and	O
2	O
)	O
Synaptic	S-Cellular_component
potentials	O
occurring	O
during	O
up	O
or	O
activated	O
states	O
of	O
the	O
cortex	S-Multi-tissue_structure
increased	O
their	O
amplitude	O
with	O
respect	O
to	O
those	O
occurring	O
during	O
down	O
states	O
.	O

Ca2	O
+	O
Dependence	O
of	O
Slob57	O
Modulation	O
of	O
the	O
Voltage	O
Dependence	O
of	O
Activation	O
of	O
dSlo	O

Ca2	O
+	O
plays	O
a	O
fundamental	O
role	O
in	O
regulating	O
the	O
dSlo	O
response	O
to	O
membrane	S-Cellular_component
depolarization	O
.	O

One	O
of	O
the	O
three	O
known	O
Ca2	O
+	O
binding	O
sites	O
(	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
,	O
known	O
as	O
the	O
calcium	O
bowl	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
)	O
,	O
contributes	O
to	O
the	O
high	O
-	O
affinity	O
Ca2	O
+	O
sensitivity	O
of	O
the	O
channel	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
;	O
Schreiber	O
et	O
al	O
.	O
,	O
1999	O
;	O
Braun	O
and	O
Sy	O
,	O
2001	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Niu	O
and	O
Magleby	O
,	O
2002	O
;	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2004	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

We	O
used	O
a	O
mutated	O
dSlo	O
channel	O
with	O
substitution	O
of	O
Asp966	O
-	O
Asp970	O
by	O
Asn966	O
-	O
Asn970	O
within	O
its	O
calcium	O
bowl	O
,	O
which	O
greatly	O
reduces	O
the	O
channel	O
'	O
s	O
calcium	O
sensitivity	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
to	O
determine	O
whether	O
Ca2	O
+	O
participates	O
in	O
Slob57	O
modulation	O
of	O
dSlo	O
.	O

This	O
mutated	O
channel	O
,	O
dSloD5N5	O
,	O
still	O
binds	O
to	O
full	O
-	O
length	O
and	O
truncated	O
Slobs	O
(	O
Fig	O
.	O
1	O
B	O
,	O
lanes	O
4	O
-	O
6	O
)	O
.	O

During	O
a	O
350	O
-	O
ms	O
test	O
pulse	O
(	O
Fig	O
.	O
7	O
E	O
)	O
,	O
Slob57	O
causes	O
dSloD5N5	O
inactivation	O
(	O
Fig	O
.	O
7	O
B	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
finding	O
that	O
the	O
inactivation	O
caused	O
by	O
Slob57	O
is	O
Ca2	O
+	O
independent	O
(	O
Zeng	O
et	O
al	O
.	O
,	O
2005a	O
)	O
.	O

After	O
deletion	O
of	O
the	O
amino	O
-	O
terminal	O
residues	O
2	O
-	O
6	O
of	O
Slob57	O
,	O
the	O
inactivation	O
of	O
dSloD5N5	O
is	O
eliminated	O
(	O
Fig	O
.	O
7	O
C	O
)	O
,	O
and	O
further	O
truncation	O
of	O
Slob57	O
to	O
Arg16	O
also	O
eliminates	O
the	O
inactivation	O
(	O
Fig	O
.	O
7	O
D	O
)	O
,	O
just	O
as	O
observed	O
with	O
wild	O
-	O
type	O
dSlo	O
(	O
Fig	O
.	O
2	O
,	O
C	O
and	O
D	O
)	O
.	O

Figure	O
7	O
.	O

Slob57	O
causes	O
inactivation	O
of	O
dSloD5N5	O
.	O

Same	O
as	O
Fig	O
.	O

2	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
instead	O
of	O
wild	O
-	O
type	O
dSlo	O
.	O

(	O
A	O
)	O
dSloD5N5	O
alone	O
,	O
(	O
B	O
)	O
dSloD5N5	O
together	O
with	O
Slob57	O
,	O
(	O
C	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN5	O
,	O
(	O
D	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN15	O
,	O
(	O
E	O
)	O
pulse	O
protocol	O
.	O

We	O
next	O
used	O
a	O
100	O
-	O
ms	O
test	O
pulse	O
(	O
during	O
which	O
no	O
inactivation	O
occurs	O
)	O
to	O
measure	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
dSloD5N5	O
in	O
the	O
presence	O
of	O
110	O
muM	O
free	O
Ca2	O
+	O
,	O
as	O
only	O
at	O
high	O
concentrations	O
of	O
free	O
Ca2	O
+	O
can	O
tail	O
current	O
saturation	O
be	O
achieved	O
with	O
the	O
mutant	O
channel	O
(	O
Fig	O
.	O
8	O
)	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

8	O
,	O
Slob57	O
does	O
not	O
rightward	O
shift	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
.	O

Because	O
dSloD5N5	O
can	O
still	O
respond	O
to	O
an	O
increment	O
of	O
free	O
Ca2	O
+	O
at	O
high	O
concentration	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
we	O
then	O
increased	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
to	O
300	O
muM	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

8	O
,	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
110	O
to	O
300	O
muM	O
,	O
but	O
again	O
the	O
V1	O
/	O
2	O
is	O
not	O
modulated	O
by	O
Slob57	O
.	O

Figure	O
8	O
.	O

Conductance	O
-	O
voltage	O
relationships	O
for	O
dSloD5N5	O
.	O

Same	O
protocol	O
as	O
Fig	O
.	O

6	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
in	O
the	O
presence	O
(	O
circles	O
)	O
or	O
absence	O
(	O
squares	O
)	O
of	O
Slob57	O
,	O
and	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
was	O
either	O
110	O
muM	O
(	O
filled	O
symbols	O
)	O
or	O
300	O
muM	O
(	O
open	O
symbols	O
)	O
.	O

We	O
next	O
measured	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
wild	O
-	O
type	O
dSlo	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Slob57	O
,	O
at	O
free	O
Ca2	O
+	O
concentrations	O
ranging	O
from	O
20	O
to	O
300	O
muM	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

9	O
A	O
(	O
and	O
by	O
many	O
previous	O
investigators	O
)	O
,	O
in	O
the	O
absence	O
of	O
Slob57	O
,	O
the	O
voltage	O
-	O
conductance	O
relationship	O
of	O
dSlo	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
as	O
the	O
free	O
Ca2	O
+	O
concentration	O
is	O
increased	O
in	O
this	O
range	O
.	O

The	O
V1	O
/	O
2	O
decreases	O
from	O
85	O
to	O
-	O
22	O
mV	O
,	O
a	O
change	O
of	O
107	O
mV	O
,	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
20	O
to	O
300	O
muM	O
.	O

In	O
contrast	O
,	O
when	O
dSlo	O
is	O
coexpressed	O
with	O
Slob57	O
,	O
this	O
increment	O
of	O
free	O
Ca2	O
+	O
concentration	O
shifts	O
the	O
V1	O
/	O
2	O
to	O
a	O
much	O
lesser	O
extent	O
(	O
Fig	O
.	O
9	O
B	O
and	O
Fig	O
.	O
10	O
A	O
)	O
.	O

Note	O
also	O
that	O
the	O
effect	O
of	O
Slob57	O
on	O
the	O
V1	O
/	O
2	O
is	O
more	O
apparent	O
at	O
higher	O
free	O
Ca2	O
+	O
concentrations	O
(	O
Fig	O
.	O
10	O
A	O
)	O
.	O

To	O
illustrate	O
this	O
better	O
,	O
we	O
plotted	O
the	O
V1	O
/	O
2	O
change	O
evoked	O
by	O
Slob57	O
(	O
DeltaV1	O
/	O
2	O
)	O
as	O
a	O
function	O
of	O
the	O
free	O
Ca2	O
+	O
concentration	O
(	O
Fig	O
.	O
10	O
B	O
)	O
to	O
demonstrate	O
that	O
the	O
magnitude	O
of	O
the	O
modulatory	O
shift	O
in	O
V1	O
/	O
2	O
evoked	O
by	O
Slob57	O
itself	O
is	O
calcium	O
dependent	O
.	O

Figure	O
9	O
.	O

Effect	O
of	O
calcium	O
on	O
dSlo	O
voltage	O
dependence	O
of	O
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Slob57	O
.	O

Same	O
as	O
Fig	O
.	O

6	O
,	O
except	O
that	O
the	O
measurements	O
of	O
dSlo	O
expressed	O
alone	O
(	O
A	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
B	O
)	O
were	O
performed	O
in	O
the	O
presence	O
of	O
different	O
concentrations	O
of	O
free	O
Ca2	O
+	O
:	O
20	O
muM	O
(	O
diamonds	O
)	O
,	O
40	O
muM	O
(	O
inverted	O
triangles	O
)	O
,	O
80	O
muM	O
(	O
triangles	O
)	O
,	O
110	O
muM	O
(	O
squares	O
)	O
,	O
and	O
300	O
muM	O
(	O
circles	O
)	O
.	O

Figure	O
10	O
.	O

Interaction	O
between	O
Slob57	O
and	O
calcium	O
.	O

The	O
V1	O
/	O
2	O
(	O
A	O
)	O
of	O
the	O
conductance	O
-	O
voltage	O
relationship	O
for	O
dSlo	O
expressed	O
alone	O
(	O
O	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
*	O
)	O
,	O
taken	O
from	O
Fig	O
.	O

9	O
,	O
and	O
the	O
difference	O
in	O
V1	O
/	O
2	O
(	O
DeltaV1	O
/	O
2	O
)	O
evoked	O
by	O
Slob57	O
(	O
B	O
)	O
are	O
plotted	O
as	O
a	O
function	O
of	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
.	O

Determination	O
of	O
As	O
metabolites	O

We	O
assessed	O
As	O
metabolism	O
using	O
the	O
percentages	O
of	O
iAs	O
,	O
MMA	O
,	O
and	O
DMA	O
in	O
urine	S-Organism_substance
,	O
as	O
well	O
as	O
two	O
methylation	O
indexes	O
[	O
i	O
.	O
e	O
.	O
,	O
primary	O
methylation	O
index	O
(	O
PMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
MMA	O
and	O
iAs	O
,	O
and	O
secondary	O
methylation	O
index	O
(	O
SMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
DMA	O
and	O
MMA	O
.	O

We	O
used	O
total	O
urinary	S-Organism_substance
As	O
[	O
U	O
-	O
As	O
;	O
the	O
sum	O
of	O
As	O
metabolites	O
(	O
iAs	O
+	O
MMA	O
+	O
DMA	O
)	O
in	O
urine	S-Organism_substance
]	O
as	O
the	O
measure	O
of	O
iAs	O
exposure	O
.	O

Concentrations	O
of	O
As	O
metabolites	O
in	O
urine	S-Organism_substance
were	O
measured	O
with	O
an	O
Agilent	O
1100	O
HPLC	O
system	O
(	O
Agilent	O
Technologies	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
,	O
coupled	O
with	O
hydride	O
generation	O
(	O
HG	O
)	O
inductively	O
coupled	O
plasma	S-Organism_substance
mass	O
spectrometry	O
(	O
ICPMS	O
)	O
(	O
Agilent	O
7500ce	O
series	O
;	O
Agilent	O
Technologies	O
,	O
Japan	O
)	O
.	O

The	O
method	O
measures	O
metabolites	O
of	O
iAs	O
[	O
iAs	O
(	O
III	O
)	O
,	O
iAs	O
(	O
V	O
)	O
,	O
MMA	O
,	O
and	O
DMA	O
]	O
,	O
but	O
not	O
organic	O
As	O
species	O
(	O
e	O
.	O
g	O
.	O
,	O
arsenobetaine	O
,	O
arsenocholine	O
)	O
originating	O
from	O
the	O
diet	O
,	O
because	O
those	O
arsenicals	O
do	O
not	O
form	O
volatile	O
arsines	O
(	O
hydride	O
generation	O
)	O
like	O
iAs	O
and	O
its	O
metabolites	O
do	O
.	O

The	O
method	O
was	O
described	O
in	O
detail	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2006	O
)	O
.	O

Determination	O
limits	O
were	O
0	O
.	O
1	O
mug	O
/	O
L	O
for	O
arsenite	O
[	O
As	O
(	O
III	O
)	O
]	O
and	O
MMA	O
and	O
0	O
.	O
2	O
mug	O
/	O
L	O
for	O
DMA	O
and	O
arsenate	O
[	O
As	O
(	O
V	O
)	O
]	O
.	O

We	O
adjusted	O
As	O
concentrations	O
for	O
variations	O
in	O
dilution	O
by	O
specific	O
gravity	O
(	O
to	O
the	O
mean	O
value	O
of	O
1	O
.	O
012	O
g	O
/	O
mL	O
)	O
;	O
U	O
-	O
Cre	O
,	O
which	O
is	O
commonly	O
used	O
for	O
dilution	O
adjustment	O
,	O
was	O
influenced	O
more	O
by	O
age	O
and	O
nutrition	O
than	O
was	O
specific	O
gravity	O
,	O
and	O
U	O
-	O
Cre	O
was	O
also	O
associated	O
with	O
urinary	S-Organism_substance
As	O
(	O
Nermell	O
et	O
al	O
.	O
2007	O
)	O
.	O

For	O
quality	O
control	O
purposes	O
,	O
we	O
analyzed	O
the	O
reference	O
material	O
(	O
CRM	O
No	O
.	O
18	O
;	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
,	O
Ibaraki	O
,	O
Japan	O
)	O
with	O
a	O
certified	O
DMA	O
concentration	O
of	O
36	O
+	O
/	O
-	O
9	O
mug	O
/	O
L	O
together	O
with	O
the	O
collected	O
urine	B-Organism_substance
samples	E-Organism_substance
.	O

The	O
concentration	O
of	O
DMA	O
was	O
41	O
+	O
/	O
-	O
3	O
.	O
4	O
mug	O
/	O
L	O
(	O
mean	O
+	O
/	O
-	O
SD	O
;	O
n	O
=	O
18	O
)	O
.	O

Urine	B-Organism_substance
samples	E-Organism_substance
were	O
also	O
analyzed	O
for	O
As	O
metabolites	O
by	O
atomic	O
fluorescence	O
spectrometry	O
(	O
AFS	O
)	O
and	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
by	O
atomic	O
absorption	O
spectrometry	O
(	O
AAS	O
)	O
,	O
as	O
reported	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2007a	O
)	O
.	O

The	O
results	O
of	O
ICPMS	O
and	O
AFS	O
showed	O
good	O
agreement	O
for	O
all	O
metabolites	O
;	O
for	O
iAs	O
[	O
As	O
(	O
III	O
)	O
+	O
As	O
(	O
V	O
)	O
]	O
,	O
MMA	O
,	O
and	O
DMA	O
,	O
R2	O
=	O
0	O
.	O
91	O
,	O
0	O
.	O
91	O
,	O
and	O
0	O
.	O
97	O
,	O
respectively	O
(	O
n	O
=	O
221	O
)	O
.	O

Further	O
,	O
we	O
obtained	O
good	O
agreement	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
between	O
the	O
three	O
different	O
methods	O
(	O
for	O
ICPMS	O
vs	O
.	O
AFS	O
,	O
R2	O
=	O
0	O
.	O
97	O
;	O
for	O
ICPMS	O
vs	O
.	O
AAS	O
,	O
R2	O
=	O
0	O
.	O
96	O
(	O
n	O
=	O
221	O
)	O
.	O

Mean	O
differences	O
of	O
scores	O
with	O
baseline	O
of	O
the	O
22	O
patients	O
who	O
competed	O
all	O
QLQ	O
-	O
C30	O
questionnaires	O
-	O
symptoms	O
scores	O
.	O

CA	O
IX	O
and	O
response	O
to	O
PMRT	O

Kaplan	O
-	O
Meier	O
probability	O
plots	O
of	O
OS	O
after	O
PMRT	O
among	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
revealed	O
improved	O
survival	O
after	O
PMRT	O
in	O
both	O
subgroups	O
of	O
patients	O
(	O
Figure	O
2	O
)	O
.	O

Fifteen	O
-	O
year	O
OS	O
probabilities	O
were	O
improved	O
by	O
7	O
%	O
and	O
9	O
%	O
after	O
PMRT	O
for	O
the	O
subgroups	O
of	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
,	O
respectively	O
.	O

The	O
HR	O
of	O
overall	O
mortality	O
after	O
PMRT	O
was	O
0	O
.	O
87	O
(	O
95	O
%	O
CI	O
0	O
.	O
60	O
to	O
1	O
.	O
27	O
)	O
for	O
the	O
small	O
subgroup	O
of	O
151	O
CA	O
IX	O
positive	O
patients	O
and	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
0	O
.	O
69	O
to	O
0	O
.	O
97	O
)	O
for	O
the	O
large	O
subgroup	O
of	O
813	O
CA	O
IX	O
negative	O
patients	O
.	O

HRs	O
and	O
95	O
%	O
CIs	O
after	O
PMRT	O
did	O
not	O
differ	O
significantly	O
between	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
for	O
OS	O
,	O
DSS	O
,	O
DM	O
,	O
or	O
LRR	O
(	O
Table	O
4	O
)	O
.	O

In	O
multivariate	O
analysis	O
by	O
Cox	O
regression	O
,	O
no	O
significant	O
interaction	O
was	O
found	O
between	O
CA	O
IX	O
and	O
randomization	O
status	O
for	O
any	O
of	O
the	O
four	O
end	O
-	O
points	O
.	O

Similar	O
tendencies	O
were	O
observed	O
when	O
the	O
women	O
were	O
separated	O
into	O
premenopausal	O
and	O
postmenopausal	O
women	O
,	O
and	O
into	O
women	O
with	O
one	O
to	O
three	O
positive	O
nodes	S-Multi-tissue_structure
and	O
those	O
with	O
more	O
than	O
three	O
positive	O
nodes	S-Multi-tissue_structure
.	O

Table	O
4	O

Hazard	O
ratios	O

CA	O
IX	O
positive	O
(	O
n	O
=	O
151	O
)	O
CA	O
IX	O
negative	O
(	O
n	O
=	O
794	O
)	O

Overall	O
mortality	O
0	O
.	O
87	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
27	O
)	O
0	O
.	O
82	O
(	O
0	O
.	O
69	O
-	O
0	O
.	O
97	O
)	O

Disease	O
-	O
specific	O
mortality	O
0	O
.	O
83	O
(	O
0	O
.	O
55	O
-	O
1	O
.	O
27	O
)	O
0	O
.	O
76	O
(	O
0	O
.	O
63	O
-	O
0	O
.	O
93	O
)	O

Distant	O
metastases	S-Cancer
0	O
.	O
83	O
(	O
0	O
.	O
54	O
-	O
1	O
.	O
25	O
)	O
0	O
.	O
76	O
(	O
0	O
.	O
63	O
-	O
0	O
.	O
91	O
)	O

Locoregional	O
recurrence	O
0	O
.	O
23	O
(	O
0	O
.	O
08	O
-	O
0	O
.	O
61	O
)	O
0	O
.	O
16	O
(	O
0	O
.	O
09	O
-	O
0	O
.	O
28	O
)	O

Presented	O
are	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
of	O
overall	O
mortality	O
,	O
disease	O
-	O
specific	O
mortality	O
,	O
distant	O
metastases	S-Cancer
and	O
loco	O
-	O
regional	O
recurrence	O
probabilities	O
after	O
postmastectomy	O
radiotherapy	O
in	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
IX	O
positive	O
and	O
in	O
CA	O
IX	O
negative	O
high	O
-	O
risk	O
breast	B-Cancer
cancer	E-Cancer
patients	O
.	O

Figure	O
2	O

Overall	O
survival	O
in	O
high	O
-	O
risk	O
breast	B-Cancer
cancer	E-Cancer
patients	O
.	O

Shown	O
are	O
Kaplan	O
-	O
Meier	O
probability	O
plots	O
of	O
overall	O
survival	O
in	O
high	O
-	O
risk	O
breast	B-Cancer
cancer	E-Cancer
patients	O
as	O
a	O
function	O
of	O
randomization	O
to	O
postmastectomy	O
radiotherapy	O
(	O
RT	O
)	O
within	O
the	O
subgroups	O
of	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
IX	O
negative	O
and	O
CA	O
IX	O
positive	O
patients	O
.	O

The	O
values	O
given	O
in	O
parentheses	O
after	O
hazard	O
ratios	O
(	O
HRs	O
)	O
are	O
the	O
95	O
%	O
confidence	O
intervals	O
.	O

Changing	O
the	O
cutpoints	O
to	O
at	O
least	O
one	O
tumour	B-Cell
cell	E-Cell
,	O
or	O
>	O
=	O
20	O
%	O
or	O
>	O
=	O
30	O
%	O
invasive	B-Cancer
tumour	E-Cancer
staining	O
did	O
not	O
improve	O
the	O
predictive	O
value	O
of	O
positive	O
CA	O
IX	O
staining	O
(	O
data	O
not	O
presented	O
)	O
.	O

Acknowledgements	O

The	O
authors	O
would	O
like	O
to	O
express	O
their	O
gratitude	O
to	O
Dr	O
.	O
Mahasti	O
Alizadeh	O
for	O
her	O
assistance	O
in	O
the	O
data	O
analysis	O
and	O
designing	O
the	O
questionnaire	O
.	O

Methods	O

RESULTS	O

Forty	O
Caucasians	O
(	O
19	O
females	O
)	O
with	O
essential	O
hypertension	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Their	O
mean	O
age	O
was	O
57	O
years	O
.	O

Most	O
of	O
them	O
were	O
overweight	O
,	O
17	O
had	O
metabolic	O
syndrome	O
according	O
to	O
the	O
updated	O
AHA	O
NHLBI	O
statement	O
(	O
defined	O
as	O
3	O
or	O
more	O
of	O
the	O
following	O
:	O
waist	O
circumference	O
>	O
102	O
cm	O
in	O
men	O
and	O
>	O
88	O
cm	O
in	O
women	O
,	O
blood	S-Organism_substance
pressure	O
>	O
=	O
130	O
/	O
85	O
mmHg	O
,	O
triglycerides	O
>	O
150	O
mg	O
/	O
dl	O
,	O
HDL	O
-	O
C	O
<	O
40	O
mg	O
/	O
dl	O
in	O
men	O
and	O
<	O
50	O
mg	O
/	O
dl	O
in	O
women	O
,	O
and	O
fasting	O
glucose	O
>	O
=	O
100	O
mg	O
/	O
dl	O
)	O
,	O
8	O
had	O
type	O
2	O
diabetes	O
and	O
18	O
were	O
smokers	O
(	O
Table	O
1	O
)	O
.	O

Eprosartan	O
reduced	O
SBP	O
by	O
8	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
DBP	O
by	O
13	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
it	O
had	O
a	O
neutral	O
effect	O
on	O
the	O
lipid	O
profile	O
and	O
apolipoprotein	O
levels	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
did	O
not	O
affect	O
plasma	S-Organism_substance
8	O
-	O
epiPGF2a	O
levels	O
,	O
whereas	O
it	O
significantly	O
increased	O
by	O
24	O
%	O
the	O
lag	O
time	O
of	O
total	O
serum	S-Organism_substance
oxidation	O
(	O
145	O
+	O
/	O
-	O
54	O
min	O
vs	O
180	O
+	O
/	O
-	O
58	O
min	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
reduced	O
by	O
14	O
%	O
the	O
aspartate	O
aminotransferase	O
(	O
form	O
21	O
to	O
18	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
by	O
21	O
%	O
the	O
alanine	O
aminotransferase	O
(	O
from	O
24	O
to	O
19	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
activity	O
(	O
Table2	O
)	O
.	O

The	O
administration	O
of	O
eprosartan	O
had	O
no	O
influence	O
on	O
glucose	O
homeostasis	O
,	O
as	O
well	O
as	O
on	O
creatinine	O
and	O
uric	O
acid	O
levels	O
(	O
Table2	O
)	O
.	O

In	O
addition	O
,	O
eprosartan	O
did	O
not	O
affect	O
clotting	O
or	O
fibrinolytic	O
activity	O
as	O
this	O
was	O
estimated	O
by	O
PAI	O
-	O
1	O
,	O
tPA	O
and	O
a2	O
-	O
antiplasmin	O
(	O
Table2	O
)	O
.	O

The	O
enzymatic	O
activity	O
of	O
Lp	O
-	O
PLA2	O
and	O
PON1	O
were	O
not	O
altered	O
significantly	O
following	O
eprosartan	O
treatment	O
(	O
Table2	O
)	O
.	O

Comparison	O
of	O
the	O
number	O
of	O
known	O
complexes	O
matched	O
by	O
the	O
predicted	O
clusters	O
generated	O
by	O
IPCA	O
and	O
other	O
previous	O
algorithms	O

Authors	O
'	O
contributions	O

OK	O
and	O
MG	O
analyzed	O
and	O
interpreted	O
the	O
patient	O
data	O
regarding	O
his	O
hospitalization	O
.	O

SP	O
and	O
PK	O
performed	O
the	O
coronary	S-Multi-tissue_structure
angiography	O
,	O
and	O
were	O
the	O
major	O
contributors	O
in	O
writing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Fragmentation	O
of	O
the	O
parent	O
ion	O
/	O
TCE	O
-	O
sulfate	O
moiety	O

The	O
mass	O
spectrum	O
of	O
compound	O
5	O
displays	O
its	O
molecular	O
ion	O
5a	O
with	O
the	O
typical	O
isotope	O
pattern	O
[	O
18	O
]	O
of	O
a	O
pentachlorinated	O
compound	O
at	O
m	O
/	O
z	O
448	O
(	O
relative	O
abundance	O
,	O
15	O
%	O
)	O
(	O
Figure	O
2	O
)	O
.	O

Scheme	O
1	O
illustrates	O
the	O
various	O
fragmentation	O
pathways	O
of	O
this	O
precursor	O
ion	O
.	O

The	O
molecular	O
ion	O
5a	O
loses	O
a	O
PCB	O
sulfate	O
(	O
ArOSO3	O
-	O
)	O
group	O
,	O
thus	O
yielding	O
TCE	O
group	O
-	O
derived	O
fragment	O
ions	O
.	O

These	O
ions	O
,	O
[	O
CH2CCl3	O
]	O
+	O
and	O
[	O
CH	O
=	O
CCl2	O
]	O
+	O
,	O
are	O
observed	O
at	O
m	O
/	O
z	O
131	O
(	O
6	O
%	O
)	O
and	O
95	O
(	O
7	O
%	O
)	O
,	O
respectively	O
.	O

Scheme	O
1	O

Principal	O
EI	O
-	O
MS	O
fragmentation	O
pathways	O
of	O
sulfuric	O
acid	O
2	O
'	O
,	O
5	O
'	O
-	O
dichlorobiphenyl	O
-	O
4yl	O
ester	O
2	O
,	O
2	O
,	O
2	O
-	O
trichloroethyl	O
ester	O
5	O
.	O

More	O
complex	O
fragmentation	O
patterns	O
are	O
observed	O
for	O
the	O
fragmentation	O
of	O
the	O
-	O
OSO3	O
-	O
TCE	O
group	O
.	O

The	O
abundant	O
fragment	O
ion	O
5g	O
(	O
m	O
/	O
z	O
237	O
,	O
28	O
%	O
)	O
can	O
be	O
formed	O
by	O
two	O
fragmentation	O
pathways	O
from	O
precursor	O
ion	O
5a	O
.	O

One	O
pathway	O
involves	O
the	O
release	O
of	O
HCl	O
and	O
Cl	O
from	O
precursor	O
ion	O
5a	O
,	O
leading	O
to	O
an	O
unstable	O
cyclic	O
fragment	O
ion	O
5b	O
(	O
m	O
/	O
z	O
377	O
,	O
5	O
%	O
)	O
.	O

In	O
turn	O
,	O
fragment	O
ion	O
5b	O
produces	O
the	O
fragment	O
ion	O
5g	O
after	O
releasing	O
chloroethyne	O
and	O
SO3	O
.	O

The	O
other	O
pathway	O
resulting	O
in	O
the	O
formation	O
of	O
fragment	O
ion	O
5g	O
involves	O
the	O
removal	O
of	O
two	O
neutral	O
molecules	O
,	O
HCHO	O
and	O
SO2	O
,	O
from	O
the	O
daughter	O
fragment	O
ion	O
5c	O
(	O
m	O
/	O
z	O
331	O
,	O
5	O
%	O
)	O
,	O
which	O
is	O
formed	O
by	O
releasing	O
the	O
free	O
radical	O
group	O
CCl3	O
from	O
fragment	O
ion	O
5a	O
.	O

Alternatively	O
,	O
the	O
fragment	O
ion	O
5c	O
can	O
also	O
produce	O
the	O
daughter	O
fragment	O
ion	O
5e	O
(	O
m	O
/	O
z	O
183	O
,	O
12	O
%	O
)	O
by	O
losing	O
one	O
molecule	O
of	O
SO3	O
.	O

In	O
addition	O
,	O
precursor	O
ion	O
5a	O
yields	O
the	O
daughter	O
ion	O
5d	O
by	O
losing	O
a	O
CHCCl3	O
fragment	O
.	O

The	O
basic	O
fragment	O
ion	O
5f	O
at	O
m	O
/	O
z	O
238	O
is	O
produced	O
from	O
the	O
daughter	O
ion	O
5d	O
(	O
m	O
/	O
z	O
318	O
,	O
20	O
%	O
)	O
by	O
releasing	O
one	O
molecule	O
of	O
SO3	O
.	O

Fragment	O
ions	O
5f	O
and	O
5g	O
can	O
produce	O
the	O
important	O
fragment	O
ion	O
5h	O
at	O
m	O
/	O
z	O
209	O
with	O
a	O
relative	O
abundance	O
of	O
26	O
%	O
by	O
losing	O
a	O
CHO	O
or	O
CO	O
fragment	O
,	O
respectively	O
.	O

The	O
same	O
fragmentation	O
pathways	O
are	O
observed	O
for	O
the	O
TCE	O
PCB	O
sulfates	O
diesters	O
1	O
and	O
3	O
-	O
10	O
.	O

The	O
only	O
exception	O
is	O
compound	O
2	O
,	O
which	O
has	O
the	O
TCE	O
sulfate	O
group	O
in	O
ortho	O
position	O
to	O
the	O
other	O
phenyl	O
ring	O
.	O

The	O
mass	O
spectrum	O
of	O
compounds	O
2	O
is	O
distinctively	O
different	O
from	O
the	O
mass	O
spectrum	O
of	O
its	O
isomer	O
,	O
compound	O
3	O
(	O
Figures	O
3	O
and	O
4	O
)	O
.	O

As	O
shown	O
in	O
Scheme	O
2	O
,	O
the	O
basic	O
fragment	O
ion	O
of	O
compound	O
2	O
is	O
the	O
stable	O
dibenzofuran	O
ion	O
2f	O
.	O

Fragment	O
ion	O
2f	O
is	O
formed	O
from	O
the	O
parent	O
ion	O
2a	O
(	O
m	O
/	O
z	O
414	O
;	O
relative	O
abundance	O
,	O
21	O
%	O
)	O
by	O
sequential	O
loss	O
of	O
CHCCl3	O
(	O
2d	O
,	O
m	O
/	O
z	O
284	O
;	O
relative	O
abundance	O
,	O
10	O
%	O
)	O
,	O
SO3	O
(	O
2e	O
,	O
m	O
/	O
z	O
204	O
;	O
relative	O
abundance	O
,	O
28	O
%	O
)	O
and	O
HCl	O
(	O
2f	O
,	O
m	O
/	O
z	O
168	O
;	O
relative	O
abundance	O
,	O
100	O
%	O
)	O
.	O

The	O
stable	O
dibenzofuran	O
cation	O
2f	O
is	O
also	O
formed	O
as	O
the	O
base	O
peak	O
ion	O
in	O
the	O
fragmentation	O
pathways	O
of	O
corresponding	O
methoxylated	O
PCB	O
11	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
other	O
2	O
-	O
methoxy	O
PCB	O
derivatives	O
also	O
form	O
a	O
stable	O
dibenzofuran	O
cation	O
after	O
losing	O
chlorine	O
atom	O
and	O
methyl	O
group	O
[	O
19	O
]	O
.	O

Scheme	O
2	O

Principal	O
EI	O
-	O
MS	O
fragmentation	O
pathways	O
of	O
sulfuric	O
acid	O
4	O
'	O
-	O
dichlorobiphenyl	O
-	O
2	O
-	O
yl	O
ester	O
2	O
,	O
2	O
,	O
2	O
-	O
trichloroethyl	O
ester	O
2	O
.	O

The	O
relative	O
abundance	O
of	O
several	O
fragment	O
ions	O
depends	O
on	O
the	O
position	O
of	O
the	O
-	O
OSO3	O
-	O
TCE	O
group	O
and	O
the	O
chlorine	O
substitution	O
pattern	O
.	O

The	O
relative	O
abundance	O
of	O
the	O
[	O
M	O
-	O
HCl2	O
]	O
+	O
and	O
[	O
M	O
-	O
CCl3	O
]	O
+	O
fragment	O
ions	O
of	O
compound	O
2	O
,	O
9	O
and	O
10	O
are	O
lower	O
compared	O
to	O
all	O
other	O
TCE	O
PCB	O
sulfate	O
diesters	O
(	O
Table	O
1	O
)	O
.	O

This	O
lower	O
relative	O
abundance	O
is	O
due	O
to	O
steric	O
and	O
/	O
or	O
electronic	O
effects	O
resulting	O
from	O
the	O
ortho	O
phenyl	O
substituent	O
in	O
compound	O
2	O
or	O
the	O
two	O
ortho	O
chlorine	O
substituents	O
in	O
compounds	O
9	O
and	O
10	O
.	O

In	O
addition	O
,	O
the	O
relative	O
abundance	O
of	O
fragment	O
ion	O
[	O
ArOSO3H	O
]	O
+	O
of	O
the	O
TCE	O
PCB	O
sulfate	O
diesters	O
9	O
and	O
10	O
is	O
low	O
compared	O
to	O
the	O
corresponding	O
fragment	O
ion	O
of	O
the	O
other	O
TCE	O
PCB	O
sulfate	O
diesters	O
,	O
with	O
only	O
a	O
trace	O
of	O
the	O
respective	O
ions	O
being	O
observed	O
(	O
Table	O
1	O
)	O
.	O

For	O
example	O
,	O
the	O
relative	O
abundance	O
of	O
[	O
ArOSO3H	O
]	O
+	O
5d	O
is	O
20	O
%	O
,	O
whereas	O
the	O
abundance	O
of	O
the	O
corresponding	O
fragment	O
ions	O
of	O
compounds	O
9	O
and	O
10	O
is	O
<	O
<	O
1	O
%	O
.	O

Since	O
compounds	O
9	O
and	O
10	O
have	O
two	O
chlorine	O
substituents	O
in	O
the	O
phenyl	O
ring	O
with	O
the	O
-	O
OSO3TCE	O
group	O
,	O
the	O
low	O
relative	O
abundance	O
of	O
fragment	O
ion	O
[	O
ArOSO3H	O
]	O
+	O
suggests	O
that	O
the	O
sulfate	O
group	O
of	O
both	O
compounds	O
is	O
less	O
stable	O
,	O
possibly	O
because	O
of	O
the	O
comparatively	O
high	O
pKa	O
value	O
of	O
the	O
Ar	O
-	O
OH	O
group	O
[	O
20	O
]	O
.	O

This	O
observation	O
is	O
in	O
agreement	O
with	O
the	O
decreasing	O
chemical	O
stability	O
of	O
aryl	O
sulfate	O
monoesters	O
with	O
increasing	O
acidity	O
of	O
the	O
phenolic	O
aryl	O
group	O
[	O
21	O
]	O
.	O

Authors	O
'	O
contributions	O

CM	O
,	O
JRH	O
,	O
HJP	O
,	O
and	O
JH	O
carried	O
animal	O
studies	O
.	O

CM	O
performed	O
the	O
statistical	O
analysis	O
.	O

JLK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Disk	O
preparation	O
phase	O

o	O
Adoption	O
of	O
a	O
two	O
-	O
stage	O
sampling	O
scheme	O
.	O

o	O
Careful	O
planning	O
and	O
choice	O
of	O
representative	O
sampling	O
groups	O
and	O
sites	O
according	O
to	O
the	O
adopted	O
network	O
sampling	O
technique	O
,	O
and	O
determining	O
certain	O
criteria	O
such	O
as	O
control	O
sites	O
where	O
major	O
sampling	O
groups	O
exist	O
(	O
i	O
.	O
e	O
.	O
surface	O
water	O
points	O
,	O
valleys	O
,	O
and	O
wells	O
)	O
,	O
impact	O
sites	O
where	O
contamination	O
is	O
expected	O
,	O
such	O
as	O
polygons	O
,	O
and	O
outlets	O
(	O
e	O
.	O
g	O
.	O
treated	O
water	O
discharges	O
site	O
)	O
to	O
maximise	O
understanding	O
the	O
quality	O
of	O
urban	O
water	O
sources	O
,	O
and	O
with	O
the	O
least	O
risk	O
of	O
missing	O
the	O
correct	O
representative	O
sampling	O
groups	O
and	O
sites	O
.	O

o	O
Attention	O
paid	O
to	O
ensure	O
inclusion	O
in	O
the	O
sampling	O
frame	O
of	O
all	O
groups	O
and	O
locations	O
(	O
sites	O
,	O
roads	O
,	O
venues	O
,	O
and	O
so	O
on	O
)	O
via	O
screening	O
,	O
browsing	O
,	O
and	O
delineation	O
from	O
a	O
satellite	O
digital	O
map	O
of	O
the	O
Khamis	O
Mushait	O
Governorate	O
zone	O
,	O
because	O
local	O
pre	O
-	O
knowledge	O
was	O
preferred	O
with	O
regard	O
to	O
accessibility	O
,	O
safety	O
,	O
and	O
permission	O
.	O

o	O
Approximation	O
of	O
the	O
number	O
of	O
the	O
target	O
study	O
population	O
in	O
each	O
group	O
and	O
sampling	O
location	O
.	O

o	O
Determination	O
of	O
the	O
proportional	O
allocation	O
of	O
samples	O
between	O
different	O
groups	O
and	O
locations	O
.	O

o	O
Training	O
of	O
interviewers	O
\	O
sample	O
collectors	O
to	O
follow	O
and	O
to	O
use	O
the	O
sampling	O
strategy	O
and	O
procedures	O
.	O

o	O
Implementation	O
of	O
ways	O
to	O
boost	O
participation	O
rates	O
in	O
the	O
screening	O
and	O
core	O
interviews	O
and	O
sample	O
collection	O
.	O

o	O
Planning	O
of	O
logistic	O
needs	O
of	O
timing	O
,	O
gathering	O
,	O
handling	O
samples	O
,	O
and	O
laboratory	O
.	O

o	O
Producing	O
sampling	O
cards	O
to	O
be	O
completed	O
to	O
record	O
observations	O
at	O
scene	O
(	O
sample	O
ID	O
and	O
data	O
/	O
information	O
:	O
date	O
,	O
time	O
,	O
temperature	O
,	O
group	O
,	O
locality	O
,	O
problems	O
in	O
the	O
area	O
,	O
sketch	O
map	O
)	O
.	O

o	O
Selection	O
of	O
an	O
appropriate	O
major	O
sampling	O
method	O
[	O
52	O
]	O
(	O
i	O
.	O
e	O
.	O
simple	O
random	O
sample	O
;	O
network	O
sampling	O
)	O
.	O

o	O
Planning	O
of	O
pilot	O
visits	O
to	O
samples	O
of	O
each	O
group	O
in	O
the	O
field	O
to	O
review	O
strategy	O
.	O

Results	O

In	O
the	O
established	O
adult	O
rat	O
NSC	B-Cell
culture	E-Cell
,	O
FGF	O
-	O
2	O
promotes	O
self	O
-	O
renewal	O
by	O
increasing	O
proliferation	O
and	O
inhibiting	O
spontaneous	O
differentiation	O
of	O
adult	O
NSCs	S-Cell
,	O
accompanied	O
with	O
activation	O
of	O
MAPK	O
and	O
PLC	O
pathways	O
.	O

Using	O
a	O
molecular	O
genetic	O
approach	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
FGF	O
receptor	O
1	O
(	O
FGFR1	O
)	O
,	O
largely	O
through	O
two	O
key	O
cytoplasmic	S-Organism_substance
amino	O
acid	O
residues	O
that	O
are	O
linked	O
to	O
MAPK	O
and	O
PLC	O
activation	O
,	O
suffices	O
to	O
promote	O
adult	O
NSC	S-Cell
self	O
-	O
renewal	O
.	O

The	O
canonical	O
MAPK	O
,	O
Erk1	O
/	O
2	O
activation	O
,	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
the	O
NSC	S-Cell
expansion	O
and	O
anti	O
-	O
differentiation	O
effects	O
of	O
FGF	O
-	O
2	O
.	O

In	O
contrast	O
,	O
PLC	O
activation	O
is	O
integral	O
to	O
the	O
maintenance	O
of	O
adult	O
NSC	S-Cell
characteristics	O
,	O
including	O
the	O
full	O
capacity	O
for	O
neuronal	S-Cell
and	O
oligodendroglial	S-Cell
differentiation	O
.	O

Stochastic	O
models	O

Stochasticity	O
inevitably	O
emerges	O
when	O
molecular	O
components	O
are	O
present	O
at	O
low	O
cellular	S-Cell
concentrations	O
(	O
McAdams	O
&	O
Arkin	O
,	O
1997	O
;	O
Kierzek	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

This	O
physical	O
phenomenon	O
generates	O
noise	O
in	O
synthetic	O
and	O
natural	O
circuits	O
(	O
Paulsson	O
,	O
2004	O
;	O
Mettetal	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
and	O
its	O
consequences	O
over	O
the	O
phenotype	O
are	O
starting	O
to	O
be	O
explored	O
(	O
Suel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

For	O
example	O
,	O
noise	O
constitutes	O
the	O
driving	O
force	O
behind	O
differentiation	O
in	O
isogenetic	O
colonies	O
(	O
Colman	O
-	O
Lerner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Biological	O
and	O
theoretical	O
studies	O
have	O
aided	O
to	O
delineate	O
the	O
regulatory	O
mechanism	O
by	O
which	O
the	O
cell	S-Cell
handles	O
noise	O
efficiently	O
and	O
effectively	O
to	O
carry	O
out	O
its	O
biological	O
functions	O
(	O
Gardner	O
&	O
Collins	O
,	O
2000	O
;	O
Orrell	O
&	O
Bolouri	O
,	O
2004	O
;	O
Raser	O
&	O
O	O
'	O
Shea	O
,	O
2005	O
)	O
.	O

From	O
a	O
theoretical	O
point	O
of	O
view	O
,	O
stochastic	O
models	O
are	O
the	O
most	O
challenging	O
but	O
also	O
the	O
most	O
realistic	O
ones	O
:	O
there	O
is	O
a	O
precise	O
counting	O
of	O
how	O
,	O
through	O
individual	O
chemical	O
reactions	O
,	O
the	O
populations	O
of	O
every	O
chemical	O
species	O
change	O
.	O

The	O
milestone	O
to	O
simulate	O
stochastic	O
processes	O
is	O
the	O
Gillespie	O
algorithm	O
(	O
Gillespie	O
,	O
1992	O
)	O
.	O

Because	O
of	O
their	O
analytical	O
and	O
computational	O
complexity	O
,	O
the	O
present	O
models	O
do	O
not	O
surpass	O
a	O
handful	O
of	O
chemical	O
species	O
.	O

Two	O
immediate	O
problems	O
must	O
be	O
solved	O
to	O
model	O
systems	O
with	O
several	O
dozens	O
of	O
genetic	O
components	O
:	O
the	O
systematic	O
determination	O
of	O
kinetic	O
constants	O
and	O
the	O
efficient	O
computation	O
of	O
thousands	O
of	O
chemical	O
stochastic	O
equations	O
(	O
Kuwahara	O
et	O
al	O
.	O
,	O
2006	O
;	O
Sanchez	O
&	O
Kondev	O
,	O
2008	O
)	O
.	O

Model	O
of	O
how	O
estrogen	O
induces	O
DNA	O
damage	O
.	O

Estrogen	O
enters	O
the	O
cell	S-Cell
and	O
is	O
bound	O
by	O
the	O
ER	O
.	O

The	O
dimeric	O
ER	O
-	O
estrogen	O
complex	O
enters	O
the	O
nucleus	S-Cellular_component
and	O
induces	O
AID	O
expression	O
.	O

This	O
leads	O
to	O
an	O
increase	O
in	O
mutations	O
and	O
translocations	O
,	O
and	O
potentially	O
cancer	S-Cancer

8	O
.	O
2	O
.	O

Species	O
Differences	O
in	O
PPARalpha	O
-	O
Associated	O
Signaling	O

The	O
PPARalpha	O
isotype	O
has	O
prime	O
importance	O
for	O
studies	O
with	O
animal	O
models	O
to	O
predict	O
the	O
effects	O
of	O
hepatic	S-Organ
PPs	O
in	O
humans	O
,	O
because	O
PPARalpha	O
agonists	O
induce	O
seemingly	O
quite	O
different	O
actions	O
in	O
rodents	O
and	O
humans	O
[	O
53	O
]	O
.	O

Originally	O
,	O
as	O
the	O
name	O
indicates	O
,	O
PPARs	O
were	O
studied	O
because	O
of	O
their	O
ability	O
to	O
bind	O
PPs	O
and	O
consequently	O
induce	O
PP	O
-	O
metabolizing	O
enzymes	O
.	O

In	O
rats	O
and	O
mice	O
,	O
but	O
not	O
in	O
humans	O
,	O
PPs	O
such	O
as	O
hypolipidemic	O
drugs	O
,	O
industrial	O
plasticizers	O
,	O
and	O
herbicides	O
are	O
non	O
-	O
genotoxic	O
carcinogens	O
that	O
cause	O
liver	B-Cancer
tumors	E-Cancer
[	O
54	O
]	O
.	O

In	O
humans	O
,	O
these	O
drugs	O
function	O
to	O
maintain	O
lipid	O
homeostasis	O
and	O
do	O
not	O
induce	O
peroxisome	S-Cellular_component
proliferation	O
.	O

Thus	O
,	O
the	O
toxicity	O
and	O
carcinogenicity	O
of	O
PPs	O
are	O
highly	O
species	O
specific	O
[	O
55	O
]	O
.	O

The	O
species	O
differences	O
may	O
be	O
attributable	O
to	O
lower	O
PPAR	O
mRNA	O
expression	O
levels	O
in	O
h	B-Cell
-	I-Cell
hepatocytes	E-Cell
compared	O
with	O
rodent	O
cells	S-Cell
[	O
56	O
,	O
57	O
]	O
.	O

Alternatively	O
,	O
or	O
additionally	O
,	O
species	O
differences	O
may	O
be	O
the	O
result	O
of	O
different	O
sensitivities	O
of	O
the	O
genes	O
associated	O
with	O
the	O
peroxisome	S-Cellular_component
proliferation	O
response	O
to	O
low	O
levels	O
of	O
PPs	O
,	O
owing	O
to	O
structural	O
differences	O
in	O
PPARalpha	O
[	O
54	O
]	O
.	O

There	O
are	O
both	O
similarities	O
and	O
differences	O
in	O
responses	O
to	O
xenobiotics	O
among	O
not	O
only	O
different	O
species	O
(	O
interspecies	O
)	O
but	O
also	O
individuals	O
of	O
the	O
same	O
species	O
(	O
intraspecies	O
)	O
.	O

Interspecific	O
PPARalpha	O
diversity	O
between	O
rodents	O
and	O
humans	O
is	O
well	O
known	O
and	O
has	O
been	O
studied	O
with	O
respect	O
to	O
drug	O
metabolism	O
.	O

NR	O
subfamily	O
1	O
members	O
have	O
at	O
least	O
two	O
functions	O
in	O
mammals	O
.	O

One	O
is	O
to	O
regulate	O
peroxisome	S-Cellular_component
proliferation	O
through	O
binding	O
to	O
PPAR	O
response	O
elements	O
(	O
PPREs	O
)	O
in	O
the	O
promoters	O
of	O
genes	O
such	O
as	O
ACO	O
[	O
58	O
,	O
59	O
]	O
,	O
bifunctional	O
dehydrogenase	O
/	O
hydratase	O
(	O
BFE	O
)	O
[	O
60	O
]	O
,	O
and	O
microsomal	O
CYP4A1	O
[	O
61	O
]	O
.	O

The	O
other	O
is	O
to	O
modulate	O
the	O
serum	S-Organism_substance
cholesterol	O
level	O
by	O
targeting	O
genes	O
such	O
as	O
the	O
lipoprotein	O
lipase	O
gene	O
[	O
62	O
]	O
and	O
the	O
apolipoprotein	O
regulating	O
genes	O
AI	O
,	O
AII	O
,	O
and	O
CII	O
[	O
63	O
]	O
.	O

The	O
former	O
mechanism	O
appears	O
to	O
function	O
in	O
rodents	O
,	O
but	O
not	O
in	O
humans	O
,	O
and	O
is	O
responsible	O
for	O
the	O
induction	O
of	O
peroxisome	S-Cellular_component
proliferation	O
and	O
hepatocarcinogenesis	O
,	O
whereas	O
the	O
latter	O
mechanism	O
controls	O
basic	O
lipid	O
metabolism	O
in	O
both	O
rodents	O
and	O
humans	O
[	O
56	O
]	O
.	O

This	O
species	O
difference	O
in	O
xenobiotic	O
receptor	O
/	O
ligand	O
signaling	O
may	O
be	O
attributable	O
to	O
differences	O
in	O
the	O
expression	O
level	O
of	O
a	O
receptor	O
,	O
or	O
to	O
differences	O
in	O
receptor	O
/	O
ligand	O
binding	O
affinity	O
,	O
and	O
causes	O
difficulty	O
in	O
determining	O
responses	O
in	O
humans	O
based	O
on	O
rodent	O
data	O
[	O
56	O
]	O
.	O

Results	O
:	O

In	O
the	O
total	O
population	O
(	O
N	O
=	O
95	O
)	O
,	O
median	O
OS	O
was	O
significantly	O
longer	O
in	O
patients	O
with	O
baseline	O
CA	O
19	O
-	O
9	O
values	O
at	O
or	O
below	O
the	O
median	O
than	O
in	O
those	O
with	O
values	O
above	O
it	O
(	O
12	O
.	O
2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
5	O
.	O
0	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
9	O
-	O
5	O
.	O
7	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

This	O
also	O
reached	O
significance	O
in	O
the	O
Gem	O
+	O
A	O
arm	O
(	O
median	O
OS	O
,	O
12	O
.	O
5	O
months	O
[	O
95	O
%	O
CI	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
4	O
.	O
9	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
6	O
-	O
5	O
.	O
6	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Patients	O
with	O
any	O
dBP	O
>	O
90	O
mmHg	O
had	O
significantly	O
longer	O
OS	O
than	O
those	O
who	O
did	O
not	O
.	O

However	O
,	O
there	O
was	O
no	O
predictive	O
significance	O
of	O
CA	O
19	O
-	O
9	O
.	O

Reagents	O

CNQX	O
,	O
colchicine	O
,	O
forskolin	O
,	O
and	O
carbenoxolone	O
were	O
purchased	O
from	O
Sigma	O
.	O

DCG	O
-	O
IV	O
,	O
ZD7288	O
,	O
CGP55845	O
and	O
DPCPX	O
were	O
obtained	O
from	O
Tocris	O
Cookson	O
(	O
Ellisville	O
,	O
MO	O
)	O
.	O

Results	O

Contrary	O
to	O
previous	O
reports	O
that	O
PON1	O
activities	O
plateau	O
by	O
2	O
years	O
of	O
age	O
,	O
we	O
observed	O
an	O
age	O
-	O
dependent	O
increase	O
in	O
all	O
three	O
PON1	O
measures	O
from	O
birth	O
through	O
7	O
years	O
of	O
age	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
PON1192	O
genotype	O
significantly	O
modified	O
the	O
effect	O
of	O
age	O
on	O
paraoxonase	O
(	O
POase	O
)	O
activity	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
such	O
that	O
increases	O
in	O
enzyme	O
activity	O
with	O
age	O
were	O
influenced	O
by	O
the	O
number	O
of	O
R	O
alleles	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Children	O
with	O
the	O
PON1	O
-	O
108CC192RR	O
diplotype	O
had	O
significantly	O
higher	O
mean	O
PON1	O
activities	O
and	O
also	O
experienced	O
steeper	O
increases	O
of	O
POase	O
activity	O
over	O
time	O
compared	O
with	O
children	O
with	O
the	O
PON1	O
-	O
108TT192QQ	O
diplotype	O
.	O

Percentage	O
reported	O
purchasing	O
intentions	O
,	O
comparing	O
ITN	O
-	O
owning	O
to	O
non	O
-	O
owning	O
households	O

School	O
environment	O

At	O
the	O
majority	O
of	O
the	O
schools	O
a	O
soft	O
drink	O
vending	O
machine	O
(	O
91	O
%	O
,	O
n	O
=	O
446	O
)	O
and	O
/	O
or	O
a	O
vending	O
machine	O
containing	O
sweets	O
and	O
candy	O
bars	O
(	O
81	O
%	O
,	O
n	O
=	O
413	O
)	O
is	O
present	O
(	O
Table	O
2	O
)	O
.	O

At	O
78	O
%	O
(	O
n	O
=	O
393	O
)	O
of	O
the	O
schools	O
there	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
or	O
a	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
(	O
within	O
1	O
km	O
of	O
the	O
school	O
)	O
.	O

At	O
68	O
%	O
(	O
n	O
=	O
345	O
)	O
of	O
the	O
schools	O
there	O
are	O
facilities	O
at	O
or	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
,	O
for	O
example	O
a	O
soccer	O
field	O
or	O
a	O
basketball	O
field	O
.	O

Table	O
2	O

The	O
school	O
environment	O

Total	O
School	O
level	O

Vocational	O
education	O
schools	O
Mixed	O
schools	O
Higher	O
education	O
schools	O
Vocational	O
education	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O
Mixed	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O

n	O
=	O
515	O
n	O
=	O
216	O
n	O
=	O
232	O
n	O
=	O
67	O

%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O

Soft	O
drink	O
vending	O
machine	O
present	O
at	O
school	O
91	O
.	O
4	O
(	O
466	O
)	O
90	O
.	O
2	O
(	O
194	O
)	O
91	O
.	O
3	O
(	O
209	O
)	O
95	O
.	O
5	O
(	O
63	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
0	O
)	O

Percentage	O
of	O
soft	O
drink	O
vending	O
machines	O
present	O
at	O
school	O
that	O
contain	O
light	O
soft	O
drinks	O
79	O
.	O
8	O
(	O
372	O
)	O
75	O
.	O
4	O
(	O
147	O
)	O
82	O
.	O
2	O
(	O
171	O
)	O
85	O
.	O
7	O
(	O
54	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O

Soft	O
drink	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
drinks	O
than	O
healthy	O
drinks	O
57	O
.	O
9	O
(	O
268	O
)	O
61	O
.	O
9	O
(	O
120	O
)	O
58	O
.	O
5	O
(	O
121	O
)	O
43	O
.	O
6	O
(	O
27	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
*	O

Vending	O
machine	O
present	O
at	O
school	O
that	O
contains	O
sweets	O
/	O
candy	O
bars	O
80	O
.	O
7	O
(	O
413	O
)	O
75	O
.	O
6	O
(	O
161	O
)	O
84	O
.	O
9	O
(	O
197	O
)	O
82	O
.	O
1	O
(	O
55	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
2	O
)	O

Sweets	O
/	O
candy	O
bars	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
than	O
healthy	O
foods	O
63	O
.	O
7	O
(	O
260	O
)	O
70	O
.	O
6	O
(	O
113	O
)	O
64	O
.	O
4	O
(	O
125	O
)	O
40	O
.	O
7	O
(	O
22	O
)	O
1	O
.	O
7	O
(	O
1	O
.	O
2	O
;	O
2	O
.	O
4	O
)	O
*	O
1	O
.	O
6	O
(	O
1	O
.	O
1	O
;	O
2	O
.	O
3	O
)	O
*	O

There	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
,	O
or	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
of	O
the	O
school	O
78	O
.	O
3	O
(	O
393	O
)	O
76	O
.	O
7	O
(	O
161	O
)	O
79	O
.	O
7	O
(	O
181	O
)	O
78	O
.	O
5	O
(	O
51	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O

The	O
students	O
are	O
allowed	O
to	O
leave	O
the	O
school	O
property	O
during	O
school	O
hours	O
57	O
.	O
4	O
(	O
295	O
)	O
42	O
.	O
6	O
(	O
92	O
)	O
65	O
.	O
8	O
(	O
152	O
)	O
76	O
.	O
1	O
(	O
51	O
)	O
0	O
.	O
6	O
(	O
0	O
.	O
5	O
;	O
0	O
.	O
8	O
)	O
*	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O

There	O
are	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
68	O
.	O
1	O
(	O
345	O
)	O
63	O
.	O
1	O
(	O
135	O
)	O
70	O
.	O
3	O
(	O
161	O
)	O
76	O
.	O
6	O
(	O
49	O
)	O
0	O
.	O
8	O
(	O
0	O
.	O
7	O
;	O
1	O
.	O
0	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
1	O
)	O

#	O
Associations	O
are	O
adjusted	O
for	O
school	O
size	O

*	O
p	O
<	O
0	O
.	O
05	O

The	O
vocational	O
education	O
schools	O
did	O
not	O
differ	O
from	O
the	O
higher	O
education	O
schools	O
with	O
regard	O
to	O
the	O
presence	O
of	O
vending	O
machines	O
and	O
a	O
canteen	O
,	O
but	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
a	O
less	O
favourable	O
selection	O
of	O
foods	O
and	O
drinks	O
.	O

The	O
vocational	O
education	O
schools	O
indicated	O
more	O
often	O
that	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
more	O
unhealthy	O
foods	O
and	O
drinks	O
than	O
healthy	O
foods	O
and	O
drinks	O
.	O

Vocational	O
education	O
schools	O
had	O
fewer	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
to	O
be	O
physical	O
than	O
the	O
higher	O
education	O
schools	O
.	O

Most	O
associations	O
were	O
attenuated	O
after	O
adjustment	O
for	O
school	O
size	O
.	O

For	O
example	O
,	O
the	O
association	O
between	O
school	O
level	O
and	O
content	O
of	O
the	O
soft	O
drink	O
vending	O
machines	O
was	O
OR	O
=	O
1	O
.	O
42	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
05	O
-	O
1	O
.	O
93	O
in	O
the	O
crude	O
analysis	O
and	O
OR	O
=	O
1	O
.	O
35	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
99	O
-	O
1	O
.	O
85	O
in	O
the	O
adjusted	O
analysis	O
.	O

Behavior	O

Across	O
all	O
participants	O
,	O
50	O
%	O
+	O
/	O
-	O
13	O
of	O
studied	O
high	O
-	O
complexity	O
scene	O
were	O
later	O
recognized	O
as	O
"	O
old	O
"	O
(	O
hit	O
rate	O
)	O
,	O
and	O
52	O
%	O
+	O
/	O
-	O
18	O
of	O
studied	O
low	O
-	O
complexity	O
scenes	O
were	O
later	O
recognized	O
as	O
"	O
old	O
"	O
.	O

For	O
new	O
scenes	O
presented	O
at	O
test	O
(	O
foils	O
)	O
,	O
22	O
%	O
+	O
/	O
-	O
16	O
of	O
high	O
-	O
complexity	O
scenes	O
were	O
falsely	O
categorized	O
as	O
"	O
old	O
"	O
(	O
false	O
alarm	O
rate	O
)	O
,	O
and	O
22	O
%	O
+	O
/	O
-	O
14	O
of	O
low	O
-	O
complexity	O
scenes	O
were	O
falsely	O
categorized	O
as	O
"	O
old	O
"	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
hit	O
rate	O
(	O
hit	O
rate	O
-	O
false	O
alarm	O
rate	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
(	O
28	O
%	O
+	O
/	O
-	O
13	O
)	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
30	O
%	O
+	O
/	O
-	O
14	O
)	O
(	O
t	O
(	O
45	O
)	O
=	O
1	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
31	O
)	O
.	O

Critically	O
,	O
the	O
adjusted	O
hit	O
rate	O
increased	O
with	O
age	O
for	O
high	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
40	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
but	O
not	O
for	O
low	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
11	O
,	O
p	O
=	O
0	O
.	O
46	O
)	O
scenes	O
.	O

Thus	O
,	O
overall	O
participants	O
had	O
similar	O
memory	O
accuracy	O
for	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
but	O
memory	O
accuracy	O
improved	O
with	O
age	O
only	O
for	O
high	O
-	O
complexity	O
scenes	O
.	O

Participants	O
categorized	O
as	O
"	O
remembered	O
"	O
(	O
RHIT	O
)	O
,	O
28	O
%	O
+	O
/	O
-	O
12	O
of	O
the	O
studied	O
high	O
-	O
complexity	O
scenes	O
,	O
and	O
29	O
%	O
+	O
/	O
-	O
15	O
of	O
the	O
studied	O
low	O
-	O
complexity	O
scenes	O
.	O

Participants	O
had	O
similar	O
rates	O
of	O
falsely	O
categorizing	O
as	O
"	O
remembered	O
"	O
(	O
RFA	O
)	O
high	O
(	O
5	O
%	O
+	O
/	O
-	O
6	O
)	O
and	O
low	O
(	O
5	O
%	O
+	O
/	O
-	O
6	O
)	O
complexity	O
foils	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
R	O
rates	O
(	O
RHIT	O
-	O
RFA	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
t	O
(	O
45	O
)	O
=	O
1	O
.	O
41	O
,	O
p	O
=	O
0	O
.	O
17	O
)	O
.	O

Adjusted	O
R	O
rates	O
increased	O
with	O
age	O
for	O
high	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
but	O
not	O
for	O
low	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
16	O
,	O
p	O
=	O
0	O
.	O
30	O
)	O
,	O
scenes	O
(	O
Figures	O
1C	O
,	O
D	O
)	O
.	O

The	O
difference	O
between	O
the	O
adjusted	O
R	O
rates	O
of	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
increased	O
with	O
age	O
(	O
r	O
=	O
0	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
03	O
;	O
1	O
-	O
tailed	O
)	O
,	O
suggesting	O
that	O
the	O
age	O
-	O
related	O
improvements	O
in	O
memory	O
performance	O
were	O
more	O
robust	O
for	O
recollected	O
high	O
-	O
complexity	O
scenes	O
.	O

Thus	O
,	O
overall	O
,	O
participants	O
had	O
similar	O
memory	O
accuracy	O
for	O
recollected	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
but	O
accuracy	O
for	O
recollected	O
high	O
-	O
complexity	O
scenes	O
improved	O
with	O
age	O
,	O
whereas	O
accuracy	O
for	O
recollected	O
low	O
-	O
complexity	O
scenes	O
did	O
not	O
change	O
with	O
age	O
.	O

Participants	O
categorized	O
as	O
"	O
familiar	O
"	O
(	O
KHIT	O
)	O
,	O
22	O
%	O
+	O
/	O
-	O
9	O
of	O
studied	O
high	O
-	O
complexity	O
scenes	O
,	O
and	O
22	O
%	O
+	O
/	O
-	O
10	O
of	O
studied	O
low	O
-	O
complexity	O
scenes	O
.	O

Participants	O
falsely	O
categorized	O
as	O
"	O
familiar	O
"	O
(	O
KFA	O
)	O
17	O
%	O
+	O
/	O
-	O
11	O
of	O
high	O
-	O
complexity	O
,	O
and	O
17	O
%	O
+	O
/	O
-	O
12	O
of	O
low	O
-	O
complexity	O
foils	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
K	O
rates	O
(	O
KHIT	O
-	O
KFA	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
t	O
(	O
45	O
)	O
=	O
0	O
.	O
06	O
,	O
p	O
=	O
0	O
.	O
95	O
)	O
.	O

Adjusted	O
K	O
rates	O
did	O
not	O
change	O
with	O
age	O
for	O
either	O
high	O
-	O
complexity	O
or	O
low	O
-	O
complexity	O
scenes	O
(	O
|	O
r	O
|	O
s	O
<	O
0	O
.	O
09	O
,	O
ps	O
>	O
0	O
.	O
56	O
)	O
(	O
Figures	O
1C	O
,	O
D	O
)	O
.	O

During	O
the	O
encoding	O
task	O
,	O
participants	O
were	O
overall	O
faster	O
to	O
respond	O
to	O
low	O
-	O
complexity	O
scenes	O
(	O
1072	O
+	O
/	O
-	O
275	O
ms	O
)	O
than	O
to	O
high	O
-	O
complexity	O
scenes	O
(	O
1093	O
+	O
/	O
-	O
287	O
ms	O
)	O
(	O
t	O
(	O
45	O
)	O
=	O
2	O
.	O
31	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Response	O
times	O
decreased	O
with	O
age	O
for	O
low	O
-	O
(	O
r	O
=	O
-	O
0	O
.	O
37	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
high	O
-	O
(	O
r	O
=	O
-	O
0	O
.	O
33	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
complexity	O
scenes	O
.	O

The	O
difference	O
between	O
the	O
response	O
times	O
for	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
however	O
,	O
did	O
not	O
change	O
with	O
age	O
(	O
r	O
=	O
0	O
.	O
14	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
.	O

Response	O
times	O
decreased	O
with	O
age	O
for	O
R	O
,	O
K	O
and	O
F	O
trial	O
types	O
for	O
both	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
(	O
-	O
0	O
.	O
36	O
<	O
r	O
<	O
-	O
0	O
.	O
30	O
,	O
ps	O
<	O
0	O
.	O
04	O
)	O
.	O

The	O
difference	O
between	O
response	O
times	O
for	O
R	O
and	O
F	O
trial	O
types	O
,	O
however	O
,	O
did	O
not	O
change	O
with	O
age	O
for	O
either	O
high	O
(	O
r	O
=	O
0	O
.	O
12	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
or	O
low	O
complexity	O
scenes	O
(	O
r	O
=	O
0	O
.	O
08	O
,	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O

NSPCs	S-Cell
protect	O
against	O
30	O
minute	O
MCAO	O
.	O

(	O
A	O
-	O
D	O
)	O
Coronal	B-Multi-tissue_structure
histological	I-Multi-tissue_structure
sections	E-Multi-tissue_structure
through	O
the	O
ischemic	O
striatum	S-Multi-tissue_structure
3	O
days	O
following	O
MCAO	O
,	O
stained	O
for	O
TUNEL	O
(	O
A	O
,	O
B	O
)	O
or	O
NeuN	O
(	O
C	O
,	O
D	O
)	O
.	O

Mice	O
received	O
intrastriatal	S-Immaterial_anatomical_entity
injections	O
of	O
exogenous	O
PBS	O
(	O
A	O
,	O
C	O
)	O
or	O
EGFP	O
+	O
NSPCs	O
(	O
B	O
,	O
D	O
,	O
E	O
)	O
72	O
hr	O
prior	O
to	O
MCAO	O
.	O

Inset	O
in	O
(	O
B	O
)	O
shows	O
40x	O
magnified	O
view	O
of	O
the	O
injection	O
site	S-Multi-tissue_structure
.	O

(	O
E	O
)	O
Monochrome	O
conversion	O
of	O
image	O
shown	O
in	O
B	O
to	O
demonstrate	O
concentric	O
ring	O
structures	O
used	O
for	O
Sholl	O
analysis	O
.	O

(	O
F	O
)	O
Quantification	O
of	O
TUNEL	O
+	O
cells	S-Cell
using	O
Sholl	O
analysis	O
performed	O
on	O
fluorescent	O
images	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
mice	O
per	O
group	O
.	O

Scale	O
bar	O
:	O
A	O
,	O
B	O
=	O
20	O
microm	O
;	O
C	O
,	O
D	O
=	O
10	O
microm	O
.	O

Background	O

Over	O
the	O
past	O
decades	O
,	O
extensive	O
comparative	O
mapping	O
research	O
has	O
been	O
performed	O
in	O
the	O
plant	O
family	O
Solanaceae	O
.	O

The	O
recent	O
identification	O
of	O
a	O
large	O
set	O
of	O
single	O
-	O
copy	O
conserved	O
orthologous	O
(	O
COSII	O
)	O
markers	O
has	O
greatly	O
accelerated	O
comparative	O
mapping	O
studies	O
among	O
major	O
solanaceous	O
species	O
including	O
tomato	O
,	O
potato	O
,	O
eggplant	O
,	O
pepper	O
and	O
diploid	O
Nicotiana	O
species	O
(	O
as	O
well	O
as	O
tetraploid	O
tobacco	O
)	O
.	O

The	O
large	O
amount	O
of	O
comparative	O
data	O
now	O
available	O
for	O
these	O
species	O
provides	O
the	O
opportunity	O
to	O
describe	O
the	O
overall	O
patterns	O
of	O
chromosomal	S-Cellular_component
evolution	O
in	O
this	O
important	O
plant	O
family	O
.	O

The	O
results	O
of	O
this	O
investigation	O
are	O
described	O
herein	O
.	O

Introduction	O

Tea	O
(	O
Camellia	O
sinensis	O
L	O
.	O
)	O
is	O
one	O
of	O
the	O
most	O
widely	O
consumed	O
beverages	O
in	O
the	O
world	O
.	O

(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
EGCG	O
)	O
,	O
which	O
is	O
the	O
major	O
green	O
tea	O
catechin	O
present	O
in	O
the	O
leaves	S-Organ
,	O
is	O
believed	O
to	O
the	O
compound	O
most	O
responsible	O
for	O
the	O
health	O
benefits	O
attributed	O
to	O
tea	O
.	O

EGCG	O
was	O
reported	O
to	O
have	O
antioxidative	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
antimutagenic	O
[	O
3	O
]	O
,	O
anti	O
-	O
inflammatory	O
[	O
4	O
]	O
,	O
and	O
anticarcinogenic	O
activities	O
[	O
5	O
]	O
.	O

Although	O
the	O
EGCG	O
concentrations	O
required	O
to	O
elicit	O
the	O
anticancer	S-Cancer
activity	O
have	O
been	O
shown	O
to	O
be	O
more	O
than	O
1	O
microM	O
,	O
the	O
blood	S-Organism_substance
level	O
of	O
EGCG	O
after	O
consuming	O
the	O
equivalent	O
of	O
2	O
-	O
3	O
cups	O
of	O
green	O
tea	O
was	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
microM	O
and	O
for	O
an	O
equivalent	O
of	O
7	O
-	O
9	O
cups	O
was	O
still	O
lower	O
than	O
1	O
microM	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

In	O
a	O
cohort	O
study	O
,	O
daily	O
consumption	O
of	O
ten	O
cups	O
of	O
green	O
tea	O
was	O
required	O
for	O
the	O
cancer	S-Cancer
preventive	O
effect	O
[	O
8	O
]	O
.	O

Moreover	O
,	O
adverse	O
effects	O
of	O
green	O
tea	O
,	O
mainly	O
hepatitis	O
,	O
by	O
consumption	O
of	O
high	O
doses	O
of	O
green	O
tea	O
have	O
been	O
reported	O
[	O
9	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
enhance	O
the	O
pharmacologic	O
effect	O
of	O
EGCG	O
to	O
obtain	O
the	O
health	O
benefit	O
in	O
reasonable	O
concentration	O
in	O
daily	O
life	O
.	O

We	O
have	O
reported	O
that	O
the	O
cell	B-Cellular_component
-	I-Cellular_component
surface	E-Cellular_component
binding	O
of	O
EGCG	O
and	O
its	O
derivatives	O
is	O
involved	O
in	O
their	O
biological	O
activities	O
[	O
10	O
]	O
-	O
[	O
15	O
]	O
.	O

We	O
have	O
identified	O
the	O
67	O
-	O
kDa	O
laminin	O
receptor	O
(	O
67LR	O
)	O
as	O
a	O
cell	B-Cellular_component
surface	E-Cellular_component
receptor	O
for	O
EGCG	O
that	O
mediates	O
the	O
anticancer	O
activity	O
of	O
EGCG	O
[	O
16	O
]	O
.	O

67LR	O
has	O
been	O
shown	O
to	O
be	O
overexpressed	O
on	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
of	O
various	O
tumor	B-Cell
cells	E-Cell
[	O
17	O
]	O
.	O

It	O
was	O
postulated	O
that	O
67LR	O
plays	O
a	O
significant	O
role	O
in	O
the	O
tumor	S-Cancer
progression	O
and	O
speculated	O
that	O
studies	O
conducted	O
to	O
define	O
the	O
function	O
of	O
67LR	O
could	O
provide	O
a	O
new	O
approach	O
to	O
cancer	S-Cancer
prevention	O
.	O

Indeed	O
,	O
expression	O
of	O
67	O
LR	O
confers	O
EGCG	O
responsiveness	O
to	O
tumor	B-Cell
cells	E-Cell
in	O
vivo	O
[	O
18	O
]	O
.	O

Vitamin	O
A	O
,	O
also	O
known	O
as	O
retinol	O
,	O
participates	O
in	O
physiological	O
activities	O
related	O
to	O
the	O
immune	B-Anatomical_system
system	E-Anatomical_system
,	O
maintenance	O
of	O
epithelial	S-Tissue
and	O
mucosa	B-Tissue
tissues	E-Tissue
,	O
growth	O
,	O
reproduction	O
,	O
and	O
bone	S-Organ
development	O
.	O

It	O
comes	O
from	O
animal	O
sources	O
,	O
such	O
as	O
eggs	S-Developing_anatomical_structure
,	O
meat	S-Organism_subdivision
,	O
milk	S-Organism_substance
,	O
cheese	O
,	O
cream	O
,	O
liver	S-Organ
,	O
kidney	S-Organ
,	O
cod	O
and	O
halibut	O
fish	O
oil	S-Organism_substance
.	O

In	O
vitro	O
and	O
in	O
animal	O
models	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
vitamin	O
A	O
is	O
involved	O
in	O
the	O
regulation	O
and	O
promotion	O
of	O
growth	O
and	O
differentiation	O
of	O
many	O
cells	S-Cell
[	O
19	O
]	O
.	O

The	O
visual	O
function	O
of	O
vitamin	O
A	O
depends	O
on	O
its	O
natural	O
and	O
synthetic	O
derivatives	O
,	O
retinoids	O
[	O
20	O
]	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
the	O
active	O
derivative	O
of	O
vitamin	O
A	O
,	O
has	O
been	O
well	O
documented	O
as	O
a	O
growth	O
and	O
differentiation	O
factor	O
in	O
many	O
tissues	S-Tissue
and	O
cells	S-Cell
,	O
and	O
proved	O
to	O
be	O
an	O
effective	O
treatment	O
to	O
many	O
diseases	O
including	O
cancers	S-Cancer
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

Retinoids	O
exert	O
their	O
physiological	O
activities	O
through	O
retinoid	O
receptor	O
nuclear	S-Cellular_component
proteins	O
that	O
belong	O
to	O
the	O
superfamily	O
of	O
steroid	O
/	O
thyroid	O
hormone	O
receptors	O
,	O
of	O
which	O
there	O
are	O
two	O
classes	O
,	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
and	O
the	O
retinoic	O
-	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
each	O
of	O
which	O
has	O
three	O
subtypes	O
,	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
natural	O
ligands	O
for	O
the	O
RARs	O
are	O
ATRA	O
and	O
its	O
stereoisomers	O
9	O
-	O
cis	O
-	O
RA	O
and	O
13	O
-	O
cis	O
-	O
RA	O
,	O
whereas	O
RXRs	O
are	O
activated	O
by	O
9	O
-	O
cis	O
-	O
RA	O
only	O
.	O

ATRA	O
acts	O
through	O
RAR	O
to	O
transcriptionally	O
activate	O
target	O
genes	O
,	O
such	O
as	O
cytochrome	O
P450	O
and	O
CRABI	O
[	O
24	O
]	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
a	O
food	O
component	O
that	O
could	O
be	O
effectively	O
used	O
in	O
combination	O
with	O
EGCG	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
action	O
of	O
this	O
combination	O
.	O

By	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
involving	O
a	O
highly	O
metastatic	O
mouse	O
B16	B-Cell
melanoma	I-Cell
cell	I-Cell
line	E-Cell
[	O
25	O
]	O
,	O
we	O
found	O
that	O
ATRA	O
enhances	O
the	O
antitumor	S-Cancer
activity	O
of	O
EGCG	O
by	O
upregulating	O
the	O
67	O
LR	O
expression	O
through	O
RAR	O
.	O

Titration	O
of	O
Ab	O
-	O
01	O
inhibition	O
of	O
ex	O
vivo	O
response	O
to	O
rhIL21	O

Samples	S-Organism_substance
from	O
4	O
individual	O
healthy	O
human	O
donors	O
were	O
pre	O
-	O
incubated	O
for	O
2	O
hours	O
at	O
the	O
indicated	O
concentration	O
of	O
Ab	O
-	O
01	O
or	O
the	O
control	O
IgG1TM	O
prior	O
to	O
addition	O
of	O
10	O
ng	O
/	O
mL	O
rhIL21	O
and	O
2	O
hr	O
incubation	O
,	O
and	O
the	O
effect	O
on	O
the	O
6	O
biomarkers	O
was	O
then	O
assessed	O
(	O
Figures	O
4	O
and	O
5	O
)	O
.	O

For	O
the	O
first	O
2	O
donors	O
tested	O
,	O
even	O
the	O
lowest	O
concentration	O
of	O
Ab	O
-	O
01	O
(	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
66	O
nM	O
)	O
resulted	O
in	O
complete	O
inhibition	O
of	O
the	O
rhIL21	O
response	O
,	O
therefore	O
the	O
two	O
subsequent	O
donors	O
were	O
tested	O
at	O
increasing	O
concentrations	O
of	O
Ab	O
-	O
01	O
starting	O
at	O
0	O
.	O
003	O
mug	O
/	O
mL	O
.	O

Ab	O
-	O
01	O
inhibited	O
the	O
response	O
of	O
all	O
6	O
genes	O
in	O
all	O
4	O
donors	O
.	O

IC50	O
values	O
ranged	O
between	O
0	O
.	O
003	O
and	O
0	O
.	O
015	O
mug	O
/	O
mL	O
Ab	O
-	O
01	O
(	O
Figure	O
5	O
)	O
.	O

Control	O
IgG1TM	O
had	O
no	O
significant	O
effect	O
on	O
rhIL21	O
response	O
(	O
Figure4B	O
)	O
.	O

Figure	O
4	O

Average	O
percent	O
inhibition	O
of	O
the	O
expression	O
level	O
of	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O

Percent	O
inhibition	O
values	O
were	O
calculated	O
based	O
on	O
RQ	O
(	O
relative	O
quantification	O
)	O
values	O
of	O
untreated	O
control	O
and	O
rhIL21	O
-	O
treated	O
samples	S-Organism_substance
for	O
each	O
of	O
the	O
4	O
donors	O
,	O
and	O
subsequently	O
the	O
mean	O
and	O
standard	O
deviation	O
were	O
determined	O
for	O
each	O
gene	O
shown	O
.	O

A	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
Ab	O
-	O
01	O
.	O

B	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
control	O
IgG1TM	O
.	O

Data	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O

Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
.	O

Figure	O
5	O

Inhibition	O
by	O
Ab	O
-	O
01	O
at	O
the	O
indicated	O
concentration	O
is	O
shown	O
for	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O

IC50	O
values	O
of	O
inhibition	O
curves	O
shown	O
in	O
Figure	O
4A	O
were	O
calculated	O
using	O
curve	O
fit	O
(	O
XLfit	O
)	O
program	O
for	O
each	O
of	O
the	O
referred	O
biomarker	O
genes	O
.	O

Values	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O

Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
each	O
.	O

The	O
effect	O
of	O
PCL	S-Multi-tissue_structure
elevation	O

Our	O
hypothesis	O
that	O
the	O
dynamics	O
of	O
the	O
flexion	O
gap	O
depend	O
on	O
the	O
orientation	O
of	O
the	O
PCL	S-Multi-tissue_structure
was	O
confirmed	O
.	O

Distraction	O
of	O
the	O
knee	S-Organism_subdivision
with	O
a	O
low	O
PCL	S-Multi-tissue_structure
elevation	O
angle	O
(	O
i	O
.	O
e	O
.	O
a	O
flat	O
PCL	S-Multi-tissue_structure
)	O
resulted	O
in	O
greater	O
increase	O
in	O
gap	O
height	O
than	O
distraction	O
of	O
a	O
knee	S-Organism_subdivision
with	O
a	O
steep	O
PCL	S-Multi-tissue_structure
.	O

This	O
result	O
was	O
to	O
be	O
expected	O
;	O
when	O
the	O
gap	O
between	O
the	O
tibia	S-Organ
and	O
femur	S-Organ
was	O
increased	O
,	O
the	O
increase	O
in	O
PCL	S-Multi-tissue_structure
tension	O
resulted	O
in	O
the	O
tibia	S-Organ
pivoting	O
around	O
the	O
femoral	S-Organ
insertion	O
of	O
the	O
PCL	S-Multi-tissue_structure
.	O

Thus	O
,	O
the	O
greatest	O
increase	O
in	O
gap	O
height	O
will	O
occur	O
when	O
the	O
PCL	S-Multi-tissue_structure
is	O
flat	O
.	O

Taking	O
this	O
finding	O
into	O
consideration	O
,	O
the	O
surgeon	O
should	O
be	O
aware	O
of	O
the	O
strong	O
effect	O
of	O
PCL	S-Multi-tissue_structure
elevation	O
on	O
the	O
relationship	O
between	O
gap	O
height	O
increase	O
and	O
tibial	S-Organ
translation	O
.	O

A	O
flat	O
PCL	S-Multi-tissue_structure
will	O
lead	O
to	O
a	O
mean	O
anterior	B-Multi-tissue_structure
tibial	E-Multi-tissue_structure
translation	O
of	O
1	O
.	O
7	O
mm	O
when	O
the	O
gap	O
is	O
distracted	O
1	O
mm	O
.	O

A	O
knee	S-Organism_subdivision
with	O
a	O
steep	O
PCL	S-Multi-tissue_structure
will	O
even	O
translate	O
2	O
.	O
3	O
mm	O
on	O
average	O
with	O
1	O
mm	O
of	O
gap	O
distraction	O
.	O

If	O
the	O
PCL	S-Multi-tissue_structure
were	O
the	O
only	O
structure	O
that	O
was	O
tensioned	O
with	O
distraction	O
of	O
the	O
flexion	O
gap	O
,	O
then	O
at	O
100	O
N	O
it	O
would	O
be	O
oriented	O
vertically	O
.	O

This	O
is	O
not	O
the	O
case	O
,	O
and	O
therefore	O
other	O
structures	S-Multi-tissue_structure
such	O
as	O
the	O
collateral	B-Multi-tissue_structure
ligaments	E-Multi-tissue_structure
must	O
have	O
restrained	O
the	O
translation	O
.	O

From	O
an	O
anatomical	O
point	O
of	O
view	O
,	O
the	O
collateral	B-Multi-tissue_structure
structures	E-Multi-tissue_structure
are	O
the	O
only	O
structures	S-Multi-tissue_structure
that	O
could	O
have	O
had	O
a	O
restraining	O
function	O
on	O
vertical	O
movements	O
.	O

For	O
obvious	O
reasons	O
,	O
in	O
this	O
in	O
vivo	O
study	O
we	O
could	O
not	O
test	O
what	O
would	O
have	O
happened	O
to	O
the	O
orientation	O
of	O
the	O
PCL	S-Multi-tissue_structure
when	O
the	O
collateral	B-Multi-tissue_structure
structures	E-Multi-tissue_structure
were	O
resected	O
.	O

In	O
addition	O
,	O
the	O
PCL	S-Multi-tissue_structure
elevation	O
angle	O
at	O
100	O
N	O
influenced	O
the	O
increase	O
in	O
PCL	S-Multi-tissue_structure
elevation	O
angle	O
between	O
100	O
N	O
and	O
200	O
N	O
(	O
DeltaPCLe	O
)	O
.	O

This	O
seems	O
logical	O
:	O
a	O
flat	O
PCL	S-Multi-tissue_structure
can	O
be	O
recruited	O
more	O
easily	O
whereas	O
knees	S-Organism_subdivision
with	O
a	O
steep	O
PCL	S-Multi-tissue_structure
might	O
already	O
be	O
tensioned	O
at	O
100	O
N	O
so	O
that	O
a	O
further	O
increase	O
in	O
PCL	S-Multi-tissue_structure
elevation	O
angle	O
would	O
be	O
hard	O
to	O
achieve	O
.	O

However	O
,	O
steep	O
PCLs	S-Multi-tissue_structure
are	O
not	O
necessarily	O
recruited	O
more	O
than	O
flat	O
PCLs	S-Multi-tissue_structure
.	O

Furthermore	O
,	O
the	O
situation	O
during	O
implantation	O
of	O
a	O
TKR	O
is	O
quite	O
unnatural	O
:	O
we	O
investigated	O
the	O
PCL	S-Multi-tissue_structure
elevation	O
after	O
the	O
tibia	S-Organ
was	O
cut	O
.	O

Differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O

Integrating	O
4849	O
CMap	O
arrays	O
with	O
40	O
,	O
656	O
drug	O
target	O
relations	O
from	O
STITCH	O
resulted	O
in	O
a	O
set	O
of	O
1	O
,	O
290	O
drug	O
-	O
target	O
relations	O
for	O
which	O
a	O
genome	O
-	O
wide	O
cellular	S-Cell
response	O
is	O
available	O
.	O

We	O
found	O
that	O
thirteen	O
out	O
of	O
167	O
distinct	O
drug	O
targets	O
in	O
this	O
set	O
(	O
8	O
%	O
;	O
86	O
drug	O
target	O
relations	O
)	O
are	O
subjected	O
to	O
significant	O
differential	O
expression	O
upon	O
drug	O
treatment	O
(	O
Figure	O
3	O
)	O
by	O
comparing	O
the	O
drug	O
-	O
induced	O
expression	O
changes	O
of	O
the	O
drug	O
target	O
against	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
(	O
see	O
methods	O
)	O
.	O

We	O
found	O
supporting	O
evidence	O
in	O
the	O
literature	O
for	O
seven	O
out	O
of	O
thirteen	O
(	O
q	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
significant	O
differential	O
regulations	O
of	O
drug	O
targets	O
shown	O
in	O
Figure	O
3	O
,	O
confirming	O
the	O
rationale	O
and	O
predictive	O
power	O
of	O
our	O
systematic	O
approach	O
.	O

For	O
the	O
remaining	O
six	O
targets	O
we	O
can	O
predict	O
a	O
hitherto	O
unknown	O
drug	O
-	O
induced	O
differential	O
regulation	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pcbi	O
.	O
1000925	O
.	O
g003	O
Figure	O
3	O

Drug	O
-	O
induced	O
differentially	O
regulated	O
drug	O
targets	O
.	O

Anova	O
is	O
used	O
to	O
assess	O
the	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O
against	O
the	O
mRNA	O
changes	O
of	O
the	O
same	O
gene	O
in	O
the	O
population	O
of	O
heterogeneous	O
drug	O
treatments	O
from	O
CMap	O
.	O

The	O
genes	O
are	O
mainly	O
ordered	O
based	O
on	O
their	O
q	O
-	O
values	O
as	O
provided	O
in	O
Table	O
S1	O
.	O

In	O
the	O
scatter	O
plots	O
,	O
inhibitors	O
/	O
activators	O
are	O
labeled	O
in	O
red	O
/	O
green	O
respectively	O
and	O
grey	O
represents	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
.	O

The	O
identified	O
,	O
differentially	O
regulated	O
drug	O
targets	O
are	O
enriched	O
in	O
G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
(	O
Figure	O
S4	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
reports	O
that	O
members	O
of	O
the	O
GPCR	O
family	O
are	O
generally	O
regulated	O
by	O
several	O
mechanisms	O
including	O
receptor	O
desensitization	O
,	O
endocytosis	O
at	O
the	O
protein	O
level	O
and	O
regulation	O
of	O
the	O
cellular	S-Cell
receptor	O
content	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
the	O
three	O
cancer	B-Cell
cell	I-Cell
lines	E-Cell
used	O
,	O
we	O
observe	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
GPCR	O
mRNAs	O
for	O
beta	O
-	O
2	O
adrenergic	O
receptor	O
(	O
ADRB2	O
)	O
,	O
prostaglandin	O
E2	O
receptor	O
subtype	O
EP2	O
and	O
prostaglandin	O
E4	O
receptor	O
subtype	O
EP4	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
4	O
,	O
12	O
)	O
,	O
which	O
were	O
previously	O
reported	O
in	O
DDT1	B-Cell
MF	I-Cell
-	I-Cell
2	I-Cell
smooth	I-Cell
muscle	I-Cell
cells	E-Cell
(	O
ADRB2	O
)	O
and	O
293	B-Cell
-	I-Cell
EBNA	I-Cell
human	I-Cell
embryonic	I-Cell
kidney	I-Cell
cells	E-Cell
(	O
prostaglandin	O
E2	O
/	O
E4	O
receptor	O
subtypes	O
EP2	O
/	O
EP4	O
)	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

This	O
indicates	O
that	O
drugs	O
can	O
induce	O
similar	O
feedback	O
loops	O
in	O
a	O
wide	O
variety	O
of	O
cell	S-Cell
types	O
.	O

However	O
,	O
we	O
cannot	O
rule	O
out	O
that	O
cross	O
-	O
regulation	O
among	O
signaling	O
pathways	O
may	O
be	O
responsible	O
for	O
the	O
regulation	O
of	O
GPCR	O
mRNAs	O
as	O
it	O
has	O
been	O
described	O
before	O
[	O
22	O
]	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
a	O
beta	O
adrenergic	O
mRNA	O
-	O
binding	O
protein	O
,	O
ELAV	O
-	O
like	O
protein	O
1	O
(	O
ELAVL1	O
)	O
can	O
be	O
induced	O
by	O
ADRB2	O
agonist	O
or	O
elevated	O
levels	O
of	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
and	O
destabilizes	O
ADRB2	O
mRNA	O
.	O

The	O
ELAVL1	O
protein	O
binds	O
to	O
GPCR	O
mRNAs	O
and	O
recognizes	O
a	O
cognate	O
sequence	O
located	O
at	O
the	O
3	O
'	O
-	O
UTR	O
of	O
ADRB2	O
,	O
proteinase	O
-	O
activated	O
receptor	O
and	O
M2	O
,	O
M3	O
muscarinic	O
acetylcholine	O
receptor	O
mRNAs	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
.	O

Therefore	O
cAMP	O
provides	O
cross	O
-	O
talk	O
among	O
GPCR	O
regulatory	O
networks	O
.	O

However	O
,	O
it	O
is	O
shown	O
that	O
intracellular	S-Immaterial_anatomical_entity
cAMP	O
accumulation	O
is	O
not	O
the	O
only	O
factor	O
contributing	O
to	O
the	O
reduction	O
of	O
ADRB2	O
mRNA	O
levels	O
[	O
20	O
]	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
GPCR	O
-	O
targeting	O
drugs	O
regulate	O
the	O
transcription	O
of	O
their	O
specific	O
targets	O
(	O
Figure	O
S5	O
)	O
.	O

We	O
conclude	O
that	O
in	O
addition	O
to	O
the	O
cross	O
-	O
regulation	O
of	O
G	O
-	O
protein	O
signaling	O
pathways	O
drug	O
target	O
-	O
specific	O
feedback	O
loops	O
are	O
also	O
responsible	O
for	O
the	O
regulation	O
of	O
drug	O
target	O
mRNAs	O
.	O

In	O
addition	O
to	O
cross	O
-	O
regulation	O
of	O
multiple	O
drugs	O
through	O
the	O
same	O
signaling	O
pathways	O
,	O
promiscuous	O
drugs	O
targeting	O
multiple	O
proteins	O
may	O
cause	O
complex	O
regulatory	O
networks	O
.	O

In	O
order	O
to	O
explore	O
the	O
cross	O
-	O
regulation	O
of	O
drug	O
targets	O
induced	O
by	O
a	O
promiscuous	O
drug	O
,	O
we	O
searched	O
and	O
found	O
that	O
259	O
out	O
of	O
466	O
total	O
drugs	O
are	O
multi	O
-	O
target	O
drugs	O
and	O
4	O
of	O
these	O
drugs	O
act	O
on	O
multiple	O
differentially	O
regulated	O
drug	O
targets	O
upon	O
drug	O
treatment	O
.	O

For	O
example	O
,	O
Podophyllotoxin	O
used	O
in	O
various	O
chemotherapies	O
is	O
known	O
to	O
target	O
both	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
.	O

The	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
both	O
down	O
-	O
regulated	O
upon	O
drug	O
treatment	O
in	O
three	O
cell	B-Cell
lines	E-Cell
(	O
Figure	O
3	O
,	O
Genes	O
8	O
,	O
13	O
)	O
.	O

Tubulin	O
beta	O
2C	O
inhibitors	O
induce	O
microtubule	S-Cellular_component
depolymerization	O
that	O
leads	O
to	O
the	O
specific	O
down	O
-	O
regulation	O
of	O
tubulin	O
beta	O
2C	O
mRNAs	O
preventing	O
the	O
translational	O
synthesis	O
and	O
thus	O
the	O
further	O
accumulation	O
of	O
abundant	O
tubulin	O
monomers	O
[	O
26	O
]	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
not	O
down	O
-	O
regulated	O
upon	O
treatment	O
of	O
other	O
tubulin	O
inhibitors	O
(	O
Figure	O
S5	O
)	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
feedback	O
loops	O
of	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
are	O
not	O
cross	O
-	O
regulated	O
.	O

Two	O
other	O
examples	O
of	O
multi	O
-	O
target	O
drugs	O
are	O
vorinostat	O
used	O
for	O
the	O
treatment	O
of	O
cutaneous	B-Cancer
T	I-Cancer
cell	I-Cancer
lymphoma	E-Cancer
and	O
trichostatin	O
A	O
that	O
serves	O
as	O
an	O
antifungal	O
antibiotic	O
.	O

Vorinostat	O
and	O
trichostatin	O
A	O
are	O
considered	O
to	O
be	O
nonspecific	O
histone	O
deacetylase	O
inhibitors	O
.	O

These	O
drugs	O
lead	O
to	O
the	O
up	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
3	O
(	O
HDAC3	O
)	O
and	O
down	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
7	O
(	O
HDAC7	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
1	O
,	O
5	O
)	O
.	O

In	O
this	O
case	O
it	O
is	O
unclear	O
whether	O
there	O
is	O
cross	O
-	O
regulation	O
,	O
although	O
HDAC7	O
siRNA	O
experiments	O
failed	O
to	O
induce	O
the	O
up	O
-	O
regulation	O
of	O
HDAC3	O
mRNAs	O
[	O
27	O
]	O
,	O
a	O
result	O
that	O
is	O
disfavoring	O
the	O
cross	O
-	O
regulation	O
.	O

While	O
the	O
above	O
cases	O
only	O
confirm	O
literature	O
reports	O
in	O
other	O
cell	B-Cell
lines	E-Cell
or	O
tissues	S-Tissue
,	O
we	O
also	O
identified	O
new	O
cases	O
of	O
drug	O
-	O
induced	O
expression	O
regulation	O
of	O
drug	O
targets	O
.	O

The	O
significant	O
novel	O
findings	O
are	O
the	O
inhibitor	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
calmodulin	O
1	O
,	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
and	O
up	O
-	O
regulation	O
of	O
endoplasmin	O
,	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
and	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
4D	O
(	O
Figure	O
3	O
,	O
Genes	O
9	O
,	O
8	O
,	O
2	O
,	O
7	O
,	O
10	O
)	O
.	O

Lanosterol	O
14	O
-	O
alpha	O
demethylase	O
is	O
actually	O
an	O
off	O
-	O
target	O
of	O
antifungal	O
drugs	O
that	O
bind	O
the	O
mammalian	O
version	O
with	O
lower	O
affinity	O
than	O
the	O
fungal	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
.	O

Probably	O
,	O
the	O
up	O
-	O
regulation	O
of	O
the	O
mammalian	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
compensates	O
for	O
the	O
undesired	O
inhibition	O
and	O
modulates	O
the	O
adverse	O
effects	O
.	O

On	O
the	O
contrary	O
,	O
we	O
observed	O
a	O
feedback	O
loop	O
that	O
accelerates	O
the	O
down	O
regulation	O
of	O
calmodulin	O
1	O
mRNA	O
induced	O
by	O
calmodulin	O
inhibitors	O
.	O

Calmodulin	O
targeting	O
drugs	O
can	O
provide	O
a	O
rapid	O
and	O
effective	O
therapeutic	O
effect	O
,	O
while	O
at	O
the	O
same	O
time	O
small	O
variations	O
of	O
drug	O
concentrations	O
can	O
increase	O
adverse	O
effects	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
interesting	O
to	O
study	O
further	O
the	O
functional	O
effects	O
upon	O
target	O
inhibition	O
of	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
,	O
endoplasmin	O
and	O
calmodulin	O
1	O
to	O
elucidate	O
the	O
roles	O
of	O
feedback	O
loops	O
in	O
drug	O
mode	O
of	O
action	O
and	O
adverse	O
effects	O
.	O

Drug	O
-	O
induced	O
target	O
regulation	O
might	O
be	O
implicated	O
in	O
tolerance	O
development	O
and	O
thus	O
identifying	O
potential	O
target	O
regulation	O
should	O
be	O
an	O
integral	O
part	O
of	O
drug	O
discovery	O
to	O
prevent	O
failures	O
in	O
later	O
stages	O
of	O
clinical	O
trials	O
.	O

For	O
example	O
,	O
we	O
have	O
observed	O
the	O
inhibitor	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
thymidylate	O
synthetase	O
(	O
TYMS	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
11	O
)	O
[	O
28	O
]	O
.	O

TYMS	O
is	O
an	O
essential	O
enzyme	O
for	O
DNA	O
replication	O
/	O
repair	O
and	O
an	O
important	O
drug	O
target	O
in	O
cancerous	B-Cell
cells	E-Cell
.	O

Indeed	O
,	O
it	O
has	O
been	O
shown	O
that	O
inhibitor	O
-	O
induced	O
TYMS	O
over	O
-	O
expression	O
obstructs	O
the	O
clinical	O
efficiency	O
by	O
inducing	O
tumor	S-Cancer
drug	O
resistance	O
[	O
29	O
]	O
.	O

In	O
addition	O
to	O
over	O
-	O
expression	O
,	O
down	O
-	O
regulation	O
of	O
drug	O
targets	O
upon	O
agonist	O
treatment	O
may	O
also	O
cause	O
treatment	O
tolerance	O
as	O
observed	O
for	O
ADRB2	O
long	O
-	O
acting	O
agonist	O
treatment	O
.	O

ADRB2	O
is	O
a	O
therapeutic	O
target	O
activated	O
to	O
treat	O
the	O
symptoms	O
of	O
asthma	O
.	O

We	O
observe	O
the	O
agonist	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
already	O
in	O
2005	O
,	O
the	O
FDA	O
warned	O
patients	O
that	O
ADRB2	O
might	O
be	O
down	O
-	O
regulated	O
(	O
desensitization	O
)	O
and	O
be	O
unresponsive	O
for	O
asthma	O
treatment	O
due	O
to	O
long	O
-	O
acting	O
agonist	O
exposure	O
[	O
20	O
]	O
,	O
[	O
30	O
]	O
.	O

Thus	O
,	O
robustness	O
in	O
biological	O
systems	O
could	O
prevent	O
the	O
applicability	O
of	O
the	O
long	O
-	O
term	O
treatments	O
via	O
positive	O
/	O
negative	O
feedback	O
loops	O
of	O
the	O
drug	O
target	O
affecting	O
the	O
clinical	O
efficiency	O
of	O
drugs	O
in	O
trial	O
and	O
on	O
the	O
market	O
.	O

Drug	O
-	O
induced	O
regulation	O
of	O
drug	O
targets	O
can	O
thus	O
be	O
linked	O
to	O
tolerance	O
development	O
,	O
which	O
restricts	O
the	O
efficiency	O
of	O
clinical	O
treatments	O
where	O
the	O
drug	O
concentration	O
is	O
limited	O
to	O
avoid	O
an	O
excess	O
of	O
adverse	O
drug	O
reactions	O
.	O

Taken	O
together	O
,	O
we	O
have	O
identified	O
drug	O
-	O
induced	O
differential	O
regulation	O
of	O
drug	O
targets	O
.	O

Due	O
to	O
the	O
limited	O
signal	O
to	O
noise	O
ratio	O
in	O
the	O
data	O
at	O
hand	O
,	O
the	O
identified	O
8	O
%	O
of	O
all	O
drug	O
targets	O
that	O
show	O
feedback	O
loops	O
has	O
to	O
be	O
seen	O
as	O
a	O
lower	O
limit	O
,	O
i	O
.	O
e	O
.	O
target	O
-	O
regulation	O
appears	O
as	O
a	O
wide	O
-	O
spread	O
biological	O
phenomenon	O
that	O
has	O
to	O
be	O
taken	O
into	O
account	O
during	O
drug	O
development	O
.	O

INTRODUCTION	O

For	O
several	O
years	O
now	O
,	O
virtual	O
microscopy	O
has	O
been	O
utilized	O
in	O
medical	O
teaching	O
,	O
research	O
,	O
proficiency	O
testing	O
,	O
American	O
Board	O
of	O
Pathology	O
examinations	O
,	O
pathology	O
meetings	O
and	O
conferences	O
,	O
and	O
quality	O
assurance	O
programs	O
.	O

In	O
diagnostic	O
practice	O
,	O
it	O
is	O
most	O
widely	O
and	O
routinely	O
used	O
in	O
image	O
analysis	O
.	O

Some	O
practices	O
are	O
beginning	O
to	O
use	O
it	O
internally	O
(	O
within	O
their	O
group	O
)	O
for	O
frozen	O
section	O
intraoperative	O
consultations	O
and	O
subspecialty	O
consultations	O
due	O
to	O
geographic	O
and	O
time	O
constrains	O
.	O

Although	O
diagnostic	O
consultation	O
for	O
expert	O
second	O
opinion	O
is	O
a	O
well	O
-	O
established	O
practice	O
in	O
pathology	O
for	O
glass	O
slides	O
,	O
similar	O
consultation	O
via	O
virtual	O
microscopy	O
poses	O
multiple	O
controversial	O
issues	O
such	O
as	O
licensing	O
,	O
liability	O
,	O
security	O
,	O
reimbursement	O
,	O
and	O
scanning	O
quality	O
and	O
its	O
validation	O
.	O

Regulations	O
and	O
standardization	O
are	O
not	O
yet	O
in	O
place	O
that	O
pathologists	O
can	O
use	O
to	O
allay	O
these	O
fears	O
.	O

Nevertheless	O
,	O
if	O
the	O
virtual	O
microscopy	O
scans	O
are	O
of	O
optimal	O
quality	O
,	O
these	O
can	O
be	O
simply	O
substituted	O
for	O
glass	O
slides	O
and	O
a	O
microscope	O
while	O
maintaining	O
all	O
other	O
practice	O
guidelines	O
for	O
second	O
opinion	O
consultation	O
.	O

Additionally	O
,	O
the	O
cost	O
and	O
maintenance	O
of	O
scanning	O
equipment	O
is	O
not	O
currently	O
affordable	O
to	O
most	O
practitioners	O
and	O
consultants	O
.	O

A	O
practice	O
model	O
that	O
offers	O
tertiary	O
consultation	O
in	O
gastrointestinal	S-Organism_subdivision
(	O
GI	S-Organism_subdivision
)	O
and	O
liver	S-Organ
pathology	O
is	O
presented	O
that	O
eliminates	O
the	O
cost	O
and	O
maintenance	O
of	O
scanners	O
by	O
the	O
consultants	O
and	O
clients	O
,	O
minimizes	O
the	O
need	O
for	O
review	O
of	O
glass	O
slides	O
,	O
facilitates	O
clinicopathological	O
and	O
radiological	O
correlation	O
and	O
serves	O
the	O
need	O
of	O
clients	O
who	O
need	O
timely	O
help	O
with	O
challenging	O
liver	S-Organ
and	O
GI	S-Organism_subdivision
cases	O
and	O
to	O
obtain	O
expert	O
opinion	O
for	O
dysplasia	S-Pathological_formation
in	O
Barrett	O
'	O
s	O
and	O
ulcerative	S-Pathological_formation
colitis	O
surveillance	O
biopsies	S-Multi-tissue_structure
required	O
by	O
the	O
American	O
Gastroenterology	O
Association	O
(	O
AGA	O
)	O
.	O

This	O
model	O
has	O
been	O
practiced	O
for	O
3	O
years	O
and	O
applied	O
to	O
over	O
2000	O
cases	O
by	O
small	O
pathology	O
practices	O
in	O
the	O
50	O
United	O
States	O
and	O
a	O
single	O
consultant	O
GI	S-Organism_subdivision
and	O
liver	S-Organ
pathologist	O
.	O

Click	O
here	O
for	O
file	O

The	O
right	B-Organ
eye	E-Organ
of	O
a	O
50	O
-	O
year	O
-	O
old	O
patient	O
with	O
severe	O
hypertension	O
at	O
the	O
first	O
visit	O
.	O

(	O
a	O
)	O
Fundus	O
photograph	O
shows	O
serous	B-Multi-tissue_structure
retinal	E-Multi-tissue_structure
detachment	O
.	O

The	O
optic	O
disc	O
is	O
pale	O
at	O
the	O
temporal	O
side	O
.	O

(	O
b	O
)	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
shows	O
retinal	S-Multi-tissue_structure
detachment	O
involving	O
the	O
fovea	S-Tissue
and	O
cystic	S-Pathological_formation
change	O
of	O
inner	B-Multi-tissue_structure
retina	E-Multi-tissue_structure
.	O

(	O
c	O
)	O
Early	O
phase	O
images	O
of	O
fluorescein	O
angiography	O
(	O
FA	O
)	O
(	O
left	O
)	O
and	O
indocyanine	O
green	O
angiography	O
(	O
IA	O
)	O
(	O
right	O
)	O
.	O

(	O
d	O
)	O
Late	O
phase	O
images	O
of	O
FA	O
(	O
left	O
)	O
and	O
IA	O
(	O
right	O
)	O
.	O

FA	O
shows	O
window	O
defect	O
associated	O
with	O
macular	S-Tissue
cystic	S-Pathological_formation
change	O
.	O

Note	O
that	O
no	O
active	O
leakage	O
is	O
observed	O
in	O
the	O
area	S-Tissue
with	O
serous	B-Multi-tissue_structure
retinal	E-Multi-tissue_structure
detachment	O
or	O
cystoid	B-Pathological_formation
edema	E-Pathological_formation
.	O

IA	O
shows	O
decreased	O
perfusion	O
of	O
the	O
choroid	S-Multi-tissue_structure
at	O
the	O
macula	S-Tissue
and	O
window	O
defect	O
with	O
the	O
damaged	O
RPE	S-Tissue
.	O

Hypofluorescence	O
(	O
arrow	O
)	O
along	O
the	O
retinal	B-Tissue
artery	E-Tissue
are	O
observed	O
.	O

These	O
are	O
unique	O
findings	O
.	O

Western	O
blots	O
showing	O
C	O
/	O
EBPalpha	O
(	O
top	O
)	O
,	O
adiponectin	O
(	O
middle	O
)	O
,	O
and	O
GAPDH	O
(	O
bottom	O
)	O
protein	O
bands	O
in	O
confluent	O
GO	B-Cell
orbital	I-Cell
fibroblast	I-Cell
cultures	E-Cell
exposed	O
throughout	O
10	O
days	O
in	O
culture	O
to	O
the	O
indicated	O
treatments	O
.	O

Lane	O
1	O
)	O
no	O
treatment	O
;	O
2	O
)	O
LY294002	O
(	O
10	O
muM	O
)	O
;	O
3	O
)	O
M22	O
(	O
10	O
ng	O
/	O
ml	O
)	O
;	O
4	O
)	O
M22	O
plus	O
LY294002	O
.	O

5	O
.	O

Conclusion	O

RLs	O
are	O
new	O
actors	O
in	O
animal	O
and	O
plant	O
defense	O
and	O
their	O
low	O
toxicity	O
and	O
biodegradability	O
make	O
them	O
promising	O
molecules	O
to	O
be	O
used	O
against	O
pathogens	O
.	O

In	O
this	O
respect	O
,	O
there	O
are	O
some	O
clues	O
now	O
available	O
for	O
the	O
success	O
of	O
RL	O
applications	O
in	O
greenhouses	O
to	O
fight	O
phytopathogens	O
.	O

A	O
better	O
understanding	O
of	O
RL	O
mode	O
of	O
action	O
,	O
especially	O
their	O
perception	O
and	O
the	O
signaling	O
pathways	O
activated	O
,	O
will	O
be	O
very	O
important	O
to	O
potentiate	O
their	O
beneficial	O
effects	O
in	O
plants	O
.	O

RLs	O
have	O
a	O
dual	O
mode	O
of	O
action	O
:	O
they	O
are	O
antimicrobial	O
and	O
also	O
stimulate	O
plant	O
defense	O
responses	O
.	O

This	O
dual	O
property	O
is	O
probably	O
very	O
important	O
for	O
the	O
efficiency	O
of	O
new	O
biopesticides	O
.	O

In	O
animals	O
,	O
the	O
use	O
of	O
RLs	O
is	O
also	O
at	O
an	O
advanced	O
stage	O
.	O

RLs	O
are	O
successfully	O
used	O
as	O
antimicrobial	O
agents	O
,	O
especially	O
for	O
skin	S-Organ
disease	O
treatment	O
.	O

Deep	O
insight	O
into	O
the	O
physiochemical	O
effects	O
of	O
RLs	O
and	O
their	O
biological	O
importance	O
would	O
reveal	O
new	O
dimensions	O
in	O
the	O
fields	O
of	O
research	O
like	O
agriculture	O
and	O
medicine	O
,	O
precisely	O
in	O
plant	O
defense	O
,	O
disease	O
control	O
and	O
pathogenesis	O
.	O

An	O
understanding	O
of	O
bacterial	O
genera	O
producing	O
RLs	O
that	O
are	O
not	O
yet	O
well	O
studied	O
would	O
provide	O
light	O
on	O
these	O
fascinating	O
aspects	O
.	O

Acknowledgements	O

We	O
thank	O
Dr	O
.	O
Neva	O
Meyer	O
for	O
confocal	O
imaging	O
and	O
generation	O
of	O
Z	O
-	O
stack	O
projection	O
,	O
and	O
the	O
following	O
members	O
of	O
the	O
Seaver	O
lab	O
for	O
their	O
continued	O
support	O
of	O
this	O
project	O
:	O
Dr	O
.	O
Neva	O
Meyer	O
,	O
Dr	O
.	O
Aldine	O
Amiel	O
,	O
and	O
Tyler	O
Smith	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Science	O
Foundation	O
(	O
REU	O
Supplement	O
of	O
10B05	O
-	O
44869	O
to	O
E	O
.	O
C	O
.	O
S	O
.	O
)	O
.	O

Cone	O
beam	O
geometry	O

Materials	O
and	O
Methods	O

Rate	O
of	O
distraction	O
calculation	O
(	O
Figs	O
.	O
6	O
,	O
7	O
and	O
8	O
)	O

Ideal	O
rate	O
for	O
new	O
bone	S-Tissue
formation	O
by	O
distraction	O
osteogenesis	O
is	O
known	O
as	O
1	O
mm	O
/	O
day	O
.	O
5	O
,	O
6	O
The	O
slower	O
rates	O
may	O
lead	O
to	O
premature	O
consolidation	O
,	O
whereas	O
the	O
faster	O
rates	O
may	O
result	O
in	O
poor	O
regenerate	O
bone	S-Tissue
formation	O
.	O

In	O
simple	O
longitudinal	O
lengthening	O
,	O
the	O
rate	O
of	O
distraction	O
is	O
equal	O
at	O
any	O
point	O
of	O
the	O
corticotomy	O
,	O
however	O
,	O
the	O
rate	O
of	O
distraction	O
at	O
any	O
given	O
portion	O
of	O
the	O
corticotomy	O
varies	O
during	O
angular	O
correction	O
.	O

Usually	O
,	O
the	O
gap	O
between	O
corticotomized	O
bone	S-Organ
ends	O
is	O
larger	O
on	O
the	O
concave	O
side	O
,	O
therefore	O
,	O
the	O
rate	O
of	O
angular	O
correction	O
should	O
be	O
adjusted	O
so	O
that	O
the	O
rate	O
of	O
distraction	O
of	O
the	O
concave	O
side	O
is	O
closer	O
to	O
1	O
mm	O
/	O
day	O
.	O

In	O
cases	O
with	O
passive	O
hinge	O
system	O
,	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
can	O
easily	O
be	O
calculated	O
by	O
the	O
geometric	O
methods	O
using	O
the	O
rule	O
of	O
similar	O
triangles	O
and	O
the	O
rule	O
of	O
concentric	O
circles	O
,	O
and	O
can	O
be	O
expressed	O
as	O
the	O
amount	O
of	O
daily	O
lengthening	O
of	O
motor	O
system	O
.	O

In	O
passive	O
hinge	O
system	O
,	O
the	O
ACA	O
is	O
fixed	O
on	O
the	O
frame	O
in	O
Ilizarov	O
system	O
or	O
on	O
the	O
convex	O
side	O
of	O
corticotomy	O
in	O
unilateral	O
fixator	O
system	O
,	O
and	O
angular	O
correction	O
is	O
achieved	O
by	O
changing	O
the	O
length	O
of	O
the	O
motor	O
(	O
Ilizarov	O
system	O
)	O
or	O
the	O
lengthener	O
(	O
unilateral	O
fixator	O
)	O
which	O
rotates	O
the	O
passive	O
hinge	O
.	O

However	O
,	O
in	O
active	O
hinge	O
system	O
,	O
angulator	O
directly	O
corrects	O
angular	O
deformity	O
,	O
and	O
the	O
lengthener	O
and	O
translator	O
adjust	O
secondary	O
displacement	O
.	O

Therefore	O
,	O
the	O
rate	O
of	O
angular	O
correction	O
cannot	O
be	O
determined	O
by	O
the	O
simple	O
geometric	O
methods	O
used	O
for	O
passive	O
hinge	O
system	O
.	O

Regardless	O
of	O
types	O
of	O
fixators	O
,	O
the	O
gap	O
opens	O
larger	O
on	O
the	O
concave	O
side	O
of	O
the	O
deformity	O
after	O
realignment	O
.	O

The	O
rate	O
of	O
angular	O
correction	O
also	O
should	O
be	O
adjusted	O
so	O
that	O
the	O
rate	O
of	O
distraction	O
of	O
concave	O
side	O
is	O
1	O
mm	O
/	O
day	O
.	O

Theoretically	O
,	O
after	O
realignment	O
by	O
Dyna	O
-	O
ATC	O
with	O
adjustment	O
of	O
secondary	O
displacement	O
,	O
the	O
convex	O
side	O
of	O
the	O
corticotomy	O
does	O
not	O
change	O
in	O
length	O
,	O
but	O
the	O
cocave	O
side	O
opens	O
to	O
correct	O
angular	O
deformity	O
.	O

The	O
amount	O
of	O
lengthening	O
on	O
the	O
concave	O
side	O
can	O
be	O
calculated	O
with	O
the	O
thickness	O
of	O
the	O
bone	S-Tissue
at	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
and	O
the	O
amount	O
of	O
angular	O
deformity	O
(	O
Fig	O
.	O
6	O
)	O
.	O

If	O
the	O
corticotomy	O
is	O
performed	O
on	O
the	O
CORA	O
,	O
no	O
translation	O
deformity	O
happens	O
,	O
however	O
,	O
if	O
not	O
,	O
translation	O
results	O
at	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
after	O
realignment	O
is	O
achieved	O
.	O

The	O
amount	O
of	O
translation	O
can	O
be	O
calculated	O
with	O
the	O
distance	O
from	O
the	O
CORA	O
to	O
the	O
corticotomy	O
over	O
the	O
longitudinal	O
bisecting	O
line	O
(	O
lBL	O
)	O
(	O
Fig	O
.	O
6	O
)	O
.	O

On	O
the	O
immediate	O
post	O
-	O
operative	O
radiographs	O
,	O
the	O
gap	O
distance	O
of	O
concave	O
side	O
after	O
realignment	O
can	O
be	O
calculated	O
with	O
the	O
expected	O
change	O
in	O
length	O
and	O
translation	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
using	O
the	O
Pythaorean	O
theorem	O
.	O

The	O
rate	O
of	O
angular	O
correction	O
should	O
be	O
given	O
as	O
the	O
amount	O
of	O
daily	O
correction	O
angle	O
,	O
but	O
not	O
as	O
the	O
amount	O
of	O
length	O
change	O
of	O
the	O
fixator	O
.	O

The	O
angular	O
change	O
of	O
angulator	O
determines	O
the	O
secondary	O
change	O
of	O
length	O
and	O
translation	O
of	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
.	O

The	O
amount	O
of	O
secondary	O
deformity	O
during	O
angular	O
correction	O
can	O
be	O
calculated	O
with	O
the	O
thickness	O
of	O
bone	S-Tissue
at	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
,	O
the	O
distance	O
between	O
the	O
ACA	O
and	O
the	O
corticotomy	O
,	O
and	O
tan	O
(	O
a	O
/	O
2	O
)	O
(	O
a	O
is	O
the	O
amount	O
of	O
angular	O
correction	O
)	O
(	O
Fig	O
.	O
6	O
)	O
.	O

The	O
thickness	O
of	O
the	O
bone	S-Tissue
at	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
and	O
the	O
distance	O
between	O
the	O
ACA	O
and	O
the	O
corticotomy	O
do	O
not	O
change	O
,	O
once	O
the	O
corticotomy	O
is	O
performed	O
after	O
Dyna	O
-	O
ATC	O
is	O
applied	O
.	O

Therefore	O
,	O
the	O
amount	O
of	O
secondary	O
deformities	O
changes	O
only	O
with	O
tan	O
(	O
a	O
/	O
2	O
)	O
value	O
.	O

If	O
tangent	O
value	O
varies	O
proportionally	O
with	O
changes	O
of	O
angle	O
,	O
the	O
gap	O
distance	O
increases	O
constantly	O
with	O
the	O
given	O
amount	O
of	O
daily	O
correction	O
angle	O
during	O
angular	O
correction	O
.	O

If	O
not	O
,	O
the	O
gap	O
distance	O
varies	O
continuously	O
with	O
changes	O
of	O
the	O
angle	O
,	O
therefore	O
,	O
the	O
amount	O
of	O
correction	O
angle	O
should	O
be	O
readjusted	O
everyday	O
to	O
maintain	O
1	O
mm	O
/	O
day	O
of	O
distraction	O
rate	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
.	O

Fortunately	O
,	O
while	O
the	O
value	O
of	O
tangent	O
angle	O
increases	O
exponentially	O
especially	O
over	O
45	O
degrees	O
,	O
tangent	O
function	O
curve	O
is	O
nearly	O
straight	O
,	O
less	O
than	O
30	O
degrees	O
(	O
Fig	O
.	O
7	O
)	O
.	O

Therefore	O
,	O
in	O
cases	O
with	O
less	O
than	O
60	O
degrees	O
of	O
angular	O
deformity	O
,	O
the	O
amount	O
of	O
daily	O
correction	O
angle	O
which	O
permits	O
1	O
mm	O
/	O
day	O
of	O
distraction	O
rate	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
can	O
be	O
obtained	O
as	O
the	O
rate	O
of	O
angular	O
correction	O
without	O
daily	O
adjustment	O
during	O
angular	O
correction	O
.	O

Once	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
is	O
determined	O
,	O
the	O
amount	O
of	O
daily	O
length	O
and	O
translation	O
compensation	O
can	O
also	O
be	O
calculated	O
with	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
.	O

Exact	O
adjustment	O
of	O
secondary	O
changes	O
in	O
length	O
and	O
translation	O
at	O
each	O
angular	O
correction	O
opens	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
1	O
mm	O
per	O
day	O
,	O
but	O
allows	O
minimal	O
gap	O
on	O
the	O
corticotomy	O
of	O
convex	O
side	O
especially	O
in	O
the	O
early	O
stage	O
of	O
angular	O
correction	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
the	O
corticotomized	O
bone	S-Organ
ends	O
of	O
convex	O
side	O
,	O
may	O
abut	O
each	O
other	O
and	O
prevent	O
angular	O
correction	O
or	O
adjustment	O
of	O
secondary	O
translation	O
.	O

For	O
the	O
cases	O
where	O
the	O
concomitant	O
lengthening	O
is	O
required	O
,	O
longitudinal	O
lengthening	O
prior	O
to	O
angular	O
correction	O
is	O
recommended	O
.	O

Otherwise	O
,	O
about	O
5	O
mm	O
pre	O
-	O
lengthening	O
and	O
re	O
-	O
shortening	O
after	O
angular	O
correction	O
could	O
be	O
helpful	O
in	O
avoiding	O
abutment	O
on	O
the	O
convex	O
side	O
of	O
the	O
corticotomy	O
site	S-Multi-tissue_structure
.	O

Inappropriate	O
sequence	O
of	O
angular	O
correction	O
and	O
adjustment	O
of	O
secondary	O
deformities	O
could	O
be	O
one	O
of	O
the	O
causes	O
of	O
the	O
impingement	O
.	O

Appropriate	O
sequence	O
of	O
correction	O
is	O
lengthening	O
-	O
translation	O
-	O
angulation	O
with	O
Dyna	O
-	O
ATC	O
on	O
the	O
concave	O
side	O
and	O
angulation	O
-	O
translation	O
-	O
shortening	O
with	O
Dyna	O
-	O
ATC	O
on	O
the	O
convex	O
side	O
.	O

Results	O

Table	O
1	O
shows	O
the	O
predicted	O
new	O
case	O
detection	O
rates	O
at	O
25	O
years	O
after	O
the	O
initiation	O
of	O
the	O
interventions	O
.	O

Under	O
the	O
baseline	O
control	O
program	O
,	O
the	O
different	O
mechanisms	O
that	O
determined	O
susceptibility	O
showed	O
up	O
to	O
three	O
-	O
fold	O
differences	O
in	O
the	O
predicted	O
number	O
of	O
cases	O
per	O
100	O
,	O
000	O
people	O
.	O

In	O
Figure	O
1	O
,	O
the	O
trends	O
in	O
the	O
new	O
case	O
detection	O
rates	O
over	O
50	O
years	O
are	O
shown	O
for	O
all	O
seven	O
interventions	O
.	O

All	O
susceptibility	O
mechanisms	O
give	O
qualitatively	O
comparable	O
trends	O
.	O

When	O
the	O
intervention	O
scenarios	O
were	O
ordered	O
after	O
50	O
years	O
by	O
the	O
amount	O
of	O
reduction	O
in	O
new	O
case	O
detection	O
rates	O
,	O
the	O
order	O
was	O
as	O
good	O
as	O
identical	O
for	O
all	O
mechanisms	O
;	O
i	O
.	O
e	O
.	O
early	O
diagnosis	O
lowest	O
;	O
then	O
no	O
BCG	O
&	O
early	O
diagnosis	O
;	O
then	O
chemoprophylaxis	O
;	O
then	O
baseline	O
;	O
then	O
no	O
BCG	O
&	O
chemoprophylaxis	O
together	O
with	O
no	O
contact	O
tracing	O
;	O
and	O
finally	O
no	O
BCG	O
had	O
the	O
highest	O
new	O
case	O
detection	O
rate	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g001	O
Figure	O
1	O

Predicted	O
decline	O
of	O
the	O
new	O
case	O
detection	O
rate	O
with	O
seven	O
intervention	O
scenarios	O
and	O
six	O
mechanisms	O
of	O
leprosy	O
susceptiblity	O
since	O
start	O
of	O
intervention	O
strategy	O
.	O

The	O
baseline	O
program	O
(	O
black	O
line	O
)	O
included	O
passive	O
detection	O
,	O
multidrug	O
therapy	O
,	O
contact	O
tracing	O
,	O
and	O
an	O
infant	O
leprosy	O
-	O
preventative	O
BCG	O
vaccination	O
given	O
at	O
the	O
population	O
level	O
.	O

The	O
other	O
six	O
intervention	O
strategies	O
included	O
the	O
baseline	O
program	O
and	O
,	O
introduction	O
of	O
a	O
new	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
leprosy	O
replacing	O
BCG	O
(	O
red	O
)	O
;	O
no	O
tracing	O
of	O
household	O
contacts	O
(	O
orange	O
)	O
;	O
a	O
single	O
chemoprophylactic	O
dose	O
of	O
rifampicin	O
that	O
cured	O
50	O
%	O
of	O
subclinically	O
infected	O
contacts	O
(	O
yellow	O
)	O
;	O
early	O
diagnosis	O
of	O
70	O
%	O
of	O
subclinically	O
infected	O
contacts	O
in	O
each	O
of	O
3	O
consecutive	O
annual	O
examinations	O
(	O
green	O
)	O
;	O
chemoprophylaxis	O
plus	O
introduction	O
of	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
leprosy	O
(	O
blue	O
)	O
;	O
and	O
detection	O
of	O
subclinically	O
infected	O
contacts	O
plus	O
introduction	O
of	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
le	O
-	O
pro	O
-	O
sy	O
(	O
purple	O
)	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
for	O
each	O
scenario	O
and	O
susceptibilty	O
mechanism	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
t001	O
Table	O
1	O

Predicted	O
new	O
case	O
detection	O
rates	O
(	O
per	O
100	O
,	O
000	O
)	O
at	O
25	O
years	O
after	O
the	O
introduction	O
of	O
the	O
indicated	O
intervention	O
scenario	O
for	O
six	O
mechanisms	O
of	O
leprosy	O
susceptibility	O
as	O
described	O
in	O
[	O
9	O
]	O
.	O

Intervention	O
Mechanism	O
determining	O
susceptibilty	O

Random	O
Household	O
Dominant	O
Recessive	O
Household	O
&	O
dominant	O
Household	O
&	O
recessive	O

Baseline	O
control	O
3	O
.	O
4	O
4	O
.	O
0	O
10	O
.	O
4	O
8	O
.	O
2	O
5	O
.	O
6	O
4	O
.	O
6	O

No	O
BCG	O
4	O
.	O
6	O
5	O
.	O
5	O
15	O
.	O
0	O
11	O
.	O
9	O
7	O
.	O
6	O
6	O
.	O
4	O

No	O
contact	O
tracing	O
3	O
.	O
8	O
4	O
.	O
1	O
10	O
.	O
5	O
8	O
.	O
5	O
5	O
.	O
5	O
4	O
.	O
8	O

Chemoprophylaxis	O
2	O
.	O
8	O
3	O
.	O
2	O
6	O
.	O
9	O
5	O
.	O
9	O
4	O
.	O
1	O
3	O
.	O
4	O

Early	O
diagnosis	O
1	O
.	O
1	O
2	O
.	O
1	O
2	O
.	O
7	O
2	O
.	O
6	O
2	O
.	O
1	O
2	O
.	O
0	O

No	O
BCG	O
&	O
chemoprophylaxis	O
3	O
.	O
6	O
4	O
.	O
0	O
10	O
.	O
5	O
8	O
.	O
5	O
5	O
.	O
9	O
5	O
.	O
1	O

No	O
BCG	O
&	O
early	O
diagnosis	O
1	O
.	O
2	O
2	O
.	O
5	O
3	O
.	O
7	O
3	O
.	O
7	O
2	O
.	O
9	O
2	O
.	O
8	O

The	O
results	O
are	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Both	O
the	O
cessation	O
of	O
contact	O
tracing	O
and	O
the	O
replacement	O
of	O
BCG	O
vaccine	O
by	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
for	O
leprosy	O
(	O
no	O
BCG	O
)	O
would	O
have	O
detrimental	O
effects	O
on	O
the	O
rate	O
of	O
decline	O
in	O
leprosy	O
(	O
Figure	O
2	O
)	O
.	O

Twenty	O
-	O
five	O
years	O
after	O
introduction	O
of	O
the	O
ineffective	O
vaccine	O
(	O
no	O
BCG	O
)	O
,	O
the	O
new	O
case	O
detection	O
of	O
leprosy	O
was	O
approximately	O
1	O
.	O
5	O
times	O
higher	O
than	O
the	O
baseline	O
(	O
Table	O
1	O
)	O
.	O

The	O
cessation	O
of	O
contact	O
tracing	O
was	O
predicted	O
to	O
have	O
a	O
smaller	O
impact	O
,	O
with	O
a	O
marked	O
drop	O
in	O
detection	O
of	O
new	O
leprosy	O
cases	O
during	O
the	O
first	O
few	O
years	O
.	O

This	O
sudden	O
drop	O
was	O
due	O
to	O
the	O
reduced	O
number	O
of	O
examinations	O
of	O
people	O
in	O
contact	O
with	O
patients	O
;	O
thus	O
,	O
these	O
cases	O
would	O
not	O
be	O
detected	O
until	O
later	O
,	O
through	O
passive	O
detection	O
(	O
self	O
-	O
reporting	O
)	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g002	O
Figure	O
2	O

Predicted	O
new	O
case	O
detection	O
rates	O
for	O
six	O
intervention	O
scenarios	O
relative	O
to	O
the	O
baseline	O
control	O
program	O
.	O

For	O
each	O
intervention	O
scenario	O
simulations	O
with	O
different	O
mechanisms	O
of	O
susceptibility	O
to	O
leprosy	O
,	O
as	O
defined	O
in	O
our	O
previous	O
paper	O
[	O
9	O
]	O
are	O
performed	O
.	O

For	O
each	O
intervention	O
scenario	O
,	O
the	O
two	O
dotted	O
lines	O
show	O
the	O
smallest	O
and	O
largest	O
deviations	O
from	O
the	O
baseline	O
control	O
program	O
.	O

The	O
solid	O
line	O
shows	O
the	O
median	O
of	O
all	O
susceptibility	O
mechanisms	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Both	O
chemoprophylaxis	O
and	O
early	O
diagnosis	O
were	O
predicted	O
to	O
have	O
substantial	O
effects	O
on	O
the	O
new	O
case	O
detection	O
of	O
leprosy	O
(	O
Figure	O
2	O
)	O
.	O

With	O
no	O
BCG	O
,	O
chemoprophylaxis	O
would	O
partially	O
compensate	O
for	O
the	O
predicted	O
increase	O
in	O
new	O
case	O
detection	O
rates	O
.	O

Furthermore	O
,	O
early	O
diagnosis	O
was	O
predicted	O
to	O
more	O
than	O
compensate	O
for	O
the	O
adverse	O
effects	O
of	O
a	O
leprosy	O
-	O
ineffective	O
tuberculosis	O
vaccine	O
,	O
and	O
reduce	O
the	O
rate	O
of	O
new	O
case	O
detection	O
compared	O
to	O
the	O
baseline	O
.	O

The	O
effects	O
were	O
more	O
promising	O
with	O
the	O
ongoing	O
presence	O
of	O
the	O
BCG	O
vaccine	O
.	O

Under	O
those	O
conditions	O
,	O
at	O
25	O
years	O
after	O
the	O
introduction	O
of	O
chemoprophylaxis	O
,	O
the	O
new	O
case	O
detection	O
rate	O
was	O
predicted	O
to	O
be	O
25	O
%	O
lower	O
than	O
baseline	O
control	O
.	O

Moreover	O
,	O
with	O
the	O
introduction	O
of	O
early	O
diagnosis	O
,	O
the	O
new	O
case	O
detection	O
rate	O
was	O
predicted	O
to	O
halve	O
the	O
baseline	O
incidence	O
after	O
25	O
years	O
(	O
Table	O
1	O
)	O
.	O

Early	O
diagnosis	O
of	O
infection	O
allows	O
the	O
detection	O
of	O
subclinical	O
cases	O
,	O
of	O
which	O
part	O
would	O
be	O
detected	O
later	O
or	O
never	O
at	O
all	O
.	O

These	O
subclinical	O
cases	O
are	O
added	O
to	O
the	O
number	O
of	O
detected	O
cases	O
.	O

This	O
is	O
seen	O
in	O
the	O
results	O
of	O
this	O
intervention	O
.	O

The	O
introduction	O
of	O
early	O
diagnosis	O
would	O
increase	O
the	O
total	O
number	O
of	O
detected	O
cases	O
in	O
the	O
first	O
18	O
years	O
,	O
simply	O
because	O
of	O
the	O
detection	O
of	O
previously	O
undetectable	O
subclinical	O
cases	O
.	O

Over	O
time	O
however	O
,	O
the	O
total	O
number	O
of	O
new	O
cases	O
(	O
subclinical	O
and	O
clinical	O
)	O
would	O
finally	O
drop	O
below	O
the	O
number	O
detected	O
in	O
the	O
baseline	O
control	O
program	O
(	O
Figure	O
3	O
)	O
.	O

In	O
Figure	O
3	O
,	O
we	O
show	O
that	O
the	O
new	O
cases	O
detected	O
under	O
the	O
chemoprophylaxis	O
intervention	O
strategy	O
drop	O
immediately	O
below	O
the	O
level	O
of	O
the	O
baseline	O
control	O
program	O
.	O

The	O
additional	O
effect	O
of	O
chemoprophylaxis	O
is	O
that	O
additional	O
new	O
infections	O
are	O
prevented	O
on	O
top	O
of	O
the	O
cure	O
of	O
subclinical	O
infections	O
.	O

These	O
additional	O
prevented	O
infections	O
are	O
due	O
to	O
a	O
shorter	O
infectious	O
period	O
of	O
the	O
cured	O
subclinical	O
infections	O
.	O

To	O
illustrate	O
this	O
effect	O
we	O
show	O
in	O
Figure	O
3	O
the	O
clinical	O
and	O
the	O
subclinical	O
cases	O
that	O
were	O
cured	O
by	O
the	O
chemoprophylactic	O
intervention	O
.	O

During	O
the	O
first	O
10	O
years	O
,	O
this	O
total	O
number	O
of	O
newly	O
detected	O
cases	O
plus	O
cured	O
cases	O
is	O
equal	O
to	O
the	O
number	O
of	O
newly	O
detected	O
cases	O
under	O
the	O
baseline	O
control	O
program	O
,	O
but	O
afterwards	O
the	O
number	O
of	O
cases	O
plus	O
cured	O
subclinical	O
cases	O
in	O
the	O
chemoprophylaxis	O
intervention	O
group	O
drops	O
under	O
the	O
baseline	O
control	O
program	O
,	O
indicating	O
the	O
prevention	O
of	O
new	O
infections	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g003	O
Figure	O
3	O

Cumulative	O
New	O
cases	O
detected	O
of	O
leprosy	O
per	O
person	O
-	O
year	O
since	O
start	O
of	O
the	O
interventions	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Effects	O
of	O
rule	O
-	O
breakers	O
on	O
intermediary	O
-	O
based	O
networks	O
.	O

Individuals	O
using	O
rule	O
-	O
breaking	O
strategy	O
primarily	O
affected	O
(	O
A	O
)	O
their	O
own	O
social	O
position	O
(	O
H	O
(	O
2	O
)	O
=	O
213	O
.	O
18	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
but	O
also	O
made	O
an	O
impact	O
on	O
the	O
other	O
aspects	O
of	O
the	O
social	O
system	O
,	O
affecting	O
(	O
B	O
)	O
the	O
social	O
position	O
of	O
others	O
(	O
H	O
(	O
2	O
)	O
=	O
6	O
.	O
79	O
,	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
(	O
C	O
)	O
group	O
organization	O
(	O
H	O
(	O
2	O
)	O
=	O
125	O
.	O
3	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
as	O
their	O
frequency	O
in	O
a	O
population	O
increased	O
.	O

The	O
boxes	O
show	O
medians	O
,	O
quartiles	O
,	O
minima	O
and	O
maxima	O
.	O

Results	O
significantly	O
different	O
from	O
a	O
relevant	O
uniform	O
network	O
with	O
no	O
rule	O
-	O
breaking	O
behavior	O
(	O
p	O
<	O
0	O
.	O
05	O
in	O
Dunn	O
'	O
s	O
multiple	O
comparison	O
test	O
for	O
comparing	O
each	O
group	O
with	O
control	O
)	O
are	O
designated	O
with	O
*	O
.	O

Objectives	O

Evaluate	O
relationships	O
between	O
MRI	O
and	O
clinical	O
/	O
laboratory	O
/	O
radiographic	O
findings	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Assessment	O
instruments	O

The	O
SCID	O
-	O
I	O
/	O
P	O
was	O
administered	O
by	O
psychiatrists	O
trained	O
and	O
certified	O
in	O
the	O
use	O
of	O
all	O
instruments	O
in	O
this	O
study	O
.	O

The	O
ICG	O
is	O
a	O
self	O
-	O
report	O
instrument	O
that	O
can	O
be	O
used	O
to	O
identify	O
CG	O
when	O
the	O
total	O
score	O
is	O
>	O
25	O
,	O
that	O
demonstrated	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
94	O
)	O
,	O
and	O
convergent	O
and	O
criterion	O
validity	O
[	O
27	O
]	O
.	O

The	O
ICG	O
total	O
score	O
also	O
showed	O
a	O
fairly	O
high	O
association	O
with	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
[	O
32	O
]	O
total	O
score	O
(	O
r	O
=	O
0	O
.	O
67	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
Texas	O
Revised	O
Inventory	O
of	O
Grief	O
(	O
TRIG	O
)	O
[	O
33	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
Grief	O
Measurement	O
Scale	O
(	O
GMS	O
)	O
[	O
34	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
70	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
ASA	O
-	O
27	O
is	O
a	O
self	O
-	O
report	O
measure	O
developed	O
to	O
rate	O
separation	O
anxiety	O
symptoms	O
in	O
adult	O
life	O
(	O
from	O
18	O
years	O
of	O
age	O
)	O
.	O

Principal	O
components	O
analysis	O
revealed	O
a	O
coherent	O
construct	O
of	O
adult	O
separation	O
anxiety	O
with	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
95	O
)	O
and	O
sound	O
test	O
-	O
retest	O
reliability	O
(	O
r	O
=	O
0	O
.	O
86	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Further	O
,	O
a	O
receiver	O
operation	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
against	O
the	O
semistructured	O
interview	O
yielded	O
a	O
high	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
index	O
of	O
0	O
.	O
9	O
,	O
suggesting	O
that	O
the	O
questionnaire	O
is	O
an	O
adequate	O
alternative	O
measure	O
of	O
adult	O
separation	O
anxiety	O
[	O
29	O
]	O
.	O

The	O
WSAS	O
is	O
a	O
self	O
-	O
report	O
scale	O
of	O
functional	O
impairment	O
that	O
includes	O
five	O
questions	O
rating	O
interference	O
of	O
psychiatric	O
symptoms	O
in	O
work	O
,	O
home	O
management	O
,	O
social	O
or	O
private	O
leisure	O
activities	O
,	O
and	O
ability	O
to	O
form	O
and	O
maintain	O
close	O
relationships	O
with	O
others	O
.	O

Each	O
question	O
is	O
rated	O
on	O
a	O
0	O
to	O
8	O
scale	O
with	O
0	O
indicating	O
no	O
impairment	O
at	O
all	O
and	O
8	O
indicating	O
very	O
severe	O
impairment	O
.	O

The	O
Cronbach	O
'	O
s	O
alpha	O
measure	O
of	O
internal	O
scale	O
consistency	O
ranged	O
from	O
0	O
.	O
70	O
to	O
0	O
.	O
94	O
,	O
the	O
test	O
-	O
retest	O
correlation	O
was	O
0	O
.	O
73	O
,	O
and	O
the	O
WSAS	O
interactive	O
voice	O
response	O
administrations	O
gave	O
correlations	O
of	O
0	O
.	O
81	O
and	O
0	O
.	O
86	O
with	O
clinician	O
interviews	O
[	O
30	O
]	O
.	O

Correlations	O
of	O
WSAS	O
with	O
severity	O
of	O
depression	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
symptoms	O
were	O
0	O
.	O
76	O
and	O
0	O
.	O
61	O
,	O
respectively	O
,	O
and	O
the	O
scores	O
were	O
sensitive	O
to	O
patient	O
differences	O
in	O
disorder	O
severity	O
and	O
treatment	O
-	O
related	O
change	O
[	O
30	O
]	O
.	O

The	O
MOODS	O
-	O
SR	O
is	O
an	O
instrument	O
developed	O
and	O
validated	O
to	O
assess	O
lifetime	O
mood	O
spectrum	O
symptoms	O
[	O
35	O
]	O
,	O
including	O
manic	O
and	O
depressive	O
features	O
,	O
rhythmicity	O
and	O
vegetative	O
functions	O
.	O

The	O
manic	O
and	O
depressive	O
components	O
are	O
subtyped	O
into	O
mood	O
,	O
energy	O
and	O
cognition	O
domains	O
,	O
focusing	O
on	O
manic	O
or	O
depressive	O
symptoms	O
,	O
respectively	O
.	O

The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
include	O
changes	O
in	O
energy	O
,	O
physical	O
wellbeing	O
,	O
mental	O
and	O
physical	O
efficiency	O
,	O
related	O
to	O
the	O
weather	O
and	O
season	O
,	O
and	O
changes	O
in	O
appetite	O
,	O
sleep	O
and	O
sexual	O
activities	O
.	O

The	O
sum	O
of	O
the	O
scores	O
on	O
the	O
3	O
manic	O
domains	O
(	O
mood	O
,	O
energy	O
,	O
cognition	O
)	O
constitutes	O
the	O
'	O
manic	O
component	O
'	O
(	O
62	O
items	O
)	O
and	O
that	O
of	O
the	O
3	O
depressive	O
domains	O
the	O
'	O
depressive	O
component	O
'	O
(	O
63	O
items	O
)	O
.	O

The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
includes	O
29	O
items	O
.	O

The	O
instrument	O
can	O
be	O
downloaded	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
spectrum	O
-	O
project	O
.	O
org	O
.	O

Methods	O

Thirteen	O
focus	O
group	O
discussions	O
with	O
first	O
-	O
time	O
parents	O
and	O
female	O
and	O
male	O
informal	O
supporters	O
were	O
analysed	O
by	O
discourse	O
analysis	O
.	O

[	O
Epidemiology	O
of	O
respiratory	S-Anatomical_system
allergy	O
in	O
children	O
]	O
.	O

Epidemiology	O
of	O
paediatric	O
respiratory	S-Anatomical_system
allergic	O
disorders	O
allows	O
the	O
approach	O
to	O
causal	O
and	O
preventive	O
risk	O
factors	O
by	O
studying	O
groups	O
or	O
sub	O
groups	O
of	O
children	O
in	O
different	O
locations	O
and	O
under	O
different	O
conditions	O
.	O

This	O
is	O
,	O
however	O
,	O
complicated	O
by	O
the	O
lack	O
of	O
consensus	O
on	O
disease	O
definitions	O
,	O
which	O
renders	O
comparisons	O
between	O
studies	O
difficult	O
.	O

Atopy	O
is	O
usually	O
defined	O
by	O
the	O
presence	O
of	O
positive	O
skin	S-Organ
tests	O
(	O
wheal	O
size	O
of	O
at	O
least	O
a	O
mean	O
diameter	O
>	O
or	O
=	O
3	O
mm	O
)	O
,	O
by	O
the	O
presence	O
of	O
specific	O
IgE	O
,	O
or	O
by	O
the	O
presence	O
of	O
increased	O
total	O
IgE	O
(	O
>	O
or	O
=	O
100	O
UI	O
/	O
mL	O
)	O
.	O

Infantile	O
asthma	O
is	O
not	O
well	O
defined	O
,	O
complicated	O
by	O
the	O
high	O
prevalence	O
of	O
bronchiolitis	O
;	O
one	O
thus	O
questions	O
between	O
wheezing	O
or	O
wheezy	O
bronchitis	O
.	O

Prevalence	O
is	O
high	O
:	O
among	O
early	O
wheezers	O
,	O
two	O
populations	O
will	O
be	O
defined	O
by	O
the	O
medium	O
term	O
evolution	O
:	O
transient	O
wheezers	O
and	O
persistent	O
wheezers	O
.	O

Risk	O
factors	O
for	O
these	O
two	O
conditions	O
are	O
different	O
.	O

Childhood	O
asthma	O
may	O
be	O
defined	O
by	O
the	O
diagnosis	O
of	O
asthma	O
(	O
specific	O
but	O
fairly	O
non	O
-	O
sensitive	O
)	O
,	O
by	O
asthmatic	O
symptoms	O
(	O
wheezing	O
,	O
waking	O
by	O
an	O
attack	O
of	O
shortness	O
of	O
breath	O
)	O
(	O
sensitive	O
but	O
not	O
very	O
specific	O
)	O
,	O
or	O
by	O
the	O
combination	O
of	O
symptoms	O
and	O
airway	S-Multi-tissue_structure
hyperresponsiveness	O
.	O

The	O
ISAAC	O
study	O
has	O
standardised	O
a	O
questionnaire	O
to	O
assess	O
the	O
prevalence	O
of	O
asthma	O
.	O

The	O
preliminary	O
results	O
show	O
that	O
there	O
are	O
wide	O
variations	O
across	O
the	O
world	O
.	O

The	O
prevalence	O
is	O
low	O
in	O
Africa	O
and	O
Asia	O
,	O
intermediate	O
in	O
Europe	O
,	O
and	O
high	O
in	O
Anglo	O
-	O
Saxon	O
countries	O
.	O

The	O
prevalence	O
of	O
asthma	O
has	O
gradually	O
increased	O
over	O
the	O
past	O
20	O
years	O
in	O
developed	O
countries	O
.	O

Asthma	O
and	O
atopy	O
are	O
closely	O
associated	O
in	O
children	O
.	O

Risk	O
factors	O
are	O
genetic	O
,	O
associated	O
with	O
sex	O
and	O
environmental	O
factors	O
.	O

Among	O
these	O
,	O
allergic	O
sensitisation	O
is	O
associated	O
with	O
the	O
degree	O
of	O
exposure	O
to	O
allergens	O
.	O

Westernization	O
of	O
way	O
of	O
life	O
is	O
associated	O
with	O
increased	O
prevalence	O
of	O
atopy	O
,	O
allergic	O
rhinitis	O
and	O
asthma	O
.	O

Atopy	O
seems	O
inversely	O
correlated	O
to	O
certain	O
infections	O
.	O

Passive	O
smoking	O
is	O
clearly	O
associated	O
with	O
early	O
wheezing	O
.	O

This	O
and	O
atmospheric	O
pollution	O
aggravate	O
childhood	O
asthma	O
.	O

However	O
,	O
the	O
inducing	O
role	O
of	O
pollution	O
on	O
asthma	O
is	O
still	O
controversial	O
.	O

Novel	O
mechanism	O
for	O
the	O
impairment	O
of	O
cell	S-Cell
proliferation	O
in	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
synthesis	O
of	O
ribonucleotides	O
is	O
essential	O
to	O
cell	S-Cell
proliferation	O
.	O

Defects	O
in	O
the	O
relevant	O
metabolic	O
pathways	O
have	O
been	O
demonstrated	O
in	O
stimulated	O
T	B-Cell
cells	E-Cell
from	O
AIDS	O
patients	O
and	O
are	O
associated	O
with	O
lymphocyte	S-Cell
necrotic	O
death	O
.	O

Here	O
,	O
Margarita	O
Bofill	O
and	O
colleagues	O
discuss	O
the	O
possibility	O
that	O
an	O
impaired	O
ribonucleotide	O
metabolism	O
might	O
be	O
common	O
to	O
all	O
rapidly	O
dividing	O
cells	S-Cell
and	O
thus	O
contribute	O
to	O
other	O
recognized	O
symptoms	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

UFT	O
and	O
its	O
metabolites	O
inhibit	O
the	O
angiogenesis	O
induced	O
by	O
murine	O
renal	B-Cancer
cell	I-Cancer
carcinoma	E-Cancer
,	O
as	O
determined	O
by	O
a	O
dorsal	B-Multi-tissue_structure
air	I-Multi-tissue_structure
sac	E-Multi-tissue_structure
assay	O
in	O
mice	O
.	O

UFT	O
,	O
an	O
anticancer	S-Cancer
agent	O
that	O
is	O
composed	O
of	O
tegafur	O
(	O
FT	O
)	O
and	O
uracil	O
at	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
4	O
,	O
is	O
widely	O
used	O
in	O
clinical	O
practice	O
in	O
Japan	O
to	O
treat	O
cancer	S-Cancer
patients	O
requiring	O
a	O
long	O
-	O
term	O
chemotherapy	O
,	O
and	O
it	O
is	O
associated	O
with	O
few	O
side	O
effects	O
,	O
if	O
any	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
inhibitory	O
effect	O
of	O
UFT	O
against	O
RENCA	B-Cell
cell	E-Cell
-	O
induced	O
angiogenesis	O
by	O
a	O
dorsal	B-Multi-tissue_structure
air	I-Multi-tissue_structure
sac	E-Multi-tissue_structure
assay	O
.	O

Marked	O
angiogenesis	O
is	O
induced	O
by	O
implantation	O
of	O
a	O
chamber	O
containing	O
RENCA	B-Cell
cells	E-Cell
into	O
mice	O
.	O

In	O
this	O
model	O
,	O
UFT	O
showed	O
a	O
strong	O
angiogenesis	O
-	O
inhibitory	O
effect	O
,	O
whereas	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
doxifluridine	O
were	O
less	O
effective	O
.	O

Additional	O
experiments	O
revealed	O
FT	O
to	O
be	O
effective	O
component	O
of	O
UFT	O
;	O
uracil	O
remained	O
ineffective	O
in	O
the	O
inhibition	O
of	O
angiogenesis	O
.	O

Moreover	O
,	O
we	O
have	O
found	O
that	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
the	O
metabolites	O
of	O
FT	O
,	O
possess	O
a	O
potent	O
angiogenesis	O
inhibitory	O
effect	O
that	O
is	O
amplified	O
when	O
the	O
compounds	O
are	O
administered	O
by	O
a	O
continuous	O
infusion	O
.	O

This	O
may	O
reflect	O
a	O
transition	O
in	O
blood	S-Organism_substance
concentration	O
of	O
each	O
metabolite	O
resulting	O
from	O
the	O
administration	O
of	O
UFT	O
.	O

Similar	O
results	O
were	O
also	O
obtained	O
with	O
respect	O
to	O
5	O
-	O
FU	O
.	O

It	O
was	O
suggested	O
that	O
UFT	O
has	O
a	O
stronger	O
angiogenesis	O
-	O
inhibitory	O
effect	O
than	O
did	O
other	O
fluorinated	O
pyrimidines	O
,	O
partly	O
due	O
to	O
its	O
pharmacokinetic	O
properties	O
characterized	O
by	O
maintaining	O
of	O
higher	O
and	O
long	O
-	O
lasting	O
blood	S-Organism_substance
levels	O
of	O
5	O
-	O
FU	O
and	O
partly	O
due	O
the	O
inhibitory	O
effects	O
derived	O
from	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
UFT	O
-	O
specific	O
metabolites	O
.	O

Nitric	O
oxide	O
synthase	O
inhibition	O
results	O
in	O
synergistic	O
anti	O
-	O
tumour	S-Cancer
activity	O
with	O
melphalan	O
and	O
tumour	O
necrosis	O
factor	O
alpha	O
-	O
based	O
isolated	O
limb	S-Organism_subdivision
perfusions	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
an	O
important	O
molecule	O
in	O
regulating	O
tumour	S-Cancer
blood	S-Organism_substance
flow	O
and	O
stimulating	O
tumour	S-Cancer
angiogenesis	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
by	O
L	O
-	O
NAME	O
might	O
induce	O
an	O
anti	O
-	O
tumour	S-Cancer
effect	O
by	O
limiting	O
nutrients	O
and	O
oxygen	O
to	O
reach	O
tumour	B-Tissue
tissue	E-Tissue
or	O
affecting	O
vascular	S-Multi-tissue_structure
growth	O
.	O

The	O
anti	O
-	O
tumour	S-Cancer
effect	O
of	O
L	O
-	O
NAME	O
after	O
systemic	O
administration	O
was	O
studied	O
in	O
a	O
renal	B-Cancer
subcapsular	I-Cancer
CC531	I-Cancer
adenocarcinoma	E-Cancer
model	O
in	O
rats	O
.	O

Moreover	O
,	O
regional	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
in	O
combination	O
with	O
TNF	O
and	O
melphalan	O
,	O
was	O
studied	O
in	O
an	O
isolated	O
limb	S-Organism_subdivision
perfusion	O
(	O
ILP	O
)	O
model	O
using	O
BN175	B-Cancer
soft	I-Cancer
-	I-Cancer
tissue	I-Cancer
sarcomas	E-Cancer
.	O

Systemic	O
treatment	O
with	O
L	O
-	O
NAME	O
inhibited	O
growth	O
of	O
adenocarcinoma	S-Cancer
significantly	O
but	O
was	O
accompanied	O
by	O
impaired	O
renal	S-Organ
function	O
.	O

In	O
ILP	O
,	O
reduced	O
tumour	S-Cancer
growth	O
was	O
observed	O
when	O
L	O
-	O
NAME	O
was	O
used	O
alone	O
.	O

In	O
combination	O
with	O
TNF	O
or	O
melphalan	O
,	O
L	O
-	O
NAME	O
increased	O
response	O
rates	O
significantly	O
compared	O
to	O
perfusions	O
without	O
L	O
-	O
NAME	O
(	O
0	O
-	O
64	O
%	O
and	O
0	O
-	O
63	O
%	O
respectively	O
)	O
.	O

An	O
additional	O
anti	O
-	O
tumour	S-Cancer
effect	O
was	O
demonstrated	O
when	O
L	O
-	O
NAME	O
was	O
added	O
to	O
the	O
synergistic	O
combination	O
of	O
melphalan	O
and	O
TNF	O
(	O
responses	O
increased	O
from	O
70	O
to	O
100	O
%	O
)	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
reduces	O
tumour	S-Cancer
growth	O
both	O
after	O
systemic	O
and	O
regional	O
(	O
ILP	O
)	O
treatment	O
.	O

A	O
synergistic	O
anti	O
-	O
tumour	S-Cancer
effect	O
of	O
L	O
-	O
NAME	O
is	O
observed	O
in	O
combination	O
with	O
melphalan	O
and	O
/	O
or	O
TNF	O
using	O
ILP	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
role	O
of	O
L	O
-	O
NAME	O
for	O
the	O
treatment	O
of	O
solid	O
tumours	S-Cancer
in	O
a	O
systemic	O
or	O
regional	O
setting	O
.	O

Apoptosis	O
induced	O
by	O
1	O
'	O
-	O
acetoxychavicol	O
acetate	O
in	O
Ehrlich	B-Cell
ascites	I-Cell
tumor	I-Cell
cells	E-Cell
is	O
associated	O
with	O
modulation	O
of	O
polyamine	O
metabolism	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

The	O
efficacy	O
of	O
the	O
antitumor	S-Cancer
activity	O
of	O
1	O
'	O
-	O
acetoxychavicol	O
acetate	O
(	O
ACA	O
)	O
,	O
reported	O
to	O
be	O
a	O
suppressor	O
of	O
chemically	O
induced	O
carcinogenesis	O
,	O
was	O
evaluated	O
in	O
Ehrlich	B-Cell
ascites	I-Cell
tumor	I-Cell
cells	E-Cell
.	O

ACA	O
treatment	O
resulted	O
in	O
changes	O
in	O
morphology	O
and	O
a	O
dose	O
-	O
dependent	O
suppression	O
of	O
cell	S-Cell
viability	O
.	O

Apoptosis	O
,	O
characterized	O
by	O
nuclear	S-Cellular_component
condensation	O
,	O
membrane	S-Cellular_component
blebbing	O
,	O
cell	S-Cell
shrinkage	O
and	O
a	O
significant	O
induction	O
of	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
at	O
8	O
h	O
in	O
a	O
time	O
-	O
course	O
study	O
were	O
observed	O
.	O

Formation	O
of	O
apoptotic	B-Cellular_component
bodies	E-Cellular_component
was	O
preceded	O
by	O
lowering	O
of	O
intracellular	S-Immaterial_anatomical_entity
polyamines	O
,	O
particularly	O
putrescine	O
,	O
and	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibitory	O
and	O
activation	O
effect	O
by	O
ACA	O
on	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
and	O
spermidine	O
/	O
spermine	O
N	O
(	O
1	O
)	O
-	O
acetyltransferase	O
(	O
SSAT	O
)	O
,	O
respectively	O
.	O

Administration	O
of	O
exogenous	O
polyamines	O
prevented	O
ACA	O
-	O
induced	O
apoptosis	O
represented	O
by	O
a	O
reduction	O
in	O
the	O
number	O
of	O
apoptotic	B-Cellular_component
bodies	E-Cellular_component
and	O
also	O
caused	O
reduction	O
in	O
the	O
induced	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
at	O
8	O
h	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
anticarcinogenic	O
effects	O
of	O
ACA	O
might	O
be	O
partly	O
due	O
to	O
perturbation	O
of	O
the	O
polyamine	O
metabolic	O
pathway	O
and	O
triggering	O
of	O
caspase	O
-	O
3	O
-	O
like	O
activity	O
,	O
which	O
result	O
in	O
apoptosis	O
.	O

A	O
pancreatic	B-Cell
beta	I-Cell
-	I-Cell
cell	E-Cell
-	O
specific	O
enhancer	O
in	O
the	O
human	O
PDX	O
-	O
1	O
gene	O
is	O
regulated	O
by	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SPs	O
transcription	O
factors	O
.	O

The	O
PDX	O
-	O
1	O
transcription	O
factor	O
plays	O
a	O
key	O
role	O
in	O
pancreas	S-Organ
development	O
.	O

Although	O
expressed	O
in	O
all	O
cells	S-Cell
at	O
the	O
early	O
stages	O
,	O
in	O
the	O
adult	O
it	O
is	O
mainly	O
restricted	O
to	O
the	O
beta	B-Cell
-	I-Cell
cell	E-Cell
.	O

To	O
characterize	O
the	O
regulatory	O
elements	O
and	O
potential	O
transcription	O
factors	O
necessary	O
for	O
human	O
PDX	O
-	O
1	O
gene	O
expression	O
in	O
beta	B-Cell
-	I-Cell
cells	E-Cell
,	O
we	O
constructed	O
a	O
series	O
of	O
5	O
'	O
and	O
3	O
'	O
deletion	O
fragments	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
,	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
by	O
transient	O
transfections	O
in	O
beta	B-Cell
-	E-Cell
and	O
non	B-Cell
-	I-Cell
beta	I-Cell
-	I-Cell
cells	E-Cell
a	O
novel	O
beta	B-Cell
-	I-Cell
cell	E-Cell
-	O
specific	O
distal	O
enhancer	O
element	O
located	O
between	O
-	O
3	O
.	O
7	O
and	O
-	O
3	O
.	O
45	O
kilobases	O
.	O

DNase	O
I	O
footprinting	O
analysis	O
revealed	O
two	O
protected	O
regions	O
,	O
one	O
binding	O
the	O
transcription	O
factors	O
SP1	O
and	O
SP3	O
and	O
the	O
other	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
and	O
HNF	O
-	O
1alpha	O
.	O

Cotransfection	O
experiments	O
suggest	O
that	O
HNF	O
-	O
3beta	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SP1	O
are	O
positive	O
regulators	O
of	O
the	O
herein	O
-	O
described	O
human	O
PDX	O
-	O
1	O
enhancer	O
element	O
.	O

Furthermore	O
,	O
mutations	O
within	O
each	O
motif	O
abolished	O
the	O
binding	O
of	O
the	O
corresponding	O
factor	O
(	O
s	O
)	O
and	O
dramatically	O
impaired	O
the	O
enhancer	O
activity	O
,	O
therefore	O
suggesting	O
cooperativity	O
between	O
these	O
factors	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
-	O
B	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
expression	O
in	O
renal	B-Cancer
cell	I-Cancer
carcinomas	E-Cancer
:	O
regulation	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
gene	O
and	O
hypoxia	O
.	O

Angiogenesis	O
is	O
essential	O
for	O
tumor	S-Cancer
growth	O
and	O
metastasis	O
.	O

It	O
is	O
regulated	O
by	O
numerous	O
angiogenic	O
factors	O
,	O
one	O
of	O
the	O
most	O
important	O
being	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

Recently	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
,	O
two	O
new	O
VEGF	O
family	O
members	O
,	O
have	O
been	O
identified	O
that	O
bind	O
to	O
the	O
tyrosine	O
kinase	O
receptors	O
flt	O
-	O
1	O
(	O
VEGFR1	O
)	O
,	O
KDR	O
(	O
VEGFR2	O
)	O
,	O
and	O
flt	O
-	O
4	O
(	O
VEGFR3	O
)	O
.	O

Although	O
the	O
importance	O
of	O
VEGF	O
-	O
A	O
has	O
been	O
shown	O
in	O
renal	B-Cancer
carcinomas	E-Cancer
,	O
the	O
contribution	O
of	O
these	O
new	O
ligands	O
in	O
kidney	B-Cancer
tumors	E-Cancer
is	O
not	O
clear	O
.	O

We	O
have	O
,	O
therefore	O
,	O
measured	O
the	O
mRNA	O
level	O
of	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
together	O
with	O
their	O
receptors	O
by	O
RNase	O
protection	O
assay	O
(	O
RPA	O
)	O
in	O
26	O
normal	O
kidney	B-Multi-tissue_structure
samples	E-Multi-tissue_structure
and	O
45	O
renal	B-Cancer
cell	I-Cancer
cancers	E-Cancer
.	O

We	O
observed	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
VEGF	O
-	O
B	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
but	O
not	O
VEGF	O
-	O
C	O
(	O
P	O
=	O
0	O
.	O
3	O
)	O
in	O
neoplastic	B-Organ
kidney	E-Organ
compared	O
with	O
normal	O
tissues	S-Tissue
.	O

In	O
addition	O
,	O
although	O
VEGF	O
receptors	O
were	O
higher	O
in	O
tumors	S-Cancer
than	O
normal	O
kidney	S-Organ
,	O
there	O
was	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
only	O
flt	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
not	O
KDR	O
(	O
P	O
=	O
0	O
.	O
12	O
)	O
or	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
VEGF	O
-	O
C	O
and	O
both	O
of	O
its	O
receptors	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
KDR	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
but	O
no	O
association	O
between	O
VEGF	O
-	O
B	O
and	O
its	O
receptor	O
flt	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
23	O
)	O
.	O

A	O
significant	O
increase	O
was	O
observed	O
in	O
flt	O
-	O
1	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
KDR	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
but	O
not	O
VEGF	O
-	O
B	O
(	O
P	O
=	O
0	O
.	O
82	O
)	O
or	O
VEGF	O
-	O
C	O
(	O
P	O
=	O
0	O
.	O
52	O
)	O
expression	O
in	O
clear	B-Cell
cell	E-Cell
compared	O
with	O
chromophil	B-Cancer
(	I-Cancer
papillary	I-Cancer
)	I-Cancer
carcinomas	E-Cancer
.	O

No	O
significant	O
association	O
was	O
demonstrated	O
between	O
VEGF	O
-	O
B	O
,	O
VEGF	O
-	O
C	O
,	O
flt	O
-	O
1	O
,	O
KDR	O
,	O
and	O
flt	O
-	O
4	O
with	O
patient	O
sex	O
,	O
patient	O
age	O
,	O
or	O
tumor	S-Cancer
size	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
and	O
hypoxia	O
on	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
expression	O
in	O
the	O
renal	B-Cell
carcinoma	I-Cell
cell	I-Cell
line	I-Cell
786	I-Cell
-	I-Cell
0	E-Cell
transfected	O
with	O
wild	O
-	O
type	O
and	O
mutant	O
VHL	O
was	O
determined	O
by	O
growing	O
cells	S-Cell
under	O
21	O
%	O
O2	O
-	O
and	O
0	O
.	O
1	O
%	O
O2	O
.	O

In	O
wild	B-Cell
-	I-Cell
type	I-Cell
VHL	I-Cell
cells	E-Cell
,	O
whereas	O
VEGF	O
-	O
A	O
was	O
significantly	O
up	O
-	O
regulated	O
under	O
hypoxic	O
compared	O
with	O
normoxic	O
conditions	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
expression	O
of	O
VEGF	O
-	O
C	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Nevertheless	O
,	O
the	O
repression	O
of	O
VEGF	O
-	O
C	O
was	O
lost	O
in	O
mutant	B-Cell
VHL	I-Cell
cell	I-Cell
lines	E-Cell
under	O
hypoxia	O
.	O

In	O
contrast	O
VEGF	O
-	O
B	O
was	O
not	O
regulated	O
by	O
VHL	O
despite	O
clear	O
up	O
-	O
regulation	O
in	O
vivo	O
.	O

These	O
findings	O
strongly	O
support	O
an	O
enhanced	O
role	O
for	O
this	O
pathway	O
in	O
clear	B-Cancer
cell	I-Cancer
carcinomas	E-Cancer
by	O
regulating	O
angiogenesis	O
and	O
/	O
or	O
lymphangiogenesis	O
.	O

The	O
study	O
shows	O
that	O
clear	B-Cancer
cell	I-Cancer
tumors	E-Cancer
are	O
able	O
to	O
up	O
-	O
regulate	O
angiogenic	O
growth	O
factor	O
receptors	O
more	O
efficiently	O
than	O
chromophil	S-Cancer
(	O
papillary	S-Cancer
)	O
,	O
that	O
clear	B-Cancer
cell	I-Cancer
tumors	E-Cancer
can	O
use	O
pathways	O
independent	O
of	O
VHL	O
to	O
regulate	O
angiogenesis	O
,	O
and	O
that	O
this	O
combined	O
regulation	O
may	O
account	O
for	O
their	O
more	O
aggressive	O
phenotype	O
,	O
which	O
suggests	O
that	O
targeting	O
VEGFR1	O
(	O
flt	O
-	O
l	O
)	O
may	O
be	O
particularly	O
effective	O
in	O
these	O
tumor	S-Cancer
types	O
.	O

Glucose	O
catabolism	O
in	O
cancer	B-Cell
cells	E-Cell
:	O
identification	O
and	O
characterization	O
of	O
a	O
marked	O
activation	O
response	O
of	O
the	O
type	O
II	O
hexokinase	O
gene	O
to	O
hypoxic	O
conditions	O
.	O

One	O
of	O
the	O
most	O
common	O
signatures	O
of	O
highly	O
malignant	B-Cancer
tumors	E-Cancer
is	O
their	O
capacity	O
to	O
metabolize	O
more	O
glucose	O
to	O
lactic	O
acid	O
than	O
their	O
tissues	S-Tissue
of	O
origin	O
.	O

Hepatomas	S-Cancer
exhibiting	O
this	O
phenotype	O
are	O
dependent	O
on	O
the	O
high	O
expression	O
of	O
type	O
II	O
hexokinase	O
,	O
which	O
supplies	O
such	O
tumors	S-Cancer
with	O
abundant	O
amounts	O
of	O
glucose	O
6	O
-	O
phosphate	O
,	O
a	O
significant	O
carbon	O
and	O
energy	O
source	O
especially	O
under	O
hypoxic	O
conditions	O
.	O

Here	O
we	O
report	O
that	O
the	O
distal	O
region	O
of	O
the	O
hepatoma	S-Cancer
type	O
II	O
hexokinase	O
promoter	O
displays	O
consensus	O
motifs	O
for	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
-	O
1	O
)	O
that	O
overlap	O
E	O
-	O
box	O
sequences	O
known	O
to	O
be	O
related	O
in	O
other	O
gene	O
promoters	O
to	O
glucose	O
response	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
subjecting	O
transfected	O
hepatoma	B-Cell
cells	E-Cell
to	O
hypoxic	O
conditions	O
activates	O
the	O
type	O
II	O
hexokinase	O
promoter	O
almost	O
3	O
-	O
fold	O
,	O
a	O
value	O
that	O
approaches	O
7	O
-	O
fold	O
in	O
the	O
presence	O
of	O
glucose	O
.	O

Consistent	O
with	O
these	O
findings	O
is	O
the	O
induction	O
under	O
hypoxic	O
conditions	O
of	O
the	O
HIF	O
-	O
1	O
protein	O
.	O

Reporter	O
gene	O
analyses	O
with	O
a	O
series	O
of	O
nested	O
deletion	O
mutants	O
of	O
the	O
hepatoma	S-Cancer
type	O
II	O
hexokinase	O
promoter	O
show	O
that	O
a	O
significant	O
fraction	O
of	O
the	O
total	O
activation	O
observed	O
under	O
hypoxic	O
conditions	O
localizes	O
to	O
the	O
distal	O
region	O
where	O
the	O
overlapping	O
HIF	O
-	O
1	O
/	O
E	O
-	O
box	O
sequences	O
are	O
located	O
.	O

Finally	O
,	O
DNase	O
I	O
footprint	O
analysis	O
with	O
a	O
segment	O
of	O
the	O
promoter	O
containing	O
these	O
elements	O
reveals	O
the	O
binding	O
of	O
several	O
nuclear	S-Cellular_component
proteins	O
.	O

In	O
summary	O
,	O
these	O
novel	O
studies	O
identify	O
and	O
characterize	O
a	O
marked	O
glucose	O
-	O
modulated	O
activation	O
response	O
of	O
the	O
type	O
II	O
hexokinase	O
gene	O
to	O
hypoxic	O
conditions	O
within	O
highly	O
glycolytic	O
hepatoma	B-Cell
cells	E-Cell
,	O
a	O
property	O
that	O
may	O
help	O
assure	O
that	O
such	O
cells	S-Cell
exhibit	O
a	O
growth	O
and	O
survival	O
advantage	O
over	O
their	O
parental	O
cells	S-Cell
of	O
origin	O
.	O

[	O
Decreased	O
stimulation	O
of	O
glycosaminoglycan	O
synthesis	O
by	O
human	O
skin	B-Cell
fibroblasts	E-Cell
by	O
interleukin	O
6	O
within	O
the	O
scope	O
of	O
in	O
vitro	O
aging	O
]	O
.	O

Addition	O
of	O
human	O
recombinant	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
to	O
culture	O
medium	O
(	O
supplemented	O
MEM	O
without	O
or	O
with	O
10	O
%	O
fetal	B-Organism_substance
calf	I-Organism_substance
serum	E-Organism_substance
(	O
FCS	S-Organism_substance
)	O
)	O
of	O
human	O
skin	B-Cell
fibroblasts	E-Cell
exerted	O
a	O
stimulating	O
effect	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
on	O
glycosaminoglycan	O
(	O
GAG	O
)	O
synthesis	O
,	O
including	O
hyaluronic	O
acid	O
(	O
hyaluronan	O
)	O
synthesis	O
,	O
of	O
young	O
(	O
phase	O
-	O
II	O
)	O
skin	B-Cell
fibroblasts	E-Cell
in	O
concentrations	O
of	O
1	O
ng	O
/	O
ml	O
and	O
10	O
ng	O
/	O
ml	O
.	O

Stimulation	O
was	O
mainly	O
due	O
to	O
an	O
increase	O
in	O
extracellular	S-Immaterial_anatomical_entity
GAGs	O
(	O
secreted	O
into	O
culture	O
medium	O
)	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
to	O
an	O
increase	O
in	O
peri	S-Immaterial_anatomical_entity
-	O
and	O
intracellular	S-Immaterial_anatomical_entity
GAGs	O
.	O

Stimulation	O
with	O
1	O
ng	O
/	O
ml	O
and	O
10	O
ng	O
/	O
ml	O
IL	O
-	O
6	O
led	O
to	O
an	O
increase	O
in	O
hyaluronic	O
acid	O
from	O
48	O
%	O
to	O
61	O
%	O
(	O
-	O
FCS	S-Organism_substance
)	O
and	O
from	O
77	O
%	O
to	O
90	O
%	O
(	O
+	O
10	O
%	O
FCS	S-Organism_substance
)	O
,	O
respectively	O
.	O

Maximum	O
stimulation	O
,	O
with	O
and	O
without	O
FCS	S-Organism_substance
,	O
was	O
achieved	O
by	O
10	O
ng	O
/	O
ml	O
IL	O
-	O
6	O
.	O

Compared	O
to	O
young	O
(	O
phase	O
-	O
II	O
)	O
cells	S-Cell
,	O
senescent	O
(	O
phase	O
-	O
III	O
)	O
cells	S-Cell
,	O
showed	O
no	O
significant	O
stimulation	O
of	O
total	O
GAG	O
(	O
including	O
hyaluronic	O
acid	O
)	O
synthesis	O
by	O
IL	O
-	O
6	O
.	O

The	O
diminished	O
response	O
of	O
GAG	O
-	O
and	O
hyaluronic	O
acid	O
synthesis	O
during	O
aging	O
of	O
these	O
in	O
vitro	O
cultured	O
fibroblasts	S-Cell
should	O
motivate	O
further	O
research	O
if	O
similar	O
processes	O
occur	O
during	O
aging	O
in	O
an	O
organism	O
.	O

Membrane	S-Cellular_component
-	O
anchored	O
Cbl	O
suppresses	O
Hck	O
protein	O
-	O
tyrosine	O
kinase	O
mediated	O
cellular	S-Cell
transformation	O
.	O

The	O
mammalian	O
proto	O
-	O
oncogene	O
Cbl	O
and	O
its	O
cellular	S-Cell
homologues	O
in	O
Caenorhabditis	O
elegans	O
(	O
Sli	O
-	O
1	O
)	O
and	O
Drosophila	O
(	O
D	O
-	O
Cbl	O
)	O
are	O
negative	O
regulators	O
of	O
some	O
growth	O
factor	O
receptor	O
signaling	O
pathways	O
.	O

Herein	O
we	O
show	O
that	O
Cbl	O
can	O
negatively	O
regulate	O
another	O
signaling	O
molecule	O
,	O
namely	O
theSrc	O
-	O
family	O
kinase	O
Hck	O
by	O
targeting	O
it	O
for	O
degradation	O
.	O

Hck	O
-	O
mediated	O
cellular	S-Cell
transformation	O
of	O
murine	O
fibroblasts	S-Cell
is	O
reverted	O
by	O
ectopic	O
expression	O
of	O
a	O
membrane	S-Cellular_component
-	O
anchored	O
allele	O
of	O
Cbl	O
as	O
assessed	O
by	O
the	O
cellular	S-Cell
morphology	O
,	O
suppression	O
of	O
anchorage	O
independent	O
growth	O
,	O
and	O
an	O
overall	O
reduction	O
in	O
the	O
total	O
tyrosine	O
phosphorylation	O
levels	O
within	O
the	O
cells	S-Cell
.	O

The	O
expression	O
of	O
Cbl	O
at	O
the	O
plasma	B-Cellular_component
membrane	E-Cellular_component
targets	O
both	O
Hck	O
and	O
itself	O
for	O
ubiquitination	O
and	O
degradation	O
,	O
requiring	O
an	O
intact	O
RING	O
finger	O
.	O

Pharmacological	O
inhibition	O
of	O
the	O
proteasome	O
prevents	O
the	O
degradation	O
of	O
Hck	O
correlating	O
with	O
an	O
increase	O
in	O
the	O
phosphotyrosine	O
levels	O
within	O
the	O
cells	S-Cell
.	O

Activated	O
Hck	O
and	O
membrane	S-Cellular_component
-	O
anchored	O
Cbl	O
are	O
present	O
in	O
similar	O
subcellular	S-Cellular_component
localizations	O
and	O
co	O
-	O
immunoprecipitate	O
,	O
suggesting	O
that	O
their	O
interaction	O
is	O
required	O
for	O
subsequent	O
ubiquitination	O
and	O
degradation	O
.	O

Interestingly	O
,	O
both	O
constitutively	O
active	O
and	O
kinase	O
-	O
inactive	O
Hck	O
interact	O
with	O
and	O
are	O
targeted	O
for	O
degradation	O
by	O
Cbl	O
.	O

This	O
work	O
illustrates	O
alternate	O
means	O
to	O
regulate	O
Src	O
-	O
family	O
kinases	O
,	O
and	O
suggests	O
that	O
Cbl	O
may	O
be	O
able	O
to	O
suppress	O
many	O
signaling	O
pathways	O
that	O
are	O
activated	O
in	O
various	O
proliferative	O
syndromes	O
including	O
cancer	S-Cancer
.	O

Multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	B-Cell
cells	E-Cell
modelled	O
by	O
co	O
-	O
expression	O
of	O
telomerase	O
reverse	O
transcriptase	O
,	O
SV40	O
T	O
antigen	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

We	O
have	O
modelled	O
multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	B-Cell
cells	E-Cell
(	O
ECs	S-Cell
)	O
by	O
overexpressing	O
the	O
catalytic	O
subunit	O
of	O
human	O
telomerase	O
(	O
hTERT	O
)	O
,	O
together	O
with	O
SV40	O
T	O
antigen	O
(	O
SV40T	O
)	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

Transfection	O
with	O
hTERT	O
alone	O
,	O
led	O
to	O
the	O
immortalization	O
of	O
two	O
out	O
of	O
three	O
cultures	S-Cell
of	O
bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
ECs	E-Cell
(	O
BMECs	S-Cell
)	O
.	O

One	O
hTERT	O
transduced	O
BMEC	B-Cell
culture	E-Cell
underwent	O
a	O
long	O
proliferative	O
lag	O
before	O
resuming	O
proliferation	O
.	O

BMECs	S-Cell
transfected	O
with	O
hTERT	O
alone	O
were	O
functionally	O
and	O
phenotypically	O
normal	O
.	O

BMECs	S-Cell
transfected	O
with	O
SV40T	O
(	O
BMSVTs	S-Cell
)	O
had	O
an	O
extended	O
lifespan	O
,	O
but	O
eventually	O
succumbed	O
to	O
crisis	O
.	O

BMSVTs	S-Cell
exhibited	O
a	O
partially	O
transformed	O
phenotype	O
,	O
demonstrating	O
growth	O
factor	O
independence	O
,	O
altered	O
antigen	O
expression	O
and	O
forming	O
tiny	O
,	O
infrequent	O
colonies	S-Cell
in	O
vitro	O
.	O

Transduction	O
of	O
BMSVTs	S-Cell
with	O
hTERT	O
resulted	O
in	O
immortalization	O
of	O
4	O
out	O
of	O
4	O
cultures	S-Cell
.	O

BMSVTs	S-Cell
immortalized	O
with	O
hTERT	O
formed	O
large	O
colonies	S-Cell
in	O
vitro	O
and	O
small	O
transient	O
tumours	S-Cancer
in	O
vivo	O
.	O

BMECs	S-Cell
co	O
-	O
expressing	O
SV40T	O
,	O
hTERT	O
and	O
N	O
-	O
ras	O
exhibited	O
an	O
overtly	O
transformed	O
phenotype	O
;	O
forming	O
very	O
large	O
colonies	S-Cell
with	O
an	O
altered	O
morphology	O
and	O
generating	O
rapidly	O
growing	O
tumours	S-Cancer
in	O
vivo	O
.	O

These	O
investigations	O
demonstrate	O
transformation	O
of	O
human	O
ECs	S-Cell
to	O
an	O
overtly	O
malignant	O
phenotype	O
.	O

This	O
model	O
will	O
be	O
useful	O
for	O
understanding	O
mechanisms	O
underlying	O
vascular	S-Cancer
and	O
angiogenic	B-Cancer
neoplasias	E-Cancer
,	O
as	O
well	O
as	O
for	O
testing	O
drugs	O
designed	O
to	O
curtail	O
aberrant	O
EC	S-Cell
growth	O
.	O

Prenatal	O
hypoxia	O
decreases	O
lung	B-Immaterial_anatomical_entity
extracellular	E-Immaterial_anatomical_entity
superoxide	O
dismutase	O
expression	O
and	O
activity	O
.	O

Extracellular	S-Immaterial_anatomical_entity
superoxide	O
dismutase	O
(	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
)	O
,	O
which	O
scavenges	O
extracellular	S-Immaterial_anatomical_entity
superoxide	O
(	O
O	O
.	O
)	O
,	O
is	O
highly	O
regulated	O
in	O
the	O
developing	O
lung	S-Organ
.	O

In	O
the	O
prenatal	O
rabbit	O
,	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
is	O
predominantly	O
intracellular	S-Immaterial_anatomical_entity
and	O
inactive	O
,	O
and	O
postnatally	O
,	O
active	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
is	O
secreted	O
.	O

We	O
hypothesized	O
that	O
prenatal	O
hypoxia	O
would	O
delay	O
the	O
normal	O
postnatal	O
secretion	O
of	O
active	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
in	O
the	O
lung	S-Organ
.	O

Pregnant	O
New	O
Zealand	O
White	O
rabbits	O
were	O
exposed	O
to	O
hypobaric	O
hypoxia	O
(	O
15	O
,	O
000	O
ft	O
x	O
36	O
h	O
)	O
to	O
alter	O
fetal	S-Developing_anatomical_structure
O	O
(	O
2	O
)	O
tension	O
or	O
were	O
maintained	O
in	O
room	O
air	O
.	O

Lungs	S-Organ
were	O
harvested	O
from	O
preterm	O
(	O
28	O
days	O
)	O
,	O
term	O
(	O
30	O
+	O
/	O
-	O
1	O
day	O
)	O
,	O
and	O
1	O
-	O
wk	O
-	O
old	O
kits	O
.	O

After	O
prenatal	O
hypobaric	O
hypoxia	O
,	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
lungs	S-Organ
of	O
full	O
-	O
term	O
kits	O
,	O
whereas	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
protein	O
decreased	O
at	O
all	O
ages	O
.	O

Immunohistochemical	O
staining	O
for	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
showed	O
that	O
hypoxia	O
delayed	O
secretion	O
of	O
the	O
isoenzyme	O
in	O
the	O
airways	S-Multi-tissue_structure
and	O
pulmonary	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

Furthermore	O
,	O
pulmonary	B-Immaterial_anatomical_entity
EC	E-Immaterial_anatomical_entity
-	O
SOD	O
enzyme	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
1	O
-	O
wk	O
-	O
old	O
kits	O
exposed	O
to	O
prenatal	O
hypoxia	O
.	O

We	O
conclude	O
that	O
prenatal	O
hypoxia	O
downregulates	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
expression	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
.	O

Furthermore	O
,	O
prenatal	O
hypoxia	O
delays	O
secretion	O
of	O
active	O
EC	S-Immaterial_anatomical_entity
-	O
SOD	O
enzyme	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
effects	O
of	O
prenatal	O
asphyxia	O
on	O
postnatal	O
response	O
to	O
oxidant	O
stress	O
.	O

Retinal	S-Multi-tissue_structure
microangiopathies	O
overlying	O
pigment	B-Tissue
epithelial	E-Tissue
detachment	O
in	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
alterations	O
in	O
the	O
retinal	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
overlying	O
pigment	B-Pathological_formation
epithelial	I-Pathological_formation
detachments	E-Pathological_formation
(	O
PED	S-Pathological_formation
)	O
in	O
exudative	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	O
(	O
ARMD	O
)	O
using	O
indocyanine	O
green	O
and	O
fluorescein	O
angiography	O
.	O

METHODS	O
:	O
Forty	O
-	O
one	O
patients	O
(	O
41	O
eyes	S-Organ
)	O
with	O
a	O
clinical	O
diagnosis	O
of	O
exudative	O
ARMD	O
with	O
PED	S-Pathological_formation
underwent	O
simultaneous	O
fluorescein	O
and	O
indocyanine	O
green	O
angiography	O
,	O
also	O
under	O
high	O
(	O
10	O
degrees	O
)	O
magnification	O
.	O

Vascular	S-Multi-tissue_structure
abnormalities	O
in	O
the	O
retina	S-Multi-tissue_structure
were	O
compared	O
between	O
patients	O
with	O
vascularized	O
(	O
n	O
=	O
34	O
,	O
group	O
1	O
)	O
and	O
nonvascularized	O
(	O
n	O
=	O
7	O
,	O
group	O
2	O
)	O
PED	S-Pathological_formation
on	O
indocyanine	O
green	O
angiography	O
and	O
correlated	O
with	O
the	O
size	O
of	O
the	O
PED	S-Pathological_formation
and	O
the	O
presence	O
of	O
serous	B-Multi-tissue_structure
retinal	E-Multi-tissue_structure
detachment	O
.	O

RESULTS	O
:	O
In	O
all	O
,	O
67	O
vascular	S-Multi-tissue_structure
abnormalities	O
were	O
found	O
by	O
indocyanine	O
green	O
angiography	O
and	O
only	O
22	O
by	O
fluorescein	O
angiography	O
;	O
this	O
finding	O
was	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
finding	O
of	O
retinal	S-Multi-tissue_structure
vasculopathy	O
(	O
32	O
patients	O
in	O
group	O
1	O
and	O
two	O
patients	O
in	O
group	O
2	O
)	O
was	O
directly	O
correlated	O
with	O
the	O
presence	O
of	O
choroidal	S-Multi-tissue_structure
neovascularizations	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

There	O
was	O
also	O
a	O
direct	O
correlation	O
between	O
the	O
presence	O
of	O
choroidal	S-Multi-tissue_structure
neovascularization	O
and	O
size	O
of	O
the	O
PED	S-Pathological_formation
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
number	O
of	O
retinal	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
findings	O
was	O
not	O
significantly	O
correlated	O
with	O
serous	S-Organism_substance
elevation	O
of	O
the	O
retina	S-Multi-tissue_structure
.	O

CONCLUSIONS	O
:	O
Retinal	S-Multi-tissue_structure
vasculopathies	O
may	O
be	O
observed	O
in	O
eyes	S-Organ
with	O
PED	S-Pathological_formation
and	O
are	O
detectable	O
by	O
indocyanine	O
green	O
and	O
fluorescein	O
angiography	O
.	O

Fas	O
-	O
Fas	O
ligand	O
signaling	O
pathway	O
mediates	O
an	O
interleukin	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
a	O
murine	O
prostate	B-Cancer
tumor	E-Cancer
system	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
anti	O
-	O
tumor	S-Cancer
activities	O
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
involve	O
the	O
induction	O
of	O
apoptosis	O
.	O

Fas	O
(	O
APO	O
-	O
1	O
/	O
CD95	O
)	O
is	O
a	O
type	O
I	O
membrane	S-Cellular_component
protein	O
that	O
is	O
capable	O
of	O
initiating	O
an	O
apoptosis	O
signaling	O
pathway	O
when	O
bound	O
to	O
its	O
ligand	O
(	O
FasL	O
)	O
.	O

We	O
undertook	O
this	O
study	O
to	O
test	O
the	O
hypothesis	O
that	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
plays	O
a	O
role	O
in	O
IL	O
-	O
12	O
-	O
induced	O
tumor	S-Cancer
regression	O
.	O

METHODS	O
:	O
An	O
mIL	O
-	O
12	O
expression	O
vector	O
driven	O
by	O
cytomegalovirus	O
promoter	O
was	O
used	O
to	O
express	O
murine	O
IL	O
-	O
12	O
cDNA	O
in	O
the	O
RM	B-Cell
-	I-Cell
9	I-Cell
murine	I-Cell
prostate	I-Cell
carcinoma	I-Cell
cell	I-Cell
line	E-Cell
.	O

Control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	E-Cell
and	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	E-Cell
stably	O
transfected	O
with	O
IL	O
-	O
12	O
gene	O
(	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
IL12	E-Cell
)	O
were	O
inoculated	O
subcutaneously	S-Immaterial_anatomical_entity
in	O
4	O
-	O
to	O
6	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
J6	O
mice	O
.	O

Tumor	S-Cancer
size	O
was	O
measured	O
every	O
3	O
days	O
.	O

Western	O
blot	O
and	O
immunohistochemical	O
assays	O
were	O
used	O
to	O
evaluate	O
Fas	O
and	O
FasL	O
protein	O
expression	O
.	O

In	O
situ	O
fluorescent	O
end	O
labeling	O
was	O
used	O
to	O
label	O
apoptotic	O
cells	S-Cell
.	O

RESULTS	O
:	O
IL	O
-	O
12	O
-	O
expressing	O
RM	B-Cell
-	I-Cell
9	I-Cell
prostate	I-Cell
carcinoma	I-Cell
cells	E-Cell
transplanted	O
into	O
C57BL	O
/	O
J6	O
mice	O
grew	O
more	O
slowly	O
than	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	E-Cell
and	O
vector	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
Luc	I-Cell
cells	E-Cell
.	O

The	O
average	O
survival	O
time	O
of	O
the	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
IL12	E-Cell
mice	O
was	O
longer	O
than	O
53	O
days	O
,	O
whereas	O
the	O
mean	O
survival	O
for	O
mice	O
transplanted	O
with	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	E-Cell
was	O
only	O
16	O
days	O
.	O

Apoptotic	O
cells	S-Cell
were	O
more	O
numerous	O
in	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
-	I-Cancer
IL12	I-Cancer
tumors	E-Cancer
:	O
10	O
.	O
3	O
%	O
vs	O
.	O
1	O
.	O
5	O
%	O
in	O
control	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Fas	O
and	O
FasL	O
proteins	O
were	O
increased	O
approximately	O
twofold	O
in	O
the	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
-	I-Cancer
IL12	I-Cancer
tumors	E-Cancer
compared	O
with	O
the	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
control	I-Cancer
tumors	E-Cancer
as	O
determined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analyses	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
pathway	O
may	O
contribute	O
to	O
the	O
IL	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
prostate	B-Cancer
carcinoma	E-Cancer
.	O

Genetic	O
differences	O
in	O
susceptibility	O
to	O
ulcerative	S-Pathological_formation
enteritis	O
in	O
Japanese	O
quail	O
.	O

Six	O
lines	O
of	O
Japanese	O
quail	O
were	O
derived	O
from	O
a	O
single	O
foundation	O
population	O
.	O

Four	O
of	O
the	O
lines	O
were	O
selected	O
on	O
the	O
basis	O
of	O
family	O
mean	O
three	O
week	O
body	S-Organism_subdivision
weight	O
,	O
two	O
were	O
unselected	O
and	O
all	O
lines	O
were	O
randomly	O
mated	O
.	O

Quail	O
were	O
housed	O
in	O
wire	O
batteries	O
during	O
the	O
brooding	O
,	O
rearing	O
and	O
laying	O
periods	O
.	O

During	O
the	O
brooding	O
period	O
,	O
hover	O
temperature	O
and	O
floor	O
space	O
per	O
chick	O
were	O
similar	O
from	O
line	O
to	O
line	O
.	O

For	O
the	O
rearing	O
and	O
laying	O
periods	O
,	O
floor	O
space	O
per	O
chick	O
was	O
approximately	O
the	O
same	O
from	O
line	O
to	O
line	O
.	O

During	O
an	O
outbreak	O
of	O
ulcerative	S-Pathological_formation
enteritis	O
(	O
diagnosed	O
on	O
the	O
basis	O
of	O
gross	O
and	O
histopathology	O
)	O
in	O
generation	O
31	O
and	O
again	O
in	O
generation	O
34	O
,	O
mortality	O
ranged	O
from	O
zero	O
for	O
males	O
of	O
one	O
control	O
line	O
to	O
approximately	O
50	O
percent	O
for	O
females	O
of	O
one	O
selected	O
line	O
.	O

Analysis	O
of	O
variance	O
showed	O
that	O
incidence	O
of	O
mortality	O
differed	O
significantly	O
among	O
lines	O
and	O
between	O
sexes	O
.	O

Mortality	O
was	O
generally	O
higher	O
in	O
selected	O
than	O
in	O
control	O
lines	O
and	O
in	O
females	O
than	O
in	O
males	O
.	O

It	O
is	O
suggested	O
that	O
susceptibility	O
to	O
ulcerative	S-Pathological_formation
enteritis	O
in	O
quail	O
may	O
be	O
a	O
polygenically	O
inherited	O
trait	O
and	O
that	O
the	O
breeding	O
which	O
accompanied	O
selection	O
for	O
body	S-Organism_subdivision
size	O
may	O
have	O
made	O
some	O
loci	O
homozygous	O
for	O
susceptibility	O
alleles	O
.	O

[	O
A	O
decline	O
in	O
the	O
French	O
demographic	O
situation	O
in	O
the	O
context	O
of	O
a	O
Europe	O
also	O
in	O
demographic	O
decline	O
]	O
.	O

The	O
author	O
analyzes	O
the	O
decline	O
in	O
French	O
fertility	O
which	O
has	O
occurred	O
over	O
the	O
past	O
two	O
years	O
using	O
data	O
from	O
official	O
sources	O
.	O

Some	O
comparisons	O
are	O
made	O
with	O
fertility	O
trends	O
in	O
other	O
European	O
countries	O
.	O

The	O
patterns	O
of	O
internal	O
migration	O
in	O
Maharashtra	O
:	O
an	O
analysis	O
of	O
1971	O
census	O
data	O
.	O

Patterns	O
of	O
internal	O
migration	O
in	O
the	O
state	O
of	O
Maharashtra	O
,	O
India	O
,	O
for	O
the	O
period	O
1961	O
-	O
1971	O
are	O
analyzed	O
using	O
1971	O
census	O
data	O
.	O

The	O
nature	O
,	O
volume	O
,	O
and	O
direction	O
of	O
migration	O
are	O
examined	O
.	O

Migrants	O
are	O
characterized	O
according	O
to	O
factors	O
including	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
and	O
areas	O
of	O
origin	O
and	O
destination	O
.	O

Adaptor	O
protein	O
Crk	O
is	O
required	O
for	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	S-Cellular_component
ruffling	O
and	O
focal	B-Cellular_component
complex	E-Cellular_component
assembly	O
of	O
human	O
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Endothelial	B-Cell
cell	E-Cell
migration	O
is	O
an	O
essential	O
step	O
in	O
vasculogenesis	O
and	O
angiogenesis	O
,	O
in	O
which	O
receptor	O
tyrosine	O
kinases	O
play	O
a	O
pivotal	O
role	O
.	O

We	O
investigated	O
the	O
mechanism	O
by	O
which	O
ephrin	O
-	O
B1	O
promotes	O
membrane	S-Cellular_component
ruffling	O
in	O
human	O
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
because	O
membrane	S-Cellular_component
ruffling	O
heralds	O
cell	B-Cell
body	E-Cell
migration	O
.	O

We	O
especially	O
focused	O
on	O
the	O
role	O
of	O
Crk	O
adaptor	O
protein	O
in	O
EphB	O
-	O
mediated	O
signaling	O
.	O

Using	O
DsRed	O
-	O
tagged	O
Crk	O
and	O
a	O
fluorescent	O
time	O
-	O
lapse	O
microscope	O
,	O
we	O
showed	O
that	O
Crk	O
was	O
recruited	O
to	O
the	O
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
after	O
ephrin	O
-	O
B1	O
stimulation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
p130	O
(	O
Cas	O
)	O
,	O
but	O
not	O
paxillin	O
,	O
recruited	O
Crk	O
to	O
the	O
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
.	O

The	O
necessity	O
of	O
Crk	O
in	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	S-Cellular_component
ruffling	O
was	O
shown	O
both	O
by	O
the	O
overexpression	O
of	O
dominant	O
negative	O
Crk	O
mutants	O
and	O
by	O
the	O
depletion	O
of	O
Crk	O
by	O
using	O
RNA	O
interference	O
.	O

Then	O
,	O
we	O
examined	O
the	O
role	O
of	O
two	O
major	O
downstream	O
molecules	O
of	O
Crk	O
,	O
Rac1	O
and	O
Rap1	O
.	O

The	O
dominant	O
negative	O
mutant	O
of	O
Rac1	O
completely	O
inhibited	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	S-Cellular_component
ruffling	O
and	O
focal	B-Cellular_component
complex	E-Cellular_component
assembly	O
.	O

In	O
contrast	O
,	O
rap1GAPII	O
,	O
a	O
negative	O
regulator	O
of	O
Rap1	O
,	O
did	O
not	O
inhibit	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	S-Cellular_component
ruffling	O
.	O

However	O
,	O
in	O
rap1GAPII	B-Cell
-	I-Cell
expressing	I-Cell
cells	E-Cell
,	O
ephrin	O
-	O
B1	O
did	O
not	O
induce	O
membrane	S-Cellular_component
spreading	O
,	O
probably	O
due	O
to	O
instability	O
of	O
the	O
focal	B-Cellular_component
complex	E-Cellular_component
.	O

These	O
results	O
indicated	O
that	O
Crk	O
plays	O
a	O
critical	O
role	O
in	O
Rac1	O
-	O
induced	O
membrane	S-Cellular_component
ruffling	O
and	O
Rap1	O
-	O
mediated	O
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
stabilization	O
contributing	O
to	O
ephrin	O
-	O
B1	O
-	O
induced	O
human	O
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
migration	O
.	O

Postoperative	O
progression	O
of	O
pulmonary	S-Organ
metastasis	O
in	O
osteosarcoma	S-Cancer
.	O

Early	O
relapse	O
with	O
distant	O
metastasis	O
often	O
is	O
observed	O
in	O
patients	O
with	O
cancer	S-Cancer
after	O
resection	O
of	O
the	O
primary	B-Cancer
tumor	E-Cancer
.	O

It	O
is	O
considered	O
that	O
resection	O
of	O
the	O
primary	B-Cancer
tumor	E-Cancer
induces	O
activation	O
of	O
systemic	O
angiogenesis	O
and	O
enhances	O
progression	O
of	O
remote	O
metastasis	O
.	O

The	O
authors	O
show	O
that	O
resection	O
of	O
the	O
primary	B-Cancer
osteosarcoma	I-Cancer
tumor	E-Cancer
enhances	O
progression	O
of	O
pulmonary	S-Organ
metastasis	O
in	O
animal	O
osteosarcoma	S-Cancer
models	O
.	O

Matrigel	O
plug	O
neovascularization	O
assay	O
revealed	O
that	O
systemic	O
angiogenic	O
activity	O
was	O
elevated	O
after	O
primary	B-Cancer
tumor	E-Cancer
removal	O
(	O
tumor	S-Cancer
intact	O
group	O
,	O
1	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
21	O
g	O
/	O
dL	O
;	O
tumor	S-Cancer
removed	O
group	O
,	O
4	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
35	O
g	O
/	O
dL	O
)	O
.	O

In	O
addition	O
,	O
serum	S-Organism_substance
concentration	O
of	O
the	O
angiogenesis	O
inhibitor	O
,	O
endostatin	O
,	O
decreased	O
significantly	O
after	O
primary	B-Cancer
tumor	E-Cancer
removal	O
.	O

Treatment	O
with	O
the	O
antiangiogenic	O
reagent	O
TNP	O
-	O
470	O
suppressed	O
postoperative	O
progression	O
of	O
pulmonary	S-Organ
metastasis	O
.	O

These	O
results	O
indicate	O
the	O
possibility	O
that	O
activation	O
of	O
angiogenic	O
activity	O
after	O
resection	O
of	O
osteosarcoma	B-Cancer
tumors	E-Cancer
enhances	O
progression	O
of	O
pulmonary	S-Organ
metastasis	O
.	O

The	O
current	O
data	O
also	O
suggest	O
that	O
administration	O
of	O
antiangiogenic	O
reagents	O
can	O
prevent	O
progression	O
of	O
pulmonary	S-Organ
metastasis	O
in	O
osteosarcoma	S-Cancer
postoperatively	O
.	O

Antiapoptotic	O
effect	O
of	O
coagulation	O
factor	O
VIIa	O
.	O

Binding	O
of	O
factor	O
VIIa	O
(	O
FVIIa	O
)	O
to	O
its	O
cellular	S-Cell
receptor	O
tissue	O
factor	O
(	O
TF	O
)	O
was	O
previously	O
shown	O
to	O
induce	O
various	O
intracellular	S-Immaterial_anatomical_entity
signaling	O
events	O
,	O
which	O
were	O
thought	O
to	O
be	O
responsible	O
for	O
TF	O
-	O
mediated	O
biologic	O
effects	O
,	O
including	O
angiogenesis	O
,	O
tumor	S-Cancer
metastasis	O
,	O
and	O
restenosis	O
.	O

To	O
understand	O
the	O
mechanisms	O
behind	O
these	O
processes	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
FVIIa	O
on	O
apoptosis	O
.	O

Serum	S-Organism_substance
deprivation	O
-	O
induced	O
apoptosis	O
of	O
BHK	B-Cell
(	I-Cell
+	I-Cell
TF	I-Cell
)	I-Cell
cells	E-Cell
was	O
characterized	O
by	O
apoptotic	O
blebs	S-Cellular_component
,	O
nuclei	S-Cellular_component
with	O
chromatin	S-Cellular_component
-	O
condensed	O
bodies	O
,	O
DNA	O
degradation	O
,	O
and	O
activation	O
of	O
caspase	O
3	O
.	O

FVIIa	O
markedly	O
decreased	O
the	O
number	O
of	O
cells	S-Cell
with	O
apoptotic	O
morphology	O
and	O
prevented	O
the	O
DNA	O
degradation	O
as	O
measured	O
by	O
means	O
of	O
TdT	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
.	O

The	O
antiapoptotic	O
effect	O
of	O
FVIIa	O
was	O
confirmed	O
by	O
the	O
observation	O
that	O
FVIIa	O
attenuated	O
caspase	O
3	O
activation	O
.	O

FVIIa	O
-	O
induced	O
antiapoptotic	O
effect	O
was	O
dependent	O
on	O
its	O
proteolytic	O
activity	O
and	O
TF	O
but	O
independent	O
of	O
factor	O
Xa	O
and	O
thrombin	O
.	O

FVIIa	O
-	O
induced	O
cell	S-Cell
survival	O
correlated	O
with	O
the	O
activation	O
of	O
Akt	O
and	O
was	O
inhibited	O
markedly	O
by	O
the	O
specific	O
PI3	O
-	O
kinase	O
inhibitor	O
,	O
LY294002	O
.	O

Blocking	O
the	O
activation	O
of	O
p44	O
/	O
42	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
by	O
the	O
specific	O
mitogen	O
-	O
induced	O
extracellular	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
,	O
U0126	O
,	O
impaired	O
modestly	O
the	O
ability	O
of	O
FVIIa	O
to	O
promote	O
cell	S-Cell
survival	O
.	O

In	O
conclusion	O
,	O
FVIIa	O
binding	O
to	O
TF	O
provided	O
protection	O
against	O
apoptosis	O
induced	O
by	O
growth	O
factor	O
deprivation	O
,	O
primarily	O
through	O
activation	O
of	O
PI3	O
-	O
kinase	O
/	O
Akt	O
pathway	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
p44	O
/	O
42	O
MAPK	O
pathway	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
of	O
a	O
specific	O
Epstein	O
-	O
Barr	O
virus	O
variant	O
derived	O
from	O
the	O
nasopharyngeal	B-Cancer
carcinoma	E-Cancer
in	O
the	O
Taiwanese	O
population	O
.	O

A	O
DNA	O
fragment	O
containing	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
terminal	O
fragment	O
sequence	O
was	O
obtained	O
from	O
a	O
genomic	O
library	O
of	O
nasopharyngeal	B-Cancer
carcinoma	E-Cancer
(	O
NPC	S-Cancer
)	O
.	O

One	O
of	O
the	O
clones	O
(	O
clone	O
1510	O
)	O
contained	O
the	O
gene	O
encoding	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
this	O
gene	O
had	O
95	O
%	O
homology	O
with	O
the	O
LMP	O
sequence	O
of	O
the	O
B95	O
-	O
8	O
strain	O
.	O

Among	O
the	O
sequence	O
variations	O
,	O
there	O
was	O
a	O
change	O
from	O
G	O
to	O
T	O
at	O
nucleotide	O
position	O
169	O
,	O
426	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
an	O
XhoI	O
site	O
in	O
exon	O
1	O
of	O
the	O
LMP	O
gene	O
.	O

A	O
pair	O
of	O
primers	O
bracketing	O
the	O
XhoI	O
site	O
were	O
designed	O
to	O
synthesize	O
the	O
EBV	O
DNA	O
fragment	O
from	O
nucleotides	O
169	O
,	O
081	O
-	O
169	O
,	O
577	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
then	O
subject	O
to	O
XhoI	O
digestion	O
and	O
to	O
DNA	O
sequencing	O
analysis	O
.	O

This	O
restriction	O
enzyme	O
site	O
polymorphism	O
along	O
with	O
the	O
sequence	O
variations	O
were	O
also	O
observed	O
in	O
50	O
biopsy	B-Tissue
tissues	E-Tissue
as	O
well	O
as	O
in	O
the	O
throat	S-Organism_subdivision
washings	O
of	O
6	O
out	O
of	O
20	O
healthy	O
individuals	O
that	O
we	O
examined	O
,	O
indicating	O
that	O
the	O
EBV	O
strain	O
predominantly	O
existing	O
in	O
these	O
biopsy	B-Tissue
tissues	E-Tissue
was	O
different	O
from	O
strains	O
of	O
B95	O
-	O
8	O
,	O
Jijoye	O
or	O
nude	O
mouse	O
passaged	O
cells	S-Cell
(	O
C15	S-Cell
)	O
with	O
an	O
African	O
origin	O
,	O
but	O
closely	O
resembled	O
other	O
nude	O
mouse	O
passaged	O
CAO	B-Cell
cells	E-Cell
which	O
were	O
originally	O
derived	O
from	O
China	O
.	O

Balb	B-Cell
/	I-Cell
c	I-Cell
3T3	I-Cell
cells	E-Cell
carrying	O
this	O
NPC	S-Cancer
-	O
LMP	O
gene	O
showed	O
a	O
transformed	O
cell	S-Cell
morphology	O
and	O
were	O
tumorigenic	O
in	O
nude	O
mice	O
.	O

The	O
relationship	O
between	O
this	O
unique	O
type	O
of	O
EBV	O
and	O
NPC	S-Cancer
has	O
yet	O
to	O
be	O
established	O
.	O

Laser	O
treatment	O
of	O
eccentric	O
leaks	O
in	O
central	O
serous	S-Organism_substance
chorioretinopathy	O
resulting	O
in	O
disappearance	O
of	O
untreated	O
juxtafoveal	S-Immaterial_anatomical_entity
leaks	O
.	O

In	O
central	O
serous	S-Organism_substance
chorioretinopathy	O
(	O
CSCR	O
)	O
laser	O
treatment	O
of	O
leaking	O
points	O
close	O
to	O
the	O
macular	B-Tissue
center	E-Tissue
should	O
be	O
avoided	O
because	O
of	O
the	O
possibility	O
of	O
producing	O
juxtafoveal	B-Pathological_formation
scotoma	E-Pathological_formation
and	O
stimulating	O
choroidal	S-Multi-tissue_structure
neovascularization	O
.	O

Nine	O
eyes	S-Organ
of	O
nine	O
consecutive	O
patients	O
with	O
CSCR	O
had	O
two	O
or	O
more	O
leaking	O
points	O
within	O
a	O
macular	S-Tissue
detachment	O
,	O
one	O
of	O
which	O
was	O
foveal	S-Tissue
or	O
near	O
to	O
the	O
fovea	S-Tissue
.	O

Photocoagulation	O
with	O
green	O
argon	O
laser	O
was	O
performed	O
in	O
all	O
eyes	S-Organ
,	O
treating	O
all	O
the	O
leaking	O
points	O
except	O
for	O
the	O
central	O
one	O
.	O

Visual	O
symptoms	O
regressed	O
after	O
treatment	O
,	O
and	O
the	O
serous	S-Organism_substance
detachment	O
was	O
resolved	O
10	O
days	O
to	O
4	O
weeks	O
after	O
photocoagulation	O
in	O
all	O
cases	O
.	O

Fluorescein	O
angiography	O
showed	O
no	O
leakage	O
at	O
either	O
the	O
central	O
leakage	O
point	O
or	O
the	O
leakage	O
point	O
that	O
had	O
been	O
treated	O
.	O

These	O
results	O
led	O
us	O
to	O
believe	O
that	O
the	O
central	O
or	O
dependent	O
leak	O
in	O
our	O
cases	O
was	O
not	O
sufficient	O
to	O
maintain	O
the	O
serous	S-Organism_substance
detachment	O
by	O
itself	O
.	O

An	O
alternative	O
hypothesis	O
is	O
that	O
the	O
untreated	O
leak	O
did	O
not	O
represent	O
real	O
fluid	S-Organism_substance
movement	O
but	O
only	O
diffusion	O
of	O
fluorescein	O
molecules	O
,	O
or	O
a	O
false	O
leak	O
.	O

In	O
cases	O
of	O
CSCR	O
with	O
multiple	O
leaks	O
within	O
a	O
single	O
macular	S-Tissue
detachment	O
,	O
we	O
believe	O
that	O
a	O
foveal	S-Tissue
leak	O
may	O
be	O
a	O
dependent	O
or	O
false	O
leak	O
and	O
that	O
direct	O
treatment	O
is	O
not	O
necessary	O
.	O

Maternal	O
antenatal	O
anxiety	O
and	O
behavioural	O
/	O
emotional	O
problems	O
in	O
children	O
:	O
a	O
test	O
of	O
a	O
programming	O
hypothesis	O
.	O

BACKGROUND	O
:	O

Previous	O
animal	O
investigations	O
link	O
antenatal	O
stress	O
with	O
a	O
range	O
of	O
persistent	O
behavioural	O
abnormalities	O
in	O
the	O
offspring	O
.	O

The	O
current	O
study	O
examined	O
if	O
the	O
effect	O
was	O
also	O
found	O
in	O
humans	O
through	O
middle	O
childhood	O
.	O

METHODS	O
:	O

The	O
current	O
study	O
is	O
based	O
on	O
the	O
Avon	O
Longitudinal	O
Study	O
of	O
Parents	O
and	O
Children	O
(	O
ALSPAC	O
)	O
,	O
a	O
prospective	O
,	O
community	O
-	O
based	O
study	O
that	O
has	O
followed	O
a	O
cohort	O
of	O
women	O
from	O
pregnancy	O
.	O

Self	O
-	O
report	O
measures	O
of	O
maternal	O
anxiety	O
and	O
depression	O
were	O
assessed	O
at	O
repeated	O
intervals	O
in	O
pregnancy	O
and	O
the	O
postnatal	O
period	O
.	O

Children	O
'	O
s	O
behavioural	O
/	O
emotional	O
problems	O
were	O
assessed	O
by	O
parent	O
report	O
at	O
age	O
47	O
and	O
81	O
months	O
.	O

Information	O
on	O
obstetric	O
and	O
psychosocial	O
factors	O
was	O
obtained	O
at	O
several	O
points	O
in	O
pregnancy	O
and	O
the	O
postnatal	O
period	O
.	O

RESULTS	O
:	O

Children	O
whose	O
mothers	O
experienced	O
high	O
levels	O
of	O
anxiety	O
in	O
late	O
pregnancy	O
exhibited	O
higher	O
rates	O
of	O
behavioural	O
/	O
emotional	O
problems	O
at	O
81	O
months	O
of	O
age	O
after	O
controlling	O
for	O
obstetric	O
risks	O
,	O
psychosocial	O
disadvantage	O
,	O
and	O
postnatal	O
anxiety	O
and	O
depression	O
(	O
for	O
girls	O
,	O
OR	O
=	O
1	O
.	O
91	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
26	O
-	O
2	O
.	O
89	O
;	O
for	O
boys	O
,	O
OR	O
=	O
2	O
.	O
16	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
41	O
-	O
3	O
.	O
30	O
)	O
.	O

Furthermore	O
,	O
the	O
effect	O
at	O
81	O
months	O
was	O
comparable	O
to	O
what	O
was	O
previously	O
obtained	O
at	O
47	O
months	O
,	O
suggesting	O
the	O
kind	O
of	O
persistent	O
effect	O
proposed	O
in	O
the	O
animal	O
literature	O
.	O

CONCLUSIONS	O
:	O

There	O
is	O
evidence	O
that	O
antenatal	O
stress	O
/	O
anxiety	O
has	O
a	O
programming	O
effect	O
on	O
the	O
fetus	S-Developing_anatomical_structure
which	O
lasts	O
at	O
least	O
until	O
middle	O
childhood	O
.	O

Endogenous	O
thyroid	O
hormones	O
modulate	O
pituitary	B-Cell
somatotroph	E-Cell
differentiation	O
during	O
chicken	O
embryonic	S-Developing_anatomical_structure
development	O
.	O

Growth	O
hormone	O
cell	S-Cell
differentiation	O
normally	O
occurs	O
between	O
day	O
14	O
and	O
day	O
16	O
of	O
chicken	O
embryonic	S-Developing_anatomical_structure
development	O
.	O

We	O
reported	O
previously	O
that	O
corticosterone	O
(	O
CORT	O
)	O
could	O
induce	O
somatotroph	S-Cell
differentiation	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
thyroid	O
hormones	O
could	O
act	O
in	O
combination	O
with	O
CORT	O
to	O
further	O
augment	O
the	O
abundance	O
of	O
somatotrophs	S-Cell
in	O
vitro	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
our	O
hypothesis	O
that	O
endogenous	O
thyroid	O
hormones	O
regulate	O
the	O
abundance	O
of	O
somatotrophs	S-Cell
during	O
chicken	O
embryonic	S-Developing_anatomical_structure
development	O
.	O

Plasma	B-Organism_substance
samples	E-Organism_substance
were	O
collected	O
on	O
embryonic	S-Developing_anatomical_structure
day	O
(	O
e	O
)	O
9	O
-	O
14	O
.	O

We	O
found	O
that	O
plasma	S-Organism_substance
CORT	O
and	O
thyroid	O
hormone	O
levels	O
increased	O
progressively	O
in	O
mid	O
-	O
embryogenesis	O
to	O
e	O
13	O
or	O
e	O
14	O
,	O
immediately	O
before	O
normal	O
somatotroph	S-Cell
differentiation	O
.	O

Administration	O
of	O
thyroxine	O
(	O
T4	O
)	O
and	O
triiodothyronine	O
(	O
T3	O
)	O
into	O
the	O
albumen	S-Organism_substance
of	O
fertile	B-Developing_anatomical_structure
eggs	E-Developing_anatomical_structure
on	O
e	O
11	O
increased	O
somatotroph	S-Cell
proportions	O
prematurely	O
on	O
e	O
13	O
in	O
the	O
developing	O
chick	O
embryos	S-Developing_anatomical_structure
in	O
vivo	O
.	O

Furthermore	O
,	O
administration	O
of	O
methimazole	O
,	O
the	O
thyroid	O
hormone	O
synthesis	O
inhibitor	O
,	O
on	O
e	O
9	O
inhibited	O
somatotroph	S-Cell
differentiation	O
in	O
vivo	O
,	O
as	O
assessed	O
on	O
e	O
14	O
;	O
this	O
suppression	O
was	O
completely	O
reversed	O
by	O
T3	O
replacement	O
on	O
e	O
11	O
.	O

Since	O
we	O
reported	O
that	O
T3	O
alone	O
was	O
ineffective	O
in	O
vitro	O
,	O
we	O
interpret	O
these	O
findings	O
to	O
indicate	O
that	O
the	O
effects	O
of	O
treatments	O
in	O
vivo	O
were	O
due	O
to	O
interactions	O
with	O
endogenous	O
glucocorticoids	O
.	O

These	O
results	O
indicate	O
that	O
treatment	O
with	O
exogenous	O
thyroid	O
hormones	O
can	O
modulate	O
somatotroph	S-Cell
abundance	O
and	O
that	O
endogenous	O
thyroid	O
hormone	O
synthesis	O
likely	O
contributes	O
to	O
normal	O
somatotroph	S-Cell
differentiation	O
.	O

Angiopoietin	O
/	O
tie	O
-	O
2	O
as	O
mediators	O
of	O
angiogenesis	O
:	O
a	O
role	O
in	O
congestive	O
heart	S-Organ
failure	O
?	O

Angiogenic	O
factors	O
,	O
in	O
particular	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
angiopoietins	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
,	O
have	O
recently	O
generated	O
significant	O
interest	O
,	O
especially	O
in	O
oncology	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
also	O
thought	O
to	O
occur	O
in	O
response	O
to	O
ischaemic	O
conditions	O
,	O
which	O
lie	O
at	O
the	O
core	O
of	O
cardiovascular	S-Anatomical_system
disease	O
states	O
such	O
as	O
coronary	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
disease	O
and	O
congestive	O
heart	S-Organ
failure	O
.	O

However	O
,	O
current	O
data	O
do	O
not	O
conclusively	O
show	O
evidence	O
of	O
angiogenesis	O
per	O
se	O
in	O
these	O
conditions	O
,	O
despite	O
(	O
for	O
example	O
)	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
and	O
Ang	O
-	O
2	O
.	O

High	O
levels	O
of	O
these	O
angiogenic	O
factors	O
in	O
heart	S-Organ
disease	O
also	O
have	O
not	O
translated	O
into	O
clinically	O
significant	O
new	O
vessel	S-Multi-tissue_structure
formation	O
,	O
as	O
in	O
accelerated	O
cancer	S-Cancer
growth	O
or	O
proliferative	O
retinopathy	O
.	O

Indeed	O
,	O
we	O
would	O
hypothesize	O
that	O
these	O
angiogenic	O
markers	O
-	O
-	O
especially	O
the	O
angiopoietins	O
-	O
-	O
do	O
not	O
necessarily	O
translate	O
into	O
new	O
vessel	S-Multi-tissue_structure
formation	O
in	O
congestive	O
heart	S-Organ
failure	O
(	O
CHF	O
)	O
,	O
but	O
may	O
well	O
reflect	O
disturbances	O
of	O
endothelial	S-Tissue
integrity	O
in	O
CHF	O
.	O

[	O
Correlation	O
between	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
in	O
tumor	B-Cell
-	I-Cell
associated	I-Cell
macrophages	E-Cell
and	O
lymphatic	S-Organ
metastasis	O
in	O
oral	B-Cancer
cancer	E-Cancer
]	O
.	O

BACKGROUND	O
&	O
#	O
38	O
;	O
OBJECTIVE	O
:	O
Previous	O
study	O
shows	O
that	O
both	O
vascular	O
endothelial	O
growth	O
-	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
and	O
tumor	B-Cell
-	I-Cell
associated	I-Cell
macrophages	E-Cell
(	O
TAMs	S-Cell
)	O
are	O
related	O
to	O
lymphatic	S-Organ
metastasis	O
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
correlation	O
between	O
the	O
expression	O
of	O
VEGF	O
-	O
C	O
in	O
TAMs	S-Cell
and	O
lymphatic	S-Organ
metastasis	O
in	O
human	O
oral	B-Cancer
squamous	I-Cancer
-	I-Cancer
cell	I-Cancer
carcinoma	E-Cancer
(	O
OSCC	S-Cancer
)	O
.	O

METHODS	O
:	O
After	O
immunohistochemical	O
staining	O
,	O
light	O
microscope	O
was	O
used	O
for	O
counting	O
macrophages	S-Cell
and	O
automated	O
image	O
analysis	O
quantification	O
was	O
used	O
to	O
determine	O
VEGF	O
-	O
C	O
expression	O
,	O
which	O
was	O
reflected	O
by	O
positive	O
index	O
(	O
PI	O
)	O
.	O

In	O
addition	O
,	O
the	O
double	O
staining	O
was	O
also	O
used	O
to	O
determine	O
VEGF	O
-	O
C	O
expression	O
in	O
TAMs	S-Cell
.	O

RESULTS	O
:	O
VEGF	O
-	O
C	O
expression	O
was	O
higher	O
in	O
lymphatic	S-Organ
metastasis	O
group	O
(	O
PI	O
=	O
12	O
.	O
169	O
+	O
/	O
-	O
2	O
.	O
778	O
)	O
than	O
in	O
no	O
-	O
metastasis	O
group	O
(	O
PI	O
=	O
8	O
.	O
498	O
+	O
/	O
-	O
2	O
.	O
674	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

TAMs	S-Cell
counts	O
was	O
related	O
to	O
VEGF	O
-	O
C	O
expression	O
in	O
OSCC	S-Cancer
(	O
r	O
=	O
0	O
.	O
370	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
result	O
of	O
double	O
staining	O
indicated	O
that	O
macrophage	S-Cell
with	O
positive	O
VEGF	O
-	O
C	O
expression	O
accounted	O
for	O
about	O
22	O
.	O
8	O
%	O
of	O
the	O
total	O
.	O

CONCLUSION	O
:	O
Not	O
only	O
tumor	B-Cell
cells	E-Cell
but	O
also	O
TAMs	S-Cell
secrete	O
the	O
VEGF	O
-	O
C	O
in	O
OSCC	S-Cancer
,	O
and	O
TAMs	S-Cell
may	O
play	O
a	O
major	O
role	O
in	O
peritumoral	B-Multi-tissue_structure
lymphatic	E-Multi-tissue_structure
neoangiogenesis	O
and	O
lymphatic	S-Organ
metastasis	O
.	O

Deletion	O
of	O
guanine	O
nucleotide	O
binding	O
protein	O
alpha	O
z	O
subunit	O
in	O
mice	O
induces	O
a	O
gene	O
dose	O
dependent	O
tolerance	O
to	O
morphine	O
.	O

The	O
mechanism	O
underlying	O
the	O
development	O
of	O
tolerance	O
to	O
morphine	O
is	O
still	O
incompletely	O
understood	O
.	O

Morphine	O
binds	O
to	O
opioid	O
receptors	O
,	O
which	O
in	O
turn	O
activates	O
downstream	O
second	O
messenger	O
cascades	O
through	O
heterotrimeric	O
guanine	O
nucleotide	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
G	O
(	O
z	O
)	O
,	O
a	O
member	O
of	O
the	O
inhibitory	O
G	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
after	O
tolerance	O
development	O
.	O

We	O
blocked	O
signaling	O
through	O
the	O
G	O
(	O
z	O
)	O
second	O
messenger	O
cascade	O
by	O
genetic	O
ablation	O
of	O
the	O
alpha	O
subunit	O
of	O
the	O
G	O
protein	O
in	O
mice	O
.	O

The	O
Galpha	O
(	O
z	O
)	O
knockout	O
mouse	O
develops	O
significantly	O
increased	O
tolerance	O
to	O
morphine	O
,	O
which	O
depends	O
on	O
Galpha	O
(	O
z	O
)	O
gene	O
dosage	O
.	O

Further	O
experiments	O
demonstrate	O
that	O
the	O
enhanced	O
morphine	O
tolerance	O
is	O
not	O
caused	O
by	O
pharmacokinetic	O
and	O
behavioural	O
learning	O
mechanisms	O
.	O

The	O
results	O
suggest	O
that	O
G	O
(	O
z	O
)	O
signaling	O
pathways	O
are	O
involved	O
in	O
transducing	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
following	O
chronic	O
morphine	O
treatment	O
.	O

Effects	O
of	O
buffer	O
properties	O
on	O
cyclodextrin	O
glucanotransferase	O
reactions	O
and	O
cyclodextrin	O
production	O
from	O
raw	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	S-Organism_substance
.	O

Results	O
from	O
the	O
present	O
study	O
have	O
shown	O
that	O
the	O
ionic	O
species	O
of	O
buffers	O
,	O
pH	O
values	O
and	O
reaction	O
temperature	O
can	O
affect	O
the	O
enzyme	O
unit	O
activities	O
and	O
product	O
specificity	O
of	O
Toruzyme	O
(	O
Novo	O
Nordisk	O
A	O
/	O
S	O
Bagsvaerd	O
,	O
Denmark	O
)	O
CGTase	O
(	O
cyclodextrin	O
glucanotransferase	O
)	O
.	O

Applying	O
a	O
similar	O
reaction	O
environment	O
(	O
acetate	O
buffer	O
,	O
pH	O
6	O
.	O
0	O
;	O
temperature	O
,	O
60	O
degrees	O
C	O
)	O
,	O
the	O
CGTase	O
was	O
found	O
to	O
be	O
capable	O
of	O
producing	O
pre	O
dominantly	O
beta	O
-	O
cyclodextrin	O
from	O
either	O
raw	O
or	O
gelatinized	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	S-Organism_substance
.	O

Changing	O
the	O
buffer	O
from	O
acetate	O
to	O
phosphate	O
reduced	O
the	O
yield	O
of	O
beta	O
-	O
cyclodextrin	O
from	O
2	O
.	O
48	O
to	O
1	O
.	O
42	O
mg	O
/	O
ml	O
and	O
also	O
affected	O
the	O
product	O
specificity	O
,	O
where	O
production	O
of	O
both	O
alpha	O
-	O
and	O
beta	O
-	O
cyclodextrins	O
were	O
more	O
pronounced	O
.	O

The	O
decrease	O
in	O
the	O
production	O
of	O
cyclodextrins	O
in	O
phosphate	O
buffer	O
was	O
significant	O
at	O
both	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
.	O

However	O
,	O
changing	O
the	O
buffer	O
to	O
Tris	O
/	O
HCl	O
(	O
pH	O
7	O
.	O
0	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
beta	O
-	O
cyclodextrin	O
production	O
.	O

Increasing	O
the	O
ionic	O
strength	O
of	O
sodium	O
acetate	O
and	O
Tris	O
/	O
HCl	O
buffers	O
at	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
to	O
equivalent	O
ionic	O
strength	O
of	O
phosphate	O
buffers	O
showed	O
no	O
significant	O
effects	O
on	O
cyclodextrin	O
production	O
.	O

Higher	O
yield	O
of	O
cyclodextrins	O
at	O
pH	O
7	O
.	O
0	O
when	O
Tris	O
/	O
HCl	O
was	O
used	O
might	O
be	O
due	O
to	O
the	O
binding	O
of	O
chloride	O
ions	O
at	O
the	O
calcium	O
-	O
binding	O
sites	O
of	O
the	O
CGTase	O
,	O
resulting	O
in	O
the	O
shift	O
of	O
the	O
optimum	O
pH	O
close	O
to	O
physiological	O
environment	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
activities	O
and	O
specificity	O
.	O

Hypothesis	O
:	O
Induced	O
angiogenesis	O
after	O
surgery	O
in	O
premenopausal	O
node	S-Multi-tissue_structure
-	O
positive	O
breast	B-Cancer
cancer	E-Cancer
patients	O
is	O
a	O
major	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	O
works	O
particularly	O
well	O
for	O
those	O
patients	O
.	O

BACKGROUND	O
:	O
We	O
suggest	O
that	O
surgical	O
extirpation	O
of	O
primary	B-Cancer
breast	I-Cancer
cancer	E-Cancer
among	O
other	O
effects	O
accelerates	O
relapse	O
for	O
some	O
premenopausal	O
node	S-Multi-tissue_structure
-	O
positive	O
patients	O
.	O

These	O
accelerated	O
relapses	O
occur	O
within	O
10	O
months	O
of	O
surgery	O
for	O
untreated	O
patients	O
.	O

The	O
mechanism	O
proposed	O
is	O
a	O
stimulation	O
of	O
angiogenesis	O
for	O
distant	B-Cancer
dormant	I-Cancer
micrometastases	E-Cancer
.	O

This	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
to	O
explain	O
the	O
mammography	O
paradox	O
for	O
women	O
aged	O
40	O
-	O
49	O
years	O
.	O

We	O
could	O
imagine	O
that	O
it	O
also	O
plays	O
a	O
role	O
in	O
adjuvant	O
chemotherapy	O
effectiveness	O
since	O
,	O
perhaps	O
not	O
coincidentally	O
,	O
this	O
is	O
most	O
beneficial	O
for	O
premenopausal	O
node	S-Multi-tissue_structure
-	O
positive	O
patients	O
.	O

HYPOTHESIS	O
:	O
We	O
speculate	O
that	O
there	O
is	O
a	O
burst	O
of	O
angiogenesis	O
of	O
distant	B-Cancer
dormant	I-Cancer
micrometastases	E-Cancer
after	O
surgery	O
in	O
approximately	O
20	O
%	O
of	O
premenopausal	O
node	S-Multi-tissue_structure
-	O
positive	O
patients	O
.	O

We	O
also	O
speculate	O
that	O
this	O
synchronizes	O
them	O
into	O
a	O
temporal	O
highly	O
chemosensitive	O
state	O
and	O
is	O
the	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	O
works	O
particularly	O
well	O
for	O
that	O
patient	O
category	O
.	O

Furthermore	O
,	O
this	O
may	O
explain	O
why	O
cancer	S-Cancer
in	O
younger	O
patients	O
is	O
more	O
often	O
'	O
aggressive	O
'	O
.	O

TESTING	O
THE	O
HYPOTHESIS	O
:	O
Stimulation	O
of	O
dormant	B-Cancer
micrometastases	E-Cancer
by	O
primary	B-Cancer
tumor	E-Cancer
removal	O
is	O
known	O
to	O
occur	O
in	O
animal	O
models	O
.	O

However	O
,	O
we	O
need	O
to	O
determine	O
whether	O
it	O
happens	O
in	O
breast	B-Cancer
cancer	E-Cancer
.	O

Transient	O
circulating	O
levels	O
of	O
angioactive	O
molecules	O
and	O
serial	O
high	O
-	O
resolution	O
imaging	O
studies	O
of	O
focal	O
angiogenesis	O
might	O
help	O
.	O

IMPLICATIONS	O
:	O
Short	O
-	O
course	O
cytotoxic	O
chemotherapy	O
after	O
surgery	O
has	O
probably	O
reached	O
its	O
zenith	O
,	O
and	O
other	O
strategies	O
,	O
perhaps	O
antiangiogenic	O
methods	O
,	O
are	O
needed	O
to	O
successfully	O
treat	O
more	O
patients	O
.	O

In	O
addition	O
,	O
the	O
hypothesis	O
predicts	O
that	O
early	O
detection	O
,	O
which	O
is	O
designed	O
to	O
find	O
more	O
patients	O
without	O
involved	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
,	O
may	O
not	O
be	O
a	O
synergistic	O
strategy	O
with	O
adjuvant	O
chemotherapy	O
,	O
which	O
works	O
best	O
with	O
positive	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
patients	O
.	O

Rational	O
synthesis	O
of	O
multicyclic	O
bis	O
[	O
2	O
]	O
catenanes	O
.	O

Bis	O
-	O
loop	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
6	O
has	O
been	O
prepared	O
by	O
acylation	O
of	O
the	O
wide	O
-	O
rim	O
calix	O
[	O
4	O
]	O
arene	O
tetraamine	O
1	O
with	O
the	O
activated	O
bis	O
(	O
urethane	O
)	O
8	O
under	O
dilution	O
conditions	O
.	O

Similarly	O
the	O
bis	O
(	O
Boc	O
-	O
protected	O
)	O
tetraamine	O
2	O
is	O
converted	O
into	O
the	O
mono	O
-	O
loop	O
derivative	O
3	O
which	O
after	O
deprotection	O
and	O
acylation	O
gives	O
the	O
bisalkenyl	O
derivative	O
5	O
.	O

In	O
apolar	O
solvents	O
this	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
5	O
forms	O
regioselectively	O
a	O
single	O
hydrogen	O
-	O
bonded	O
homodimer	O
,	O
from	O
which	O
the	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
is	O
formed	O
in	O
49	O
%	O
by	O
a	O
metathesis	O
reaction	O
followed	O
by	O
hydrogenation	O
.	O

Bis	O
-	O
loop	O
derivative	O
6	O
forms	O
no	O
homodimers	O
for	O
steric	O
reasons	O
,	O
but	O
a	O
stoichiometric	O
mixture	O
with	O
the	O
open	O
-	O
chain	O
tetraalkenyl	O
derivative	O
7a	O
contains	O
exclusively	O
the	O
heterodimer	O
.	O

Metathesis	O
and	O
subsequent	O
hydrogenation	O
now	O
yields	O
65	O
%	O
of	O
the	O
pure	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
which	O
could	O
not	O
be	O
isolated	O
from	O
the	O
complex	O
reaction	O
mixture	O
obtained	O
from	O
the	O
homodimer	O
7a	O
.	O
7a	O
.	O

The	O
chirality	O
of	O
10a	O
(	O
D	O
(	O
2	O
)	O
symmetry	O
)	O
has	O
been	O
verified	O
by	O
optical	O
resolution	O
using	O
HPLC	O
on	O
a	O
chiral	O
stationary	O
phase	O
.	O

The	O
learning	O
curve	O
:	O
the	O
advantages	O
and	O
disadvantages	O
in	O
the	O
use	O
of	O
focus	O
groups	O
as	O
a	O
method	O
of	O
data	O
collection	O
.	O

Focus	O
groups	O
are	O
not	O
simply	O
a	O
discussion	O
between	O
people	O
,	O
but	O
are	O
focused	O
interviews	O
exploring	O
interactions	O
between	O
participants	O
.	O

In	O
this	O
paper	O
,	O
Ian	O
Mansell	O
,	O
Glynis	O
Bennett	O
,	O
Ruth	O
Northway	O
,	O
Donna	O
Mead	O
and	O
Laurie	O
Moseley	O
explore	O
the	O
complexities	O
and	O
practicalities	O
of	O
using	O
focus	O
groups	O
in	O
research	O
,	O
with	O
reference	O
to	O
a	O
study	O
of	O
palliative	O
care	O
services	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
seizures	O
:	O
a	O
double	O
-	O
edged	O
sword	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
vascular	S-Multi-tissue_structure
growth	O
factor	O
which	O
induces	O
angiogenesis	O
(	O
the	O
development	O
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
)	O
,	O
vascular	S-Multi-tissue_structure
permeability	O
,	O
and	O
inflammation	O
.	O

In	O
brain	S-Organ
,	O
receptors	O
for	O
VEGF	O
have	O
been	O
localized	O
to	O
vascular	B-Tissue
endothelium	E-Tissue
,	O
neurons	S-Cell
,	O
and	O
glia	S-Cell
.	O

VEGF	O
is	O
upregulated	O
after	O
hypoxic	O
injury	O
to	O
the	O
brain	S-Organ
,	O
which	O
can	O
occur	O
during	O
cerebral	S-Organ
ischemia	O
or	O
high	O
-	O
altitude	O
edema	S-Pathological_formation
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	O
associated	O
with	O
these	O
conditions	O
.	O

Given	O
its	O
recently	O
-	O
described	O
role	O
as	O
an	O
inflammatory	O
mediator	O
,	O
VEGF	O
could	O
also	O
contribute	O
to	O
the	O
inflammatory	O
responses	O
observed	O
in	O
cerebral	S-Organ
ischemia	O
.	O

After	O
seizures	O
,	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	O
and	O
inflammation	O
is	O
also	O
observed	O
in	O
brain	S-Organ
,	O
albeit	O
on	O
a	O
lower	O
scale	O
than	O
that	O
observed	O
after	O
stroke	O
.	O

Recent	O
evidence	O
has	O
suggested	O
a	O
role	O
for	O
inflammation	O
in	O
seizure	O
disorders	O
.	O

We	O
have	O
described	O
striking	O
increases	O
in	O
VEGF	O
protein	O
in	O
both	O
neurons	S-Cell
and	O
glia	S-Cell
after	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
in	O
the	O
brain	S-Organ
.	O

Increases	O
in	O
VEGF	O
could	O
contribute	O
to	O
the	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	O
and	O
inflammation	O
observed	O
after	O
seizures	O
.	O

However	O
,	O
VEGF	O
has	O
also	O
been	O
shown	O
to	O
be	O
neuroprotective	O
across	O
several	O
experimental	O
paradigms	O
,	O
and	O
hence	O
could	O
potentially	O
protect	O
vulnerable	O
cells	S-Cell
from	O
damage	O
associated	O
with	O
seizures	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
VEGF	O
after	O
seizures	O
could	O
be	O
either	O
protective	O
or	O
destructive	O
.	O

Although	O
only	O
further	O
research	O
will	O
determine	O
the	O
exact	O
nature	O
of	O
VEGF	O
'	O
s	O
role	O
after	O
seizures	O
,	O
preliminary	O
data	O
indicate	O
that	O
VEGF	O
plays	O
a	O
protective	O
role	O
after	O
seizures	O
.	O

Safety	O
of	O
verteporfin	O
for	O
treatment	O
of	O
subfoveal	B-Multi-tissue_structure
choroidal	I-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
associated	O
with	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	O
.	O

Photodynamic	O
therapy	O
(	O
PDT	O
)	O
is	O
a	O
novel	O
treatment	O
entity	O
that	O
exploits	O
the	O
photophysical	O
properties	O
of	O
various	O
photosensitive	O
chemical	O
entities	O
which	O
,	O
upon	O
light	O
activation	O
,	O
results	O
in	O
targeted	O
photooxidation	O
and	O
subsequent	O
tissue	S-Tissue
destruction	O
.	O

The	O
antiangiogenic	O
properties	O
of	O
PDT	O
have	O
been	O
adapted	O
for	O
treatment	O
of	O
subfoveal	B-Multi-tissue_structure
choroidal	I-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
due	O
to	O
disease	O
states	O
such	O
as	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	O
(	O
AMD	O
)	O
.	O

Historically	O
,	O
PDT	O
has	O
been	O
limited	O
by	O
a	O
lack	O
of	O
suitable	O
photosensitive	O
dyes	O
.	O

However	O
,	O
agents	O
such	O
as	O
verteporfin	O
,	O
a	O
second	O
-	O
generation	O
benzoporphyrin	O
derivative	O
,	O
appear	O
to	O
be	O
free	O
from	O
the	O
extensive	O
phototoxicity	O
that	O
limited	O
the	O
success	O
of	O
previous	O
agents	O
.	O

Verteporfin	O
has	O
a	O
high	O
affinity	O
for	O
choroidal	B-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
,	O
typically	O
found	O
with	O
exudative	O
AMD	O
,	O
and	O
upon	O
photoactivation	O
results	O
in	O
targeted	O
microvascular	S-Tissue
damage	O
and	O
thrombus	S-Pathological_formation
formation	O
with	O
resultant	O
vessel	S-Multi-tissue_structure
occlusion	O
.	O

Scrutiny	O
of	O
diagnostic	O
indicators	O
for	O
verteporfin	O
administration	O
,	O
including	O
critical	O
angiographic	O
evaluation	O
of	O
lesion	S-Pathological_formation
size	O
and	O
visual	O
acuity	O
,	O
is	O
essential	O
to	O
treatment	O
success	O
.	O

Large	O
lesions	S-Pathological_formation
with	O
relatively	O
good	O
visual	O
acuity	O
(	O
20	O
/	O
50	O
or	O
better	O
)	O
may	O
be	O
at	O
particular	O
risk	O
for	O
marked	O
vision	O
loss	O
following	O
verteporfin	O
administration	O
.	O

Lesion	S-Pathological_formation
composition	O
also	O
appears	O
to	O
influence	O
visual	O
outcome	O
with	O
verteporfin	O
use	O
.	O

The	O
safety	O
of	O
verteporfin	O
is	O
directly	O
dependent	O
upon	O
the	O
appropriate	O
integration	O
of	O
dosage	O
,	O
infusion	O
and	O
light	O
activation	O
required	O
for	O
a	O
suitable	O
pharmacotherapeutic	O
outcome	O
.	O

When	O
used	O
appropriately	O
,	O
and	O
with	O
adequate	O
patient	O
education	O
regarding	O
photosensitivity	O
,	O
the	O
risk	O
-	O
benefit	O
of	O
verteporfin	O
for	O
the	O
medical	O
treatment	O
of	O
neovascular	O
AMD	O
is	O
favourable	O
.	O

Retrospective	O
case	O
series	O
of	O
juxtafoveal	B-Multi-tissue_structure
choroidal	E-Multi-tissue_structure
neovascularization	O
treated	O
with	O
photodynamic	O
therapy	O
with	O
verteporfin	O
.	O

PURPOSE	O
:	O
To	O
describe	O
visual	O
acuity	O
and	O
angiographic	O
outcomes	O
of	O
juxtafoveal	B-Multi-tissue_structure
choroidal	E-Multi-tissue_structure
neovascularization	O
(	O
CNV	O
)	O
treated	O
with	O
photodynamic	O
therapy	O
and	O
verteporfin	O
(	O
PDT	O
)	O
.	O

METHODS	O
:	O
Four	O
hundred	O
eighty	O
-	O
four	O
consecutive	O
eyes	S-Organ
of	O
446	O
patients	O
treated	O
with	O
PDT	O
from	O
January	O
1	O
,	O
2001	O
,	O
to	O
June	O
30	O
,	O
2002	O
,	O
were	O
identified	O
from	O
billing	O
records	O
.	O

Fluorescein	O
angiograms	O
were	O
reviewed	O
retrospectively	O
to	O
identify	O
juxtafoveal	S-Immaterial_anatomical_entity
CNV	O
.	O

Eligible	O
patients	O
had	O
CNV	O
in	O
which	O
the	O
central	O
boundary	O
of	O
the	O
lesion	S-Pathological_formation
was	O
between	O
1	O
and	O
199	O
microm	O
from	O
the	O
geometric	O
center	O
of	O
the	O
foveal	B-Tissue
avascular	I-Tissue
zone	E-Tissue
(	O
FAZ	S-Tissue
)	O
.	O

Patient	O
charts	O
were	O
reviewed	O
for	O
visual	O
acuity	O
of	O
the	O
treated	O
eye	S-Organ
before	O
PDT	O
and	O
at	O
6	O
-	O
and	O
12	O
-	O
month	O
follow	O
-	O
up	O
examinations	O
.	O

Presence	O
of	O
subfoveal	O
CNV	O
at	O
6	O
and	O
12	O
months	O
of	O
follow	O
-	O
up	O
was	O
determined	O
by	O
review	O
of	O
fluorescein	O
angiograms	O
.	O

A	O
lesion	S-Pathological_formation
was	O
considered	O
subfoveal	O
if	O
it	O
extended	O
underneath	O
the	O
geometric	O
center	O
of	O
the	O
FAZ	S-Tissue
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
eyes	S-Organ
had	O
juxtafoveal	S-Immaterial_anatomical_entity
CNV	O
.	O

Median	O
change	O
in	O
visual	O
acuity	O
both	O
6	O
and	O
12	O
months	O
after	O
the	O
initial	O
PDT	O
was	O
0	O
lines	O
(	O
n	O
=	O
18	O
at	O
6	O
months	O
,	O
range	O
-	O
14	O
to	O
+	O
8	O
lines	O
;	O
n	O
=	O
17	O
at	O
12	O
months	O
,	O
range	O
-	O
18	O
to	O
+	O
7	O
lines	O
)	O
.	O

Eleven	O
lesions	S-Pathological_formation
progressed	O
to	O
a	O
subfoveal	O
location	O
by	O
12	O
months	O
.	O

Visual	O
acuity	O
in	O
eyes	S-Organ
with	O
progressive	O
lesions	S-Pathological_formation
decreased	O
a	O
median	O
of	O
4	O
lines	O
of	O
vision	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
small	O
sample	O
size	O
and	O
limited	O
length	O
of	O
follow	O
-	O
up	O
,	O
this	O
study	O
shows	O
that	O
visual	O
acuity	O
on	O
average	O
can	O
remain	O
stable	O
for	O
at	O
least	O
12	O
months	O
after	O
PDT	O
of	O
juxtafoveal	B-Pathological_formation
lesions	E-Pathological_formation
.	O

Growth	O
through	O
the	O
foveal	B-Tissue
center	E-Tissue
still	O
can	O
occur	O
,	O
however	O
,	O
and	O
this	O
can	O
be	O
associated	O
with	O
substantial	O
visual	O
loss	O
.	O

[	O
Epidemiology	O
of	O
fractures	O
of	O
the	O
proximal	O
femur	S-Organ
]	O
.	O

Fractures	O
of	O
the	O
upper	O
end	O
of	O
the	O
femur	S-Organ
constitute	O
a	O
major	O
public	O
health	O
problem	O
which	O
,	O
for	O
demographic	O
reasons	O
,	O
will	O
become	O
worse	O
during	O
the	O
next	O
decades	O
.	O

The	O
clinical	O
determination	O
of	O
femoral	B-Multi-tissue_structure
neck	E-Multi-tissue_structure
fractures	O
is	O
imperfectly	O
known	O
.	O

Two	O
factors	O
seem	O
to	O
be	O
determinant	O
:	O
bone	S-Tissue
fragility	O
and	O
fall	O
,	O
but	O
these	O
factors	O
are	O
frequent	O
in	O
the	O
elderly	O
and	O
other	O
factors	O
seem	O
to	O
intervene	O
,	O
notably	O
the	O
modality	O
of	O
the	O
impact	O
and	O
the	O
protection	O
reflexes	O
during	O
the	O
fall	O
.	O

The	O
epidemiology	O
of	O
proximal	O
femur	S-Organ
fractures	O
therefore	O
cannot	O
be	O
restricted	O
to	O
the	O
diminution	O
of	O
bone	S-Tissue
mass	O
.	O

Beside	O
age	O
and	O
female	O
sex	O
,	O
the	O
confirmed	O
risk	O
factors	O
for	O
these	O
fractures	O
are	O
:	O
ethnic	O
origin	O
,	O
absence	O
of	O
replacement	O
hormonal	O
therapy	O
in	O
menopausal	O
women	O
,	O
slight	O
build	O
and	O
absorption	O
of	O
certain	O
psychotropic	O
drugs	O
.	O

To	O
be	O
efficient	O
,	O
preventive	O
measures	O
must	O
rest	O
on	O
a	O
better	O
knowledge	O
of	O
the	O
determinant	O
factors	O
.	O

Epidemiological	O
research	O
should	O
develop	O
rationally	O
and	O
aim	O
at	O
identifying	O
more	O
accurate	O
risk	O
factors	O
,	O
taking	O
into	O
account	O
the	O
mechanisms	O
responsible	O
for	O
proximal	O
femur	S-Organ
fractures	O
:	O
fall	O
,	O
lack	O
of	O
cushioning	O
and	O
protection	O
during	O
the	O
fall	O
,	O
and	O
bone	S-Tissue
fragility	O
.	O

Expression	O
of	O
DCC	O
and	O
netrin	O
-	O
1	O
in	O
normal	O
human	O
endometrium	S-Multi-tissue_structure
and	O
its	O
implication	O
in	O
endometrial	S-Multi-tissue_structure
carcinogenesis	O
.	O

OBJECTIVE	O
:	O
Although	O
DCC	O
has	O
been	O
considered	O
as	O
a	O
candidate	O
tumor	S-Cancer
suppressor	O
,	O
the	O
roles	O
it	O
plays	O
in	O
the	O
uterine	B-Multi-tissue_structure
endometrium	E-Multi-tissue_structure
and	O
in	O
the	O
carcinogenic	O
process	O
remains	O
unclear	O
.	O

To	O
define	O
these	O
roles	O
more	O
clearly	O
,	O
we	O
examined	O
the	O
expression	O
of	O
DCC	O
and	O
its	O
ligand	O
,	O
netrin	O
-	O
1	O
,	O
in	O
the	O
normal	O
endometrium	S-Multi-tissue_structure
and	O
in	O
endometrial	B-Cancer
cancer	E-Cancer
.	O

METHODS	O
:	O
The	O
expression	O
of	O
DCC	O
and	O
netrin	O
-	O
1	O
in	O
normal	O
endometrial	B-Multi-tissue_structure
glands	E-Multi-tissue_structure
and	O
in	O
cancer	B-Cell
cell	I-Cell
lines	E-Cell
was	O
examined	O
by	O
RT	O
-	O
PCR	O
and	O
immunohistochemistry	O
.	O

The	O
effects	O
of	O
exogenous	O
DCC	O
and	O
netrin	O
-	O
1	O
expression	O
were	O
observed	O
together	O
with	O
the	O
respective	O
expression	O
vector	O
transfection	O
.	O

RESULTS	O
:	O
Endometrial	B-Multi-tissue_structure
glands	E-Multi-tissue_structure
in	O
the	O
proliferative	O
and	O
early	O
secretory	O
phase	O
expressed	O
both	O
DCC	O
and	O
netrin	O
-	O
1	O
,	O
but	O
glands	S-Multi-tissue_structure
in	O
the	O
late	O
-	O
secretory	O
phase	O
tended	O
to	O
silence	O
DCC	O
expression	O
.	O

In	O
addition	O
,	O
all	O
of	O
the	O
endometrial	B-Cell
cancer	I-Cell
cell	I-Cell
lines	E-Cell
lost	O
normal	O
DCC	O
expression	O
.	O

Restored	O
DCC	O
expression	O
in	O
the	O
cancer	B-Cell
cell	I-Cell
lines	E-Cell
in	O
the	O
absence	O
of	O
netrin	O
-	O
1	O
induced	O
apoptosis	O
.	O

However	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
presence	O
of	O
netrin	O
-	O
1	O
.	O

CONCLUSION	O
:	O
Our	O
observations	O
suggest	O
that	O
DCC	O
/	O
netrin	O
-	O
1	O
signaling	O
may	O
commit	O
cells	S-Cell
to	O
the	O
transition	O
of	O
endometrial	B-Multi-tissue_structure
gland	E-Multi-tissue_structure
architecture	O
or	O
function	O
from	O
a	O
proliferating	O
to	O
a	O
secretory	O
phase	O
.	O

In	O
addition	O
,	O
the	O
silencing	O
of	O
DCC	O
expression	O
may	O
contribute	O
to	O
the	O
escape	O
of	O
endometrial	B-Cell
cancer	I-Cell
cells	E-Cell
from	O
a	O
DCC	O
-	O
regulated	O
apoptotic	O
program	O
,	O
thereby	O
promoting	O
malignant	O
phenotypes	O
.	O

Structural	O
evolution	O
in	O
cationic	O
micelles	O
upon	O
incorporation	O
of	O
a	O
polar	O
organic	O
dopant	O
.	O

Micelles	O
of	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
,	O
when	O
doped	O
with	O
increasing	O
levels	O
of	O
4	O
-	O
ethylphenol	O
,	O
show	O
microstructural	O
transitions	O
from	O
spherical	O
micelles	O
to	O
elongated	O
wormlike	O
micelles	O
,	O
disks	O
,	O
and	O
subsequently	O
to	O
globular	O
and	O
then	O
to	O
tubular	O
vesicles	O
.	O

Wormlike	O
micelles	O
are	O
observed	O
at	O
a	O
dopant	O
-	O
to	O
-	O
CTAB	O
molar	O
ratio	O
of	O
1	O
:	O
3	O
.	O

At	O
higher	O
dopant	O
ratios	O
(	O
1	O
:	O
1	O
)	O
,	O
globular	O
vesicles	O
are	O
observed	O
which	O
transition	O
to	O
tubular	O
vesicles	O
when	O
the	O
dopant	O
becomes	O
the	O
predominant	O
species	O
at	O
a	O
ratio	O
of	O
3	O
:	O
1	O
.	O

These	O
transitions	O
are	O
reflected	O
in	O
small	O
-	O
angle	O
neutron	O
scattering	O
analysis	O
and	O
,	O
interestingly	O
,	O
can	O
be	O
directly	O
observed	O
through	O
cryo	O
-	O
transmission	O
electron	O
microscopy	O
.	O

The	O
para	O
-	O
substituted	O
phenol	O
is	O
interfacially	O
active	O
and	O
modulates	O
interfacial	O
curvature	O
of	O
the	O
micelles	O
.	O

The	O
observations	O
of	O
microstructure	O
modifications	O
have	O
relevance	O
to	O
the	O
synthesis	O
of	O
mesoporous	O
materials	O
using	O
CTAB	O
as	O
the	O
template	O
.	O

An	O
evaluation	O
of	O
low	O
molecular	O
weight	O
heparin	O
and	O
hyperbaric	O
oxygen	O
treatment	O
in	O
the	O
prevention	O
of	O
intra	O
-	O
abdominal	O
adhesions	O
and	O
wound	S-Pathological_formation
healing	O
.	O

BACKGROUND	O
:	O
Abdominal	S-Organism_subdivision
surgery	O
can	O
lead	O
to	O
intra	O
-	O
abdominal	O
adhesions	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

To	O
prevent	O
adhesions	O
,	O
an	O
experimental	O
study	O
was	O
planned	O
to	O
designate	O
the	O
effects	O
of	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
heparins	O
and	O
hyperbaric	O
oxygen	O
(	O
HBO	O
)	O
therapy	O
both	O
on	O
the	O
formation	O
of	O
adhesions	O
and	O
wound	S-Pathological_formation
healing	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
Wistar	O
albino	O
rats	O
underwent	O
laparotomy	O
to	O
cause	O
intra	O
-	O
abdominal	O
adhesions	O
by	O
mechanical	O
abrasion	O
of	O
the	O
cecum	S-Multi-tissue_structure
and	O
ethanol	O
application	O
.	O

The	O
rats	O
were	O
divided	O
into	O
4	O
groups	O
.	O

In	O
the	O
control	O
group	O
(	O
group	O
1	O
)	O
no	O
further	O
management	O
was	O
undertaken	O
.	O

Group	O
2	O
was	O
treated	O
by	O
Enoxaparine	O
Na	O
,	O
group	O
3	O
received	O
HBO	O
therapy	O
,	O
and	O
group	O
4	O
was	O
given	O
both	O
enoxaparine	O
Na	O
and	O
HBO	O
treatment	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
control	O
and	O
enoxaparine	O
Na	O
groups	O
regarding	O
adhesions	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
1	O
and	O
4	O
and	O
between	O
groups	O
1	O
and	O
3	O
regarding	O
the	O
hydroxyproline	O
content	O
of	O
the	O
abdominal	B-Pathological_formation
wounds	E-Pathological_formation
.	O

In	O
the	O
pathologic	O
analysis	O
of	O
the	O
abdominal	B-Pathological_formation
wounds	E-Pathological_formation
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
groups	O
,	O
including	O
the	O
control	O
group	O
,	O
regarding	O
inflammation	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
regarding	O
angiogenesis	O
between	O
the	O
control	O
group	O
and	O
groups	O
3	O
and	O
4	O
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
difference	O
regarding	O
fibrosis	O
between	O
groups	O
1	O
and	O
4	O
.	O

CONCLUSIONS	O
:	O
Enoxaparine	O
Na	O
decreased	O
intra	O
-	O
abdominal	O
adhesions	O
,	O
and	O
HBO	O
therapy	O
had	O
no	O
beneficial	O
effect	O
on	O
adhesions	O
.	O

Enoxaparine	O
Na	O
had	O
no	O
harmful	O
effects	O
on	O
wound	S-Pathological_formation
healing	O
,	O
and	O
HBO	O
therapy	O
increased	O
the	O
process	O
of	O
wound	S-Pathological_formation
healing	O
.	O

Treatment	O
of	O
transplanted	O
CT26	B-Cancer
tumour	E-Cancer
with	O
dendritic	B-Cell
cell	E-Cell
vaccine	O
in	O
combination	O
with	O
blockade	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
and	O
CTLA	O
-	O
4	O
.	O

We	O
investigated	O
the	O
anti	O
CT26	B-Cancer
tumour	E-Cancer
effect	O
of	O
dendritic	B-Cell
cell	E-Cell
based	O
vaccination	O
with	O
the	O
MuLV	O
gp70	O
envelope	S-Cellular_component
protein	O
-	O
derived	O
peptides	O
AH1	O
and	O
p320	O
-	O
333	O
.	O

Vaccination	O
lead	O
to	O
generation	O
of	O
AH1	O
specific	O
cytotoxic	B-Cell
lymphocytes	E-Cell
(	O
CTL	S-Cell
)	O
and	O
some	O
decrease	O
in	O
tumour	S-Cancer
growth	O
of	O
simultaneously	O
inoculated	O
CT26	B-Cell
cells	E-Cell
.	O

After	O
combination	O
with	O
an	O
antibody	O
against	O
VEGF	O
receptor	O
2	O
(	O
DC101	O
)	O
,	O
a	O
significant	O
increase	O
in	O
survival	O
of	O
the	O
tumour	B-Cell
cell	E-Cell
recipients	O
was	O
observed	O
.	O

Also	O
,	O
monotherapy	O
with	O
an	O
antibody	O
against	O
CTLA	O
-	O
4	O
(	O
9H10	O
)	O
,	O
led	O
to	O
approximately	O
100	O
%	O
survival	O
of	O
tumour	B-Cell
cell	E-Cell
recipients	O
.	O

However	O
,	O
effective	O
treatment	O
of	O
mice	O
with	O
already	O
established	O
tumours	S-Cancer
was	O
only	O
obtained	O
after	O
combination	O
of	O
vaccination	O
,	O
DC101	O
and	O
9H10	O
treatment	O
in	O
which	O
setting	O
80	O
%	O
of	O
the	O
mice	O
rejected	O
their	O
tumours	S-Cancer
.	O

VEGF	O
-	O
targeted	O
therapy	O
:	O
therapeutic	O
potential	O
and	O
recent	O
advances	O
.	O

After	O
over	O
30	O
years	O
of	O
theorizing	O
,	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
as	O
anticancer	S-Cancer
therapy	O
has	O
finally	O
moved	O
from	O
the	O
realm	O
of	O
research	O
to	O
reality	O
.	O

Normal	O
adult	O
vasculature	S-Anatomical_system
is	O
generally	O
quiescent	O
in	O
nature	O
,	O
with	O
endothelial	B-Cell
cells	E-Cell
dividing	O
approximately	O
every	O
10	O
years	O
.	O

In	O
contrast	O
,	O
the	O
growth	O
of	O
tumors	S-Cancer
requires	O
constant	O
vascular	S-Multi-tissue_structure
growth	O
and	O
remodeling	O
in	O
order	O
for	O
solid	B-Cancer
tumors	E-Cancer
to	O
grow	O
beyond	O
1	O
-	O
2	O
mm	O
(	O
3	O
)	O
in	O
size	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
receptors	O
are	O
key	O
regulators	O
of	O
the	O
process	O
of	O
angiogenesis	O
,	O
which	O
makes	O
them	O
attractive	O
therapeutic	O
targets	O
.	O

A	O
multitude	O
of	O
VEGF	O
-	O
targeted	O
inhibitory	O
agents	O
are	O
currently	O
being	O
investigated	O
for	O
the	O
treatment	O
of	O
cancer	S-Cancer
.	O

This	O
review	O
article	O
focuses	O
on	O
recent	O
developments	O
in	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
breast	S-Cancer
,	O
lung	S-Cancer
,	O
and	O
colorectal	B-Cancer
cancers	E-Cancer
.	O

MDM2	O
as	O
a	O
predictor	O
of	O
prostate	B-Cancer
carcinoma	E-Cancer
outcome	O
:	O
an	O
analysis	O
of	O
Radiation	O
Therapy	O
Oncology	O
Group	O
Protocol	O
8610	O
.	O

BACKGROUND	O
:	O
The	O
MDM2	O
oncoprotein	O
promotes	O
p53	O
degradation	O
via	O
ubiquitin	O
,	O
establishing	O
negative	O
feedback	O
control	O
of	O
p53	O
and	O
consequently	O
affecting	O
cell	S-Cell
cycle	O
arrest	O
and	O
apoptosis	O
.	O

The	O
authors	O
evaluated	O
the	O
association	O
between	O
MDM2	O
expression	O
and	O
local	O
failure	O
,	O
distant	O
metastasis	O
(	O
DM	O
)	O
,	O
cause	O
-	O
specific	O
mortality	O
,	O
and	O
overall	O
mortality	O
in	O
men	O
treated	O
in	O
Radiation	O
Therapy	O
Oncology	O
Group	O
8610	O
with	O
radiotherapy	O
,	O
with	O
or	O
without	O
androgen	O
deprivation	O
.	O

METHODS	O
:	O
Of	O
the	O
456	O
eligible	O
and	O
analyzable	O
patients	O
(	O
parent	O
cohort	O
)	O
,	O
adequate	O
archival	O
diagnostic	O
tissue	B-Tissue
specimens	E-Tissue
from	O
108	O
patients	O
were	O
available	O
for	O
MDM2	O
analysis	O
(	O
MDM2	O
cohort	O
)	O
.	O

Cox	O
proportional	O
hazards	O
multivariate	O
analysis	O
(	O
MVA	O
)	O
was	O
used	O
to	O
determine	O
the	O
relation	O
of	O
MDM2	O
to	O
the	O
endpoints	O
.	O

MDM2	O
overexpression	O
was	O
manually	O
classified	O
as	O
>	O
5	O
%	O
nuclear	S-Cellular_component
staining	O
.	O

An	O
image	O
analysis	O
system	O
was	O
also	O
used	O
to	O
quantify	O
the	O
proportion	O
of	O
tumor	B-Cellular_component
nuclei	E-Cellular_component
with	O
MDM2	O
staining	O
(	O
ACIS	O
index	O
)	O
and	O
staining	O
intensity	O
.	O

RESULTS	O
:	O
Overexpression	O
of	O
MDM2	O
by	O
manual	O
counts	O
was	O
seen	O
in	O
44	O
%	O
(	O
n	O
=	O
47	O
)	O
of	O
the	O
patients	O
.	O

In	O
the	O
manual	O
count	O
analysis	O
,	O
there	O
was	O
no	O
significant	O
relation	O
between	O
MDM2	O
overexpression	O
and	O
outcome	O
.	O

The	O
ACIS	O
index	O
,	O
using	O
a	O
cutoff	O
point	O
defined	O
by	O
the	O
median	O
value	O
,	O
<	O
or	O
=	O
3	O
%	O
versus	O
>	O
3	O
%	O
,	O
was	O
related	O
to	O
5	O
-	O
year	O
DM	O
rates	O
in	O
univariate	O
analyses	O
(	O
32	O
.	O
6	O
%	O
vs	O
.	O
45	O
.	O
8	O
%	O
;	O
P	O
=	O
0	O
.	O
057	O
)	O
and	O
MVA	O
(	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

The	O
intensity	O
of	O
MDM2	O
staining	O
was	O
not	O
significant	O
.	O

CONCLUSIONS	O
:	O
MDM2	O
expression	O
quantified	O
by	O
image	O
analysis	O
was	O
weakly	O
associated	O
with	O
DM	O
.	O

The	O
cohort	O
examined	O
was	O
relatively	O
small	O
and	O
with	O
larger	O
patient	O
numbers	O
,	O
MDM2	O
overexpression	O
may	O
emerge	O
as	O
a	O
more	O
significant	O
covariate	O
.	O

Thrombospondins	O
,	O
metallo	O
proteases	O
and	O
thrombospondin	O
receptors	O
messenger	O
RNA	O
and	O
protein	O
expression	O
in	O
different	O
tumour	B-Cancer
sublines	E-Cancer
of	O
the	O
Dunning	B-Cancer
prostate	I-Cancer
cancer	E-Cancer
model	O
.	O

Thrombospondin	O
is	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	O
and	O
might	O
therefore	O
be	O
important	O
in	O
controlling	O
tumour	S-Cancer
growth	O
.	O

TSP	O
interacts	O
with	O
a	O
number	O
of	O
proteases	O
and	O
receptors	O
and	O
in	O
this	O
way	O
inhibits	O
stimulation	O
of	O
angiogenesis	O
.	O

An	O
earlier	O
study	O
showed	O
that	O
thrombospondin	O
is	O
expressed	O
in	O
benign	B-Pathological_formation
prostatic	I-Pathological_formation
hyperplasia	E-Pathological_formation
(	O
BPH	S-Pathological_formation
)	O
and	O
high	B-Pathological_formation
-	I-Pathological_formation
grade	I-Pathological_formation
prostatic	I-Pathological_formation
intraepithelial	I-Pathological_formation
neoplasia	E-Pathological_formation
(	O
PIN	S-Pathological_formation
)	O
but	O
is	O
absent	O
in	O
prostate	B-Cancer
cancer	E-Cancer
.	O

The	O
present	O
study	O
was	O
therefore	O
designed	O
to	O
evaluate	O
the	O
expression	O
of	O
thrombospondin	O
1	O
and	O
2	O
(	O
TSP	O
-	O
1	O
,	O
TSP	O
-	O
2	O
)	O
,	O
TSP	O
receptors	O
CD36	O
and	O
CD47	O
,	O
and	O
matrix	O
-	O
metalloproteases	O
2	O
and	O
9	O
(	O
MMP	O
-	O
,	O
MMP	O
-	O
9	O
)	O
in	O
a	O
rat	O
prostate	B-Cancer
cancer	E-Cancer
model	O
.	O

By	O
using	O
immunohistochemistry	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
PCR	O
the	O
expression	O
patterns	O
of	O
TSP	O
-	O
1	O
,	O
TSP	O
-	O
2	O
,	O
CD36	O
,	O
CD47	O
,	O
MMP	O
-	O
2	O
,	O
and	O
MMP	O
-	O
9	O
were	O
investigated	O
in	O
normal	O
rat	O
prostate	B-Tissue
tissue	E-Tissue
and	O
five	O
malignant	B-Tissue
Dunning	I-Tissue
sublines	I-Tissue
tissue	E-Tissue
.	O

TSP	O
-	O
1	O
mRNA	O
levels	O
were	O
decreased	O
in	O
all	O
tumours	S-Cancer
compared	O
with	O
normal	O
prostate	S-Organ
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
expression	O
of	O
TSP	O
-	O
2	O
and	O
CD36	O
mRNA	O
in	O
these	O
samples	S-Tissue
.	O

MMP	O
-	O
2	O
was	O
increased	O
with	O
malignancy	O
,	O
but	O
no	O
expression	O
of	O
MMP	O
-	O
9	O
was	O
seen	O
.	O

The	O
CD47	O
receptor	O
did	O
slightly	O
increase	O
with	O
malignancy	O
except	O
for	O
H3327	S-Cancer
.	O

The	O
results	O
showed	O
that	O
thrombospondin	O
is	O
expressed	O
in	O
normal	O
prostate	S-Organ
but	O
not	O
in	O
prostate	B-Cancer
tumours	E-Cancer
in	O
a	O
rat	O
model	O
.	O

Simultaneously	O
,	O
MMP	O
-	O
2	O
expression	O
increases	O
with	O
malignancy	O
.	O

Bovine	O
papillomavirus	O
E7	O
transformation	O
function	O
correlates	O
with	O
cellular	S-Cell
p600	O
protein	O
binding	O
.	O

The	O
E7	O
oncoprotein	O
of	O
bovine	O
papillomavirus	O
type	O
1	O
(	O
BPV	O
-	O
1	O
)	O
is	O
required	O
for	O
the	O
full	O
transformation	O
activity	O
of	O
the	O
virus	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
E7	O
contributes	O
to	O
cellular	S-Cell
transformation	O
is	O
unknown	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
the	O
proteomic	O
approach	O
of	O
tandem	O
affinity	O
purification	O
to	O
identify	O
cellular	S-Cell
proteins	O
that	O
are	O
in	O
complex	O
with	O
E7	O
,	O
and	O
identified	O
the	O
600	O
-	O
kDa	O
protein	O
,	O
p600	O
,	O
as	O
a	O
binding	O
partner	O
of	O
E7	O
.	O

The	O
ability	O
of	O
E7	O
to	O
complex	O
with	O
p600	O
correlated	O
with	O
its	O
ability	O
to	O
enhance	O
anchorage	O
independence	O
of	O
BPV	O
-	O
1	O
E6	O
-	O
expressing	O
cells	S-Cell
.	O

Furthermore	O
,	O
E7	O
mutant	O
proteins	O
impaired	O
in	O
their	O
ability	O
to	O
bind	O
p600	O
were	O
transformation	O
defective	O
.	O

Additionally	O
,	O
knockdown	O
of	O
p600	O
reduced	O
transformation	O
of	O
cells	S-Cell
expressing	O
both	O
BPV	O
-	O
1	O
E6	O
and	O
E7	O
,	O
as	O
well	O
as	O
E6	O
alone	O
,	O
suggesting	O
that	O
the	O
ability	O
of	O
E7	O
to	O
transformed	O
cells	S-Cell
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
its	O
ability	O
to	O
bind	O
p600	O
.	O

These	O
data	O
complement	O
work	O
that	O
shows	O
that	O
HPV16	O
E7	O
also	O
interacts	O
with	O
p600	O
,	O
and	O
that	O
this	O
interaction	O
correlates	O
with	O
the	O
ability	O
of	O
HPV16	O
E7	O
to	O
transform	O
cells	S-Cell
.	O

These	O
studies	O
thus	O
identify	O
p600	O
as	O
a	O
shared	O
target	O
of	O
the	O
E7	O
proteins	O
of	O
multiple	O
papillomaviruses	O
.	O

Molecular	O
requirements	O
for	O
epithelial	S-Cell
-	O
mesenchymal	S-Cell
transition	O
during	O
tumor	S-Cancer
progression	O
.	O

Epithelial	S-Cell
-	O
mesenchymal	S-Cell
transitions	O
(	O
EMTs	O
)	O
occur	O
as	O
key	O
steps	O
during	O
embryonic	S-Developing_anatomical_structure
morphogenesis	O
,	O
and	O
are	O
now	O
implicated	O
in	O
the	O
progression	O
of	O
primary	B-Cancer
tumors	E-Cancer
towards	O
metastases	S-Cancer
.	O

Recent	O
advances	O
have	O
fostered	O
a	O
more	O
detailed	O
understanding	O
of	O
molecular	O
mechanisms	O
and	O
networks	O
governing	O
EMT	O
in	O
tumor	S-Cancer
progression	O
.	O

Besides	O
TGFbeta	O
and	O
RTK	O
/	O
Ras	O
signaling	O
,	O
autocrine	O
factors	O
and	O
Wnt	O
-	O
,	O
Notch	O
-	O
,	O
Hedgehog	O
-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pathways	O
were	O
found	O
to	O
contribute	O
to	O
EMT	O
.	O

Repression	O
of	O
E	O
-	O
cadherin	O
by	O
transcriptional	O
regulators	O
such	O
as	O
Snail	O
or	O
Twist	O
emerges	O
as	O
one	O
critical	O
step	O
driving	O
EMT	O
,	O
and	O
this	O
stage	O
is	O
currently	O
being	O
molecularly	O
linked	O
with	O
many	O
of	O
the	O
new	O
players	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
EMT	O
plays	O
a	O
specific	O
role	O
in	O
the	O
migration	O
of	O
cells	S-Cell
from	O
a	O
primary	B-Cancer
tumor	E-Cancer
into	O
the	O
circulation	O
and	O
may	O
provide	O
a	O
rationale	O
for	O
developing	O
more	O
effective	O
cancer	S-Cancer
therapies	O
.	O

Minimal	O
contribution	O
of	O
marrow	B-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
precursors	E-Cell
to	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

During	O
embryogenesis	O
,	O
vascular	S-Cell
and	O
hemopoietic	B-Cell
cells	E-Cell
originate	O
from	O
a	O
common	O
precursor	S-Cell
,	O
the	O
hemangioblast	S-Cell
.	O

Recent	O
evidence	O
suggests	O
the	O
existence	O
of	O
endothelial	B-Cell
precursors	E-Cell
in	O
adult	O
bone	B-Cell
marrow	I-Cell
cells	E-Cell
,	O
but	O
it	O
is	O
unclear	O
whether	O
those	O
precursors	S-Cell
have	O
a	O
role	O
in	O
tumor	S-Cancer
neovascularization	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
murine	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
contains	O
endothelial	B-Cell
progenitors	E-Cell
,	O
which	O
arise	O
from	O
a	O
cell	S-Cell
with	O
self	O
-	O
renewing	O
capacity	O
,	O
and	O
can	O
integrate	O
into	O
tumor	B-Tissue
microvasculature	E-Tissue
,	O
albeit	O
at	O
a	O
very	O
low	O
frequency	O
.	O

A	O
transgenic	O
double	O
-	O
reporter	O
strategy	O
allowed	O
us	O
to	O
demonstrate	O
definitively	O
that	O
tumor	B-Cell
bone	I-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
cells	E-Cell
arise	O
by	O
transdifferentiation	O
of	O
marrow	B-Cell
progenitors	E-Cell
rather	O
than	O
by	O
cell	S-Cell
fusion	O
.	O

Single	O
cell	S-Cell
transplants	O
showed	O
that	O
a	O
common	O
precursor	S-Cell
contributes	O
to	O
both	O
the	O
hemopoietic	S-Cell
and	O
endothelial	B-Cell
lineages	E-Cell
,	O
thus	O
demonstrating	O
the	O
presence	O
of	O
an	O
adult	O
hemangioblast	S-Cell
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
increased	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
A	O
secretion	O
by	O
tumor	B-Cell
cells	E-Cell
,	O
as	O
well	O
as	O
activation	O
of	O
VEGF	O
receptor	O
-	O
2	O
in	O
bone	B-Cell
marrow	I-Cell
cells	E-Cell
does	O
not	O
alter	O
the	O
mobilization	O
and	O
incorporation	O
of	O
marrow	B-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
progenitors	E-Cell
into	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

Finally	O
,	O
in	O
human	O
umbilical	B-Cell
cord	I-Cell
blood	I-Cell
cells	E-Cell
,	O
we	O
show	O
that	O
endothelial	B-Cell
precursors	E-Cell
make	O
up	O
only	O
approximately	O
1	O
in	O
10	O
(	O
7	O
)	O
mononuclear	B-Cell
cells	E-Cell
but	O
are	O
highly	O
enriched	O
in	O
the	O
CD133	B-Cell
+	I-Cell
cell	I-Cell
population	E-Cell
.	O

By	O
ruling	O
out	O
cell	S-Cell
fusion	O
,	O
we	O
clearly	O
demonstrate	O
the	O
existence	O
of	O
an	O
adult	O
hemangioblast	S-Cell
,	O
but	O
the	O
differentiation	O
of	O
marrow	B-Cell
stem	I-Cell
cells	E-Cell
toward	O
the	O
endothelial	B-Cell
lineage	E-Cell
is	O
an	O
extremely	O
rare	O
event	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
VEGF	O
-	O
A	O
stimulation	O
of	O
hemopoietic	B-Cell
cells	E-Cell
does	O
not	O
significantly	O
alter	O
this	O
process	O
.	O

Histopathological	O
development	O
of	O
gastric	B-Cancer
tumors	E-Cancer
induced	O
by	O
N	O
-	O
methyl	O
-	O
N	O
'	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
in	O
rats	O
.	O

The	O
development	O
of	O
carcinoma	S-Cancer
was	O
examined	O
in	O
male	O
Wistar	O
rats	O
(	O
n	O
=	O
120	O
)	O
exposed	O
to	O
N	O
-	O
methyl	O
-	O
N	O
'	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
(	O
MNNG	O
)	O
in	O
the	O
drinking	O
water	O
(	O
83	O
micrograms	O
/	O
ml	O
)	O
for	O
16	O
weeks	O
.	O

After	O
MNNG	O
administration	O
,	O
rats	O
were	O
investigated	O
by	O
endoscopic	O
observation	O
,	O
visualization	O
of	O
microvascular	S-Tissue
structure	O
,	O
and	O
estimation	O
of	O
lectin	O
binding	O
sites	O
.	O

Changes	O
of	O
bile	S-Organism_substance
reflux	O
to	O
the	O
stomach	S-Organ
was	O
observed	O
endoscopically	O
at	O
24	O
weeks	O
as	O
well	O
as	O
the	O
development	O
of	O
gastric	B-Pathological_formation
mucosal	I-Pathological_formation
erosions	E-Pathological_formation
.	O

Protruding	O
and	O
expansive	O
ulcerating	B-Cancer
carcinomas	E-Cancer
developed	O
at	O
36	O
weeks	O
and	O
had	O
a	O
microvascular	S-Tissue
pattern	O
similar	O
to	O
that	O
of	O
human	O
adenocarcinoma	S-Cancer
.	O

Estimation	O
of	O
lectin	O
binding	O
site	O
and	O
pattern	O
was	O
useful	O
to	O
evaluate	O
the	O
malignant	O
potential	O
of	O
cell	S-Cell
proliferation	O
.	O

We	O
postulate	O
that	O
endoscopic	O
observation	O
is	O
valuable	O
in	O
investigating	O
the	O
development	O
of	O
gastric	B-Cancer
carcinoma	E-Cancer
,	O
and	O
microvascular	S-Tissue
structure	O
and	O
lectin	O
binding	O
pattern	O
may	O
be	O
useful	O
to	O
demonstrate	O
the	O
mechanism	O
of	O
growth	O
of	O
gastric	B-Cancer
carcinoma	E-Cancer
.	O

Decrease	O
in	O
c	O
-	O
Myc	O
activity	O
enhances	O
cancer	B-Cell
cell	E-Cell
sensitivity	O
to	O
vinblastine	O
.	O

The	O
c	O
-	O
myc	O
oncogene	O
encodes	O
for	O
a	O
transcriptional	O
factor	O
involved	O
in	O
many	O
cellular	S-Cell
processes	O
such	O
as	O
proliferation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

According	O
to	O
these	O
different	O
functions	O
,	O
the	O
role	O
of	O
c	O
-	O
Myc	O
protein	O
in	O
cellular	S-Cell
sensitivity	O
to	O
anti	O
-	O
cancer	S-Cancer
drugs	O
is	O
controversial	O
.	O

We	O
defined	O
the	O
role	O
of	O
c	O
-	O
Myc	O
in	O
cancer	B-Cell
cell	E-Cell
sensitivity	O
to	O
vinblastine	O
(	O
VLB	O
)	O
using	O
human	O
colon	B-Cell
cancer	I-Cell
cells	E-Cell
:	O
LoVo	S-Cell
wild	O
-	O
type	O
or	O
transfected	O
with	O
a	O
plasmid	S-Cellular_component
containing	O
the	O
human	O
c	O
-	O
myc	O
gene	O
in	O
antisense	O
orientation	O
(	O
LoVo	B-Cell
-	I-Cell
mycANS	E-Cell
)	O
.	O

Analysis	O
of	O
VLB	O
cytotoxicity	O
demonstrated	O
a	O
3	O
-	O
fold	O
increase	O
in	O
VLB	O
sensitivity	O
in	O
LoVo	B-Cell
-	I-Cell
mycANS	I-Cell
cells	E-Cell
.	O

Comparison	O
between	O
cells	S-Cell
revealed	O
different	O
apoptosis	O
kinetics	O
:	O
accumulation	O
of	O
cells	S-Cell
in	O
sub	O
-	O
G1	O
phase	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
occurred	O
earlier	O
in	O
LoVo	B-Cell
-	I-Cell
mycANS	E-Cell
.	O

Then	O
,	O
we	O
demonstrated	O
a	O
mitochondrial	B-Cellular_component
membrane	E-Cellular_component
potential	O
disruption	O
followed	O
by	O
cytochrome	O
c	O
release	O
that	O
indicates	O
the	O
involvement	O
of	O
mitochondria	S-Cellular_component
in	O
this	O
apoptotic	O
signaling	O
pathway	O
.	O

This	O
earlier	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
Bcl	O
-	O
2	O
decrease	O
and	O
a	O
p53	O
increase	O
.	O

In	O
conclusion	O
,	O
the	O
decrease	O
in	O
c	O
-	O
Myc	O
expression	O
enhanced	O
the	O
VLB	O
sensitivity	O
,	O
triggering	O
earlier	O
apoptosis	O
through	O
induction	O
of	O
the	O
intrinsic	O
pathway	O
.	O

Thus	O
,	O
c	O
-	O
myc	O
induction	O
is	O
a	O
resistance	O
factor	O
and	O
our	O
findings	O
suggest	O
that	O
tumors	S-Cancer
carrying	O
low	O
levels	O
of	O
c	O
-	O
Myc	O
protein	O
could	O
be	O
more	O
responsive	O
to	O
vinca	O
alkaloids	O
treatment	O
.	O

Moreover	O
,	O
the	O
downregulation	O
of	O
c	O
-	O
myc	O
oncogene	O
by	O
an	O
antisense	O
strategy	O
might	O
represent	O
a	O
useful	O
goal	O
for	O
improving	O
the	O
efficacy	O
of	O
this	O
anti	O
-	O
neoplastic	S-Cancer
drug	O
family	O
.	O

Complications	O
after	O
plate	O
fixation	O
of	O
phalangeal	S-Organism_subdivision
fractures	O
.	O

PURPOSE	O
:	O

To	O
assess	O
the	O
complications	O
after	O
plate	O
fixation	O
of	O
phalangeal	S-Organism_subdivision
fractures	O
,	O
their	O
correlation	O
with	O
the	O
type	O
of	O
injury	O
,	O
and	O
the	O
outcome	O
.	O

METHODS	O
:	O

We	O
retrospectively	O
reviewed	O
the	O
clinical	O
records	O
and	O
the	O
x	O
-	O
rays	O
of	O
54	O
consecutive	O
patients	O
with	O
64	O
phalangeal	S-Organism_subdivision
fractures	O
treated	O
by	O
open	O
reduction	O
and	O
plate	O
fixation	O
with	O
regard	O
to	O
fracture	O
healing	O
,	O
plate	O
loosening	O
or	O
failure	O
,	O
infection	O
,	O
complex	O
regional	O
pain	O
syndrome	O
,	O
pain	O
,	O
return	O
to	O
work	O
,	O
and	O
range	O
of	O
motion	O
.	O

RESULTS	O
:	O

In	O
31	O
out	O
of	O
54	O
patients	O
(	O
57	O
%	O
)	O
and	O
33	O
out	O
of	O
64	O
fractures	O
(	O
52	O
%	O
)	O
,	O
one	O
or	O
more	O
major	O
complications	O
occurred	O
.	O

Stiffness	O
(	O
definition	O
is	O
composite	O
range	O
of	O
motion	O
of	O
metaphalangeal	S-Multi-tissue_structure
,	O
proximal	B-Multi-tissue_structure
interphalangeal	E-Multi-tissue_structure
,	O
and	O
distal	B-Multi-tissue_structure
interphalangeal	I-Multi-tissue_structure
joints	E-Multi-tissue_structure
added	O
together	O
equaling	O
<	O
180	O
degrees	O
)	O
contributed	O
the	O
highest	O
number	O
(	O
22	O
patients	O
,	O
24	O
fractures	O
)	O
.	O

The	O
complication	O
rates	O
were	O
not	O
different	O
whether	O
the	O
fracture	O
was	O
open	O
or	O
closed	O
,	O
if	O
it	O
was	O
located	O
in	O
the	O
proximal	O
or	O
middle	B-Organism_subdivision
phalanx	E-Organism_subdivision
,	O
the	O
presence	O
or	O
absence	O
of	O
an	O
associated	O
soft	B-Pathological_formation
tissue	I-Pathological_formation
lesion	E-Pathological_formation
,	O
and	O
the	O
patient	O
'	O
s	O
occupation	O
.	O

CONCLUSIONS	O
:	O

In	O
spite	O
of	O
early	O
mobilization	O
,	O
stiffness	O
is	O
the	O
most	O
frequent	O
complication	O
after	O
open	O
reduction	O
and	O
plate	O
fixation	O
of	O
phalangeal	S-Organism_subdivision
fractures	O
.	O

The	O
undue	O
amount	O
of	O
scarring	O
and	O
adhesion	O
may	O
arise	O
from	O
the	O
implant	O
itself	O
or	O
the	O
difficulty	O
in	O
finding	O
the	O
perfect	O
mixture	O
between	O
the	O
minimal	O
surgical	O
invasiveness	O
and	O
a	O
sufficient	O
restoration	O
of	O
skeletal	S-Anatomical_system
stability	O
.	O

Otherwise	O
,	O
plate	O
fixation	O
of	O
unstable	O
and	O
complex	O
phalangeal	S-Organism_subdivision
fractures	O
proved	O
efficient	O
and	O
reliable	O
,	O
although	O
not	O
free	O
of	O
potential	O
problems	O
.	O

Alteration	O
of	O
homeobox	O
gene	O
expression	O
by	O
N	O
-	O
ras	O
transformation	O
of	O
PA	B-Cell
-	I-Cell
1	I-Cell
human	I-Cell
teratocarcinoma	I-Cell
cells	E-Cell
.	O

We	O
used	O
a	O
series	O
of	O
cell	B-Cell
clones	E-Cell
from	O
a	O
human	O
teratocarcinoma	B-Cell
cell	I-Cell
line	E-Cell
,	O
PA	B-Cell
-	I-Cell
1	E-Cell
,	O
to	O
study	O
the	O
effect	O
of	O
transformation	O
by	O
an	O
activated	O
N	O
-	O
ras	O
oncogene	O
on	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
differentiation	O
and	O
growth	O
regulation	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
expression	O
of	O
human	O
HOX	O
2	O
genes	O
is	O
sequentially	O
activated	O
by	O
RA	O
beginning	O
from	O
Hox	O
2	O
.	O
9	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
HOX	O
2	O
cluster	O
(	O
A	O
.	O
Simeone	O
,	O
D	O
.	O
Acampora	O
,	O
L	O
.	O
Arcioni	O
,	O
P	O
.	O
W	O
.	O
Andrews	O
,	O
E	O
.	O
Boncinelli	O
,	O
and	O
F	O
.	O
Mavilio	O
,	O
Nature	O
[	O
London	O
]	O
346	O
:	O
763	O
-	O
766	O
,	O
1990	O
)	O
.	O

We	O
now	O
report	O
that	O
six	O
different	O
genes	O
of	O
the	O
cluster	O
HOX	O
1	O
are	O
sequentially	O
induced	O
by	O
RA	O
in	O
a	O
similar	O
temporal	O
pattern	O
,	O
beginning	O
with	O
genes	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
cluster	O
.	O

However	O
,	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cell	B-Cell
clones	E-Cell
,	O
RA	O
-	O
induced	O
expression	O
of	O
these	O
homeobox	O
genes	O
is	O
delayed	O
.	O

Hox	O
1	O
.	O
4	O
and	O
Hox	O
1	O
.	O
3	O
,	O
genes	O
abundantly	O
induced	O
in	O
nontransformed	O
clones	S-Cell
after	O
3	O
days	O
of	O
RA	O
treatment	O
,	O
are	O
expressed	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	S-Cell
only	O
after	O
10	O
days	O
of	O
RA	O
treatment	O
.	O

At	O
this	O
time	O
,	O
the	O
cells	S-Cell
'	O
growth	O
is	O
arrested	O
at	O
very	O
high	O
density	O
,	O
and	O
no	O
differentiated	O
morphologic	O
characteristics	O
are	O
observed	O
.	O

Constitutive	O
expression	O
of	O
a	O
transfected	O
Hox	O
1	O
.	O
4	O
gene	O
under	O
the	O
control	O
of	O
a	O
simian	O
virus	O
40	O
promotor	O
leads	O
to	O
differentiated	O
cell	S-Cell
morphology	O
similar	O
to	O
that	O
of	O
the	O
RA	O
-	O
induced	O
phenotype	O
and	O
restores	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
RA	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	S-Cell
.	O

These	O
observations	O
provide	O
evidence	O
that	O
enhanced	O
proliferation	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	S-Cell
compromises	O
teratocarcinoma	B-Cell
cell	E-Cell
differentiation	O
by	O
a	O
mechanism	O
that	O
transiently	O
suppresses	O
homeobox	O
gene	O
induction	O
and	O
implies	O
a	O
central	O
role	O
for	O
homeobox	O
genes	O
in	O
RA	O
-	O
induced	O
cell	S-Cell
differentiation	O
.	O

We	O
conclude	O
that	O
stimulation	O
of	O
a	O
putative	O
growth	O
factor	O
signal	O
pathway	O
,	O
associated	O
with	O
ras	O
-	O
induced	O
proliferation	O
,	O
transiently	O
suppresses	O
the	O
induction	O
of	O
transcription	O
factors	O
functionally	O
involved	O
in	O
cell	S-Cell
growth	O
and	O
differentiation	O
.	O

High	O
-	O
Dose	O
celecoxib	O
and	O
metronomic	O
"	O
low	O
-	O
dose	O
"	O
cyclophosphamide	O
is	O
an	O
effective	O
and	O
safe	O
therapy	O
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
aggressive	O
histology	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	E-Cancer
.	O

PURPOSE	O
:	O
Angiogenesis	O
is	O
increased	O
in	O
aggressive	O
histology	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	E-Cancer
and	O
may	O
be	O
a	O
target	O
with	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibition	O
and	O
metronomic	O
chemotherapy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
assessed	O
response	O
,	O
toxicity	O
,	O
and	O
biomarkers	O
of	O
angiogenesis	O
to	O
low	O
-	O
dose	O
cyclophosphamide	O
(	O
50	O
mg	O
p	O
.	O
o	O
.	O
o	O
.	O
d	O
.	O
)	O
and	O
high	O
-	O
dose	O
celecoxib	O
(	O
400	O
mg	O
p	O
.	O
o	O
.	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
in	O
adult	O
patients	O
with	O
relapsed	O
or	O
refractory	O
aggressive	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	E-Cancer
in	O
a	O
multicenter	O
phase	O
II	O
prospective	O
study	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
of	O
35	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
are	O
evaluable	O
for	O
response	O
.	O

Patients	O
had	O
primarily	O
relapsed	O
diffuse	O
large	O
B	B-Cancer
-	I-Cancer
cell	I-Cancer
lymphoma	E-Cancer
(	O
63	O
%	O
)	O
were	O
heavily	O
pretreated	O
(	O
median	O
of	O
three	O
regimens	O
)	O
and	O
high	O
risk	O
(	O
79	O
%	O
international	O
prognostic	O
index	O
,	O
greater	O
than	O
or	O
=	O
2	O
)	O
and	O
34	O
%	O
were	O
relapsed	O
after	O
autologous	O
stem	B-Cell
cell	E-Cell
transplant	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
8	O
.	O
4	O
months	O
,	O
the	O
overall	O
best	O
response	O
rate	O
is	O
37	O
%	O
(	O
2	O
complete	O
clinical	O
response	O
/	O
complete	O
clinical	O
response	O
unconfirmed	O
and	O
9	O
partial	O
response	O
)	O
,	O
with	O
22	O
%	O
achieving	O
stable	O
disease	O
.	O

Median	O
overall	O
and	O
progression	O
-	O
free	O
survivals	O
are	O
14	O
.	O
4	O
and	O
4	O
.	O
7	O
months	O
,	O
respectively	O
.	O

The	O
median	O
response	O
duration	O
was	O
8	O
.	O
2	O
months	O
.	O

The	O
most	O
common	O
toxicity	O
was	O
skin	S-Organ
rash	O
(	O
40	O
%	O
)	O
;	O
myelosuppression	O
and	O
gastrointestinal	S-Organism_subdivision
side	O
effects	O
were	O
uncommon	O
.	O

Three	O
patients	O
developed	O
deep	B-Pathological_formation
vein	I-Pathological_formation
thromboses	E-Pathological_formation
and	O
two	O
heavily	O
pretreated	O
patients	O
developed	O
treatment	O
-	O
related	O
acute	B-Cancer
myelogenous	I-Cancer
leukemia	E-Cancer
or	O
myelodysplasia	S-Pathological_formation
after	O
3	O
.	O
7	O
and	O
12	O
months	O
of	O
therapy	O
.	O

Circulating	O
endothelial	B-Cell
cells	E-Cell
and	O
their	O
precursors	S-Cell
declined	O
and	O
remained	O
low	O
in	O
responders	O
,	O
whereas	O
plasma	S-Organism_substance
vascular	O
endothelial	O
growth	O
factor	O
trended	O
to	O
decline	O
in	O
responding	O
patients	O
but	O
increase	O
in	O
nonresponders	O
.	O

Trough	O
celecoxib	O
levels	O
achieved	O
targeted	O
"	O
antiangiogenic	O
"	O
levels	O
.	O

CONCLUSIONS	O
:	O
Low	O
-	O
dose	O
cyclophosphamide	O
and	O
high	O
-	O
dose	O
celecoxib	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
pretreated	O
aggressive	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	E-Cancer
.	O

Close	O
surveillance	O
for	O
arterial	S-Multi-tissue_structure
and	O
venous	S-Multi-tissue_structure
thrombotic	O
events	O
is	O
recommended	O
.	O

The	O
decline	O
in	O
circulating	B-Cell
endothelial	I-Cell
cells	E-Cell
and	O
their	O
precursors	S-Cell
suggests	O
that	O
this	O
combination	O
may	O
be	O
working	O
by	O
inhibiting	O
angiogenesis	O
but	O
should	O
be	O
validated	O
in	O
a	O
larger	O
patient	O
sample	O
.	O

Photodynamic	O
therapy	O
with	O
verteporfin	O
for	O
subfoveal	B-Multi-tissue_structure
choroidal	E-Multi-tissue_structure
neovascularization	O
secondary	O
to	O
pathologic	O
myopia	O
:	O
long	O
-	O
term	O
study	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
safety	O
and	O
effectiveness	O
of	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
with	O
verteporfin	O
for	O
subfoveal	B-Multi-tissue_structure
choroidal	E-Multi-tissue_structure
neovascularization	O
(	O
CNV	O
)	O
secondary	O
to	O
pathologic	O
myopia	O
(	O
PM	O
)	O
.	O

METHODS	O
:	O
Sixty	O
-	O
two	O
patients	O
(	O
62	O
eyes	S-Organ
)	O
with	O
PM	O
underwent	O
PDT	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
Verteporfin	O
in	O
Photodynamic	O
Therapy	O
Study	O
.	O

Clinical	O
evaluations	O
performed	O
at	O
all	O
study	O
visits	O
included	O
measurement	O
of	O
best	O
-	O
corrected	O
Snellen	O
visual	O
acuity	O
,	O
slit	O
-	O
lamp	O
biomicroscopy	O
,	O
and	O
fundus	S-Multi-tissue_structure
fluorescein	O
angiography	O
.	O

Patients	O
were	O
followed	O
up	O
at	O
1	O
month	O
and	O
3	O
months	O
after	O
treatment	O
and	O
thereafter	O
at	O
3	O
-	O
month	O
intervals	O
.	O

RESULTS	O
:	O
The	O
final	O
visual	O
acuity	O
of	O
the	O
study	O
patients	O
,	O
after	O
a	O
median	O
follow	O
-	O
up	O
of	O
31	O
months	O
,	O
improved	O
by	O
greater	O
than	O
or	O
=	O
1	O
Snellen	O
lines	O
in	O
8	O
patients	O
(	O
13	O
%	O
)	O
,	O
deteriorated	O
in	O
20	O
(	O
32	O
%	O
)	O
,	O
and	O
remained	O
stable	O
in	O
34	O
(	O
55	O
%	O
)	O
.	O

The	O
baseline	O
visual	O
acuity	O
was	O
similar	O
in	O
the	O
various	O
study	O
groups	O
.	O

The	O
final	O
mean	O
visual	O
acuity	O
in	O
group	O
A	O
(	O
55	O
years	O
of	O
age	O
or	O
younger	O
)	O
was	O
20	O
/	O
80	O
and	O
significantly	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
better	O
than	O
that	O
(	O
20	O
/	O
138	O
)	O
in	O
group	O
B	O
(	O
older	O
than	O
55	O
years	O
of	O
age	O
)	O
.	O

The	O
mean	O
final	O
visual	O
acuity	O
in	O
eyes	S-Organ
with	O
higher	O
refractive	O
error	O
at	O
baseline	O
(	O
greater	O
than	O
-	O
17	O
diopters	O
)	O
was	O
significantly	O
better	O
(	O
P	O
=	O
0	O
.	O
014	O
)	O
than	O
that	O
in	O
eyes	S-Organ
with	O
lower	O
refractive	O
error	O
(	O
-	O
6	O
to	O
-	O
10	O
diopters	O
)	O
.	O

CNV	O
size	O
did	O
not	O
affect	O
visual	O
outcomes	O
.	O

CONCLUSION	O
:	O
PDT	O
preserves	O
vision	O
in	O
patients	O
with	O
CNV	O
associated	O
with	O
PM	O
.	O

Younger	O
patients	O
and	O
eyes	S-Organ
with	O
higher	O
refractive	O
error	O
appear	O
more	O
likely	O
to	O
benefit	O
from	O
PDT	O
with	O
verteporfin	O
.	O

Carcinogenesis	O
and	O
transcriptional	O
regulation	O
through	O
Maf	O
recognition	O
elements	O
.	O

Many	O
studies	O
on	O
carcinogenesis	O
carried	O
out	O
early	O
in	O
the	O
last	O
century	O
are	O
united	O
on	O
the	O
consensus	O
that	O
cancer	S-Cancer
is	O
a	O
genetic	O
disease	O
.	O

Cancer	B-Cell
cells	E-Cell
typically	O
display	O
gene	O
dysfunction	O
and	O
endogenous	O
or	O
exogenous	O
insults	O
resulting	O
in	O
gene	O
dysfunction	O
are	O
often	O
carcinogenic	O
.	O

Recent	O
advances	O
in	O
stem	B-Cell
cell	E-Cell
biology	O
added	O
the	O
new	O
concept	O
that	O
cancer	S-Cancer
originates	O
from	O
a	O
single	O
cancer	S-Cancer
-	O
initiating	O
cell	S-Cell
.	O

To	O
understand	O
the	O
molecular	O
basis	O
of	O
carcinogenesis	O
from	O
the	O
beginning	O
to	O
the	O
full	O
acquirement	O
of	O
malignancy	O
,	O
factors	O
concerned	O
with	O
carcinogenesis	O
were	O
categorized	O
into	O
three	O
groups	O
:	O
those	O
guarding	O
and	O
stabilizing	O
genomes	O
,	O
those	O
regulating	O
cell	S-Cell
proliferation	O
,	O
and	O
those	O
conferring	O
resistance	O
to	O
various	O
micro	O
-	O
environmental	O
stresses	O
.	O

One	O
example	O
of	O
particular	O
interest	O
is	O
the	O
Keap1	O
-	O
Nrf2	O
system	O
since	O
,	O
according	O
to	O
recent	O
studies	O
,	O
it	O
has	O
turned	O
out	O
to	O
be	O
ambivalent	O
.	O

Nrf2	O
heterodimerizes	O
with	O
small	O
Maf	O
protein	O
to	O
strongly	O
activate	O
transcription	O
through	O
the	O
Maf	O
recognition	O
element	O
(	O
MARE	O
)	O
and	O
Keap1	O
is	O
an	O
inhibitory	O
regulator	O
of	O
Nrf2	O
.	O

The	O
genes	O
regulated	O
by	O
Nrf2	O
are	O
very	O
important	O
for	O
cellular	S-Cell
protection	O
of	O
the	O
genome	O
from	O
xenobiotic	O
and	O
oxidative	O
stresses	O
and	O
,	O
consequently	O
,	O
for	O
preventing	O
carcinogenesis	O
.	O

This	O
implies	O
that	O
enhancing	O
Nrf2	O
activity	O
is	O
a	O
promising	O
method	O
for	O
thwarting	O
cancer	S-Cancer
.	O

On	O
the	O
contrary	O
,	O
the	O
constitutive	O
activation	O
of	O
Nrf2	O
due	O
to	O
mutations	O
in	O
the	O
keap1	O
gene	O
is	O
characteristically	O
observed	O
in	O
lung	B-Cell
cancer	I-Cell
cells	E-Cell
,	O
suggesting	O
that	O
induced	O
expression	O
of	O
Nrf2	O
target	O
genes	O
favors	O
the	O
prevalence	O
of	O
cancer	B-Cell
cells	E-Cell
.	O

Angiotensin	O
II	O
induces	O
soluble	O
fms	O
-	O
Like	O
tyrosine	O
kinase	O
-	O
1	O
release	O
via	O
calcineurin	O
signaling	O
pathway	O
in	O
pregnancy	O
.	O

Maternal	O
endothelial	S-Cell
dysfunction	O
in	O
preeclampsia	O
is	O
associated	O
with	O
increased	O
soluble	O
fms	O
-	O
like	O
tyrosine	O
kinase	O
-	O
1	O
(	O
sFlt	O
-	O
1	O
)	O
,	O
a	O
circulating	O
antagonist	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
placental	O
growth	O
factor	O
.	O

Angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
is	O
a	O
potent	O
vasoconstrictor	O
that	O
increases	O
concomitant	O
with	O
sFlt	O
-	O
1	O
during	O
pregnancy	O
.	O

Therefore	O
,	O
we	O
speculated	O
that	O
Ang	O
II	O
may	O
promote	O
the	O
expression	O
of	O
sFlt	O
-	O
1	O
in	O
pregnancy	O
.	O

Here	O
we	O
report	O
that	O
infusion	O
of	O
Ang	O
II	O
significantly	O
increases	O
circulating	O
levels	O
of	O
sFlt	O
-	O
1	O
in	O
pregnant	O
mice	O
,	O
thereby	O
demonstrating	O
that	O
Ang	O
II	O
is	O
a	O
regulator	O
of	O
sFlt	O
-	O
1	O
secretion	O
in	O
vivo	O
.	O

Furthermore	O
,	O
Ang	O
II	O
stimulated	O
sFlt	O
-	O
1	O
production	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
from	O
human	O
villous	O
explants	O
and	O
cultured	O
trophoblasts	S-Cell
but	O
not	O
from	O
endothelial	B-Cell
cells	E-Cell
,	O
suggesting	O
that	O
trophoblasts	S-Cell
are	O
the	O
primary	O
source	O
of	O
sFlt	O
-	O
1	O
during	O
pregnancy	O
.	O

As	O
expected	O
,	O
Ang	O
II	O
-	O
induced	O
sFlt	O
-	O
1	O
secretion	O
resulted	O
in	O
the	O
inhibition	O
of	O
endothelial	B-Cell
cell	E-Cell
migration	O
and	O
in	O
vitro	O
tube	S-Tissue
formation	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
with	O
losartan	O
,	O
small	O
interfering	O
RNA	O
specific	O
for	O
calcineurin	O
and	O
FK506	O
demonstrated	O
that	O
Ang	O
II	O
-	O
mediated	O
sFlt	O
-	O
1	O
release	O
was	O
via	O
Ang	O
II	O
type	O
1	O
receptor	O
activation	O
and	O
calcineurin	O
signaling	O
,	O
respectively	O
.	O

These	O
findings	O
reveal	O
a	O
previously	O
unrecognized	O
regulatory	O
role	O
for	O
Ang	O
II	O
on	O
sFlt	O
-	O
1	O
expression	O
in	O
murine	O
and	O
human	O
pregnancy	O
and	O
suggest	O
that	O
elevated	O
sFlt	O
-	O
1	O
levels	O
in	O
preeclampsia	O
may	O
be	O
caused	O
by	O
a	O
dysregulation	O
of	O
the	O
local	O
renin	O
/	O
angiotensin	O
system	O
.	O

p21	O
delays	O
tumor	S-Cancer
onset	O
by	O
preservation	O
of	O
chromosomal	S-Cellular_component
stability	O
.	O

The	O
p53	O
protein	O
suppresses	O
tumorigenesis	O
by	O
initiating	O
cellular	S-Cell
functions	O
such	O
as	O
cell	S-Cell
cycle	O
arrest	O
and	O
apoptosis	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

A	O
p53	O
mutant	O
,	O
p53R172P	O
,	O
which	O
is	O
deficient	O
for	O
apoptosis	O
but	O
retains	O
a	O
partial	O
cell	S-Cell
cycle	O
arrest	O
function	O
,	O
delays	O
tumor	S-Cancer
onset	O
in	O
mice	O
.	O

Remarkably	O
,	O
lymphomas	S-Cancer
arising	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
(	O
encoding	O
p53R172P	O
)	O
retain	O
stable	O
genomes	O
.	O

Given	O
the	O
dominant	O
role	O
of	O
p21	O
in	O
p53	O
cell	S-Cell
cycle	O
control	O
,	O
we	O
crossed	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
onto	O
a	O
p21	O
-	O
null	O
background	O
to	O
determine	O
whether	O
p21	O
was	O
required	O
for	O
maintaining	O
chromosomal	S-Cellular_component
stability	O
and	O
delaying	O
tumor	S-Cancer
onset	O
.	O

Loss	O
of	O
p21	O
completely	O
abolished	O
the	O
cell	S-Cell
cycle	O
arrest	O
function	O
of	O
p53R172P	O
and	O
accelerated	O
tumor	S-Cancer
onset	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
.	O

Cytogenetic	O
examination	O
of	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
p21	O
(	O
-	O
/	O
-	O
)	O
sarcomas	S-Cancer
and	O
lymphomas	S-Cancer
revealed	O
aneuploidy	O
and	O
chromosomal	B-Pathological_formation
aberrations	E-Pathological_formation
that	O
were	O
absent	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
malignancies	S-Cancer
.	O

Thus	O
,	O
p21	O
coupled	O
p53	O
-	O
dependent	O
checkpoint	O
control	O
and	O
preservation	O
of	O
chromosomal	S-Cellular_component
stability	O
,	O
and	O
cooperated	O
with	O
apoptosis	O
in	O
suppressing	O
tumor	S-Cancer
onset	O
in	O
mice	O
.	O

[	O
Diagnostic	O
value	O
of	O
DNA	O
,	O
RNA	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
examination	O
in	O
malignant	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
by	O
flow	O
cytometry	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
study	O
the	O
diagnostic	O
value	O
of	O
DNA	O
,	O
RNA	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
examination	O
in	O
malignant	B-Organism_substance
effusion	E-Organism_substance
by	O
multiparametric	O
flow	O
cytometry	O
,	O
and	O
therefore	O
to	O
provide	O
proof	O
for	O
clinical	O
application	O
.	O

METHODS	O
:	O

Forty	O
seven	O
patients	O
with	O
pleural	B-Organism_substance
effusions	E-Organism_substance
in	O
our	O
hospital	O
from	O
August	O
2003	O
to	O
February	O
2004	O
were	O
divided	O
into	O
two	O
groups	O
:	O
19	O
suffering	O
from	O
benign	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
and	O
28	O
from	O
malignant	B-Organism_substance
effusions	E-Organism_substance
confirmed	O
by	O
pathologic	O
examination	O
.	O

The	O
cells	S-Cell
for	O
diagnosis	O
were	O
divided	O
into	O
four	O
groups	O
stained	O
by	O
PI	O
(	O
Propidium	O
-	O
iodide	O
)	O
,	O
PY	O
(	O
Pyronin	O
)	O
,	O
PCNA	O
-	O
FITC	O
and	O
PCNA	O
-	O
mouse	O
-	O
alpha	O
-	O
2a	O
.	O

The	O
specimens	S-Organism_substance
were	O
analyzed	O
by	O
a	O
flow	O
cytometer	O
(	O
FacS	O
Caliber	O
,	O
Becton	O
Dickinson	O
)	O
.	O

The	O
sensitivity	O
and	O
the	O
specificity	O
of	O
each	O
examination	O
and	O
combined	O
examination	O
were	O
calculated	O
by	O
statistic	O
software	O
SPSS	O
13	O
.	O
0	O
.	O

RESULTS	O
:	O

(	O
1	O
)	O
The	O
expression	O
of	O
DI	O
,	O
RI	O
,	O
and	O
PI	O
in	O
benign	B-Organism_substance
pleural	I-Organism_substance
effusion	E-Organism_substance
was	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
06	O
,	O
10	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
54	O
,	O
and	O
(	O
4	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
72	O
)	O
%	O
,	O
respectively	O
,	O
and	O
those	O
in	O
malignant	B-Organism_substance
ones	E-Organism_substance
was	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
17	O
,	O
11	O
.	O
65	O
+	O
/	O
-	O
1	O
.	O
45	O
,	O
and	O
(	O
11	O
.	O
97	O
+	O
/	O
-	O
1	O
.	O
50	O
)	O
%	O
,	O
respectively	O
,	O
the	O
difference	O
being	O
statistically	O
significant	O
.	O

The	O
cutoff	O
value	O
of	O
DI	O
,	O
RI	O
and	O
PI	O
was	O
1	O
.	O
10	O
%	O
,	O
10	O
.	O
75	O
%	O
and	O
4	O
.	O
56	O
%	O
,	O
and	O
the	O
sensitivity	O
of	O
DI	O
examination	O
was	O
89	O
.	O
3	O
%	O
,	O
78	O
.	O
6	O
%	O
,	O
75	O
.	O
0	O
%	O
,	O
and	O
the	O
specificity	O
was	O
89	O
.	O
5	O
%	O
,	O
98	O
.	O
5	O
%	O
,	O
84	O
.	O
2	O
%	O
,	O
respectively	O
.	O

(	O
2	O
)	O
In	O
6	O
cases	O
suffering	O
from	O
malignant	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
,	O
RI	O
was	O
positive	O
but	O
DI	O
was	O
negative	O
,	O
indicating	O
that	O
DI	O
combined	O
with	O
RI	O
examination	O
was	O
better	O
than	O
DI	O
examination	O
alone	O
.	O

(	O
3	O
)	O
In	O
5	O
cases	O
suffering	O
from	O
malignant	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
confirmed	O
by	O
tissue	S-Tissue
examination	O
,	O
the	O
cytology	O
was	O
negative	O
,	O
but	O
the	O
result	O
of	O
DI	O
and	O
RI	O
was	O
abnormal	O
,	O
indicating	O
that	O
flow	O
cytometry	O
was	O
complementary	O
to	O
pathologic	O
examination	O
.	O

(	O
4	O
)	O
The	O
sensitivity	O
of	O
DI	O
+	O
RI	O
,	O
DI	O
+	O
PI	O
,	O
RI	O
+	O
PI	O
and	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
was	O
98	O
.	O
2	O
%	O
,	O
89	O
.	O
3	O
%	O
,	O
89	O
.	O
3	O
%	O
,	O
92	O
.	O
9	O
%	O
;	O
the	O
specificity	O
was	O
84	O
.	O
2	O
%	O
,	O
89	O
.	O
5	O
%	O
,	O
84	O
.	O
2	O
%	O
,	O
94	O
.	O
2	O
%	O
respectively	O
.	O

The	O
results	O
demonstrated	O
that	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
was	O
the	O
best	O
,	O
which	O
showed	O
the	O
least	O
false	O
negative	O
and	O
false	O
positive	O
results	O
.	O

The	O
sensitivity	O
of	O
DI	O
+	O
RI	O
combined	O
examination	O
was	O
98	O
.	O
2	O
%	O
,	O
but	O
the	O
specificity	O
was	O
84	O
.	O
2	O
%	O
,	O
the	O
false	O
positive	O
rate	O
being	O
higher	O
than	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
.	O

In	O
none	O
of	O
the	O
benign	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
was	O
the	O
DI	O
+	O
RI	O
+	O
PI	O
higher	O
than	O
the	O
cutoff	O
value	O
,	O
suggesting	O
that	O
combined	O
examination	O
can	O
exclude	O
benign	B-Organism_substance
pleural	I-Organism_substance
effusions	E-Organism_substance
.	O

CONCLUSIONS	O
:	O

DNA	O
,	O
RNA	O
and	O
PCNA	O
examinations	O
by	O
flow	O
cytometry	O
are	O
of	O
value	O
in	O
the	O
diagnosis	O
of	O
malignant	B-Organism_substance
effusion	E-Organism_substance
,	O
especially	O
for	O
cases	O
which	O
can	O
not	O
be	O
diagnosed	O
by	O
cytological	O
examination	O
.	O

DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
showed	O
better	O
results	O
with	O
the	O
lowest	O
false	O
negative	O
and	O
false	O
positive	O
rates	O
.	O

Schizophrenia	O
:	O
a	O
common	O
disease	O
caused	O
by	O
multiple	O
rare	O
alleles	O
.	O

Schizophrenia	O
is	O
widely	O
held	O
to	O
stem	O
from	O
the	O
combined	O
effects	O
of	O
multiple	O
common	O
polymorphisms	O
,	O
each	O
with	O
a	O
small	O
impact	O
on	O
disease	O
risk	O
.	O

We	O
suggest	O
an	O
alternative	O
view	O
:	O
that	O
schizophrenia	O
is	O
highly	O
heterogeneous	O
genetically	O
and	O
that	O
many	O
predisposing	O
mutations	O
are	O
highly	O
penetrant	O
and	O
individually	O
rare	O
,	O
even	O
specific	O
to	O
single	O
cases	O
or	O
families	O
.	O

This	O
"	O
common	O
disease	O
-	O
-	O
rare	O
alleles	O
"	O
hypothesis	O
is	O
supported	O
by	O
recent	O
findings	O
in	O
human	O
genomics	O
and	O
by	O
allelic	O
and	O
locus	O
heterogeneity	O
for	O
other	O
complex	O
traits	O
.	O

We	O
review	O
the	O
implications	O
of	O
this	O
model	O
for	O
gene	O
discovery	O
research	O
in	O
schizophrenia	O
.	O

Mechanisms	O
for	O
the	O
magnolol	O
-	O
induced	O
cell	S-Cell
death	O
of	O
CGTH	B-Cell
W	I-Cell
-	I-Cell
2	I-Cell
thyroid	I-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

Magnolol	O
,	O
a	O
substance	O
purified	O
from	O
the	O
bark	S-Tissue
of	O
Magnolia	O
officialis	O
,	O
inhibits	O
cell	S-Cell
proliferation	O
and	O
induces	O
apoptosis	O
in	O
a	O
variety	O
of	O
cancer	B-Cell
cells	E-Cell
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
the	O
effects	O
of	O
magnolol	O
on	O
CGTH	B-Cell
W	I-Cell
-	I-Cell
2	I-Cell
thyroid	I-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

After	O
24	O
h	O
treatment	O
with	O
80	O
microM	O
magnolol	O
in	O
serum	S-Organism_substance
-	O
containing	O
medium	O
,	O
about	O
50	O
%	O
of	O
the	O
cells	S-Cell
exhibited	O
apoptotic	O
features	O
and	O
20	O
%	O
necrotic	O
features	O
.	O

Cytochrome	O
-	O
c	O
staining	O
was	O
diffused	O
in	O
the	O
cytoplasm	S-Organism_substance
of	O
the	O
apoptotic	O
cells	S-Cell
,	O
but	O
restricted	O
to	O
the	O
mitochondria	S-Cellular_component
in	O
control	O
cells	S-Cell
.	O

Western	O
blot	O
analyses	O
showed	O
an	O
increase	O
in	O
levels	O
of	O
activated	O
caspases	O
(	O
caspase	O
-	O
3	O
and	O
-	O
7	O
)	O
and	O
of	O
cleaved	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
by	O
magnolol	O
.	O

Concomitantly	O
,	O
immunostaining	O
for	O
apoptosis	O
inducing	O
factor	O
(	O
AIF	O
)	O
showed	O
a	O
time	O
-	O
dependent	O
translocation	O
from	O
the	O
mitochondria	S-Cellular_component
to	O
the	O
nucleus	S-Cellular_component
.	O

Inhibition	O
of	O
either	O
PARP	O
or	O
caspase	O
activity	O
blocked	O
magnolol	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
involvement	O
of	O
the	O
caspases	O
and	O
PARP	O
.	O

In	O
addition	O
,	O
magnolol	O
activated	O
phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
and	O
inactivated	O
Akt	O
by	O
decreasing	O
levels	O
of	O
phosphorylated	O
PTEN	O
and	O
phosphorylated	O
Akt	O
.	O

These	O
data	O
suggest	O
that	O
magnolol	O
promoted	O
apoptosis	O
probably	O
by	O
alleviating	O
the	O
inhibitory	O
effect	O
of	O
Akt	O
on	O
caspase	O
9	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
PARP	O
activity	O
,	O
but	O
not	O
of	O
caspase	O
activity	O
,	O
completely	O
prevented	O
magnolol	O
-	O
induced	O
necrosis	O
,	O
suggesting	O
the	O
notion	O
that	O
it	O
might	O
be	O
caused	O
by	O
depletion	O
of	O
intracellular	S-Immaterial_anatomical_entity
ATP	O
levels	O
due	O
to	O
PARP	O
activation	O
.	O

These	O
results	O
show	O
that	O
magnolol	O
initiates	O
apoptosis	O
via	O
the	O
cytochrome	O
-	O
c	O
/	O
caspase	O
3	O
/	O
PARP	O
/	O
AIF	O
and	O
PTEN	O
/	O
Akt	O
/	O
caspase	O
9	O
/	O
PARP	O
pathways	O
and	O
necrosis	O
via	O
PARP	O
activation	O
.	O

Antimicrobial	O
prophylaxis	O
in	O
vaginal	S-Multi-tissue_structure
gynecologic	O
surgery	O
:	O
a	O
prospective	O
randomized	O
study	O
comparing	O
amoxicillin	O
-	O
clavulanic	O
acid	O
with	O
cefazolin	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
,	O
randomized	O
study	O
was	O
to	O
compare	O
amoxicillin	O
-	O
clavulanic	O
acid	O
with	O
cefazolin	O
as	O
ultra	O
-	O
short	O
term	O
prophylaxis	O
in	O
vaginal	S-Multi-tissue_structure
gynecologic	O
surgery	O
.	O

It	O
was	O
conducted	O
at	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
University	O
of	O
Bari	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
amoxicillin	O
-	O
clavulanic	O
acid	O
(	O
2	O
.	O
2	O
g	O
)	O
[	O
Group	O
A	O
]	O
or	O
cefazolin	O
(	O
2	O
g	O
)	O
[	O
Group	O
B	O
]	O
as	O
a	O
single	O
dose	O
30	O
minutes	O
before	O
surgery	O
.	O

Each	O
patient	O
was	O
assessed	O
daily	O
until	O
discharge	O
to	O
evidence	O
febrile	O
status	O
and	O
the	O
presence	O
of	O
infections	O
at	O
the	O
operative	O
site	S-Multi-tissue_structure
,	O
urinary	B-Organism_subdivision
tract	E-Organism_subdivision
and	O
respiratory	B-Organism_subdivision
tract	E-Organism_subdivision
.	O

In	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
(	O
Group	O
A	O
)	O
and	O
cefazolin	O
(	O
Group	O
B	O
)	O
groups	O
,	O
overall	O
88	O
and	O
90	O
patients	O
,	O
respectively	O
,	O
were	O
evaluable	O
for	O
prophylactic	O
efficacy	O
at	O
hospital	O
discharge	O
.	O

Infectious	O
complications	O
were	O
infrequent	O
in	O
both	O
arms	S-Organism_subdivision
,	O
with	O
febrile	O
morbidity	O
occurring	O
in	O
4	O
(	O
4	O
.	O
5	O
%	O
)	O
and	O
16	O
(	O
8	O
.	O
9	O
%	O
)	O
patients	O
respectively	O
in	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
and	O
cefazolin	O
groups	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Urinary	B-Organism_subdivision
tract	E-Organism_subdivision
infections	O
were	O
higher	O
but	O
not	O
significantly	O
in	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
group	O
(	O
6	O
.	O
8	O
%	O
versus	O
4	O
.	O
4	O
%	O
)	O
,	O
whereas	O
asymptomatic	O
bacteriuria	O
was	O
detected	O
in	O
2	O
.	O
2	O
%	O
of	O
the	O
patients	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
respiratory	B-Organism_subdivision
tract	E-Organism_subdivision
infection	O
or	O
septic	O
death	O
in	O
either	O
group	O
.	O

It	O
is	O
concluded	O
that	O
ultra	O
-	O
short	O
term	O
prophylaxis	O
with	O
both	O
amoxicillin	O
-	O
clavulanic	O
acid	O
and	O
cefazolin	O
is	O
safe	O
and	O
effective	O
in	O
elective	O
vaginal	S-Multi-tissue_structure
gynecologic	O
surgery	O
.	O

Quantitative	O
sequencing	O
of	O
complex	O
mixtures	O
of	O
heterochitooligosaccharides	O
by	O
vMALDI	O
-	O
linear	O
ion	O
trap	O
mass	O
spectrometry	O
.	O

Heterochitooligosaccharides	O
possess	O
interesting	O
biological	O
properties	O
.	O

Isobaric	O
mixtures	O
of	O
such	O
linear	O
heterochitooligosaccharides	O
can	O
be	O
obtained	O
by	O
chemical	O
or	O
enzymatic	O
degradation	O
of	O
chitosan	O
.	O

However	O
,	O
the	O
separation	O
of	O
such	O
mixtures	O
is	O
a	O
challenging	O
analytical	O
problem	O
which	O
is	O
so	O
far	O
unresolved	O
.	O

It	O
is	O
shown	O
that	O
these	O
isobaric	O
mixtures	O
can	O
be	O
sequenced	O
and	O
quantified	O
simultaneously	O
using	O
standard	O
derivatization	O
and	O
multistage	O
tandem	O
mass	O
spectrometric	O
techniques	O
.	O

A	O
linear	O
ion	O
trap	O
mass	O
spectrometer	O
equipped	O
with	O
a	O
vacuum	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
(	O
vMALDI	O
)	O
source	O
is	O
used	O
to	O
perform	O
MS2	O
as	O
well	O
as	O
MS3	O
experiments	O
.	O

Adaptive	O
landscapes	O
and	O
emergent	O
phenotypes	O
:	O
why	O
do	O
cancers	S-Cancer
have	O
high	O
glycolysis	O
?	O

Investigating	O
the	O
causes	O
of	O
increased	O
aerobic	O
glycolysis	O
in	O
tumors	S-Cancer
(	O
Warburg	O
Effect	O
)	O
has	O
gone	O
in	O
and	O
out	O
of	O
fashion	O
many	O
times	O
since	O
it	O
was	O
first	O
described	O
almost	O
a	O
century	O
ago	O
.	O

The	O
field	O
is	O
currently	O
in	O
ascendance	O
due	O
to	O
two	O
factors	O
.	O

Over	O
a	O
million	O
FDG	O
-	O
PET	O
studies	O
have	O
unequivocally	O
identified	O
increased	O
glucose	O
uptake	O
as	O
a	O
hallmark	O
of	O
metastatic	B-Cancer
cancer	E-Cancer
in	O
humans	O
.	O

These	O
observations	O
,	O
combined	O
with	O
new	O
molecular	O
insights	O
with	O
HIF	O
-	O
1alpha	O
and	O
c	O
-	O
myc	O
,	O
have	O
rekindled	O
an	O
interest	O
in	O
this	O
important	O
phenotype	O
.	O

A	O
preponderance	O
of	O
work	O
has	O
been	O
focused	O
on	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
effect	O
,	O
with	O
the	O
expectation	O
that	O
a	O
mechanistic	O
understanding	O
may	O
lead	O
to	O
novel	O
therapeutic	O
approaches	O
.	O

There	O
is	O
also	O
an	O
implicit	O
assumption	O
that	O
a	O
mechanistic	O
understanding	O
,	O
although	O
fundamentally	O
reductionist	O
,	O
will	O
nonetheless	O
lead	O
to	O
a	O
more	O
profound	O
teleological	O
understanding	O
of	O
the	O
need	O
for	O
altered	O
metabolism	O
in	O
invasive	B-Cancer
cancers	E-Cancer
.	O

In	O
this	O
communication	O
,	O
we	O
describe	O
an	O
alternative	O
approach	O
that	O
begins	O
with	O
teleology	O
;	O
i	O
.	O
e	O
.	O
adaptive	O
landscapes	O
and	O
selection	O
pressures	O
that	O
promote	O
emergence	O
of	O
aerobic	O
glycolysis	O
during	O
the	O
somatic	O
evolution	O
of	O
invasive	B-Cancer
cancer	E-Cancer
.	O

Mathematical	O
models	O
and	O
empirical	O
observations	O
are	O
used	O
to	O
define	O
the	O
adaptive	O
advantage	O
of	O
aerobic	O
glycolysis	O
that	O
would	O
explain	O
its	O
remarkable	O
prevalence	O
in	O
human	O
cancers	S-Cancer
.	O

These	O
studies	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
increased	O
consumption	O
of	O
glucose	O
in	O
metastatic	B-Cancer
lesions	E-Cancer
is	O
not	O
used	O
for	O
substantial	O
energy	O
production	O
via	O
Embden	O
-	O
Meyerhoff	O
glycolysis	O
,	O
but	O
rather	O
for	O
production	O
of	O
acid	O
,	O
which	O
gives	O
the	O
cancer	B-Cell
cells	E-Cell
a	O
competitive	O
advantage	O
for	O
invasion	O
.	O

Alternative	O
hypotheses	O
,	O
wherein	O
the	O
glucose	O
is	O
used	O
for	O
generation	O
of	O
reducing	O
equivalents	O
(	O
NADPH	O
)	O
or	O
anabolic	O
precursors	O
(	O
ribose	O
)	O
are	O
also	O
discussed	O
.	O

Ectopic	O
decorin	O
expression	O
up	O
-	O
regulates	O
VEGF	O
expression	O
in	O
mouse	O
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
via	O
activation	O
of	O
the	O
transcription	O
factors	O
Sp1	O
,	O
HIF1alpha	O
,	O
and	O
Stat3	O
.	O

We	O
demonstrate	O
that	O
a	O
proteoglycan	O
decorin	O
(	O
DCN	O
)	O
up	O
-	O
regulates	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
with	O
activation	O
of	O
VEGF	O
regulating	O
transcription	O
factors	O
Sp1	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
(	O
HIF1alpha	O
)	O
,	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
via	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
and	O
protein	O
kinase	O
B	O
(	O
AKT	O
)	O
pathways	O
in	O
DCN	O
transfected	O
mouse	O
cerebral	B-Cell
endothelial	I-Cell
(	I-Cell
MCE	I-Cell
)	I-Cell
cells	E-Cell
.	O

Treatment	O
with	O
pharmacological	O
inhibitors	O
and	O
small	O
interfering	O
RNAs	O
reveal	O
that	O
induction	O
and	O
activation	O
of	O
Sp1	O
,	O
HIF1alpha	O
,	O
and	O
Stat3	O
facilitate	O
their	O
nuclear	S-Cellular_component
localization	O
and	O
binding	O
to	O
their	O
specific	O
motifs	O
of	O
the	O
VEGF	O
promoter	O
and	O
induce	O
VEGF	O
expression	O
via	O
two	O
independent	O
pathways	O
,	O
DCN	O
/	O
EGFR	O
/	O
phosphoinositide	O
-	O
3	O
kinase	O
/	O
AKT	O
and	O
DCN	O
/	O
EGFR	O
/	O
ERK1	O
/	O
2	O
,	O
respectively	O
,	O
in	O
DCN	O
synthesizing	O
MCE	B-Cell
cells	E-Cell
.	O

The	O
cell	S-Cell
type	O
specific	O
glycosylation	O
protects	O
Sp1	O
and	O
HIF1alpha	O
from	O
proteosome	O
degradation	O
and	O
plays	O
an	O
important	O
and	O
novel	O
role	O
in	O
the	O
regulation	O
of	O
VEGF	O
in	O
DCN	O
transfected	O
MCE	B-Cell
cells	E-Cell
.	O

Induction	O
of	O
gelatinases	O
(	O
matrix	O
metalloproteinase	O
2	O
and	O
9	O
)	O
,	O
the	O
serine	O
protease	O
tissue	O
plasminogen	O
activator	O
and	O
plasmin	O
by	O
DCN	O
transfection	O
in	O
MCE	B-Cell
cells	E-Cell
leads	O
to	O
extracellular	S-Immaterial_anatomical_entity
proteolysis	O
and	O
to	O
release	O
of	O
matrix	O
-	O
bound	O
VEGF	O
and	O
activation	O
of	O
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
two	O
independent	O
downstream	O
signal	O
pathways	O
,	O
DCN	O
/	O
EGFR	O
/	O
ERK1	O
/	O
2	O
and	O
DCN	O
/	O
EGFR	O
/	O
phosphoinositide	O
-	O
3	O
kinase	O
/	O
AKT	O
,	O
mediate	O
up	O
-	O
regulation	O
and	O
activation	O
of	O
transcription	O
factors	O
of	O
VEGF	O
such	O
as	O
HIF1alpha	O
,	O
Stat3	O
,	O
and	O
Sp1	O
and	O
increase	O
VEGF	O
transcription	O
and	O
angiogenesis	O
in	O
MCE	B-Cell
cells	E-Cell
.	O

Effects	O
of	O
spironolactone	O
on	O
corneal	B-Multi-tissue_structure
allograft	E-Multi-tissue_structure
survival	O
in	O
the	O
rat	O
.	O

PURPOSE	O
:	O
Spironolactone	O
has	O
recently	O
been	O
shown	O
to	O
have	O
suppressive	O
effects	O
on	O
several	O
immunoactive	O
and	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
spironolactone	O
on	O
the	O
prevention	O
of	O
corneal	B-Multi-tissue_structure
allograft	E-Multi-tissue_structure
rejection	O
in	O
a	O
MHC	O
class	O
I	O
/	O
II	O
mismatch	O
rat	O
corneal	S-Multi-tissue_structure
transplant	O
model	O
.	O

METHODS	O
:	O
Grafted	O
animals	O
for	O
corneal	S-Multi-tissue_structure
survival	O
analysis	O
were	O
assigned	O
to	O
receive	O
either	O
spironolactone	O
suspension	O
(	O
orally	S-Organism_subdivision
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
n	O
=	O
7	O
)	O
,	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
orally	S-Organism_subdivision
,	O
same	O
volume	O
as	O
spironolactone	O
,	O
n	O
=	O
9	O
)	O
or	O
remained	O
untreated	O
(	O
n	O
=	O
16	O
)	O
.	O

Additional	O
grafted	O
rats	O
treated	O
with	O
spironolactone	O
(	O
n	O
=	O
6	O
)	O
or	O
PBS	O
(	O
n	O
=	O
8	O
)	O
were	O
sacrificed	O
on	O
day	O
12	O
for	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
for	O
mechanistic	O
studies	O
.	O

RESULTS	O
:	O
Mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
graft	S-Multi-tissue_structure
survival	O
was	O
significantly	O
prolonged	O
in	O
animals	O
receiving	O
spironolactone	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
0	O
days	O
)	O
compared	O
with	O
both	O
PBS	O
-	O
treated	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
days	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
untreated	O
controls	O
(	O
13	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
0	O
days	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

We	O
found	O
a	O
decrease	O
in	O
corneal	S-Multi-tissue_structure
neovascularization	O
in	O
spironolactone	O
-	O
treated	O
rats	O
compared	O
with	O
the	O
PBS	O
-	O
treated	O
group	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Spironolactone	O
affected	O
both	O
systemic	O
(	O
down	O
-	O
regulation	O
of	O
CD25	B-Cell
+	I-Cell
cells	E-Cell
in	O
spleen	S-Organ
)	O
and	O
local	O
immune	O
response	O
(	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
10	O
in	O
cornea	S-Multi-tissue_structure
)	O
.	O

CONCLUSION	O
:	O
We	O
present	O
initial	O
results	O
demonstrating	O
anti	O
-	O
inflammatory	O
effects	O
of	O
spironolactone	O
.	O

FAS	O
-	O
1377	O
G	O
/	O
A	O
polymorphism	O
and	O
the	O
risk	O
of	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
in	O
cervical	B-Cancer
cancer	E-Cancer
.	O

Single	O
-	O
nucleotide	O
polymorphisms	O
of	O
the	O
FAS	O
-	O
1377G	O
/	O
A	O
,	O
FAS	O
-	O
670A	O
/	O
G	O
,	O
and	O
FASL	O
-	O
844T	O
/	O
C	O
genes	O
may	O
alter	O
transcriptional	O
activity	O
of	O
these	O
genes	O
.	O

Recent	O
evidence	O
suggests	O
an	O
association	O
of	O
these	O
polymorphisms	O
with	O
an	O
increased	O
risk	O
of	O
cervical	B-Cancer
cancer	E-Cancer
,	O
so	O
we	O
explored	O
this	O
relationship	O
.	O

Genotypes	O
of	O
155	O
patients	O
with	O
cervical	B-Cancer
cancer	E-Cancer
and	O
160	O
healthy	O
control	O
subjects	O
were	O
determined	O
using	O
polymerase	O
chain	O
reaction	O
-	O
based	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
.	O

Associations	O
with	O
cancer	S-Cancer
risk	O
were	O
estimated	O
using	O
two	O
-	O
sided	O
logistic	O
regression	O
.	O

We	O
observed	O
a	O
significantly	O
increased	O
risk	O
of	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
associated	O
with	O
the	O
FAS	O
-	O
1377	O
GA	O
or	O
AA	O
polymorphism	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
4	O
.	O
16	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
10	O
to	O
15	O
.	O
74	O
;	O
P	O
=	O
0	O
.	O
036	O
]	O
.	O

In	O
addition	O
,	O
the	O
FAS	O
-	O
670AG	O
or	O
GG	O
genotype	O
showed	O
an	O
increased	O
incidence	O
of	O
node	S-Multi-tissue_structure
metastasis	O
,	O
but	O
these	O
findings	O
were	O
not	O
statistically	O
significant	O
(	O
OR	O
=	O
3	O
.	O
67	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
96	O
-	O
14	O
.	O
00	O
,	O
P	O
=	O
0	O
.	O
059	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
an	O
increased	O
risk	O
of	O
cervical	B-Cancer
cancer	E-Cancer
and	O
polymorphisms	O
of	O
the	O
death	O
pathway	O
genes	O
FAS	O
and	O
FASL	O
.	O

None	O
of	O
the	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
advanced	O
stage	O
or	O
histologic	O
subtype	O
of	O
cervical	B-Cancer
cancer	E-Cancer
.	O

In	O
conclusion	O
,	O
FAS	O
-	O
1377	O
G	O
-	O
-	O
>	O
A	O
polymorphism	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
in	O
Korean	O
cervical	B-Cancer
cancer	E-Cancer
patients	O
.	O

Detection	O
of	O
lymphovascular	S-Multi-tissue_structure
invasion	O
in	O
early	O
breast	B-Cancer
cancer	E-Cancer
by	O
D2	O
-	O
40	O
(	O
podoplanin	O
)	O
:	O
a	O
clinically	O
useful	O
predictor	O
for	O
axillary	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	E-Cancer
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
use	O
of	O
D2	O
-	O
40	O
for	O
the	O
detection	O
of	O
lymphovascular	S-Multi-tissue_structure
invasion	O
(	O
LVI	O
)	O
in	O
node	S-Multi-tissue_structure
positive	O
and	O
negative	O
early	O
breast	B-Cancer
cancer	E-Cancer
.	O

LVI	O
is	O
associated	O
with	O
axillary	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	E-Cancer
(	O
ALNM	S-Cancer
)	O
and	O
a	O
long	O
-	O
term	O
prognostic	O
factor	O
.	O

A	O
precise	O
identification	O
of	O
LVI	O
would	O
have	O
a	O
strong	O
clinical	O
impact	O
for	O
breast	B-Cancer
cancer	E-Cancer
patients	O
.	O

METHODS	O
:	O
Immunohistochemical	O
staining	O
with	O
D2	O
-	O
40	O
and	O
CD34	O
was	O
performed	O
on	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	B-Tissue
sections	E-Tissue
of	O
254	O
invasive	B-Cancer
breast	I-Cancer
tumors	E-Cancer
of	O
247	O
patients	O
with	O
node	S-Multi-tissue_structure
negative	O
and	O
node	S-Multi-tissue_structure
positive	O
early	O
breast	B-Cancer
cancer	E-Cancer
.	O

All	O
slides	O
were	O
screened	O
for	O
the	O
presence	O
of	O
LVI	O
.	O

Correlation	O
with	O
clinico	O
-	O
pathological	O
factors	O
including	O
LVI	O
as	O
retrieved	O
by	O
routine	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
.	O
E	O
.	O
)	O
stained	O
sections	S-Tissue
and	O
the	O
eligibility	O
for	O
the	O
prediction	O
of	O
ALNM	O
was	O
assessed	O
.	O

RESULTS	O
:	O
Using	O
the	O
D2	O
-	O
40	O
antibody	O
for	O
immunostaining	O
,	O
our	O
results	O
demonstrate	O
a	O
significant	O
higher	O
detection	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
of	O
LVI	O
as	O
compared	O
with	O
routine	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	B-Cancer
cancer	E-Cancer
.	O

LVI	O
was	O
correctly	O
identified	O
by	O
D2	O
-	O
40	O
(	O
D2	O
-	O
40	O
+	O
)	O
in	O
70	O
out	O
of	O
254	O
tumors	S-Cancer
(	O
28	O
%	O
)	O
as	O
compared	O
to	O
40	O
tumors	S-Cancer
(	O
16	O
%	O
)	O
by	O
routine	O
HE	O
staining	O
(	O
HE	O
+	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
age	O
,	O
t	O
-	O
stage	O
,	O
nodal	S-Multi-tissue_structure
status	O
,	O
grading	O
and	O
hormonreceptor	O
-	O
status	O
.	O

Correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
menopausal	O
-	O
status	O
,	O
HER2	O
-	O
status	O
and	O
histological	O
type	O
was	O
not	O
significant	O
,	O
while	O
there	O
was	O
a	O
significant	O
correlation	O
of	O
D2	O
-	O
40	O
and	O
so	O
called	O
"	O
triple	O
negative	O
"	O
tumors	S-Cancer
(	O
ER	O
/	O
PR	O
and	O
HER2neu	O
-	O
negative	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
D2	O
-	O
40	O
+	O
was	O
the	O
strongest	O
predictor	O
for	O
ALNM	O
with	O
an	O
odds	O
ratio	O
of	O
3	O
.	O
489	O
and	O
a	O
P	O
-	O
value	O
of	O
P	O
=	O
0	O
.	O
0003	O
,	O
followed	O
only	O
by	O
T	O
-	O
stage	O
and	O
grading	O
with	O
odds	O
ratios	O
of	O
3	O
.	O
167	O
and	O
1	O
.	O
953	O
and	O
P	O
-	O
values	O
P	O
=	O
0	O
.	O
0003	O
and	O
P	O
=	O
0	O
.	O
0352	O
.	O

CONCLUSION	O
:	O
Immunostaining	O
with	O
D2	O
-	O
40	O
significantly	O
increased	O
the	O
frequency	O
of	O
detection	O
of	O
lymphatic	S-Multi-tissue_structure
invasion	O
compared	O
to	O
conventional	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	B-Cancer
cancer	E-Cancer
.	O

As	O
LVI	O
is	O
a	O
strong	O
predictive	O
and	O
prognostic	O
marker	O
,	O
the	O
monoclonal	O
antibody	O
D2	O
-	O
40	O
has	O
the	O
potential	O
to	O
play	O
a	O
significant	O
role	O
in	O
pathological	O
routine	O
workup	O
of	O
breast	B-Cancer
tumors	E-Cancer
.	O

Further	O
prospective	O
studies	O
are	O
needed	O
to	O
prove	O
the	O
clinical	O
impact	O
of	O
D2	O
-	O
40	O
.	O

N	O
-	O
myc	O
augments	O
death	O
and	O
attenuates	O
protective	O
effects	O
of	O
Bcl	O
-	O
2	O
in	O
trophically	O
stressed	O
neuroblastoma	B-Cell
cells	E-Cell
.	O

N	O
-	O
myc	O
has	O
proapoptotic	O
functions	O
,	O
yet	O
it	O
acts	O
as	O
an	O
oncogene	O
in	O
neuroblastoma	S-Cancer
.	O

Thus	O
,	O
antiapoptotic	O
mechanisms	O
have	O
to	O
be	O
operative	O
in	O
neuroblastoma	B-Cell
cells	E-Cell
that	O
antagonize	O
the	O
proapoptotic	O
effects	O
of	O
N	O
-	O
myc	O
.	O

We	O
conditionally	O
activated	O
N	O
-	O
myc	O
in	O
SH	B-Cell
-	I-Cell
EP	I-Cell
neuroblastoma	I-Cell
cells	E-Cell
subjected	O
to	O
the	O
trophic	O
stress	O
of	O
serum	S-Organism_substance
or	O
nutrient	O
deprivation	O
while	O
changing	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
survivin	O
and	O
FLIP	O
(	O
L	O
)	O
,	O
antiapoptotic	O
molecules	O
often	O
overexpressed	O
in	O
poor	O
prognosis	O
neuroblastomas	S-Cancer
.	O

Bcl	O
-	O
2	O
protected	O
SH	B-Cell
-	I-Cell
EP	I-Cell
cells	E-Cell
from	O
death	O
during	O
nutritional	O
deprivation	O
by	O
activating	O
energetically	O
advantageous	O
oxidative	O
phosphorylation	O
.	O

N	O
-	O
myc	O
overrode	O
the	O
metabolic	O
protection	O
provided	O
by	O
Bcl	O
-	O
2	O
-	O
induced	O
oxidative	O
phosphorylation	O
by	O
reestablishing	O
the	O
glycolytic	O
phenotype	O
and	O
attenuated	O
the	O
antiapoptotic	O
effect	O
of	O
Bcl	O
-	O
2	O
during	O
metabolic	O
stress	O
.	O

Survivin	O
partially	O
antagonized	O
the	O
growth	O
suppressive	O
function	O
of	O
N	O
-	O
myc	O
in	O
SH	B-Cell
-	I-Cell
EP	I-Cell
neuroblastoma	I-Cell
cells	E-Cell
during	O
serum	S-Organism_substance
deprivation	O
whereas	O
FLIP	O
(	O
L	O
)	O
did	O
not	O
.	O

These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
functions	O
of	O
N	O
-	O
myc	O
in	O
neuroblastoma	B-Cell
cells	E-Cell
.	O

A	O
new	O
autosomal	O
dominant	O
vascular	S-Multi-tissue_structure
retinopathy	O
syndrome	O
.	O

We	O
describe	O
a	O
new	O
syndrome	O
with	O
autosomal	O
dominant	O
transmission	O
whose	O
most	O
striking	O
feature	O
is	O
vascular	S-Multi-tissue_structure
retinopathy	O
.	O

The	O
retinopathy	O
is	O
often	O
associated	O
with	O
migraine	O
,	O
Raynaud	O
'	O
s	O
phenomenon	O
and	O
mental	O
changes	O
,	O
mainly	O
forgetfulness	O
,	O
aggression	O
and	O
depression	O
.	O

To	O
define	O
this	O
syndrome	O
we	O
collected	O
medical	O
data	O
on	O
110	O
family	O
members	O
.	O

General	O
ophthalmological	O
examination	O
and	O
fluorescein	O
angiography	O
were	O
performed	O
in	O
61	O
persons	O
.	O

The	O
retinopathy	O
,	O
as	O
diagnosed	O
in	O
22	O
persons	O
,	O
is	O
characterized	O
by	O
central	O
and	O
peripheral	O
microangiopathy	O
,	O
areas	O
of	O
capillary	S-Tissue
non	O
-	O
perfusion	O
,	O
haemorrhages	O
,	O
cotton	O
wool	O
spots	O
and	O
,	O
in	O
a	O
more	O
advanced	O
stage	O
,	O
occlusion	O
of	O
large	O
retinal	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
which	O
can	O
induce	O
a	O
neovascular	O
response	O
.	O

A	O
vascular	S-Multi-tissue_structure
occlusive	O
disorder	O
may	O
be	O
the	O
common	O
aetiological	O
factor	O
of	O
the	O
various	O
manifestation	O
of	O
this	O
syndrome	O
.	O

The	O
element	O
effect	O
and	O
nucleophilicity	O
in	O
nucleophilic	O
aromatic	O
photosubstitution	O
(	O
SN2Ar	O
*	O
)	O
.	O

Local	O
atom	O
effects	O
as	O
mechanistic	O
probes	O
of	O
very	O
fast	O
reactions	O
.	O

Photoreactions	O
of	O
4	O
-	O
nitroanisole	O
and	O
the	O
2	O
-	O
halo	O
-	O
4	O
-	O
nitroanisoles	O
(	O
halogen	O
=	O
F	O
,	O
Cl	O
,	O
Br	O
,	O
and	O
I	O
)	O
with	O
the	O
nucleophiles	O
hydroxide	O
ion	O
and	O
pyridine	O
have	O
been	O
investigated	O
quantitatively	O
to	O
extend	O
the	O
findings	O
recently	O
communicated	O
for	O
cyanide	O
ion	O
.	O

The	O
halonitroanisoles	O
on	O
excitation	O
form	O
triplet	O
pi	O
,	O
pi	O
*	O
states	O
,	O
which	O
undergo	O
substitution	O
of	O
the	O
halogen	O
by	O
nucleophiles	O
.	O

Chemical	O
yields	O
of	O
photoproducts	O
,	O
Stern	O
-	O
Volmer	O
kinetic	O
plots	O
,	O
triplet	O
lifetimes	O
,	O
and	O
triplet	O
yields	O
are	O
reported	O
for	O
the	O
five	O
compounds	O
with	O
the	O
three	O
nucleophiles	O
.	O

Following	O
a	O
standard	O
kinetic	O
treatment	O
,	O
73	O
rate	O
constants	O
are	O
determined	O
for	O
elementary	O
reactions	O
of	O
the	O
triplets	O
including	O
quenching	O
and	O
various	O
nucleophilic	O
addition	O
processes	O
.	O

The	O
photoadditions	O
are	O
roughly	O
14	O
orders	O
of	O
magnitude	O
faster	O
than	O
thermal	O
counterparts	O
.	O

Rate	O
constants	O
for	O
attack	O
at	O
the	O
fluorine	O
-	O
bearing	O
carbon	O
of	O
triplet	O
2	O
-	O
fluoro	O
-	O
4	O
-	O
nitroanisole	O
are	O
2	O
.	O
9	O
x	O
10	O
(	O
9	O
)	O
,	O
1	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
,	O
and	O
6	O
.	O
3	O
x	O
10	O
(	O
8	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
for	O
cyanide	O
ion	O
,	O
hydroxide	O
ion	O
,	O
and	O
pyridine	O
,	O
respectively	O
.	O

The	O
relative	O
rates	O
for	O
attack	O
at	O
the	O
halogen	O
-	O
bearing	O
carbons	O
for	O
F	O
/	O
Cl	O
/	O
Br	O
/	O
I	O
are	O
27	O
:	O
1	O
.	O
9	O
:	O
1	O
.	O
9	O
:	O
1	O
(	O
cyanide	O
ion	O
)	O
,	O
29	O
:	O
2	O
.	O
6	O
:	O
2	O
.	O
4	O
:	O
1	O
(	O
hydroxide	O
ion	O
)	O
,	O
and	O
39	O
:	O
3	O
.	O
9	O
:	O
3	O
.	O
5	O
:	O
1	O
(	O
pyridine	O
)	O
,	O
respectively	O
.	O

The	O
relative	O
nucleophilicities	O
vary	O
somewhat	O
with	O
the	O
attack	O
site	O
;	O
they	O
are	O
about	O
5	O
:	O
2	O
:	O
1	O
for	O
cyanide	O
ion	O
,	O
hydroxide	O
ion	O
,	O
and	O
pyridine	O
for	O
attack	O
at	O
the	O
halogen	O
-	O
bearing	O
carbons	O
.	O

The	O
trend	O
of	O
the	O
element	O
effect	O
opposes	O
that	O
of	O
aliphatic	O
substitution	O
and	O
elimination	O
but	O
is	O
similar	O
in	O
size	O
and	O
parallel	O
to	O
that	O
of	O
thermal	O
nucleophilic	O
aromatic	O
substitution	O
.	O

Relative	O
nucleophilicities	O
in	O
the	O
photoreactions	O
are	O
also	O
similar	O
to	O
those	O
of	O
comparable	O
but	O
vastly	O
slower	O
thermal	O
reactions	O
.	O

The	O
findings	O
imply	O
that	O
the	O
efficiency	O
-	O
determining	O
step	O
of	O
the	O
halogen	O
photosubstitution	O
is	O
simple	O
formation	O
of	O
a	O
sigma	O
-	O
complex	O
through	O
electron	O
-	O
paired	O
bonding	O
within	O
the	O
triplet	O
manifold	O
.	O

Sciatic	B-Multi-tissue_structure
nerve	E-Multi-tissue_structure
repair	O
by	O
microgrooved	O
nerve	S-Multi-tissue_structure
conduits	O
made	O
of	O
chitosan	O
-	O
gold	O
nanocomposites	O
.	O

BACKGROUND	O
:	O

To	O
better	O
direct	O
the	O
repair	O
of	O
peripheral	B-Multi-tissue_structure
nerve	E-Multi-tissue_structure
after	O
injury	O
,	O
an	O
implant	O
consisting	O
of	O
a	O
multicomponent	O
micropatterned	O
conduit	O
seeded	O
with	O
NSC	S-Cell
was	O
designed	O
.	O

METHODS	O
:	O

The	O
mechanical	O
properties	O
of	O
the	O
chi	O
-	O
Au	O
nanocomposites	O
were	O
tested	O
.	O

In	O
vitro	O
,	O
the	O
effect	O
of	O
chi	O
-	O
Au	O
on	O
cell	S-Cell
behavior	O
(	O
NSC	S-Cell
and	O
glial	B-Cell
cell	I-Cell
line	I-Cell
C6	E-Cell
)	O
and	O
the	O
influence	O
of	O
micropattern	O
on	O
cell	S-Cell
alignment	O
were	O
evaluated	O
.	O

In	O
vivo	O
,	O
the	O
micropatterned	O
conduits	O
with	O
/	O
without	O
the	O
preseeded	O
NSC	S-Cell
were	O
implanted	O
to	O
bridge	O
a	O
10	O
-	O
mm	O
-	O
long	O
defect	O
of	O
the	O
sciatic	B-Multi-tissue_structure
nerve	E-Multi-tissue_structure
in	O
9	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
repair	O
outcome	O
was	O
investigated	O
6	O
weeks	O
after	O
the	O
surgery	O
.	O

RESULTS	O
:	O

Based	O
on	O
the	O
dynamic	O
modulus	O
,	O
chitosan	O
with	O
50	O
ppm	O
or	O
more	O
gold	O
was	O
a	O
stronger	O
material	O
than	O
others	O
.	O

In	O
vitro	O
,	O
gold	O
at	O
25	O
or	O
50	O
ppm	O
led	O
to	O
better	O
cell	S-Cell
performance	O
for	O
NSC	S-Cell
;	O
and	O
gold	O
at	O
50	O
ppm	O
gave	O
better	O
cell	S-Cell
performance	O
for	O
C6	S-Cell
.	O

On	O
the	O
microgrooved	O
substrate	O
,	O
the	O
NSC	S-Cell
had	O
elongated	O
processes	O
oriented	O
parallel	O
to	O
the	O
grooves	O
,	O
whereas	O
the	O
NSC	S-Cell
on	O
the	O
nonpatterned	O
surfaces	O
did	O
not	O
exhibit	O
a	O
particular	O
bias	O
in	O
alignment	O
.	O

In	O
vivo	O
,	O
the	O
number	O
of	O
regenerated	O
axons	S-Cellular_component
,	O
the	O
regenerated	O
area	S-Multi-tissue_structure
,	O
and	O
the	O
number	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
were	O
significantly	O
higher	O
in	O
the	O
NSC	S-Cell
-	O
preseeded	O
conduit	O
.	O

CONCLUSION	O
:	O

Modification	O
of	O
the	O
chitosan	O
matrix	O
by	O
gold	O
nanoparticles	O
not	O
only	O
provides	O
the	O
mechanical	O
strength	O
but	O
also	O
affects	O
the	O
cellular	S-Cell
response	O
.	O

The	O
preliminary	O
in	O
vivo	O
data	O
demonstrated	O
that	O
the	O
biodegradable	O
micropatterned	O
conduits	O
preseeded	O
with	O
NSC	S-Cell
provided	O
a	O
combination	O
of	O
physical	O
and	O
biological	O
guidance	O
cues	O
for	O
regenerating	O
axons	S-Cellular_component
at	O
the	O
cellular	S-Cell
level	O
and	O
offered	O
a	O
better	O
alternative	O
for	O
repairing	O
sciatic	B-Multi-tissue_structure
nerve	E-Multi-tissue_structure
transactions	O
.	O

[	O
Parotid	B-Cancer
gland	I-Cancer
'	I-Cancer
s	I-Cancer
tumors	E-Cancer
in	O
children	O
]	O
.	O

The	O
tumors	S-Cancer
of	O
the	O
salivary	B-Organ
glands	E-Organ
are	O
infrequent	O
in	O
children	O
,	O
and	O
parotid	B-Organ
gland	E-Organ
is	O
involved	O
in	O
80	O
%	O
of	O
them	O
.	O

When	O
a	O
salivary	B-Cancer
gland	I-Cancer
tumor	E-Cancer
is	O
present	O
,	O
the	O
chance	O
of	O
malignancy	O
is	O
greater	O
in	O
the	O
child	O
than	O
in	O
the	O
adult	O
.	O

We	O
reviewed	O
8	O
cases	O
identified	O
in	O
patients	O
aged	O
14	O
years	O
and	O
younger	O
in	O
our	O
hospital	O
,	O
analyzing	O
its	O
antecedents	O
,	O
signs	O
and	O
symptoms	O
,	O
histological	O
features	O
,	O
diagnosis	O
,	O
treatment	O
and	O
evolution	O
.	O

All	O
the	O
patients	O
displayed	O
preauricular	S-Organism_subdivision
painless	O
,	O
non	O
-	O
inflammatory	O
and	O
slow	O
-	O
growing	O
masses	S-Pathological_formation
to	O
an	O
age	O
between	O
10	O
months	O
and	O
14	O
years	O
.	O

Four	O
or	O
them	O
were	O
pleomorphic	B-Pathological_formation
adenomas	E-Pathological_formation
,	O
two	O
haemangiomas	S-Pathological_formation
,	O
one	O
epidermal	B-Pathological_formation
cysts	E-Pathological_formation
and	O
one	O
myoepithelial	B-Cancer
carcinoma	E-Cancer
.	O

We	O
emphasize	O
the	O
exceptional	O
nature	O
of	O
the	O
carcinoma	S-Cancer
for	O
its	O
rareness	O
and	O
for	O
the	O
high	O
degree	O
of	O
malignancy	O
expressed	O
.	O

We	O
made	O
a	O
fine	O
needle	O
aspiration	O
biopsy	O
in	O
four	O
cases	O
but	O
they	O
were	O
conclusive	O
only	O
in	O
three	O
.	O

All	O
were	O
treated	O
by	O
surgical	O
resection	O
of	O
the	O
tumour	S-Cancer
except	O
for	O
the	O
myoepithelial	B-Cancer
carcinoma	E-Cancer
and	O
the	O
recurrent	O
pleomorphic	B-Pathological_formation
adenoma	E-Pathological_formation
that	O
were	O
treated	O
by	O
total	O
parotidectomy	O
.	O

The	O
malignant	B-Cancer
tumours	E-Cancer
of	O
the	O
parotid	B-Organ
gland	E-Organ
are	O
clinically	O
indistinguishable	O
of	O
the	O
benign	B-Pathological_formation
ones	E-Pathological_formation
,	O
thus	O
when	O
any	O
palpable	B-Pathological_formation
mass	E-Pathological_formation
appears	O
in	O
the	O
zone	O
of	O
the	O
parotid	B-Organ
gland	E-Organ
,	O
an	O
accurate	O
diagnosis	O
should	O
be	O
made	O
without	O
delay	O
.	O

The	O
treatment	O
of	O
choice	O
is	O
the	O
surgical	O
excision	O
with	O
wide	O
margins	O
,	O
being	O
other	O
adjuvant	O
treatments	O
less	O
useful	O
to	O
this	O
age	O
than	O
in	O
the	O
adult	O
age	O
.	O

The	O
tyrosine	O
kinase	O
inhibitor	O
cediranib	O
blocks	O
ligand	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Solid	B-Cancer
tumors	E-Cancer
express	O
a	O
range	O
of	O
factors	O
required	O
to	O
sustain	O
their	O
growth	O
and	O
promote	O
their	O
dissemination	O
.	O

Among	O
these	O
are	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
,	O
the	O
key	O
angiogenic	O
stimulant	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
a	O
primary	O
mediator	O
of	O
lymphangiogenesis	O
.	O

Small	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
offer	O
the	O
potential	O
to	O
inhibit	O
more	O
than	O
one	O
kinase	O
and	O
impede	O
tumor	S-Cancer
growth	O
by	O
multiple	O
mechanisms	O
.	O

However	O
,	O
their	O
potency	O
toward	O
individual	O
targets	O
can	O
vary	O
.	O

Cediranib	O
(	O
RECENTIN	O
;	O
AZD2171	O
)	O
is	O
an	O
inhibitor	O
of	O
VEGF	O
signaling	O
that	O
has	O
been	O
shown	O
in	O
experimental	O
models	O
to	O
prevent	O
VEGF	O
-	O
A	O
-	O
induced	O
angiogenesis	O
and	O
primary	B-Cancer
tumor	E-Cancer
growth	O
,	O
yet	O
the	O
effects	O
of	O
cediranib	O
on	O
VEGF	O
receptor	O
(	O
VEGFR	O
)	O
-	O
3	O
-	O
mediated	O
endothelial	B-Cell
cell	E-Cell
function	O
and	O
lymphangiogenesis	O
are	O
unknown	O
.	O

To	O
better	O
understand	O
the	O
activity	O
of	O
cediranib	O
against	O
VEGFR	O
-	O
3	O
and	O
its	O
associated	O
signaling	O
events	O
compared	O
with	O
its	O
activity	O
against	O
VEGFR	O
-	O
2	O
,	O
we	O
used	O
the	O
receptor	O
-	O
specific	O
ligands	O
VEGF	O
-	O
E	O
and	O
VEGF	O
-	O
C156S	O
.	O

In	O
human	O
endothelial	B-Cell
cells	E-Cell
,	O
cediranib	O
inhibited	O
VEGF	O
-	O
E	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
VEGF	O
-	O
C156S	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
3	O
at	O
concentrations	O
of	O
less	O
than	O
/	O
=	O
1nmol	O
/	O
L	O
and	O
inhibited	O
activation	O
of	O
downstream	O
signaling	O
molecules	O
.	O

Additionally	O
,	O
cediranib	O
blocked	O
VEGF	O
-	O
C156S	O
-	O
induced	O
and	O
VEGF	O
-	O
E	O
-	O
induced	O
proliferation	O
,	O
survival	O
,	O
and	O
migration	O
of	O
lymphatic	S-Cell
and	O
blood	B-Cell
vascular	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

In	O
vivo	O
,	O
cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
d	O
)	O
prevented	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
VEGF	O
-	O
E	O
-	O
expressing	O
and	O
VEGF	O
-	O
C156S	O
-	O
expressing	O
adenoviruses	O
,	O
respectively	O
.	O

Cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
day	O
)	O
also	O
blocked	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
adenoviruses	O
expressing	O
VEGF	O
-	O
A	O
or	O
VEGF	O
-	O
C	O
and	O
compromised	O
the	O
blood	S-Organism_substance
and	O
lymphatic	B-Multi-tissue_structure
vasculatures	E-Multi-tissue_structure
of	O
VEGF	O
-	O
C	O
-	O
expressing	O
tumors	S-Cancer
.	O

Cediranib	O
may	O
,	O
therefore	O
,	O
be	O
an	O
effective	O
means	O
of	O
preventing	O
tumor	S-Cancer
progression	O
,	O
not	O
only	O
by	O
inhibiting	O
VEGFR	O
-	O
2	O
activity	O
and	O
angiogenesis	O
,	O
but	O
also	O
by	O
concomitantly	O
inhibiting	O
VEGFR	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Artemisinin	O
inhibits	O
tumor	S-Cancer
lymphangiogenesis	O
by	O
suppression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
.	O

We	O
have	O
previously	O
reported	O
that	O
dihydroartemisinin	O
is	O
found	O
to	O
have	O
a	O
potent	O
ability	O
in	O
influencing	O
lymphatic	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	O
and	O
tube	S-Tissue
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
artemisinin	O
on	O
tumor	S-Cancer
growth	O
,	O
lymphangiogenesis	O
,	O
metastasis	O
and	O
survival	O
in	O
mouse	O
Lewis	B-Cancer
lung	I-Cancer
carcinoma	E-Cancer
(	O
LLC	S-Cancer
)	O
models	O
.	O

We	O
found	O
that	O
orally	S-Organism_subdivision
administered	O
artemisinin	O
inhibited	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
and	O
lung	S-Organ
metastasis	O
and	O
prolonged	O
survival	O
without	O
retarding	O
tumor	S-Cancer
growth	O
.	O

Consistent	O
with	O
the	O
decrease	O
in	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
,	O
tumor	S-Cancer
lymphangiogenesis	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
was	O
significantly	O
decreased	O
in	O
artemisinin	O
-	O
treated	O
mice	O
,	O
as	O
compared	O
to	O
control	O
mice	O
.	O

Furthermore	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
and	O
upregulation	O
of	O
VEGF	O
-	O
C	O
mRNA	O
and	O
protein	O
in	O
LLC	B-Cell
cells	E-Cell
was	O
also	O
suppressed	O
by	O
artemisinin	O
or	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB	O
-	O
203580	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
could	O
serve	O
as	O
a	O
mediator	O
of	O
proinflammatory	O
cytokine	O
-	O
induced	O
VEGF	O
-	O
C	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
artemisinin	O
may	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
by	O
downregulating	O
VEGF	O
-	O
C	O
and	O
reducing	O
tumor	S-Cancer
lymphangiogenesis	O
.	O

Bevacizumab	O
and	O
irinotecan	O
therapy	O
in	O
glioblastoma	B-Cancer
multiforme	E-Cancer
:	O
a	O
series	O
of	O
13	O
cases	O
.	O

OBJECT	O
:	O
Endothelial	S-Cell
proliferation	O
has	O
been	O
recognized	O
as	O
a	O
marker	O
of	O
high	B-Cancer
-	I-Cancer
grade	E-Cancer
or	O
aggressive	B-Cancer
glioma	E-Cancer
.	O

Bevacizumab	O
is	O
a	O
humanized	O
immunoglobulin	O
G1	O
monoclonal	O
antibody	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
that	O
has	O
been	O
shown	O
to	O
have	O
activity	O
in	O
malignant	B-Cancer
gliomas	E-Cancer
when	O
combined	O
with	O
irinotecan	O
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
series	O
of	O
13	O
patients	O
with	O
recurrent	O
heavily	O
pretreated	O
malignant	B-Cancer
glioma	E-Cancer
that	O
was	O
treated	O
with	O
the	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
.	O

METHODS	O
:	O
Standard	O
therapy	O
with	O
primary	O
resection	O
followed	O
by	O
adjuvant	O
chemotherapy	O
and	O
radiation	O
had	O
failed	O
in	O
all	O
patients	O
.	O

The	O
median	O
number	O
of	O
therapies	O
applied	O
,	O
including	O
initial	O
surgery	O
,	O
was	O
5	O
(	O
range	O
3	O
-	O
7	O
therapies	O
)	O
.	O

Nine	O
patients	O
were	O
started	O
on	O
bevacizumab	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
m2	O
every	O
2	O
weeks	O
.	O

Four	O
patients	O
received	O
bevacizumab	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
m2	O
;	O
irinotecan	O
was	O
given	O
at	O
a	O
dose	O
of	O
125	O
mg	O
/	O
m2	O
every	O
week	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
Of	O
the	O
13	O
treated	O
patients	O
,	O
10	O
(	O
77	O
%	O
)	O
had	O
a	O
radiologically	O
demonstrated	O
partial	O
response	O
and	O
3	O
(	O
23	O
%	O
)	O
had	O
stable	O
disease	O
.	O

Six	O
patients	O
(	O
46	O
%	O
)	O
had	O
a	O
clinical	O
response	O
.	O

The	O
median	O
time	O
to	O
disease	O
progression	O
while	O
on	O
treatment	O
was	O
24	O
weeks	O
.	O

The	O
median	O
overall	O
survival	O
was	O
27	O
weeks	O
.	O

The	O
disease	O
progressed	O
in	O
8	O
patients	O
,	O
despite	O
an	O
initial	O
response	O
.	O

Five	O
patients	O
are	O
still	O
responding	O
to	O
therapy	O
.	O

Six	O
of	O
the	O
8	O
patients	O
whose	O
disease	O
progressed	O
have	O
died	O
.	O

Bevacizumab	O
was	O
discontinued	O
in	O
2	O
patients	O
because	O
of	O
nonfatal	O
intracranial	S-Immaterial_anatomical_entity
bleeding	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
is	O
safe	O
and	O
has	O
excellent	O
activity	O
even	O
in	O
this	O
relapsed	O
,	O
heavily	O
pretreated	O
population	O
of	O
patients	O
with	O
high	B-Cancer
-	I-Cancer
grade	I-Cancer
malignant	I-Cancer
glioma	E-Cancer
,	O
most	O
of	O
whom	O
would	O
not	O
be	O
candidates	O
for	O
clinical	O
trials	O
.	O

Demographic	O
consequences	O
of	O
terrestrial	O
habitat	O
loss	O
for	O
pool	O
-	O
breeding	O
amphibians	O
:	O
predicting	O
extinction	O
risks	O
associated	O
with	O
inadequate	O
size	O
of	O
buffer	O
zones	O
.	O

Much	O
of	O
the	O
biodiversity	O
associated	O
with	O
isolated	O
wetlands	O
requires	O
aquatic	O
and	O
terrestrial	O
habitat	O
to	O
maintain	O
viable	O
populations	O
.	O

Current	O
federal	O
wetland	O
regulations	O
in	O
the	O
United	O
States	O
do	O
not	O
protect	O
isolated	O
wetlands	O
or	O
extend	O
protection	O
to	O
surrounding	O
terrestrial	O
habitat	O
.	O

Consequently	O
,	O
some	O
land	O
managers	O
,	O
city	O
planners	O
,	O
and	O
policy	O
makers	O
at	O
the	O
state	O
and	O
local	O
levels	O
are	O
making	O
an	O
effort	O
to	O
protect	O
these	O
wetland	O
and	O
neighboring	O
upland	O
habitats	O
.	O

Balancing	O
human	O
land	O
-	O
use	O
and	O
habitat	O
conservation	O
is	O
challenging	O
,	O
and	O
well	O
-	O
informed	O
land	O
-	O
use	O
policy	O
is	O
hindered	O
by	O
a	O
lack	O
of	O
knowledge	O
of	O
the	O
specific	O
risks	O
of	O
varying	O
amounts	O
of	O
habitat	O
loss	O
.	O

Using	O
projections	O
of	O
wood	O
frog	O
(	O
Rana	O
sylvatica	O
)	O
and	O
spotted	O
salamander	O
(	O
Ambystoma	O
maculatum	O
)	O
populations	O
,	O
we	O
related	O
the	O
amount	O
of	O
high	O
-	O
quality	O
terrestrial	O
habitat	O
surrounding	O
isolated	O
wetlands	O
to	O
the	O
decline	O
and	O
risk	O
of	O
extinction	O
of	O
local	O
amphibian	O
populations	O
.	O

These	O
simulations	O
showed	O
that	O
current	O
state	O
-	O
level	O
wetland	O
regulations	O
protecting	O
30	O
m	O
or	O
less	O
of	O
surrounding	O
terrestrial	O
habitat	O
are	O
inadequate	O
to	O
support	O
viable	O
populations	O
of	O
pool	O
-	O
breeding	O
amphibians	O
.	O

We	O
also	O
found	O
that	O
species	O
with	O
different	O
life	O
-	O
history	O
strategies	O
responded	O
differently	O
to	O
the	O
loss	O
and	O
degradation	O
of	O
terrestrial	O
habitat	O
.	O

The	O
wood	O
frog	O
,	O
with	O
a	O
short	O
life	O
span	O
and	O
high	O
fecundity	O
,	O
was	O
most	O
sensitive	O
to	O
habitat	O
loss	O
and	O
isolation	O
,	O
whereas	O
the	O
longer	O
-	O
lived	O
spotted	O
salamander	O
with	O
lower	O
fecundity	O
was	O
most	O
sensitive	O
to	O
habitat	O
degradation	O
that	O
lowered	O
adult	O
survival	O
rates	O
.	O

Our	O
model	O
results	O
demonstrate	O
that	O
a	O
high	O
probability	O
of	O
local	O
amphibian	O
population	O
persistence	O
requires	O
sufficient	O
terrestrial	O
habitat	O
,	O
the	O
maintenance	O
of	O
habitat	O
quality	O
,	O
and	O
connectivity	O
among	O
local	O
populations	O
.	O

Our	O
results	O
emphasize	O
the	O
essential	O
role	O
of	O
adequate	O
terrestrial	O
habitat	O
to	O
the	O
maintenance	O
of	O
wetland	O
biodiversity	O
and	O
ecosystem	O
function	O
and	O
offer	O
a	O
means	O
of	O
quantifying	O
the	O
risks	O
associated	O
with	O
terrestrial	O
habitat	O
loss	O
and	O
degradation	O
.	O

Endosialin	O
/	O
TEM	O
1	O
/	O
CD248	O
is	O
a	O
pericyte	S-Cell
marker	O
of	O
embryonic	S-Developing_anatomical_structure
and	O
tumor	S-Cancer
neovascularization	O
.	O

The	O
formation	O
of	O
functional	O
,	O
mature	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
depends	O
on	O
the	O
interaction	O
between	O
endothelial	B-Cell
cells	E-Cell
and	O
pericytes	S-Cell
.	O

Commonality	O
exists	O
in	O
the	O
processes	O
involved	O
in	O
vasculature	S-Multi-tissue_structure
development	O
between	O
tissues	S-Tissue
whether	O
healthy	O
or	O
diseased	O
.	O

Endosialin	O
/	O
TEM	O
1	O
is	O
a	O
cell	B-Cellular_component
membrane	E-Cellular_component
protein	O
that	O
is	O
expressed	O
in	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
during	O
embryogenesis	O
and	O
tumorigenesis	O
but	O
not	O
in	O
normal	O
mature	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Antibodies	O
developed	O
to	O
human	O
endosialin	O
were	O
used	O
to	O
investigate	O
endosialin	O
expression	O
and	O
function	O
in	O
human	O
prenatal	B-Cell
brain	I-Cell
pericytes	E-Cell
and	O
pericytes	S-Cell
residing	O
in	O
tumors	S-Cancer
.	O

Anti	O
-	O
endosialin	O
was	O
capable	O
of	O
preventing	O
pericyte	B-Tissue
tube	E-Tissue
formation	O
in	O
culture	O
and	O
inhibited	O
migration	O
.	O

Brain	B-Cell
pericytes	E-Cell
in	O
culture	O
had	O
higher	O
levels	O
of	O
endosialin	O
/	O
TEM	O
1	O
than	O
TEMs	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4	O
,	O
-	O
5	O
,	O
-	O
7	O
,	O
and	O
-	O
8	O
.	O

Immunocytochemistry	O
revealed	O
that	O
endosialin	O
was	O
present	O
in	O
the	O
cytoplasmic	B-Organism_substance
body	E-Organism_substance
and	O
in	O
the	O
elongated	O
extensions	O
essential	O
to	O
pericyte	S-Cell
function	O
.	O

Transgenic	O
mice	O
engineered	O
to	O
express	O
human	O
endosialin	O
bred	O
on	O
an	O
immunocompromised	O
background	O
allowed	O
the	O
growth	O
of	O
human	O
tumor	B-Cancer
xenografts	E-Cancer
.	O

In	O
human	O
colon	B-Cancer
carcinoma	I-Cancer
Colo205	E-Cancer
and	O
HT29	B-Cancer
xenografts	E-Cancer
grown	O
in	O
human	O
endosialin	O
-	O
transgenic	O
mice	O
,	O
endosialin	O
expression	O
was	O
largely	O
confined	O
to	O
NG2	O
-	O
expressing	O
perivascular	B-Cell
cells	E-Cell
and	O
not	O
CD31	B-Cell
-	I-Cell
positive	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Similar	O
methods	O
applied	O
to	O
human	O
ovarian	S-Cancer
and	O
colon	B-Cancer
tumors	E-Cancer
confirmed	O
endosialin	O
expression	O
by	O
pericytes	S-Cell
.	O

The	O
data	O
indicate	O
that	O
endosialin	O
is	O
strongly	O
expressed	O
by	O
pericytes	S-Cell
during	O
periods	O
of	O
active	O
angiogenesis	O
during	O
embryonic	S-Developing_anatomical_structure
and	O
tumor	S-Cancer
development	O
.	O

Anti	O
-	O
endosialin	O
antibodies	O
may	O
have	O
value	O
in	O
identifying	O
vasculature	S-Multi-tissue_structure
in	O
malignant	B-Tissue
tissues	E-Tissue
.	O

With	O
the	O
appropriate	O
agent	O
,	O
targeting	O
endosialin	O
may	O
interfere	O
with	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	O
during	O
tumor	S-Cancer
development	O
.	O

Efficient	O
inhibition	O
of	O
ovarian	B-Cancer
cancer	E-Cancer
growth	O
and	O
prolonged	O
survival	O
by	O
transfection	O
with	O
a	O
novel	O
pro	O
-	O
apoptotic	O
gene	O
,	O
hPNAS	O
-	O
4	O
,	O
in	O
a	O
mouse	O
model	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
.	O

OBJECTIVE	O
:	O
We	O
transfected	O
ovarian	B-Cell
cancer	I-Cell
cells	E-Cell
and	O
administered	O
recombinant	O
plasmid	S-Cellular_component
encoding	O
hPNAS	O
-	O
4	O
to	O
nude	O
mice	O
bearing	O
ovarian	B-Cancer
cancer	E-Cancer
,	O
aiming	O
to	O
evaluate	O
the	O
effect	O
of	O
hPNAS	O
-	O
4	O
against	O
ovarian	B-Cancer
cancer	E-Cancer
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
Ovarian	B-Cell
cancer	I-Cell
SKOV3	I-Cell
cells	E-Cell
were	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
plasmid	S-Cellular_component
,	O
and	O
cell	S-Cell
proliferation	O
was	O
evaluated	O
by	O
MTT	O
assay	O
;	O
apoptosis	O
was	O
examined	O
by	O
DNA	O
ladder	O
,	O
Hoechst33258	O
staining	O
and	O
flow	O
-	O
cytometric	O
assays	O
.	O

Nude	O
mice	O
bearing	O
ovarian	B-Cancer
cancers	E-Cancer
were	O
treated	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
/	O
liposome	S-Cellular_component
.	O

Tumor	S-Cancer
growth	O
was	O
determined	O
and	O
survival	O
was	O
recorded	O
.	O

TUNEL	O
assay	O
and	O
microvessel	S-Tissue
density	O
was	O
assessed	O
to	O
evaluate	O
apoptosis	O
and	O
angiogenesis	O
.	O

RESULTS	O
:	O
Both	O
inhibition	O
of	O
proliferation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
induction	O
of	O
apoptosis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
SKOV3	B-Cell
cells	E-Cell
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
in	O
vitro	O
.	O

In	O
hPNAS	O
-	O
4	O
-	O
p	O
-	O
treated	O
tumor	B-Cell
cells	E-Cell
in	O
vivo	O
,	O
tumor	S-Cancer
growth	O
significantly	O
decreased	O
,	O
while	O
the	O
survival	O
time	O
of	O
tumor	S-Cancer
-	O
bearing	O
mice	O
was	O
prolonged	O
compared	O
with	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
apoptosis	O
of	O
tumor	B-Cell
cells	E-Cell
and	O
decreased	O
angiogenesis	O
in	O
tumor	B-Tissue
tissue	E-Tissue
were	O
also	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
promising	O
results	O
on	O
the	O
potential	O
antitumor	S-Cancer
effects	O
of	O
hPNAS	O
-	O
4	O
on	O
ovarian	B-Cancer
cancer	E-Cancer
in	O
vitro	O
and	O
in	O
vivo	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
.	O

Consequently	O
,	O
hPNAS	O
-	O
4	O
has	O
potential	O
as	O
a	O
new	O
gene	O
therapy	O
for	O
human	O
ovarian	B-Cancer
cancer	E-Cancer
.	O

The	O
in	O
vivo	O
properties	O
of	O
STX243	O
:	O
a	O
potent	O
angiogenesis	O
inhibitor	O
in	O
breast	B-Cancer
cancer	E-Cancer
.	O

The	O
steroidal	O
-	O
based	O
drug	O
2	O
-	O
ethyloestradiol	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX243	O
)	O
has	O
been	O
developed	O
as	O
a	O
potent	O
antiangiogenic	O
and	O
antitumour	S-Cancer
compound	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
STX243	O
is	O
more	O
active	O
in	O
vivo	O
than	O
the	O
clinically	O
relevant	O
drug	O
2	O
-	O
methoxyoestradiol	O
(	O
2	O
-	O
MeOE2	O
)	O
and	O
the	O
structurally	O
similar	O
compound	O
2	O
-	O
MeOE2	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX140	O
)	O
.	O

The	O
tumour	S-Cancer
growth	O
inhibition	O
efficacy	O
,	O
antiangiogenic	O
potential	O
and	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
using	O
four	O
in	O
vivo	O
models	O
.	O

Both	O
STX243	O
and	O
STX140	O
were	O
capable	O
of	O
retarding	O
the	O
growth	O
of	O
MDA	B-Cancer
-	I-Cancer
MB	I-Cancer
-	I-Cancer
231	I-Cancer
xenograft	I-Cancer
tumours	E-Cancer
(	O
72	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
no	O
inhibition	O
was	O
observed	O
for	O
animals	O
treated	O
with	O
2	O
-	O
MeOE2	O
.	O

Further	O
tumour	S-Cancer
inhibition	O
studies	O
showed	O
that	O
STX243	O
was	O
also	O
active	O
against	O
MCF	B-Cancer
-	I-Cancer
7	I-Cancer
paclitaxel	I-Cancer
-	I-Cancer
resistant	I-Cancer
tumours	E-Cancer
.	O

Using	O
a	O
Matrigel	O
plug	O
-	O
based	O
model	O
,	O
in	O
vivo	O
angiogenesis	O
was	O
restricted	O
with	O
STX243	O
and	O
STX140	O
(	O
50	O
and	O
72	O
%	O
,	O
respectively	O
,	O
using	O
a	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
oral	S-Organism_subdivision
dose	O
)	O
,	O
thereby	O
showing	O
the	O
antiangiogenic	O
activity	O
of	O
both	O
compounds	O
.	O

The	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
at	O
two	O
different	O
doses	O
using	O
adult	O
female	O
rats	O
.	O

The	O
compound	O
was	O
orally	S-Organism_subdivision
bioavailable	O
(	O
31	O
%	O
after	O
a	O
single	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dose	O
)	O
and	O
resistant	O
to	O
metabolism	O
.	O

These	O
results	O
show	O
that	O
STX243	O
is	O
a	O
potent	O
in	O
vivo	O
drug	O
and	O
could	O
be	O
clinically	O
effective	O
at	O
treating	O
a	O
number	O
of	O
oncological	O
conditions	O
.	O

[	O
The	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	B-Cancer
promyelocytic	I-Cancer
leukemia	E-Cancer
:	O
an	O
analysis	O
of	O
513	O
cases	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	B-Cancer
promyelocytic	I-Cancer
leukemia	E-Cancer
(	O
APL	S-Cancer
)	O
.	O

METHODS	O
:	O

513	O
APL	S-Cancer
patients	O
in	O
the	O
last	O
two	O
decades	O
were	O
retrospectively	O
analyzed	O
in	O
this	O
research	O
.	O

We	O
investigated	O
the	O
clinical	O
features	O
including	O
age	O
,	O
sex	O
,	O
abnormality	O
of	O
peripheral	O
hemogram	O
before	O
treatment	O
,	O
therapeutic	O
effect	O
and	O
follow	O
-	O
up	O
and	O
laboratory	O
data	O
such	O
as	O
morphology	O
,	O
immunology	O
,	O
cytogenetics	O
and	O
molecular	O
biology	O
(	O
MICM	O
)	O
.	O

RESULTS	O
:	O

The	O
median	O
age	O
of	O
the	O
APL	S-Cancer
patients	O
was	O
33	O
years	O
old	O
and	O
the	O
ratio	O
of	O
male	O
and	O
female	O
was	O
1	O
.	O
21	O
:	O
1	O
.	O

Before	O
treatment	O
,	O
the	O
median	O
level	O
of	O
WBC	S-Cell
was	O
4	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
the	O
detection	O
rate	O
of	O
abnormal	O
promyelocyte	S-Cell
on	O
blood	S-Organism_substance
film	O
was	O
85	O
.	O
8	O
%	O
;	O
with	O
immunophenotypic	O
detection	O
,	O
the	O
expression	O
levels	O
of	O
CD117	O
,	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD7	O
,	O
CD14	O
and	O
CD19	O
in	O
APL	S-Cancer
were	O
found	O
to	O
be	O
lower	O
and	O
the	O
expression	O
levels	O
of	O
CD2	O
,	O
CD33	O
and	O
MPO	O
higher	O
than	O
those	O
in	O
other	O
subtypes	O
of	O
acute	B-Cancer
myelocytic	I-Cancer
leukemia	E-Cancer
(	O
AML	S-Cancer
)	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Specific	O
abnormal	O
chromosome	S-Cellular_component
t	O
(	O
15	O
;	O
17	O
)	O
was	O
detected	O
in	O
91	O
.	O
7	O
%	O
of	O
the	O
patients	O
,	O
of	O
whom	O
75	O
.	O
9	O
%	O
had	O
standard	O
translocation	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
being	O
the	O
most	O
common	O
one	O
and	O
15	O
.	O
8	O
%	O
of	O
the	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
additional	O
abnormal	O
chromosome	S-Cellular_component
.	O

There	O
was	O
only	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
with	O
normal	O
karyotype	O
.	O

However	O
,	O
the	O
presence	O
of	O
both	O
simple	O
translocation	O
and	O
complex	O
translocation	O
was	O
seldom	O
seen	O
.	O

With	O
molecular	O
biological	O
detection	O
,	O
PML	O
/	O
RARalpha	O
fusion	O
gene	O
positive	O
rate	O
was	O
99	O
.	O
6	O
%	O
.	O

In	O
a	O
relatively	O
long	O
clinical	O
follow	O
-	O
up	O
,	O
we	O
found	O
that	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
in	O
APL	S-Cancer
patients	O
was	O
84	O
.	O
7	O
%	O
,	O
incidence	O
of	O
DIC	O
was	O
13	O
.	O
4	O
%	O
and	O
five	O
-	O
year	O
survival	O
rate	O
was	O
30	O
.	O
7	O
%	O
.	O

The	O
median	O
count	O
of	O
WBC	S-Cell
in	O
CR	O
group	O
was	O
lower	O
than	O
that	O
non	O
-	O
remission	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
on	O
expressions	O
of	O
CD34	O
and	O
CD2	O
and	O
changes	O
of	O
cytogenetics	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

Comprehensive	O
evaluation	O
of	O
MICM	O
could	O
be	O
of	O
important	O
significance	O
in	O
the	O
diagnosis	O
and	O
prognosis	O
judgment	O
for	O
APL	S-Cancer
patients	O
.	O

The	O
CR	O
rate	O
in	O
these	O
patients	O
with	O
high	O
WBC	S-Cell
count	O
was	O
considerable	O
low	O
.	O

Grape	B-Organism_substance
seed	I-Organism_substance
extract	E-Organism_substance
inhibits	O
angiogenesis	O
via	O
suppression	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Blockade	O
of	O
angiogenesis	O
is	O
an	O
important	O
approach	O
for	O
cancer	S-Cancer
treatment	O
and	O
prevention	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
critical	O
factors	O
that	O
induce	O
angiogenesis	O
and	O
has	O
thus	O
become	O
an	O
attractive	O
target	O
for	O
antiangiogenesis	O
treatment	O
.	O

However	O
,	O
most	O
current	O
anti	O
-	O
VEGF	O
agents	O
often	O
cause	O
some	O
side	O
effects	O
when	O
given	O
chronically	O
.	O

Identification	O
of	O
naturally	O
occurring	O
VEGF	O
inhibitors	O
derived	O
from	O
diet	O
would	O
be	O
one	O
alternative	O
approach	O
with	O
an	O
advantage	O
of	O
known	O
safety	O
.	O

Grape	B-Organism_substance
seed	I-Organism_substance
extract	E-Organism_substance
(	O
GSE	S-Organism_substance
)	O
,	O
a	O
widely	O
used	O
dietary	O
supplement	O
,	O
is	O
known	O
to	O
have	O
antitumor	S-Cancer
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
activity	O
of	O
GSE	S-Organism_substance
on	O
VEGF	O
receptor	O
and	O
angiogenesis	O
.	O

We	O
found	O
that	O
GSE	S-Organism_substance
could	O
directly	O
inhibit	O
the	O
kinase	O
activity	O
of	O
purified	O
VEGF	O
receptor	O
2	O
,	O
a	O
novel	O
activity	O
of	O
GSE	S-Organism_substance
that	O
has	O
not	O
been	O
characterized	O
.	O

GSE	S-Organism_substance
could	O
also	O
inhibit	O
the	O
VEGF	O
receptor	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
mediated	O
signaling	O
pathway	O
in	O
endothelial	B-Cell
cells	E-Cell
.	O

As	O
a	O
result	O
,	O
GSE	S-Organism_substance
could	O
inhibit	O
VEGF	O
-	O
induced	O
endothelial	B-Cell
cell	E-Cell
proliferation	O
and	O
migration	O
as	O
well	O
as	O
sprout	S-Tissue
formation	O
from	O
aorta	B-Multi-tissue_structure
ring	E-Multi-tissue_structure
.	O

In	O
vivo	O
assay	O
further	O
showed	O
that	O
GSE	S-Organism_substance
could	O
inhibit	O
tumor	S-Cancer
growth	O
and	O
tumor	S-Cancer
angiogenesis	O
of	O
MDA	B-Cell
-	I-Cell
MB	I-Cell
-	I-Cell
231	I-Cell
breast	I-Cell
cancer	I-Cell
cells	E-Cell
in	O
mice	O
.	O

Consistent	O
with	O
the	O
in	O
vitro	O
data	O
,	O
GSE	S-Organism_substance
treatment	O
of	O
tumor	S-Cancer
-	O
bearing	O
mice	O
led	O
to	O
concomitant	O
reduction	O
of	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
density	O
and	O
phosphorylation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Depletion	O
of	O
polyphenol	O
with	O
polyvinylpyrrolidone	O
abolished	O
the	O
antiangiogenic	O
activity	O
of	O
GSE	S-Organism_substance
,	O
suggesting	O
a	O
water	O
-	O
soluble	O
fraction	O
of	O
polyphenol	O
in	O
GSE	S-Organism_substance
is	O
responsible	O
for	O
the	O
antiangiogenic	O
activity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
GSE	S-Organism_substance
is	O
a	O
well	O
-	O
tolerated	O
and	O
inexpensive	O
natural	O
VEGF	O
inhibitor	O
and	O
could	O
potentially	O
be	O
useful	O
in	O
cancer	S-Cancer
prevention	O
or	O
treatment	O
.	O

Role	O
of	O
the	O
interferon	O
-	O
inducible	O
IFI16	O
gene	O
in	O
the	O
induction	O
of	O
ICAM	O
-	O
1	O
by	O
TNF	O
-	O
alpha	O
.	O

The	O
Interferon	O
-	O
inducible	O
gene	O
IFI16	O
,	O
a	O
member	O
of	O
the	O
HIN200	O
family	O
,	O
is	O
activated	O
by	O
oxidative	O
stress	O
and	O
cell	S-Cell
density	O
,	O
in	O
addition	O
to	O
Interferons	O
,	O
and	O
it	O
is	O
implicated	O
in	O
the	O
regulation	O
of	O
endothelial	B-Cell
cell	E-Cell
proliferation	O
and	O
vessel	S-Multi-tissue_structure
formation	O
in	O
vitro	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IFI16	O
is	O
required	O
for	O
proinflammatory	O
gene	O
stimulation	O
by	O
IFN	O
-	O
gamma	O
through	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

To	O
examine	O
whether	O
IFI16	O
induction	O
might	O
be	O
extended	O
to	O
other	O
proinflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
we	O
used	O
the	O
strategy	O
of	O
the	O
RNA	O
interference	O
to	O
knock	O
down	O
IFI16	O
expression	O
,	O
and	O
analyze	O
the	O
capability	O
of	O
TNF	O
-	O
alpha	O
to	O
stimulate	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
or	O
CD54	O
)	O
expression	O
in	O
the	O
absence	O
of	O
functional	O
IFI16	O
.	O

Our	O
studies	O
demonstrate	O
that	O
IFI16	O
mediates	O
ICAM	O
-	O
1	O
stimulation	O
by	O
TNF	O
-	O
alpha	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
thus	O
reinforcing	O
the	O
role	O
of	O
the	O
IFI16	O
molecule	O
in	O
the	O
inflammation	O
process	O
.	O

Impact	O
of	O
tumor	B-Cell
cell	E-Cell
VEGF	O
expression	O
on	O
the	O
in	O
vivo	O
efficacy	O
of	O
vandetanib	O
(	O
ZACTIMA	O
;	O
ZD6474	O
)	O
.	O

VEGF	O
is	O
the	O
key	O
player	O
in	O
tumor	S-Cancer
angiogenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
impact	O
of	O
VEGF	O
expression	O
on	O
the	O
response	O
of	O
tumors	S-Cancer
to	O
the	O
VEGFR2	O
associated	O
tyrosine	O
kinase	O
inhibitor	O
vandetanib	O
was	O
evaluated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
colon	B-Cell
carcinoma	I-Cell
(	I-Cell
HT29	I-Cell
)	E-Cell
and	O
murine	O
squamous	B-Cell
carcinoma	I-Cell
(	I-Cell
SCCVII	I-Cell
)	I-Cell
clonal	I-Cell
cell	I-Cell
lines	E-Cell
expressing	O
varying	O
levels	O
of	O
VEGF	O
were	O
established	O
and	O
their	O
response	O
to	O
vandetanib	O
was	O
assessed	O
in	O
tissue	S-Tissue
culture	O
and	O
as	O
solid	B-Cancer
tumors	E-Cancer
.	O

RESULTS	O
:	O
Vandetanib	O
treatment	O
had	O
no	O
effect	O
on	O
tumor	B-Cell
cell	E-Cell
clonogenic	O
cell	S-Cell
survival	O
in	O
vitro	O
but	O
doses	O
>	O
or	O
=	O
10	O
nM	O
significantly	O
reduced	O
endothelial	B-Cell
cell	E-Cell
migration	O
.	O

In	O
vivo	O
,	O
tumors	S-Cancer
derived	O
from	O
cell	B-Cell
clones	E-Cell
expressing	O
high	O
levels	O
of	O
VEGF	O
displayed	O
significantly	O
enhanced	O
angiogenesis	O
and	O
more	O
aggressive	O
growth	O
.	O

An	O
intradermal	S-Immaterial_anatomical_entity
angiogenesis	O
assay	O
was	O
used	O
to	O
demonstrate	O
that	O
a	O
4	O
-	O
day	O
treatment	O
with	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
able	O
to	O
significantly	O
inhibit	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	O
induced	O
by	O
both	O
parental	O
and	O
high	O
VEGF	O
-	O
expressing	O
tumor	B-Cell
cell	I-Cell
clones	E-Cell
.	O

In	O
the	O
HT29	B-Cancer
tumor	E-Cancer
model	O
,	O
treatment	O
response	O
to	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
Monday	O
-	O
Friday	O
for	O
2	O
weeks	O
)	O
was	O
greatest	O
in	O
xenografts	S-Cancer
derived	O
from	O
the	O
highest	O
VEGF	O
-	O
expressing	O
cell	B-Cell
clones	E-Cell
.	O

A	O
similar	O
trend	O
was	O
noted	O
in	O
the	O
SCCVII	B-Cancer
tumor	E-Cancer
model	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
vandetanib	O
therapy	O
effectively	O
counteracted	O
the	O
aggressive	O
feature	O
of	O
tumor	S-Cancer
growth	O
resulting	O
from	O
VEGF	O
over	O
-	O
expressing	O
tumor	B-Cell
cells	E-Cell
and	O
suggest	O
that	O
such	O
tumors	S-Cancer
may	O
be	O
particularly	O
well	O
suited	O
for	O
anti	O
-	O
VEGF	O
interventions	O
.	O

The	O
Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
short	O
variant	O
promoters	O
direct	O
vascular	B-Multi-tissue_structure
bed	E-Multi-tissue_structure
-	O
specific	O
gene	O
expression	O
during	O
inflammation	O
in	O
mice	O
.	O

Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
(	O
DSCR	O
-	O
1	O
)	O
short	O
variant	O
(	O
DSCR	O
-	O
1s	O
)	O
is	O
an	O
inhibitor	O
of	O
calcineurin	O
/	O
NFAT	O
signaling	O
encoded	O
by	O
exons	O
4	O
-	O
7	O
of	O
DSCR1	O
.	O

We	O
previously	O
reported	O
that	O
VEGF	O
induces	O
DSCR	O
-	O
1s	O
expression	O
in	O
endothelial	B-Cell
cells	E-Cell
,	O
which	O
in	O
turn	O
negatively	O
feeds	O
back	O
to	O
attenuate	O
endothelial	B-Cell
cell	E-Cell
activation	O
.	O

Here	O
,	O
in	O
order	O
to	O
characterize	O
the	O
role	O
of	O
the	O
promoter	O
that	O
drives	O
DSCR	O
-	O
1s	O
expression	O
in	O
mediating	O
inducible	O
expression	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
functional	O
relevance	O
of	O
DSCR	O
-	O
1s	O
in	O
inflammation	O
,	O
we	O
targeted	O
a	O
DNA	O
construct	O
containing	O
1	O
.	O
7	O
kb	O
of	O
the	O
human	O
DSCR1s	O
promoter	O
coupled	O
to	O
the	O
lacZ	O
reporter	O
to	O
the	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
Hprt	O
)	O
locus	O
of	O
mice	O
.	O

We	O
determined	O
that	O
lacZ	O
was	O
uniformly	O
expressed	O
in	O
the	O
endothelium	S-Tissue
of	O
transgenic	O
embryos	S-Developing_anatomical_structure
but	O
was	O
markedly	O
downregulated	O
postnatally	O
.	O

Systemic	O
administration	O
of	O
VEGF	O
or	O
LPS	O
in	O
adult	O
mice	O
resulted	O
in	O
cyclosporine	O
A	O
-	O
sensitive	O
reactivation	O
of	O
the	O
DSCR1s	O
promoter	O
and	O
endogenous	O
gene	O
expression	O
in	O
a	O
subset	O
of	O
organs	S-Organ
,	O
including	O
the	O
heart	S-Organ
and	O
brain	S-Organ
.	O

The	O
DSCR1s	O
promoter	O
was	O
similarly	O
induced	O
in	O
the	O
endothelium	S-Tissue
of	O
tumor	B-Cancer
xenografts	E-Cancer
.	O

In	O
a	O
mouse	O
model	O
of	O
endotoxemia	O
,	O
DSCR	O
-	O
1s	O
-	O
deficient	O
mice	O
demonstrated	O
increased	O
sepsis	O
mortality	O
,	O
whereas	O
adenovirus	O
-	O
mediated	O
DSCR	O
-	O
1s	O
overexpression	O
protected	O
against	O
LPS	O
-	O
induced	O
lethality	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
DSCR1s	O
promoter	O
directs	O
vascular	B-Multi-tissue_structure
bed	E-Multi-tissue_structure
-	O
specific	O
expression	O
in	O
activated	O
endothelium	S-Tissue
and	O
that	O
DSCR	O
-	O
1s	O
serves	O
to	O
dampen	O
the	O
host	O
response	O
to	O
infection	O
.	O

Nicked	O
{	O
beta	O
}	O
2	O
-	O
glycoprotein	O
I	O
binds	O
angiostatin	O
4	O
.	O
5	O
(	O
plasminogen	O
kringle	O
1	O
-	O
5	O
)	O
and	O
attenuates	O
its	O
antiangiogenic	O
property	O
.	O

Angiostatin	O
was	O
first	O
discovered	O
as	O
a	O
plasminogen	O
fragment	O
with	O
antitumor	S-Cancer
/	O
antiangiogenic	O
property	O
.	O

One	O
of	O
the	O
angiostatin	O
isoforms	O
,	O
that	O
is	O
,	O
angiostatin	O
4	O
.	O
5	O
(	O
AS4	O
.	O
5	O
)	O
,	O
consisting	O
of	O
plasminogen	O
kringle	O
1	O
to	O
4	O
and	O
a	O
most	O
part	O
of	O
kringle	O
5	O
,	O
is	O
produced	O
by	O
autoproteolysis	O
and	O
present	O
in	O
human	O
plasma	S-Organism_substance
.	O

beta2	O
-	O
glycoprotein	O
I	O
(	O
beta2GPI	O
)	O
is	O
proteolytically	O
cleaved	O
by	O
plasmin	O
in	O
its	O
domain	O
V	O
(	O
nicked	O
beta2GPI	O
)	O
,	O
resulting	O
in	O
binding	O
to	O
plasminogen	O
.	O

Antiangiogenic	O
properties	O
have	O
been	O
recently	O
reported	O
in	O
nicked	O
beta2GPI	O
as	O
well	O
as	O
in	O
intact	O
beta2GPI	O
at	O
higher	O
concentrations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
significant	O
binding	O
of	O
nicked	O
beta2GPI	O
to	O
AS4	O
.	O
5	O
(	O
K	O
(	O
D	O
)	O
=	O
3	O
.	O
27	O
x	O
10	O
(	O
6	O
)	O
M	O
(	O
-	O
1	O
)	O
)	O
.	O

Via	O
this	O
binding	O
,	O
nicked	O
beta2GPI	O
attenuates	O
the	O
antiangiogenic	O
functions	O
of	O
AS4	O
.	O
5	O
in	O
the	O
proliferation	O
of	O
arterial	S-Cell
/	O
venous	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
in	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
invasion	O
and	O
the	O
tube	S-Tissue
formation	O
of	O
venous	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
and	O
in	O
vivo	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
intact	O
beta2GPI	O
does	O
not	O
bind	O
to	O
AS4	O
.	O
5	O
or	O
inhibit	O
its	O
antiangiogenic	O
activity	O
.	O

Thus	O
,	O
nicked	O
beta2GPI	O
exerts	O
dual	O
effects	O
on	O
angiogenesis	O
,	O
that	O
is	O
,	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
in	O
the	O
presence	O
of	O
AS4	O
.	O
5	O
,	O
whereas	O
nicked	O
beta2GPI	O
inhibits	O
angiogenesis	O
at	O
concentrations	O
high	O
enough	O
to	O
neutralize	O
AS4	O
.	O
5	O
.	O

Our	O
data	O
suggest	O
that	O
plasmin	O
-	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
by	O
interacting	O
with	O
plasmin	O
-	O
generated	O
AS4	O
.	O
5	O
in	O
sites	O
of	O
increased	O
fibrinolysis	O
such	O
as	O
thrombus	S-Pathological_formation
.	O

[	O
An	O
experimental	O
study	O
on	O
angiogenesis	O
of	O
non	O
-	O
vascularized	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
with	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	O
in	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
on	O
angiogenesis	O
.	O

METHODS	O
:	O
Thirty	O
-	O
six	O
New	O
Zealand	O
white	O
rabbits	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

A	O
portion	O
of	O
bilateral	B-Organ
radial	I-Organ
bones	E-Organ
of	O
a	O
rabbit	O
were	O
removed	O
as	O
free	O
bone	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
,	O
whose	O
periostea	S-Tissue
were	O
peeled	O
off	O
.	O

In	O
test	O
group	O
,	O
the	O
external	B-Multi-tissue_structure
maxillary	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
bundle	E-Multi-tissue_structure
was	O
passed	O
through	O
the	O
marrow	B-Immaterial_anatomical_entity
cavity	E-Immaterial_anatomical_entity
of	O
the	O
bone	S-Organ
.	O

In	O
control	O
group	O
,	O
there	O
was	O
no	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	O
.	O

Each	O
bone	S-Organ
was	O
placed	O
in	O
masseter	B-Organ
muscle	E-Organ
separately	O
.	O

The	O
rabbits	O
were	O
sacrificed	O
and	O
the	O
specimens	S-Multi-tissue_structure
were	O
procured	O
at	O
3	O
days	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
6	O
weeks	O
after	O
surgery	O
for	O
histological	O
observation	O
,	O
Chinese	O
ink	O
perfusion	O
and	O
CD34	O
immunohistochemistry	O
.	O

Microvessel	S-Tissue
density	O
(	O
MVD	O
)	O
was	O
assessed	O
in	O
order	O
to	O
evaluate	O
angiogenesis	O
of	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
grafts	E-Multi-tissue_structure
.	O

RESULTS	O
:	O
The	O
bone	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
were	O
found	O
revascularization	O
in	O
3	O
days	O
after	O
surgery	O
in	O
the	O
test	O
group	O
,	O
whereas	O
at	O
2	O
weeks	O
in	O
the	O
control	O
group	O
.	O

In	O
3	O
days	O
,	O
1	O
week	O
,	O
2	O
weeks	O
,	O
3	O
weeks	O
and	O
4	O
weeks	O
after	O
surgery	O
,	O
the	O
MVD	O
of	O
test	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

In	O
4	O
weeks	O
after	O
surgery	O
,	O
angiogenesis	O
of	O
test	O
group	O
reached	O
to	O
peak	O
.	O

CONCLUSION	O
:	O
Vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	O
improved	O
angiogenesis	O
in	O
non	O
-	O
vascularized	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
in	O
this	O
study	O
.	O

Targeting	O
glucose	O
consumption	O
and	O
autophagy	O
in	O
myeloma	S-Cancer
with	O
the	O
novel	O
nucleoside	O
analogue	O
8	O
-	O
aminoadenosine	O
.	O

Multiple	O
myeloma	S-Cancer
,	O
an	O
incurable	O
plasma	B-Cancer
cell	I-Cancer
malignancy	E-Cancer
,	O
is	O
characterized	O
by	O
altered	O
cellular	S-Cell
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
.	O

Recent	O
connections	O
between	O
glucose	O
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
provide	O
a	O
compelling	O
rationale	O
for	O
targeting	O
metabolic	O
changes	O
in	O
cancer	S-Cancer
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
the	O
purine	O
analogue	O
8	O
-	O
aminoadenosine	O
to	O
acutely	O
reduce	O
glucose	O
consumption	O
by	O
regulating	O
localization	O
and	O
expression	O
of	O
key	O
glucose	O
transporters	O
.	O

Myeloma	B-Cell
cells	E-Cell
counteracted	O
the	O
metabolic	O
stress	O
by	O
activating	O
autophagy	O
.	O

Co	O
-	O
treatment	O
with	O
inhibitors	O
of	O
autophagy	O
results	O
in	O
marked	O
enhancement	O
of	O
cell	S-Cell
death	O
.	O

Glucose	O
consumption	O
by	O
drug	O
-	O
resistant	O
myeloma	B-Cell
cells	E-Cell
was	O
unaffected	O
by	O
8	O
-	O
aminoadenosine	O
,	O
and	O
accordingly	O
,	O
no	O
activation	O
of	O
autophagy	O
was	O
observed	O
.	O

However	O
,	O
these	O
cells	S-Cell
can	O
be	O
sensitized	O
to	O
8	O
-	O
aminoadenosine	O
under	O
glucose	O
-	O
limiting	O
conditions	O
.	O

The	O
prosurvival	O
autophagic	O
response	O
of	O
myeloma	S-Cancer
to	O
nutrient	O
deprivation	O
or	O
to	O
nucleoside	O
analogue	O
treatment	O
has	O
not	O
been	O
described	O
previously	O
.	O

This	O
study	O
establishes	O
the	O
potential	O
of	O
metabolic	O
targeting	O
as	O
a	O
broader	O
means	O
to	O
kill	O
and	O
sensitize	O
myeloma	S-Cancer
and	O
identifies	O
a	O
compound	O
that	O
can	O
achieve	O
this	O
goal	O
.	O

Dopamine	O
regulates	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
by	O
engaging	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
2	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
receptor	O
phosphorylation	O
is	O
the	O
crucial	O
step	O
for	O
initiating	O
downstream	O
signaling	O
pathways	O
that	O
lead	O
to	O
angiogenesis	O
or	O
related	O
pathophysiological	O
outcomes	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
neurotransmitter	O
dopamine	O
could	O
inhibit	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
(	O
VEGFR	O
-	O
2	O
)	O
,	O
endothelial	B-Cell
cell	E-Cell
proliferation	O
,	O
migration	O
,	O
microvascular	S-Tissue
permeability	O
,	O
and	O
thus	O
,	O
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
address	O
the	O
mechanism	O
by	O
which	O
VEGFR	O
-	O
2	O
phosphorylation	O
is	O
regulated	O
by	O
dopamine	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
D2	O
dopamine	O
receptor	O
(	O
D2DR	O
)	O
colocalizes	O
with	O
VEGFR	O
-	O
2	O
at	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
.	O

Dopamine	O
pretreatment	O
increases	O
the	O
translocation	O
and	O
colocalization	O
of	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
(	O
SHP	O
-	O
2	O
)	O
with	O
D2DR	O
at	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
.	O

Dopamine	O
administration	O
leads	O
to	O
increased	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
SHP	O
-	O
2	O
and	O
this	O
increased	O
phosphorylation	O
parallels	O
the	O
increased	O
phosphatase	O
activity	O
of	O
SHP	O
-	O
2	O
.	O

Active	O
SHP	O
-	O
2	O
then	O
dephosphorylates	O
VEGFR	O
-	O
2	O
at	O
Y951	O
,	O
Y996	O
and	O
Y1059	O
,	O
but	O
not	O
Y1175	O
.	O

We	O
also	O
observe	O
that	O
SHP	O
-	O
2	O
knockdown	O
impairs	O
the	O
dopamine	O
-	O
regulated	O
inhibition	O
of	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
,	O
subsequently	O
,	O
Src	O
phosphorylation	O
and	O
migration	O
.	O

Our	O
data	O
establish	O
a	O
novel	O
role	O
for	O
SHP	O
-	O
2	O
phosphatase	O
in	O
the	O
dopamine	O
-	O
mediated	O
regulation	O
of	O
VEGFR	O
-	O
2	O
phosphorylation	O
.	O

Glioma	B-Cell
tumor	I-Cell
stem	I-Cell
-	I-Cell
like	I-Cell
cells	E-Cell
promote	O
tumor	S-Cancer
angiogenesis	O
and	O
vasculogenesis	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
.	O

Cancer	B-Cell
stem	I-Cell
cells	E-Cell
(	O
CSC	S-Cell
)	O
are	O
predicted	O
to	O
be	O
critical	O
drivers	O
of	O
tumor	S-Cancer
progression	O
due	O
to	O
their	O
self	O
-	O
renewal	O
capacity	O
and	O
limitless	O
proliferative	O
potential	O
.	O

An	O
emerging	O
area	O
of	O
research	O
suggests	O
that	O
CSC	S-Cell
may	O
also	O
support	O
tumor	S-Cancer
progression	O
by	O
promoting	O
tumor	S-Cancer
angiogenesis	O
.	O

To	O
investigate	O
how	O
CSC	S-Cell
contribute	O
to	O
tumor	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
development	O
,	O
we	O
used	O
an	O
approach	O
comparing	O
tumor	B-Cancer
xenografts	E-Cancer
of	O
the	O
C6	B-Cell
glioma	I-Cell
cell	I-Cell
line	E-Cell
containing	O
either	O
a	O
low	O
or	O
a	O
high	O
fraction	O
of	O
CSC	S-Cell
.	O

Compared	O
with	O
CSC	B-Cancer
-	I-Cancer
low	I-Cancer
tumors	E-Cancer
,	O
CSC	B-Cancer
-	I-Cancer
high	I-Cancer
tumors	E-Cancer
exhibited	O
increased	O
microvessel	S-Tissue
density	O
and	O
blood	S-Organism_substance
perfusion	O
and	O
induced	O
increased	O
mobilization	O
and	O
tumor	S-Cancer
recruitment	O
of	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
-	O
derived	O
endothelial	B-Cell
progenitor	I-Cell
cells	E-Cell
(	O
EPC	S-Cell
)	O
.	O

CSC	B-Cell
-	I-Cell
high	I-Cell
C6	I-Cell
cell	I-Cell
cultures	E-Cell
also	O
induced	O
higher	O
levels	O
of	O
endothelial	B-Cell
cell	E-Cell
proliferation	O
and	O
tubule	S-Multi-tissue_structure
organization	O
in	O
vitro	O
compared	O
with	O
CSC	B-Cell
-	I-Cell
low	I-Cell
cultures	E-Cell
.	O

CSC	B-Cell
-	I-Cell
high	I-Cell
cultures	E-Cell
and	O
tumors	S-Cancer
expressed	O
increased	O
levels	O
of	O
the	O
proangiogenic	O
factors	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
,	O
and	O
when	O
signaling	O
by	O
either	O
factor	O
was	O
blocked	O
,	O
all	O
aspects	O
of	O
angiogenesis	O
observed	O
in	O
CSC	B-Cell
-	I-Cell
high	I-Cell
cultures	E-Cell
and	O
tumors	S-Cancer
,	O
including	O
microvessel	S-Tissue
density	O
,	O
perfusion	O
,	O
EPC	S-Cell
mobilization	O
/	O
recruitment	O
,	O
and	O
stimulation	O
of	O
endothelial	B-Cell
cell	E-Cell
activity	O
,	O
were	O
reduced	O
to	O
levels	O
comparable	O
with	O
those	O
observed	O
in	O
CSC	B-Cell
-	I-Cell
low	I-Cell
cultures	E-Cell
/	O
tumors	S-Cancer
.	O

These	O
results	O
suggest	O
that	O
CSC	S-Cell
contribute	O
to	O
tumor	S-Cancer
angiogenesis	O
by	O
promoting	O
both	O
local	O
endothelial	B-Cell
cell	E-Cell
activity	O
and	O
systemic	O
angiogenic	O
processes	O
involving	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
-	O
derived	O
EPC	S-Cell
in	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
dependent	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
-	O
dependent	O
manner	O
.	O

Cognitive	O
function	O
and	O
number	O
of	O
teeth	S-Organ
in	O
a	O
community	O
-	O
dwelling	O
elderly	O
population	O
without	O
dementia	O
.	O

Although	O
the	O
number	O
of	O
sound	O
or	O
decayed	O
teeth	S-Organ
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
cognitive	O
function	O
in	O
elderly	O
populations	O
with	O
dementia	O
,	O
little	O
is	O
known	O
about	O
this	O
association	O
in	O
elderly	O
populations	O
without	O
dementia	O
.	O

We	O
evaluated	O
this	O
relationship	O
,	O
with	O
adjustment	O
for	O
confounding	O
factors	O
,	O
in	O
Japanese	O
populations	O
of	O
60	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
270	O
;	O
120	O
males	O
and	O
150	O
females	O
)	O
and	O
65	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
123	O
;	O
57	O
males	O
and	O
66	O
females	O
)	O
individuals	O
residing	O
in	O
Fukuoka	O
Prefecture	O
of	O
Japan	O
.	O

Dental	S-Organ
examinations	O
were	O
performed	O
in	O
all	O
subjects	O
,	O
along	O
with	O
the	O
Mini	O
-	O
mental	O
state	O
examination	O
(	O
MMSE	O
)	O
for	O
assessing	O
cognitive	O
function	O
.	O

Among	O
the	O
total	O
of	O
393	O
subjects	O
,	O
the	O
mean	O
MMSE	O
score	O
was	O
27	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
and	O
391	O
subjects	O
scored	O
24	O
or	O
higher	O
.	O

The	O
mean	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	S-Organ
were	O
12	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
3	O
and	O
0	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
respectively	O
.	O

Associations	O
were	O
found	O
between	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	S-Organ
and	O
MMSE	O
in	O
total	O
subjects	O
and	O
males	O
,	O
but	O
not	O
in	O
females	O
,	O
by	O
multiple	O
regression	O
analysis	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
level	O
of	O
education	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
working	O
status	O
,	O
systolic	O
blood	S-Organism_substance
pressure	O
and	O
blood	S-Organism_substance
glucose	O
.	O

An	O
association	O
was	O
also	O
found	O
between	O
MMSE	O
and	O
the	O
number	O
of	O
sound	O
teeth	S-Organ
in	O
a	O
logistic	O
regression	O
analysis	O
.	O

In	O
conclusion	O
,	O
associations	O
were	O
found	O
between	O
normal	O
-	O
range	O
cognitive	O
function	O
and	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	S-Organ
,	O
after	O
adjustment	O
for	O
various	O
confounding	O
factors	O
,	O
in	O
an	O
elderly	O
Japanese	O
population	O
.	O

Inducible	O
nitric	O
oxide	O
synthase	O
modulates	O
angiogenesis	O
in	O
ischemic	O
hindlimb	S-Organism_subdivision
of	O
rat	O
.	O

BACKGROUND	O
:	O
Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
adequate	O
oxygen	O
delivery	O
,	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
potential	O
regulator	O
of	O
angiogenesis	O
.	O

NO	O
is	O
synthesized	O
through	O
three	O
isoforms	O
of	O
NO	O
synthase	O
(	O
NOS	O
)	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
NO	O
derived	O
from	O
inducible	O
NOS	O
(	O
iNOS	O
)	O
may	O
promote	O
survival	O
of	O
ischemic	O
tissue	S-Tissue
through	O
angiogenesis	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
iNOS	O
deficiency	O
(	O
by	O
L	O
-	O
NIL	O
)	O
on	O
angiogenesis	O
in	O
a	O
hindlimb	S-Organism_subdivision
ischemia	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
male	O
wistar	O
rats	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

In	O
groups	O
1	O
&	O
2	O
,	O
hindlimb	S-Organism_subdivision
ischemia	O
was	O
induced	O
by	O
ligation	O
of	O
femoral	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
and	O
they	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
.	O

The	O
animals	O
in	O
groups	O
3	O
and	O
4	O
also	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
without	O
surgical	O
procedure	O
.	O

After	O
21	O
days	O
,	O
the	O
serum	S-Organism_substance
concentration	O
of	O
nitrite	O
,	O
capillary	S-Tissue
density	O
and	O
expression	O
of	O
HIF1alpha	O
were	O
determined	O
.	O

RESULTS	O
:	O
Serum	S-Organism_substance
nitrite	O
levels	O
were	O
significantly	O
lower	O
in	O
L	O
-	O
NIL	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
capillary	S-Tissue
density	O
in	O
group	O
1	O
(	O
ischemia	O
+	O
L	O
-	O
NIL	O
)	O
was	O
significantly	O
different	O
from	O
group	O
2	O
(	O
ischemia	O
+	O
saline	O
)	O
;	O
group	O
1	O
:	O
360	O
.	O
33	O
+	O
/	O
-	O
77	O
.	O
02	O
,	O
group	O
2	O
:	O
549	O
+	O
/	O
-	O
81	O
.	O
85	O
/	O
mm2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
expression	O
of	O
HIF1alpha	O
was	O
significantly	O
increased	O
in	O
ischemic	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Selective	O
inhibition	O
of	O
iNOS	O
by	O
L	O
-	O
NIL	O
inhibits	O
angiogenesis	O
in	O
a	O
hindlimb	S-Organism_subdivision
ischemic	O
rat	O
model	O
.	O

In	O
addition	O
,	O
ischemia	O
induces	O
expression	O
of	O
HIF1alpha	O
in	O
hypoxic	B-Tissue
tissue	E-Tissue
.	O

Phenolic	O
fraction	O
of	O
tobacco	O
smoke	O
condensate	O
potentiates	O
benzo	O
[	O
a	O
]	O
pyerene	O
diol	O
epoxide	O
-	O
induced	O
cell	S-Cell
transformation	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
.	O

In	O
this	O
study	O
we	O
separated	O
weakly	O
acidic	O
phenolic	O
components	O
from	O
other	O
neutral	O
,	O
acidic	O
and	O
basic	O
components	O
of	O
tobacco	O
smoke	O
condensate	O
(	O
TSC	O
)	O
and	O
observed	O
that	O
phenolic	O
fraction	O
of	O
TSC	O
significantly	O
increased	O
the	O
number	O
of	O
colonies	S-Cell
of	O
promotion	O
-	O
sensitive	O
JB6	B-Cell
Cl41	I-Cell
cells	E-Cell
that	O
showed	O
anchorage	O
-	O
independent	O
growth	O
on	O
soft	O
agar	O
in	O
response	O
to	O
BPDE	O
(	O
an	O
ultimate	O
carcinogen	O
produced	O
by	O
metabolic	O
activation	O
of	O
the	O
PAH	O
benzo	O
[	O
a	O
]	O
pyrene	O
)	O
.	O

Anchorage	O
-	O
independent	O
cell	S-Cell
growth	O
is	O
indicative	O
of	O
cell	S-Cell
transformation	O
resulting	O
in	O
acquisition	O
of	O
tumorigenic	O
potential	O
.	O

In	O
order	O
to	O
understand	O
the	O
underlying	O
mechanism	O
by	O
which	O
TSC	O
phenolic	O
fraction	O
potentiates	O
BPDE	O
-	O
induced	O
tumorigenicity	O
,	O
we	O
examined	O
its	O
effect	O
on	O
the	O
activation	O
of	O
two	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
which	O
are	O
known	O
to	O
be	O
influenced	O
by	O
established	O
tumor	S-Cancer
promoter	O
TPA	O
.	O

BPDE	O
treatment	O
caused	O
induction	O
of	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
activity	O
as	O
determined	O
by	O
luciferase	O
reporter	O
assay	O
and	O
only	O
NF	O
-	O
kappaB	O
induction	O
in	O
response	O
to	O
BPDE	O
was	O
significantly	O
attenuated	O
by	O
TSC	O
phenolic	O
fraction	O
whereas	O
AP	O
-	O
1	O
induction	O
remains	O
unaltered	O
.	O

Attenuation	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
TSC	O
phenolic	O
fraction	O
was	O
associated	O
with	O
significant	O
decrease	O
of	O
intracellular	S-Immaterial_anatomical_entity
PKC	O
substrate	O
phosphorylation	O
in	O
BPDE	O
treated	O
cells	S-Cell
.	O

Non	O
-	O
specific	O
PKC	O
inhibitors	O
staurosporine	O
and	O
bisindolylmaleimide	O
II	O
as	O
well	O
as	O
inhibitors	O
specific	O
to	O
conventional	O
PKCs	O
(	O
Go6976	O
)	O
and	O
PKC	O
-	O
delta	O
(	O
rottlerin	O
)	O
attenuated	O
NF	O
-	O
kappaB	O
activation	O
in	O
BPDE	O
treated	O
cells	S-Cell
to	O
a	O
varying	O
degree	O
indicating	O
a	O
possible	O
link	O
between	O
PKC	O
down	O
-	O
regulation	O
and	O
the	O
attenuation	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Treatment	O
of	O
cells	S-Cell
with	O
PKC	O
inhibitors	O
also	O
potentiated	O
anchorage	O
-	O
independent	O
growth	O
of	O
BPDE	O
treated	O
cells	S-Cell
on	O
soft	O
agar	O
.	O

Our	O
data	O
suggest	O
a	O
possible	O
role	O
of	O
PKC	O
down	O
-	O
regulation	O
in	O
potentiation	O
of	O
BPDE	O
-	O
induced	O
tumorogenicity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Killing	O
tumor	B-Cell
cells	E-Cell
through	O
their	O
surface	S-Cellular_component
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
or	O
major	O
histocompatibility	O
complex	O
class	O
I	O
molecules	O
.	O

Targeted	O
antibody	O
-	O
based	O
therapy	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
cancers	S-Cancer
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
tumor	B-Cell
cells	E-Cell
treated	O
with	O
antibodies	O
specific	O
for	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
(	O
beta	O
(	O
2	O
)	O
M	O
)	O
or	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
mouse	O
models	O
)	O
.	O

Antibodies	O
against	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
induce	O
tumor	B-Cell
cell	E-Cell
apoptosis	O
by	O
1	O
)	O
recruiting	O
MHC	O
class	O
I	O
molecules	O
to	O
lipid	B-Organism_substance
rafts	E-Organism_substance
and	O
activating	O
LYN	O
kinase	O
and	O
the	O
signal	O
-	O
transducing	O
enzyme	O
phospholipase	O
C	O
-	O
gamma2	O
-	O
dependent	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
and	O
2	O
)	O
expelling	O
interleukin	O
6	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptors	O
out	O
of	O
lipid	B-Organism_substance
rafts	E-Organism_substance
and	O
inhibiting	O
the	O
growth	O
and	O
survival	O
factor	O
-	O
induced	O
activation	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
and	O
extracellular	O
signal	O
-	O
related	O
kinase	O
pathways	O
.	O

Consequently	O
,	O
mitochondrial	S-Cellular_component
integrity	O
is	O
compromised	O
,	O
and	O
the	O
caspase	O
-	O
9	O
-	O
dependent	O
cascade	O
is	O
activated	O
in	O
treated	O
tumor	B-Cell
cells	E-Cell
.	O

However	O
,	O
although	O
beta	O
(	O
2	O
)	O
M	O
and	O
MHC	O
class	O
I	O
are	O
expressed	O
on	O
normal	O
hematopoietic	B-Cell
cells	E-Cell
,	O
which	O
is	O
a	O
potential	O
safety	O
concern	O
,	O
the	O
monoclonal	O
antibodies	O
were	O
selective	O
to	O
tumor	B-Cell
cells	E-Cell
and	O
did	O
not	O
damage	O
normal	O
cells	S-Cell
in	O
vitro	O
or	O
in	O
human	O
-	O
like	O
mouse	O
models	O
.	O

These	O
findings	O
suggest	O
that	O
targeting	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
by	O
using	O
antibodies	O
or	O
other	O
agents	O
offers	O
a	O
potential	O
therapeutic	O
approach	O
for	O
beta	O
(	O
2	O
)	O
M	O
/	O
MHC	O
class	O
I	O
-	O
expressing	O
malignancies	S-Cancer
.	O

Cancer	O
2010	O
.	O

(	O
c	O
)	O
2010	O
American	O
Cancer	O
Society	O
.	O

Comment	O
on	O
"	O
Why	O
reduced	O
-	O
form	O
regression	O
models	O
of	O
health	O
effects	O
versus	O
exposures	O
should	O
not	O
replace	O
QRA	O
:	O
livestock	O
production	O
and	O
infant	O
mortality	O
as	O
an	O
example	O
,	O
"	O
by	O
Louis	O
Anthony	O
(	O
Tony	O
)	O
Cox	O
,	O
Jr	O
.	O
,	O
Risk	O
Analysis	O
2009	O
,	O
Vol	O
.	O

29	O
,	O
No	O
.	O
12	O
.	O

While	O
a	O
recent	O
paper	O
by	O
Cox	O
in	O
this	O
journal	O
uses	O
as	O
its	O
motivating	O
factor	O
the	O
benefits	O
of	O
quantitative	O
risk	O
assessment	O
,	O
its	O
content	O
is	O
entirely	O
devoted	O
to	O
critiquing	O
Sneeringer	O
'	O
s	O
article	O
in	O
the	O
American	O
Journal	O
of	O
Agricultural	O
Economics	O
.	O

Cox	O
'	O
s	O
two	O
main	O
critiques	O
of	O
Sneeringer	O
are	O
fundamentally	O
flawed	O
and	O
misrepresent	O
the	O
original	O
article	O
.	O

Cox	O
posits	O
that	O
Sneeringer	O
did	O
A	O
and	O
B	O
,	O
and	O
then	O
argues	O
why	O
A	O
and	O
B	O
are	O
incorrect	O
.	O

However	O
,	O
Sneeringer	O
in	O
fact	O
did	O
C	O
and	O
D	O
;	O
thus	O
critiques	O
of	O
A	O
and	O
B	O
are	O
not	O
applicable	O
to	O
Sneeringer	O
'	O
s	O
analysis	O
.	O

Loss	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	B-Cancer
carcinoma	E-Cancer
.	O

BACKGROUND	O
:	O
CDC4	O
/	O
FBXW7	O
,	O
encoding	O
a	O
ubiquitin	O
ligase	O
,	O
maps	O
to	O
4q32	O
and	O
has	O
been	O
implicated	O
as	O
a	O
tumor	S-Cancer
suppressor	O
gene	O
and	O
therapeutic	O
target	O
in	O
many	O
tumor	S-Cancer
types	O
.	O

Mutations	O
in	O
colonic	B-Cancer
adenomas	E-Cancer
,	O
and	O
the	O
frequent	O
losses	O
on	O
4q	S-Cellular_component
described	O
in	O
gastric	B-Cancer
cancer	E-Cancer
prompt	O
speculation	O
about	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	S-Organ
carcinogenesis	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	B-Cancer
cancer	E-Cancer
,	O
through	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
on	O
47	O
flow	O
-	O
sorted	O
gastric	B-Cancer
carcinomas	E-Cancer
including	O
early	B-Cancer
-	I-Cancer
onset	I-Cancer
gastric	I-Cancer
cancers	E-Cancer
(	O
EOGC	S-Cancer
)	O
and	O
xenografted	O
conventional	O
gastric	B-Cancer
carcinomas	E-Cancer
.	O

Ploidy	O
analysis	O
was	O
carried	O
out	O
on	O
39	O
EOGCs	S-Cancer
and	O
immunohistochemistry	O
of	O
CDC4	O
/	O
FBXW7	O
and	O
its	O
substrates	O
c	O
-	O
myc	O
,	O
c	O
-	O
jun	O
,	O
Notch	O
and	O
cyclin	O
E	O
was	O
performed	O
on	O
204	O
gastric	B-Cancer
carcinomas	E-Cancer
using	O
tissue	S-Tissue
microarrays	O
(	O
TMAs	O
)	O
.	O

Sequence	O
analysis	O
of	O
CDC4	O
/	O
FBXW7	O
was	O
carried	O
out	O
on	O
gastric	B-Cell
carcinoma	I-Cell
cell	I-Cell
lines	E-Cell
and	O
xenografts	S-Cancer
.	O

RESULTS	O
:	O
Loss	O
of	O
heterozygosity	O
of	O
CDC4	O
/	O
FBXW7	O
occurred	O
in	O
32	O
%	O
of	O
EOGCs	S-Cancer
,	O
and	O
correlated	O
with	O
loss	O
of	O
expression	O
in	O
26	O
%	O
.	O

Loss	O
of	O
expression	O
was	O
frequent	O
in	O
both	O
EOGC	S-Cancer
and	O
conventional	O
gastric	B-Cancer
cancers	E-Cancer
.	O

No	O
CDC4	O
/	O
FBXW7	O
mutations	O
were	O
found	O
and	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
did	O
not	O
correlate	O
with	O
ploidy	O
status	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
expression	O
and	O
upregulation	O
of	O
c	O
-	O
myc	O
.	O

CONCLUSION	O
:	O
Loss	O
of	O
CDC4	O
/	O
FBXW7	O
appears	O
to	O
play	O
a	O
role	O
in	O
both	O
EOGC	S-Cancer
and	O
conventional	O
gastric	S-Organ
carcinogenesis	O
,	O
and	O
c	O
-	O
myc	O
overexpression	O
is	O
likely	O
to	O
be	O
an	O
important	O
oncogenic	O
consequence	O
of	O
CDC4	O
/	O
FBXW7	O
loss	O
.	O

Angiogenesis	O
inhibitors	O
:	O
current	O
strategies	O
and	O
future	O
prospects	O
.	O

Angiogenesis	O
has	O
become	O
an	O
attractive	O
target	O
for	O
drug	O
therapy	O
because	O
of	O
its	O
key	O
role	O
in	O
tumor	S-Cancer
growth	O
.	O

An	O
extensive	O
array	O
of	O
compounds	O
is	O
currently	O
in	O
preclinical	O
development	O
,	O
with	O
many	O
now	O
entering	O
the	O
clinic	O
and	O
/	O
or	O
achieving	O
approval	O
from	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
.	O

Several	O
regulatory	O
and	O
signaling	O
molecules	O
governing	O
angiogenesis	O
are	O
of	O
interest	O
,	O
including	O
growth	O
factors	O
(	O
eg	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
,	O
fibroblast	O
growth	O
factor	O
,	O
and	O
epidermal	O
growth	O
factor	O
)	O
,	O
receptor	O
tyrosine	O
kinases	O
,	O
and	O
transcription	O
factors	O
such	O
as	O
hypoxia	O
inducible	O
factor	O
,	O
as	O
well	O
as	O
molecules	O
involved	O
in	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
signaling	O
.	O

Pharmacologic	O
agents	O
have	O
been	O
identified	O
that	O
target	O
these	O
pathways	O
,	O
yet	O
for	O
some	O
agents	O
(	O
notably	O
thalidomide	O
)	O
,	O
an	O
understanding	O
of	O
the	O
specific	O
mechanisms	O
of	O
antitumor	S-Cancer
action	O
has	O
proved	O
elusive	O
.	O

The	O
following	O
review	O
describes	O
key	O
molecular	O
mechanisms	O
and	O
novel	O
therapies	O
that	O
are	O
on	O
the	O
horizon	O
for	O
antiangiogenic	O
tumor	S-Cancer
therapy	O
.	O

Prognostic	O
significance	O
of	O
TRAIL	O
signaling	O
molecules	O
in	O
stage	B-Cancer
II	I-Cancer
and	I-Cancer
III	I-Cancer
colorectal	I-Cancer
cancer	E-Cancer
.	O

PURPOSE	O
:	O

We	O
previously	O
found	O
that	O
cellular	O
FLICE	O
-	O
inhibitory	O
protein	O
(	O
c	O
-	O
FLIP	O
)	O
,	O
caspase	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
receptor	O
2	O
(	O
DR5	O
)	O
are	O
major	O
regulators	O
of	O
cell	S-Cell
viability	O
and	O
chemotherapy	O
-	O
induced	O
apoptosis	O
in	O
colorectal	B-Cancer
cancer	E-Cancer
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
c	O
-	O
FLIP	O
,	O
caspase	O
8	O
,	O
TRAIL	O
and	O
DR5	O
expression	O
in	O
tissues	S-Tissue
from	O
patients	O
with	O
stage	B-Cancer
II	I-Cancer
and	I-Cancer
III	I-Cancer
colorectal	I-Cancer
cancer	E-Cancer
.	O

EXPERIMENTAL	O
DESIGN	O
:	O

Tissue	S-Tissue
microarrays	O
were	O
constructed	O
from	O
matched	O
normal	O
and	O
tumor	B-Tissue
tissue	E-Tissue
derived	O
from	O
patients	O
(	O
n	O
=	O
253	O
)	O
enrolled	O
in	O
a	O
phase	O
III	O
trial	O
of	O
adjuvant	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
versus	O
postoperative	O
observation	O
alone	O
.	O

TRAIL	O
,	O
DR5	O
,	O
caspase	O
8	O
,	O
and	O
c	O
-	O
FLIP	O
expression	O
levels	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O

Colorectal	B-Cancer
tumors	E-Cancer
displayed	O
significantly	O
higher	O
expression	O
levels	O
of	O
c	O
-	O
FLIP	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
caspase	O
8	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
DR5	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
lower	O
levels	O
of	O
TRAIL	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
matched	O
normal	O
tissue	S-Tissue
.	O

In	O
univariate	O
analysis	O
,	O
higher	O
TRAIL	O
expression	O
in	O
the	O
tumor	S-Cancer
was	O
associated	O
with	O
worse	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
026	O
)	O
,	O
with	O
a	O
trend	O
to	O
decreased	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
;	O
P	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
higher	O
tumor	S-Cancer
c	O
-	O
FLIP	O
expression	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
RFS	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

Using	O
multivariate	O
predictive	O
modeling	O
for	O
RFS	O
in	O
all	O
patients	O
and	O
including	O
all	O
biomarkers	O
,	O
age	O
,	O
treatment	O
,	O
and	O
stage	O
,	O
we	O
found	O
that	O
the	O
model	O
was	O
significant	O
when	O
the	O
mean	O
tumor	S-Cancer
c	O
-	O
FLIP	O
expression	O
score	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

As	O
regards	O
overall	O
survival	O
,	O
the	O
overall	O
model	O
was	O
predictive	O
when	O
both	O
TRAIL	O
expression	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O

High	O
c	O
-	O
FLIP	O
and	O
TRAIL	O
expression	O
may	O
be	O
independent	O
adverse	O
prognostic	O
markers	O
in	O
stage	B-Cancer
II	I-Cancer
and	I-Cancer
III	I-Cancer
colorectal	I-Cancer
cancer	E-Cancer
and	O
might	O
identify	O
patients	O
most	O
at	O
risk	O
of	O
relapse	O
.	O

Overexpression	O
of	O
Bax	O
inhibitor	O
-	O
1	O
(	O
BI	O
-	O
1	O
)	O
induces	O
cell	S-Cell
transformation	O
in	O
NIH3T3	B-Cell
cells	E-Cell
.	O

BI	O
-	O
1	O
(	O
Bax	O
inhibitor	O
-	O
1	O
)	O
,	O
an	O
apoptosis	O
-	O
inhibiting	O
gene	O
belonging	O
to	O
the	O
Bcl	O
-	O
2	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mitochondrial	S-Cellular_component
apoptosis	O
pathway	O
to	O
suppress	O
Bax	O
-	O
induced	O
apoptosis	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
BI	O
-	O
1	O
in	O
promoting	O
cell	S-Cell
growth	O
and	O
tumorigenesis	O
,	O
in	O
the	O
present	O
study	O
we	O
overexpressed	O
the	O
BI	O
-	O
1	O
gene	O
in	O
NIH3T3	B-Cell
cells	E-Cell
using	O
the	O
lentivirus	O
-	O
mediated	O
gene	O
expression	O
system	O
.	O

Our	O
in	O
vitro	O
studies	O
showed	O
that	O
NIH3T3	B-Cell
cells	E-Cell
overexpressing	O
BI	O
-	O
1	O
displayed	O
a	O
significantly	O
higher	O
growth	O
rate	O
and	O
formed	O
more	O
and	O
larger	O
colonies	S-Cell
than	O
the	O
control	O
cells	S-Cell
.	O

In	O
addition	O
,	O
our	O
in	O
vivo	O
studies	O
indicated	O
that	O
the	O
lenti	O
-	O
BI	O
-	O
1	O
-	O
infected	O
cells	S-Cell
formed	O
obvious	O
tumours	S-Cancer
,	O
while	O
no	O
tumours	S-Cancer
were	O
formed	O
by	O
the	O
control	O
cells	S-Cell
after	O
subcutaneously	S-Immaterial_anatomical_entity
injected	O
into	O
nude	O
mice	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
BI	O
-	O
1	O
gene	O
might	O
play	O
a	O
crucial	O
role	O
in	O
neoplastic	S-Cancer
genesis	O
and	O
development	O
.	O

Anti	O
-	O
metastasis	O
effects	O
of	O
gallic	O
acid	O
on	O
gastric	B-Cell
cancer	I-Cell
cells	E-Cell
involves	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
downregulation	O
of	O
PI3K	O
/	O
AKT	O
/	O
small	O
GTPase	O
signals	O
.	O

Polyphenols	O
are	O
natural	O
antioxidants	O
that	O
are	O
thought	O
to	O
contribute	O
to	O
prevention	O
of	O
cardiovascular	S-Anatomical_system
disease	O
and	O
malignancy	S-Cancer
.	O

Although	O
many	O
studies	O
have	O
been	O
carried	O
out	O
to	O
investigate	O
the	O
chemopreventive	O
role	O
of	O
flavonoids	O
,	O
less	O
attention	O
has	O
been	O
focused	O
on	O
phenolic	O
acids	O
.	O

In	O
this	O
study	O
,	O
the	O
aim	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
phenolic	O
acids	O
found	O
abundantly	O
in	O
vegetables	S-Organism_subdivision
,	O
i	O
.	O
e	O
.	O
gallic	O
acid	O
(	O
GA	O
)	O
,	O
caffeic	O
acid	O
(	O
CA	O
)	O
and	O
protocatechuic	O
acid	O
(	O
PCA	O
)	O
,	O
on	O
the	O
inhibition	O
of	O
gastric	B-Cell
adenocarcinoma	I-Cell
(	I-Cell
AGS	I-Cell
)	I-Cell
cell	E-Cell
metastasis	O
.	O

The	O
results	O
showed	O
0	O
.	O
01	O
mM	O
GA	O
induced	O
the	O
same	O
level	O
of	O
cell	S-Cell
toxicity	O
as	O
4	O
.	O
0mM	O
PCA	O
.	O

Using	O
wound	S-Pathological_formation
-	O
healing	O
assay	O
and	O
Boyden	O
chamber	O
assay	O
,	O
GA	O
had	O
potent	O
inhibitory	O
effects	O
on	O
AGS	B-Cell
cell	E-Cell
migration	O
.	O

The	O
expression	O
of	O
MMP	O
-	O
2	O
/	O
9	O
of	O
AGS	B-Cell
cells	E-Cell
was	O
inhibited	O
by	O
2	O
.	O
0	O
microM	O
of	O
GA	O
.	O

It	O
is	O
possible	O
that	O
the	O
suppressive	O
effect	O
of	O
GA	O
on	O
MMP	O
-	O
2	O
/	O
9	O
might	O
involve	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

Multiple	O
proteins	O
involved	O
in	O
metastasis	O
and	O
the	O
cytoskeletal	S-Cellular_component
reorganization	O
signal	O
pathway	O
,	O
including	O
Ras	O
,	O
Cdc42	O
,	O
Rac1	O
,	O
RhoA	O
,	O
RhoB	O
,	O
PI3K	O
and	O
p38MAPK	O
,	O
were	O
also	O
inhibited	O
by	O
GA	O
.	O

Furthermore	O
,	O
immunoreactivity	O
assay	O
of	O
cytoskeletal	S-Cellular_component
F	O
-	O
actin	O
demonstrated	O
a	O
significant	O
inhibitory	O
effect	O
of	O
GA	O
treatment	O
.	O

In	O
conclusion	O
,	O
GA	O
may	O
have	O
the	O
potential	O
to	O
be	O
an	O
effective	O
agent	O
for	O
prevention	O
and	O
treatment	O
of	O
gastric	B-Cancer
cancer	E-Cancer
metastasis	O
.	O

1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
,	O
but	O
not	O
selenomethionine	O
,	O
inhibits	O
androgen	O
receptor	O
and	O
Akt	O
signaling	O
in	O
human	O
prostate	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

The	O
lack	O
of	O
treatment	O
for	O
worried	O
-	O
well	O
patients	O
with	O
high	B-Pathological_formation
-	I-Pathological_formation
grade	I-Pathological_formation
prostatic	I-Pathological_formation
intraepithelial	I-Pathological_formation
neoplasia	E-Pathological_formation
combined	O
with	O
issues	O
of	O
recurrence	O
and	O
hormone	O
resistance	O
in	O
prostate	B-Cancer
cancer	E-Cancer
survivors	O
remains	O
a	O
major	O
public	O
health	O
obstacle	O
.	O

The	O
long	O
latency	O
of	O
prostate	B-Cancer
cancer	E-Cancer
development	O
provides	O
an	O
opportunity	O
to	O
intervene	O
with	O
agents	O
of	O
known	O
mechanisms	O
at	O
various	O
stages	O
of	O
disease	O
progression	O
.	O

A	O
number	O
of	O
signaling	O
cascades	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
prostate	B-Cancer
cancer	E-Cancer
development	O
and	O
progression	O
,	O
including	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathways	O
.	O

Crosstalk	O
between	O
these	O
two	O
pathways	O
is	O
also	O
thought	O
to	O
contribute	O
to	O
progression	O
and	O
hormone	O
-	O
refractory	O
prostate	B-Cancer
disease	E-Cancer
.	O

Our	O
initial	O
investigations	O
show	O
that	O
the	O
naturally	O
occurring	O
organoselenium	O
compound	O
selenomethionine	O
(	O
SM	O
)	O
and	O
the	O
synthetic	O
1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
(	O
p	O
-	O
XSC	O
)	O
can	O
inhibit	O
human	O
prostate	B-Cell
cancer	I-Cell
cell	E-Cell
viability	O
;	O
however	O
,	O
in	O
contrast	O
to	O
SM	O
,	O
p	O
-	O
XSC	O
is	O
active	O
at	O
physiologically	O
relevant	O
doses	O
.	O

In	O
the	O
current	O
investigation	O
,	O
we	O
show	O
that	O
p	O
-	O
XSC	O
,	O
but	O
not	O
an	O
equivalent	O
dose	O
of	O
SM	O
,	O
alters	O
molecular	O
targets	O
and	O
induces	O
apoptosis	O
in	O
androgen	O
-	O
responsive	O
LNCaP	S-Cell
and	O
androgen	O
-	O
independent	O
LNCaP	B-Cell
C4	I-Cell
-	I-Cell
2	I-Cell
human	I-Cell
prostate	I-Cell
cancer	I-Cell
cells	E-Cell
.	O

p	O
-	O
XSC	O
effectively	O
inhibits	O
AR	O
expression	O
and	O
transcriptional	O
activity	O
in	O
both	O
cell	B-Cell
lines	E-Cell
.	O

p	O
-	O
XSC	O
also	O
decreases	O
Akt	O
phosphorylation	O
as	O
well	O
as	O
Akt	O
-	O
specific	O
phosphorylation	O
of	O
the	O
AR	O
.	O

Inhibition	O
of	O
Akt	O
,	O
however	O
,	O
does	O
not	O
fully	O
attenuate	O
p	O
-	O
XSC	O
-	O
mediated	O
downregulation	O
of	O
AR	O
activity	O
,	O
suggesting	O
that	O
inhibition	O
of	O
AR	O
signaling	O
by	O
p	O
-	O
XSC	O
does	O
not	O
occur	O
solely	O
through	O
alterations	O
in	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
survival	O
pathway	O
.	O

Our	O
data	O
suggest	O
that	O
p	O
-	O
XSC	O
inhibits	O
multiple	O
signaling	O
pathways	O
in	O
prostate	B-Cancer
cancer	E-Cancer
,	O
likely	O
accounting	O
for	O
the	O
downstream	O
effects	O
on	O
proliferation	O
and	O
apoptosis	O
.	O

Sanguinarine	O
induces	O
apoptosis	O
of	O
human	O
osteosarcoma	B-Cell
cells	E-Cell
through	O
the	O
extrinsic	O
and	O
intrinsic	O
pathways	O
.	O

The	O
quaternary	O
benzo	O
[	O
c	O
]	O
phenanthridine	O
alkaloid	O
sanguinarine	O
inhibits	O
the	O
proliferation	O
of	O
cancerous	B-Cell
cells	E-Cell
from	O
different	O
origins	O
,	O
including	O
lung	S-Organ
,	O
breast	S-Organism_subdivision
,	O
pancreatic	S-Organ
and	O
colon	S-Organ
,	O
but	O
nothing	O
is	O
known	O
of	O
its	O
effects	O
on	O
osteosarcoma	S-Cancer
,	O
a	O
primary	B-Cancer
malignant	I-Cancer
bone	I-Cancer
tumour	E-Cancer
.	O

We	O
have	O
found	O
that	O
sanguinarine	O
alters	O
the	O
morphology	O
and	O
reduces	O
the	O
viability	O
of	O
MG	B-Cell
-	I-Cell
63	E-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
human	I-Cell
osteosarcoma	I-Cell
cell	I-Cell
lines	E-Cell
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
1	O
micromol	O
/	O
L	O
sanguinarine	O
for	O
4	O
and	O
24h	O
killed	O
more	O
efficiently	O
MG	B-Cell
-	I-Cell
63	I-Cell
cells	E-Cell
than	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
,	O
while	O
incubation	O
with	O
5	O
micromol	O
/	O
L	O
sanguinarine	O
killed	O
almost	O
100	O
%	O
of	O
both	O
cell	B-Cell
populations	E-Cell
within	O
24h	O
.	O

This	O
treatment	O
also	O
changed	O
the	O
mitochondrial	B-Cellular_component
membrane	E-Cellular_component
potential	O
in	O
both	O
MG	B-Cell
-	I-Cell
63	E-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
within	O
1h	O
,	O
caused	O
chromatin	S-Cellular_component
condensation	O
and	O
the	O
formation	O
of	O
apoptotic	B-Cellular_component
bodies	E-Cellular_component
.	O

It	O
activated	O
multicaspases	O
,	O
and	O
increased	O
the	O
activities	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
in	O
both	O
MG	B-Cell
-	I-Cell
63	E-Cell
and	O
SaOS	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

These	O
data	O
highlight	O
sanguinarine	O
as	O
a	O
novel	O
potential	O
agent	O
for	O
bone	B-Cancer
cancer	E-Cancer
therapy	O
.	O

Actin	O
-	O
sequestering	O
protein	O
,	O
thymosin	O
beta	O
-	O
4	O
,	O
is	O
a	O
novel	O
hypoxia	O
responsive	O
regulator	O
.	O

Angiogenesis	O
is	O
induced	O
by	O
soluble	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
released	O
from	O
tumor	B-Cell
cells	E-Cell
in	O
hypoxia	O
.	O

It	O
enhances	O
solid	B-Cancer
tumor	E-Cancer
growth	O
and	O
provides	O
an	O
ability	O
to	O
establish	O
metastasis	O
at	O
peripheral	B-Multi-tissue_structure
sites	E-Multi-tissue_structure
by	O
tumor	B-Cell
cell	E-Cell
migration	O
.	O

Thymosin	O
beta	O
-	O
4	O
(	O
TB4	O
)	O
is	O
an	O
actin	O
-	O
sequestering	O
protein	O
to	O
control	O
cytoskeletal	S-Cellular_component
reorganization	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
angiogenesis	O
and	O
tumor	S-Cancer
metastasis	O
are	O
dependent	O
on	O
hypoxia	O
conditioning	O
-	O
induced	O
TB4	O
expression	O
in	O
B16F10	B-Cell
melanoma	I-Cell
cells	E-Cell
.	O

TB4	O
expression	O
in	O
B16F10	B-Cell
cells	E-Cell
was	O
increased	O
by	O
hypoxia	O
conditioning	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
we	O
found	O
an	O
increase	O
of	O
angiogenesis	O
and	O
HIF	O
-	O
1alpha	O
expression	O
in	O
TB4	O
-	O
transgenic	O
(	O
Tg	O
)	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

When	O
wound	S-Pathological_formation
healing	O
assay	O
was	O
used	O
to	O
assess	O
in	O
vitro	O
tumor	B-Cell
cell	E-Cell
migration	O
,	O
hypoxia	O
conditioning	O
for	O
1	O
h	O
enhanced	O
B16F10	B-Cell
cell	E-Cell
migration	O
.	O

When	O
TB4	O
expression	O
in	O
B16F10	B-Cell
cells	E-Cell
was	O
inhibited	O
by	O
the	O
infection	O
with	O
small	O
hairpin	O
(	O
sh	O
)	O
RNA	O
of	O
TB4	O
cloned	O
in	O
lentiviral	O
vector	O
,	O
tumor	B-Cell
cell	E-Cell
migration	O
was	O
retarded	O
.	O

In	O
addition	O
,	O
hypoxia	O
conditioning	O
-	O
induced	O
tumor	B-Cell
cell	E-Cell
migration	O
was	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
.	O

HIF	O
-	O
1alpha	O
stabilization	O
and	O
the	O
expression	O
of	O
VEGF	O
isoform	O
165	O
and	O
121	O
in	O
hypoxia	O
were	O
also	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
in	O
B16F10	B-Cell
cells	E-Cell
.	O

We	O
also	O
found	O
an	O
increase	O
of	O
tumor	S-Cancer
growth	O
and	O
lung	S-Organ
metastasis	O
count	O
in	O
TB4	O
-	O
Tg	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

Collectively	O
,	O
hypoxia	O
conditioning	O
induced	O
tumor	B-Cell
cell	E-Cell
migration	O
by	O
TB4	O
expression	O
-	O
dependent	O
HIF	O
-	O
1alpha	O
stabilization	O
.	O

It	O
suggests	O
that	O
TB4	O
could	O
be	O
a	O
hypoxia	O
responsive	O
regulator	O
to	O
control	O
tumor	B-Cell
cell	E-Cell
migration	O
in	O
angiogenesis	O
and	O
tumor	S-Cancer
metastasis	O
.	O

Androgen	O
stimulates	O
glycolysis	O
for	O
de	O
novo	O
lipid	O
synthesis	O
by	O
increasing	O
the	O
activities	O
of	O
hexokinase	O
2	O
and	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
2	O
in	O
prostate	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Up	O
-	O
regulation	O
of	O
lipogenesis	O
by	O
androgen	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
metabolic	O
features	O
of	O
LNCaP	B-Cell
prostate	I-Cell
cancer	I-Cell
cells	E-Cell
.	O

The	O
present	O
study	O
revealed	O
that	O
androgen	O
increases	O
glucose	O
utilization	O
for	O
de	O
novo	O
lipogenesis	O
in	O
LNCaP	B-Cell
cells	E-Cell
through	O
the	O
activation	O
of	O
HK2	O
(	O
hexokinase	O
2	O
)	O
and	O
activation	O
of	O
the	O
cardiac	S-Organ
isoform	O
of	O
PFKFB2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
)	O
.	O

Activation	O
of	O
PKA	O
(	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
)	O
by	O
androgen	O
increased	O
phosphorylation	O
of	O
CREB	O
[	O
CRE	O
(	O
cAMP	O
-	O
response	O
element	O
)	O
-	O
binding	O
protein	O
]	O
,	O
which	O
in	O
turn	O
bound	O
to	O
CRE	O
on	O
the	O
promoter	O
of	O
the	O
HK2	O
gene	O
resulting	O
in	O
transcriptional	O
activation	O
of	O
the	O
HK2	O
gene	O
.	O

Up	O
-	O
regulation	O
of	O
PFKFB2	O
expression	O
was	O
mediated	O
by	O
the	O
direct	O
binding	O
of	O
ligand	O
-	O
activated	O
androgen	O
receptor	O
to	O
the	O
PFKFB2	O
promoter	O
.	O

The	O
activated	O
PI3K	O
(	O
phosphoinositide	O
3	O
-	O
kinase	O
)	O
/	O
Akt	O
signalling	O
pathway	O
in	O
LNCaP	B-Cell
cells	E-Cell
contributes	O
to	O
the	O
phosphorylation	O
of	O
PFKFB2	O
at	O
Ser466	O
and	O
Ser483	O
,	O
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
PFK	O
-	O
2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
)	O
activity	O
.	O

Glucose	O
uptake	O
and	O
lipogenesis	O
were	O
severely	O
blocked	O
by	O
knocking	O
-	O
down	O
of	O
PFKFB2	O
using	O
siRNA	O
(	O
small	O
interfering	O
RNA	O
)	O
or	O
by	O
inhibition	O
of	O
PFK	O
-	O
2	O
activity	O
with	O
LY294002	O
treatment	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
de	O
novo	O
lipid	O
synthesis	O
by	O
androgen	O
requires	O
the	O
transcriptional	O
up	O
-	O
regulation	O
of	O
HK2	O
and	O
PFKFB2	O
,	O
and	O
phosphorylation	O
of	O
PFKFB2	O
generated	O
by	O
the	O
PI3K	O
/	O
Akt	O
signalling	O
pathway	O
to	O
supply	O
the	O
source	O
for	O
lipogenesis	O
from	O
glucose	O
in	O
prostate	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Influences	O
on	O
the	O
pharmacokinetics	O
of	O
oxycodone	O
:	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
in	O
439	O
adult	O
cancer	S-Cancer
patients	O
.	O

OBJECTIVE	O
:	O

Oxycodone	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
cancer	S-Cancer
pain	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
pharmacokinetics	O
in	O
cancer	S-Cancer
pain	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationships	O
between	O
ordinary	O
patient	O
characteristics	O
and	O
serum	S-Organism_substance
concentrations	O
of	O
oxycodone	O
and	O
the	O
ratios	O
noroxycodone	O
or	O
oxymorphone	O
/	O
oxycodone	O
in	O
cancer	S-Cancer
patients	O
.	O

METHODS	O
:	O

Four	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
using	O
oral	S-Organism_subdivision
oxycodone	O
for	O
cancer	S-Cancer
pain	O
were	O
included	O
.	O

The	O
patients	O
'	O
characteristics	O
(	O
sex	O
,	O
age	O
,	O
body	S-Organism_subdivision
mass	O
index	O
[	O
BMI	O
]	O
,	O
Karnofsky	O
performance	O
status	O
,	O
"	O
time	O
since	O
starting	O
opioids	O
"	O
,	O
"	O
oxycodone	O
total	O
daily	O
dose	O
"	O
,	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
,	O
use	O
of	O
CYP3A4	O
inducer	O
/	O
inhibitor	O
,	O
"	O
use	O
of	O
systemic	O
steroids	O
"	O
,	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
,	O
glomerular	S-Multi-tissue_structure
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
albumin	O
serum	S-Organism_substance
concentrations	O
)	O
influence	O
on	O
oxycodone	O
serum	S-Organism_substance
concentrations	O
or	O
metabolite	O
/	O
oxycodone	O
ratios	O
were	O
explored	O
by	O
multiple	O
regression	O
analyses	O
.	O

RESULTS	O
:	O

Sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
predicted	O
oxycodone	O
concentrations	O
.	O

CYP3A4	O
inducers	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
predicted	O
the	O
oxymorphone	O
/	O
oxycodone	O
ratio	O
.	O

Total	O
daily	O
dose	O
,	O
"	O
time	O
from	O
last	O
dose	O
to	O
blood	B-Organism_substance
sample	E-Organism_substance
"	O
,	O
albumin	O
,	O
sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
steroids	O
,	O
BMI	O
and	O
GFR	O
predicted	O
the	O
noroxycodone	O
/	O
oxycodone	O
ratio	O
.	O

CONCLUSION	O
:	O

Women	O
had	O
lower	O
oxycodone	O
serum	S-Organism_substance
concentrations	O
than	O
men	O
.	O

CYP3A4	O
inducers	O
/	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
as	O
these	O
are	O
predicted	O
to	O
have	O
a	O
significant	O
impact	O
on	O
oxycodone	O
pharmacokinetics	O
.	O

Other	O
characteristics	O
explained	O
only	O
minor	O
parts	O
of	O
the	O
variability	O
of	O
the	O
outcomes	O
.	O

Geometric	O
correlations	O
and	O
breakdown	O
of	O
mesoscopic	O
universality	O
in	O
spin	O
transport	O
.	O

We	O
construct	O
a	O
unified	O
semiclassical	O
theory	O
of	O
charge	O
and	O
spin	O
transport	O
in	O
chaotic	O
ballistic	O
and	O
disordered	O
diffusive	O
mesoscopic	O
systems	O
with	O
spin	O
-	O
orbit	O
interaction	O
.	O

Neglecting	O
dynamic	O
effects	O
of	O
spin	O
-	O
orbit	O
interaction	O
,	O
we	O
reproduce	O
the	O
random	O
matrix	O
theory	O
results	O
that	O
the	O
spin	O
conductance	O
fluctuates	O
universally	O
around	O
zero	O
average	O
.	O

Incorporating	O
these	O
effects	O
into	O
the	O
theory	O
,	O
we	O
show	O
that	O
geometric	O
correlations	O
generate	O
finite	O
average	O
spin	O
conductances	O
,	O
but	O
that	O
they	O
do	O
not	O
affect	O
the	O
charge	O
conductance	O
to	O
leading	O
order	O
.	O

The	O
theory	O
,	O
which	O
is	O
confirmed	O
by	O
numerical	O
transport	O
calculations	O
,	O
allows	O
us	O
to	O
investigate	O
the	O
entire	O
range	O
from	O
the	O
weak	O
to	O
the	O
previously	O
unexplored	O
strong	O
spin	O
-	O
orbit	O
regime	O
,	O
where	O
the	O
spin	O
rotation	O
time	O
is	O
shorter	O
than	O
the	O
momentum	O
relaxation	O
time	O
.	O

Development	O
and	O
validation	O
of	O
an	O
approach	O
to	O
produce	O
large	O
-	O
scale	O
quantities	O
of	O
CpG	O
-	O
methylated	O
plasmid	S-Cellular_component
DNA	O
.	O

The	O
prokaryotic	O
CpG	O
-	O
specific	O
DNA	O
methylase	O
from	O
Spiroplasma	O
,	O
SssI	O
methylase	O
,	O
has	O
been	O
extensively	O
used	O
to	O
methylate	O
plasmid	S-Cellular_component
DNA	O
in	O
vitro	O
to	O
investigate	O
the	O
effects	O
of	O
methylation	O
in	O
vertebrate	O
systems	O
.	O

Currently	O
available	O
methods	O
to	O
produce	O
CpG	O
-	O
methylated	O
plasmid	S-Cellular_component
DNA	O
have	O
certain	O
limitations	O
and	O
cannot	O
generate	O
large	O
quantities	O
of	O
methylated	O
DNA	O
without	O
cost	O
or	O
problems	O
of	O
purity	O
.	O

Here	O
we	O
describe	O
an	O
approach	O
in	O
which	O
the	O
SssI	O
methylase	O
gene	O
has	O
been	O
introduced	O
into	O
the	O
Escherichia	O
coli	O
bacterial	O
genome	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Plasmid	S-Cellular_component
DNA	O
propagated	O
in	O
this	O
bacterium	O
under	O
conditions	O
which	O
induce	O
the	O
methylase	O
gene	O
result	O
in	O
significant	O
(	O
>	O
90	O
%	O
)	O
CpG	O
methylation	O
.	O

Methylated	O
DNA	O
produced	O
by	O
this	O
approach	O
behaves	O
similarly	O
to	O
methylated	O
DNA	O
produced	O
in	O
vitro	O
using	O
the	O
purified	O
methylase	O
.	O

The	O
approach	O
is	O
scalable	O
allowing	O
for	O
the	O
production	O
of	O
milligram	O
quantities	O
of	O
methylated	O
plasmid	S-Cellular_component
DNA	O
.	O

Diallyl	O
trisulfide	O
(	O
DATS	O
)	O
inhibits	O
mouse	O
colon	B-Cancer
tumor	E-Cancer
in	O
mouse	O
CT	B-Cell
-	I-Cell
26	I-Cell
cells	E-Cell
allograft	O
model	O
in	O
vivo	O
.	O

Our	O
earlier	O
studies	O
showed	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
human	O
colon	B-Cell
cancer	I-Cell
HT29	E-Cell
and	O
colo	B-Cell
205	I-Cell
cell	I-Cell
lines	E-Cell
in	O
vitro	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
to	O
show	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
vitro	O
and	O
inhibited	O
CT26	B-Cell
cancer	I-Cell
cells	E-Cell
in	O
vivo	O
on	O
a	O
murine	O
allograft	O
animal	O
model	O
.	O

In	O
vitro	O
studies	O
,	O
the	O
results	O
indicated	O
that	O
DATS	O
induced	O
morphological	O
changes	O
and	O
induction	O
of	O
apoptosis	O
in	O
CT26	B-Cell
cells	E-Cell
.	O

In	O
vivo	O
studies	O
,	O
CT26	B-Cell
cancer	I-Cell
cells	E-Cell
were	O
implanted	O
into	O
BALB	O
/	O
c	O
mice	O
and	O
groups	O
of	O
mice	O
were	O
treated	O
with	O
vehicle	O
,	O
DATS	O
(	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
body	S-Organism_subdivision
weight	O
)	O
.	O

DATS	O
were	O
injected	O
once	O
per	O
four	O
days	O
intraperitoneally	S-Immaterial_anatomical_entity
(	O
i	O
.	O
p	O
.	O
)	O
,	O
with	O
treatment	O
starting	O
4	O
weeks	O
prior	O
to	O
cells	S-Cell
inoculation	O
.	O

Treatment	O
with	O
vehicle	O
or	O
with	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
DATS	O
resulted	O
in	O
a	O
reduction	O
in	O
tumor	S-Cancer
volume	O
and	O
weight	O
.	O

Tumor	S-Cancer
volume	O
and	O
total	O
hemoglobin	O
in	O
allograft	O
mice	O
treated	O
with	O
50	O
mg	O
/	O
kg	O
DATS	O
were	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

These	O
findings	O
indicated	O
that	O
DATS	O
inhibits	O
tumor	S-Cancer
growth	O
in	O
an	O
allograft	O
animal	O
model	O
.	O

Thus	O
,	O
DATS	O
may	O
represent	O
a	O
colon	B-Cancer
cancer	E-Cancer
preventive	O
agent	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
.	O

High	O
-	O
mobility	O
group	O
A2	O
protein	O
modulates	O
hTERT	O
transcription	O
to	O
promote	O
tumorigenesis	O
.	O

The	O
high	O
-	O
mobility	O
group	O
A2	O
gene	O
(	O
HMGA2	O
)	O
is	O
one	O
of	O
the	O
most	O
frequently	O
amplified	O
genes	O
in	O
human	O
cancers	S-Cancer
.	O

However	O
,	O
functions	O
of	O
HMGA2	O
in	O
tumorigenesis	O
are	O
not	O
fully	O
understood	O
due	O
to	O
limited	O
knowledge	O
of	O
its	O
targets	O
in	O
tumor	B-Cell
cells	E-Cell
.	O

Our	O
study	O
reveals	O
a	O
novel	O
link	O
between	O
HMGA2	O
and	O
the	O
regulation	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
,	O
the	O
catalytic	O
subunit	O
of	O
telomerase	O
,	O
which	O
offers	O
critical	O
insight	O
into	O
how	O
HMGA2	O
contributes	O
to	O
tumorigenesis	O
.	O

The	O
expression	O
of	O
HMGA2	O
modulates	O
the	O
expression	O
of	O
hTERT	O
,	O
resulting	O
in	O
cells	S-Cell
with	O
enhanced	O
telomerase	O
activities	O
and	O
increased	O
telomere	S-Cellular_component
length	O
.	O

Treatment	O
with	O
suberoylanilide	O
hydroxamide	O
(	O
SAHA	O
)	O
,	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
,	O
causes	O
dose	O
-	O
dependent	O
hTERT	O
reporter	O
activation	O
,	O
mimicking	O
HMGA2	O
overexpression	O
.	O

By	O
interacting	O
with	O
Sp1	O
,	O
HMGA2	O
interferes	O
with	O
the	O
recruitment	O
of	O
HDAC2	O
to	O
the	O
hTERT	O
proximal	O
promoter	O
,	O
enhancing	O
localized	O
histone	O
H3	O
-	O
K9	O
acetylation	O
and	O
thereby	O
stimulating	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
.	O

Moreover	O
,	O
HMGA2	O
knockdown	O
by	O
short	O
hairpin	O
HMGA2	O
in	O
HepG2	B-Cell
cells	E-Cell
leads	O
to	O
progressive	O
telomere	S-Cellular_component
shortening	O
and	O
a	O
concurrent	O
decrease	O
of	O
steady	O
-	O
state	O
hTERT	O
mRNA	O
levels	O
,	O
attenuating	O
their	O
ability	O
to	O
form	O
colonies	S-Cell
in	O
soft	O
agar	O
.	O

Importantly	O
,	O
HMGA2	O
partially	O
replaces	O
the	O
function	O
of	O
hTERT	O
during	O
the	O
tumorigenic	O
transformation	O
of	O
normal	O
human	O
fibroblasts	S-Cell
.	O

These	O
findings	O
are	O
potentially	O
clinically	O
relevant	O
,	O
because	O
HMGA2	O
expression	O
is	O
reported	O
to	O
be	O
upregulated	O
in	O
a	O
number	O
of	O
human	O
cancers	S-Cancer
as	O
telomere	S-Cellular_component
maintenance	O
is	O
essential	O
for	O
tumorigenesis	O
.	O

Hedgehog	O
signaling	O
:	O
networking	O
to	O
nurture	O
a	O
promalignant	B-Cancer
tumor	E-Cancer
microenvironment	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
embryonic	S-Developing_anatomical_structure
development	O
,	O
the	O
Hedgehog	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
participant	O
in	O
cancer	S-Cancer
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

Although	O
this	O
pathway	O
is	O
activated	O
by	O
autocrine	O
signaling	O
by	O
Hedgehog	O
ligands	O
,	O
it	O
can	O
also	O
initiate	O
paracrine	O
signaling	O
with	O
cells	S-Cell
in	O
the	O
microenvironment	O
.	O

This	O
creates	O
a	O
network	O
of	O
Hedgehog	O
signaling	O
that	O
determines	O
the	O
malignant	O
behavior	O
of	O
the	O
tumor	B-Cell
cells	E-Cell
.	O

As	O
a	O
result	O
of	O
paracrine	O
signal	O
transmission	O
,	O
the	O
effects	O
of	O
Hedgehog	O
signaling	O
most	O
profoundly	O
influence	O
the	O
stromal	B-Cell
cells	E-Cell
that	O
constitute	O
the	O
tumor	S-Cancer
microenvironment	O
.	O

The	O
stromal	B-Cell
cells	E-Cell
in	O
turn	O
produce	O
factors	O
that	O
nurture	O
the	O
tumor	S-Cancer
.	O

Thus	O
,	O
such	O
a	O
resonating	O
cross	O
-	O
talk	O
can	O
amplify	O
Hedgehog	O
signaling	O
,	O
resulting	O
in	O
molecular	O
chatter	O
that	O
overall	O
promotes	O
tumor	S-Cancer
progression	O
.	O

Inhibitors	O
of	O
Hedgehog	O
signaling	O
have	O
been	O
the	O
subject	O
of	O
intense	O
research	O
.	O

Several	O
of	O
these	O
inhibitors	O
are	O
currently	O
being	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
review	O
the	O
role	O
of	O
the	O
Hedgehog	O
pathway	O
in	O
the	O
signature	O
characteristics	O
of	O
cancer	B-Cell
cells	E-Cell
that	O
determine	O
tumor	S-Cancer
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

This	O
review	O
condenses	O
the	O
latest	O
findings	O
on	O
the	O
signaling	O
pathways	O
that	O
are	O
activated	O
and	O
/	O
or	O
regulated	O
by	O
molecules	O
generated	O
from	O
Hedgehog	O
signaling	O
in	O
cancer	S-Cancer
and	O
cites	O
promising	O
clinical	O
interventions	O
.	O

Finally	O
,	O
we	O
discuss	O
future	O
directions	O
for	O
identifying	O
the	O
appropriate	O
patients	O
for	O
therapy	O
,	O
developing	O
reliable	O
markers	O
of	O
efficacy	O
of	O
treatment	O
,	O
and	O
combating	O
resistance	O
to	O
Hedgehog	O
pathway	O
inhibitors	O
.	O

Analysis	O
of	O
molecular	O
aberrations	O
of	O
Wnt	O
pathway	O
gladiators	O
in	O
colorectal	B-Cancer
cancer	E-Cancer
in	O
the	O
Kashmiri	O
population	O
.	O

The	O
development	O
and	O
progression	O
of	O
colorectal	B-Cancer
cancer	E-Cancer
(	O
CRC	S-Cancer
)	O
is	O
a	O
multi	O
-	O
step	O
process	O
,	O
and	O
the	O
Wnt	O
pathways	O
with	O
its	O
two	O
molecular	O
gladiators	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
transforming	O
a	O
normal	O
tissue	S-Tissue
into	O
a	O
malignant	B-Cancer
one	E-Cancer
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
aberrations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
the	O
pathogenesis	O
of	O
CRC	S-Cancer
in	O
the	O
Kashmir	O
valley	O
,	O
and	O
to	O
correlate	O
it	O
with	O
various	O
clinicopathological	O
variables	O
.	O

We	O
examined	O
the	O
paired	O
tumour	S-Cancer
and	O
normal	O
-	O
tissue	B-Tissue
specimens	E-Tissue
of	O
86	O
CRC	S-Cancer
patients	O
for	O
the	O
occurrence	O
of	O
aberrations	O
in	O
the	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
of	O
the	O
APC	O
gene	O
and	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
/	O
or	O
PCR	O
-	O
direct	O
sequencing	O
.	O

Analysis	O
of	O
promoter	O
hypermethylation	O
of	O
the	O
APC	O
gene	O
was	O
also	O
carried	O
out	O
using	O
methylation	O
-	O
specific	O
PCR	O
(	O
MS	O
-	O
PCR	O
)	O
.	O

The	O
overall	O
mutation	O
rate	O
of	O
the	O
MCR	O
of	O
the	O
APC	O
gene	O
among	O
86	O
CRC	S-Cancer
cases	O
was	O
12	O
.	O
8	O
per	O
cent	O
(	O
11	O
of	O
86	O
)	O
.	O

Promoter	O
hypermethylation	O
of	O
APC	O
was	O
observed	O
in	O
54	O
.	O
65	O
per	O
cent	O
(	O
47	O
of	O
86	O
)	O
of	O
cases	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
significant	O
association	O
between	O
tumour	S-Cancer
location	O
,	O
tumour	S-Cancer
grade	O
and	O
node	S-Multi-tissue_structure
status	O
and	O
the	O
methylation	O
status	O
of	O
the	O
APC	O
gene	O
(	O
p	O
<	O
=	O
0	O
.	O
05	O
)	O
.	O

Although	O
the	O
number	O
of	O
mutations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
our	O
CRC	S-Cancer
cases	O
was	O
very	O
low	O
,	O
the	O
study	O
confirms	O
the	O
role	O
of	O
epigenetic	O
gene	O
silencing	O
of	O
the	O
pivotal	O
molecular	O
gladiator	O
,	O
APC	O
,	O
of	O
the	O
Wnt	O
pathway	O
in	O
the	O
development	O
of	O
CRC	S-Cancer
in	O
the	O
Kashmiri	O
population	O
.	O

Aglycon	O
of	O
rhizochalin	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
apoptosis	O
via	O
activation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
in	O
HT	B-Cell
-	I-Cell
29	I-Cell
colon	I-Cell
cancer	I-Cell
cells	E-Cell
.	O

Rhizochalin	O
is	O
a	O
two	O
-	O
headed	O
sphingolipid	O
-	O
like	O
compound	O
isolated	O
from	O
the	O
sponge	O
Rhizochalina	O
incrustata	O
.	O

It	O
has	O
been	O
reported	O
that	O
rhizocalin	O
and	O
its	O
derivates	O
have	O
a	O
chemopreventive	O
and	O
chemotherapeutic	O
effect	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
these	O
effects	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
aglycon	O
of	O
rhizochalin	O
(	O
AglRhz	O
)	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
phosphorylation	O
,	O
and	O
thereby	O
inhibits	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
-	O
p70S6	O
kinase	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
signaling	O
and	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
activity	O
via	O
phosphorylation	O
of	O
Raptor	O
in	O
HT	B-Cell
-	I-Cell
29	I-Cell
cells	E-Cell
.	O

In	O
addition	O
,	O
AglRhz	O
induced	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
and	O
DNA	O
fragmentation	O
in	O
HT	B-Cell
-	I-Cell
29	I-Cell
cells	E-Cell
,	O
leads	O
to	O
induction	O
of	O
apoptosis	O
as	O
well	O
as	O
suppression	O
of	O
tumorigenicity	O
of	O
HT	B-Cell
-	I-Cell
29	I-Cell
cells	E-Cell
.	O

Notably	O
,	O
AglRhz	O
inhibits	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-	O
1	O
-	O
induced	O
AP	O
-	O
1	O
activity	O
and	O
cell	S-Cell
transformation	O
in	O
JB6	B-Cell
Cl41	I-Cell
cells	E-Cell
.	O

Overall	O
,	O
our	O
findings	O
identify	O
AMPK	O
as	O
an	O
important	O
target	O
protein	O
for	O
mediating	O
the	O
anti	O
-	O
tumor	S-Cancer
properties	O
of	O
AglRhz	O
in	O
HT	B-Cell
-	I-Cell
29	I-Cell
colon	I-Cell
cancer	I-Cell
cells	E-Cell
and	O
have	O
important	O
implication	O
for	O
sponges	O
,	O
the	O
most	O
important	O
marine	O
source	O
,	O
in	O
colon	B-Cancer
cancer	E-Cancer
.	O

Expression	O
of	O
thymidylate	O
synthase	O
and	O
dihydropyrimidine	O
dehydrogenase	O
in	O
primary	B-Cancer
oral	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	E-Cancer
and	O
corresponding	O
metastases	S-Cancer
in	O
cervical	B-Multi-tissue_structure
lymph	I-Multi-tissue_structure
nodes	E-Multi-tissue_structure
:	O
association	O
with	O
the	O
metastasis	O
suppressor	O
CD82	O
.	O

Thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
are	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
metabolizing	O
enzymes	O
and	O
are	O
involved	O
in	O
the	O
sensitivity	O
of	O
carcinoma	S-Cancer
patients	O
to	O
5	O
-	O
FU	O
.	O

Although	O
5	O
-	O
FU	O
is	O
often	O
used	O
for	O
the	O
treatment	O
of	O
oral	B-Cancer
carcinoma	E-Cancer
,	O
there	O
has	O
not	O
been	O
any	O
investigation	O
into	O
the	O
expression	O
of	O
these	O
enzymes	O
in	O
metastatic	B-Multi-tissue_structure
lymph	I-Multi-tissue_structure
nodes	E-Multi-tissue_structure
or	O
of	O
their	O
roles	O
in	O
the	O
effectiveness	O
of	O
5	O
-	O
FU	O
in	O
treating	O
lymph	B-Cancer
node	I-Cancer
-	I-Cancer
metastatic	I-Cancer
cancer	E-Cancer
.	O

Oral	B-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	E-Cancer
(	O
OSCC	S-Cancer
)	O
often	O
metastasizes	O
to	O
the	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
,	O
and	O
these	O
enzymes	O
may	O
be	O
significant	O
in	O
the	O
survival	O
of	O
patients	O
with	O
this	O
disease	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
TS	O
and	O
DPD	O
in	O
cervical	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	E-Cancer
and	O
its	O
relationship	O
with	O
primary	B-Cancer
OSCC	E-Cancer
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
these	O
enzymes	O
and	O
Kangai	O
1	O
(	O
KAI1	O
/	O
CD82	O
)	O
which	O
is	O
a	O
metastasis	O
suppressor	O
protein	O
.	O

Surgical	B-Cancer
specimens	E-Cancer
from	O
20	O
cases	O
of	O
OSCC	S-Cancer
with	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
,	O
20	O
cases	O
of	O
OSCC	S-Cancer
without	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
,	O
and	O
10	O
cases	O
of	O
normal	O
mucosa	S-Multi-tissue_structure
were	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
relationship	O
between	O
TS	O
and	O
DPD	O
expression	O
and	O
clinicopathological	O
data	O
was	O
analyzed	O
.	O

TS	O
and	O
DPD	O
proteins	O
were	O
overexpressed	O
in	O
primary	B-Cancer
OSCC	E-Cancer
compared	O
to	O
that	O
in	O
normal	O
mucosa	S-Multi-tissue_structure
.	O

TS	O
expression	O
of	O
the	O
primary	B-Cell
oral	I-Cell
cancer	I-Cell
cells	E-Cell
in	O
the	O
group	O
with	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
was	O
higher	O
than	O
that	O
of	O
those	O
without	O
.	O

DPD	O
expression	O
did	O
not	O
significantly	O
correlate	O
with	O
the	O
occurrence	O
of	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
,	O
nor	O
was	O
it	O
different	O
between	O
primary	B-Cell
oral	I-Cell
cancer	I-Cell
cells	E-Cell
and	O
cervical	B-Cancer
metastases	E-Cancer
.	O

CD82	O
expression	O
was	O
significantly	O
reduced	O
in	O
lymph	B-Cancer
node	I-Cancer
metastases	E-Cancer
.	O

These	O
findings	O
indicate	O
that	O
TS	O
and	O
CD82	O
may	O
be	O
of	O
great	O
value	O
in	O
assessing	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
of	O
OSCC	S-Cancer
,	O
and	O
could	O
be	O
taken	O
as	O
new	O
targets	O
for	O
therapy	O
of	O
metastatic	B-Cancer
OSCC	E-Cancer
.	O

Impaired	O
CK1	O
delta	O
activity	O
attenuates	O
SV40	O
-	O
induced	O
cellular	S-Cell
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	S-Organ
carcinogenesis	O
in	O
vivo	O
.	O

Simian	O
virus	O
40	O
(	O
SV40	O
)	O
is	O
a	O
powerful	O
tool	O
to	O
study	O
cellular	S-Cell
transformation	O
in	O
vitro	O
,	O
as	O
well	O
as	O
tumor	S-Cancer
development	O
and	O
progression	O
in	O
vivo	O
.	O

Various	O
cellular	S-Cell
kinases	O
,	O
among	O
them	O
members	O
of	O
the	O
CK1	O
family	O
,	O
play	O
an	O
important	O
role	O
in	O
modulating	O
the	O
transforming	O
activity	O
of	O
SV40	O
,	O
including	O
the	O
transforming	O
activity	O
of	O
T	O
-	O
Ag	O
,	O
the	O
major	O
transforming	O
protein	O
of	O
SV40	O
,	O
itself	O
.	O

Here	O
we	O
characterized	O
the	O
effects	O
of	O
mutant	O
CK1delta	O
variants	O
with	O
impaired	O
kinase	O
activity	O
on	O
SV40	O
-	O
induced	O
cell	S-Cell
transformation	O
in	O
vitro	O
,	O
and	O
on	O
SV40	O
-	O
induced	O
mammary	S-Organ
carcinogenesis	O
in	O
vivo	O
in	O
a	O
transgenic	O
/	O
bi	O
-	O
transgenic	O
mouse	O
model	O
.	O

CK1delta	O
mutants	O
exhibited	O
a	O
reduced	O
kinase	O
activity	O
compared	O
to	O
wtCK1delta	O
in	O
in	O
vitro	O
kinase	O
assays	O
.	O

Molecular	O
modeling	O
studies	O
suggested	O
that	O
mutation	O
N172D	O
,	O
located	O
within	O
the	O
substrate	O
binding	O
region	O
,	O
is	O
mainly	O
responsible	O
for	O
impaired	O
mutCK1delta	O
activity	O
.	O

When	O
stably	O
over	O
-	O
expressed	O
in	O
maximal	O
transformed	O
SV	B-Cell
-	I-Cell
52	I-Cell
cells	E-Cell
,	O
CK1delta	O
mutants	O
induced	O
reversion	O
to	O
a	O
minimal	O
transformed	O
phenotype	O
by	O
dominant	O
-	O
negative	O
interference	O
with	O
endogenous	O
wtCK1delta	O
.	O

To	O
characterize	O
the	O
effects	O
of	O
CK1delta	O
on	O
SV40	O
-	O
induced	O
mammary	S-Organ
carcinogenesis	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
mutant	O
CK1delta	O
under	O
the	O
control	O
of	O
the	O
whey	O
acidic	O
protein	O
(	O
WAP	O
)	O
gene	O
promoter	O
,	O
and	O
crossed	O
them	O
with	O
SV40	O
transgenic	O
WAP	O
-	O
T	O
-	O
antigen	O
(	O
WAP	O
-	O
T	O
)	O
mice	O
.	O

Both	O
WAP	O
-	O
T	O
mice	O
as	O
well	O
as	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
mice	O
developed	O
breast	B-Cancer
cancer	E-Cancer
.	O

However	O
,	O
tumor	S-Cancer
incidence	O
was	O
lower	O
and	O
life	O
span	O
was	O
significantly	O
longer	O
in	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
animals	O
.	O

The	O
reduced	O
CK1delta	O
activity	O
did	O
not	O
affect	O
early	O
lesion	S-Pathological_formation
formation	O
during	O
tumorigenesis	O
,	O
suggesting	O
that	O
impaired	O
CK1delta	O
activity	O
reduces	O
the	O
probability	O
for	O
outgrowth	O
of	O
in	B-Cancer
situ	I-Cancer
carcinomas	E-Cancer
to	O
invasive	B-Cancer
carcinomas	E-Cancer
.	O

The	O
different	O
tumorigenic	O
potential	O
of	O
SV40	O
in	O
WAP	O
-	O
T	O
and	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
tumors	S-Cancer
was	O
also	O
reflected	O
by	O
a	O
significantly	O
different	O
expression	O
of	O
various	O
genes	O
known	O
to	O
be	O
involved	O
in	O
tumor	S-Cancer
progression	O
,	O
specifically	O
of	O
those	O
involved	O
in	O
wnt	O
-	O
signaling	O
and	O
DNA	O
repair	O
.	O

Our	O
data	O
show	O
that	O
inactivating	O
mutations	O
in	O
CK1delta	O
impair	O
SV40	O
-	O
induced	O
cellular	S-Cell
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	S-Organ
carcinogenesis	O
in	O
vivo	O
.	O

Amplification	O
of	O
mineralocorticoid	O
activity	O
of	O
aldosterone	O
by	O
18	O
-	O
hydroxy	O
-	O
corticosterone	O
and	O
18	O
-	O
hydroxy	O
-	O
19	O
-	O
nor	O
-	O
corticosterone	O
in	O
adrenalectomized	O
rats	O
.	O

A	O
combination	O
of	O
aldosterone	O
(	O
1	O
micrograms	O
)	O
with	O
either	O
18	O
-	O
OH	O
-	O
corticosterone	O
(	O
1	O
micrograms	O
)	O
or	O
18	O
-	O
OH	O
-	O
19	O
-	O
norcorticosterone	O
(	O
1	O
micrograms	O
)	O
injected	O
to	O
adrenalectomized	O
rats	O
indicated	O
an	O
amplification	O
of	O
mineralocorticoid	O
activity	O
as	O
expressed	O
by	O
Na	O
/	O
K	O
ratio	O
in	O
urine	S-Organism_substance
.	O

Without	O
aldosterone	O
their	O
mineralocorticoid	O
potency	O
was	O
negligible	O
.	O

Osteonectin	O
transcript	O
and	O
metastatic	O
behavior	O
in	O
v	O
-	O
Ki	O
-	O
ras	O
transformed	O
fibroblasts	S-Cell
.	O

Osteonectin	O
is	O
one	O
of	O
the	O
major	O
non	O
-	O
collagenous	O
proteins	O
of	O
bone	S-Tissue
.	O

However	O
,	O
its	O
transcript	O
has	O
been	O
found	O
in	O
many	O
soft	B-Tissue
,	I-Tissue
extracellular	I-Tissue
matrix	I-Tissue
-	I-Tissue
producing	I-Tissue
tissues	E-Tissue
;	O
an	O
osteonectin	O
-	O
related	O
protein	O
was	O
detected	O
in	O
tumor	B-Cellular_component
basement	I-Cellular_component
membrane	E-Cellular_component
.	O

We	O
have	O
investigated	O
the	O
expression	O
of	O
osteonectin	O
gene	O
in	O
fresh	O
BALB	B-Cell
/	I-Cell
c	I-Cell
fibroblasts	E-Cell
transformed	O
by	O
v	O
-	O
Ki	O
-	O
ras	O
.	O

Transformed	O
cells	S-Cell
exhibited	O
lower	O
levels	O
of	O
RNA	O
as	O
compared	O
with	O
normal	O
fibroblasts	S-Cell
.	O

The	O
transformed	O
cells	S-Cell
were	O
cloned	O
after	O
in	O
vivo	O
tumorigenic	O
assay	O
,	O
and	O
4	O
clones	S-Cell
were	O
analyzed	O
for	O
osteonectin	O
expression	O
by	O
Northern	O
blots	O
.	O

Two	O
of	O
them	O
were	O
selected	O
for	O
high	O
or	O
low	O
osteonectin	O
expression	O
and	O
tested	O
in	O
vivo	O
in	O
spontaneous	O
and	O
artificial	O
metastasis	O
assays	O
.	O

High	O
osteonectin	O
expression	O
was	O
correlated	O
with	O
high	O
lung	S-Organ
colonization	O
.	O

When	O
10	O
(	O
5	O
)	O
cells	S-Cell
were	O
injected	O
i	B-Immaterial_anatomical_entity
.	I-Immaterial_anatomical_entity
v	I-Immaterial_anatomical_entity
.	E-Immaterial_anatomical_entity
,	O
median	O
colony	S-Cell
value	O
was	O
55	O
and	O
20	O
in	O
higher	O
expressor	O
vs	O
.	O
lower	O
expressor	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Spontaneous	O
metastasis	O
indicates	O
a	O
possible	O
reverse	O
correlation	O
.	O

Our	O
data	O
align	O
osteonectin	O
with	O
other	O
matrix	S-Cellular_component
-	O
components	O
and	O
adhesion	O
molecules	O
in	O
affecting	O
potential	O
metastatic	O
spreading	O
of	O
transformed	O
cells	S-Cell
.	O

[	O
Intraepithelial	B-Cancer
neoplasm	E-Cancer
of	O
the	O
uterine	B-Multi-tissue_structure
cervix	E-Multi-tissue_structure
and	O
angiogenesis	O
:	O
morphologic	O
study	O
]	O

Thirty	O
uterine	B-Multi-tissue_structure
cervix	I-Multi-tissue_structure
specimens	E-Multi-tissue_structure
sampled	O
following	O
conization	O
or	O
total	O
hysterectomy	O
were	O
studied	O
using	O
histology	O
,	O
histoenzymology	O
(	O
vessel	S-Multi-tissue_structure
phosphatase	O
alkaline	O
activity	O
)	O
,	O
and	O
immunohistochemistry	O
(	O
demonstration	O
of	O
laminin	O
and	O
type	O
IV	O
collagen	O
in	O
epithelium	S-Tissue
and	O
vessel	B-Cellular_component
basement	I-Cellular_component
membranes	E-Cellular_component
)	O
.	O

Pathologic	O
conditions	O
included	O
dystrophia	O
,	O
moderate	O
dysplasia	S-Pathological_formation
,	O
severe	O
dysplasia	S-Pathological_formation
,	O
and	O
intraepithelial	B-Cancer
carcinoma	E-Cancer
.	O

Results	O
were	O
compared	O
to	O
findings	O
in	O
a	O
control	O
group	O
.	O

We	O
found	O
that	O
the	O
severity	O
of	O
vascular	S-Multi-tissue_structure
abnormalities	O
correlated	O
positively	O
with	O
the	O
severity	O
of	O
histologic	O
epithelial	B-Pathological_formation
lesions	E-Pathological_formation
;	O
this	O
finding	O
is	O
consistent	O
with	O
colposcopic	O
results	O
.	O

Anarchic	O
angiogenesis	O
with	O
large	O
,	O
moniliform	O
,	O
tortuous	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
was	O
seen	O
in	O
severe	O
dysplasias	O
and	O
carcinomas	S-Cancer
.	O

The	O
vascular	S-Multi-tissue_structure
anomalies	O
seem	O
to	O
precede	O
the	O
development	O
of	O
histologic	B-Pathological_formation
lesions	E-Pathological_formation
in	O
some	O
instances	O
.	O

Histogenesis	O
of	O
the	O
abnormal	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
may	O
involve	O
production	O
of	O
an	O
angiogenic	O
factor	O
by	O
the	O
cancerized	B-Tissue
epithelia	E-Tissue
.	O

Glycolysis	O
and	O
glutaminolysis	O
in	O
perifused	O
Ehrlich	B-Cell
ascites	I-Cell
tumour	I-Cell
cells	E-Cell
.	O

A	O
perifusion	O
system	O
was	O
designed	O
in	O
order	O
to	O
study	O
glucose	O
and	O
glutamine	O
metabolism	O
by	O
freshly	O
harvested	O
Ehrlich	B-Cell
ascites	I-Cell
tumour	I-Cell
cells	E-Cell
in	O
steady	O
state	O
conditions	O
.	O

Cells	S-Cell
were	O
perifused	O
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
,	O
0	O
.	O
5	O
mM	O
glutamine	O
or	O
5	O
mM	O
glucose	O
and	O
0	O
.	O
5	O
mM	O
glutamine	O
.	O

The	O
results	O
in	O
steady	O
state	O
reveal	O
that	O
both	O
substrates	O
glucose	O
and	O
glutamine	O
are	O
continuously	O
wasted	O
by	O
tumour	B-Cell
cells	E-Cell
,	O
excreting	O
two	O
moles	O
of	O
lactate	O
per	O
mol	O
of	O
glucose	O
and	O
one	O
mol	O
of	O
glutamate	O
and	O
ammonia	O
per	O
mol	O
of	O
glutamine	O
consumed	O
into	O
the	O
medium	O
.	O

Glutamine	O
consumption	O
in	O
the	O
presence	O
of	O
glucose	O
was	O
higher	O
than	O
with	O
glutamine	O
alone	O
.	O

Phase	O
II	O
trial	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
in	O
prostatic	B-Cancer
carcinoma	E-Cancer
:	O
comparison	O
with	O
other	O
hormonal	O
agents	O
.	O

Various	O
approaches	O
to	O
hormonal	O
treatment	O
of	O
prostate	B-Cancer
carcinoma	E-Cancer
are	O
discussed	O
.	O

Eighty	O
-	O
one	O
patients	O
with	O
prostatic	B-Cancer
carcinoma	E-Cancer
,	O
eight	O
with	O
stage	O
B	O
,	O
nine	O
with	O
stage	O
C	O
,	O
and	O
64	O
with	O
stage	O
D	O
disease	O
,	O
were	O
treated	O
subcutaneously	S-Immaterial_anatomical_entity
daily	O
for	O
3	O
months	O
with	O
the	O
LH	O
-	O
RH	O
agonist	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
Decapeptyl	O
)	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
remissions	O
according	O
to	O
WHO	O
recommendations	O
for	O
oncologic	O
trials	O
.	O

The	O
findings	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
other	O
hormonal	O
therapies	O
of	O
prostatic	B-Cancer
carcinoma	E-Cancer
according	O
to	O
the	O
statistical	O
method	O
of	O
"	O
expected	O
response	O
rate	O
"	O
as	O
adapted	O
by	O
Lee	O
and	O
Wesley	O
for	O
phase	O
II	O
trials	O
.	O

Treatment	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
greatly	O
reduced	O
serum	S-Organism_substance
LH	O
and	O
testosterone	O
levels	O
without	O
raising	O
serum	S-Organism_substance
prolactin	O
.	O

After	O
1	O
-	O
2	O
weeks	O
of	O
therapy	O
,	O
there	O
was	O
relief	O
of	O
subjective	O
symptoms	O
and	O
a	O
reversal	O
of	O
the	O
signs	O
of	O
prostatism	O
as	O
well	O
as	O
a	O
marked	O
decrease	O
in	O
bone	S-Organ
pain	O
.	O

At	O
90	O
days	O
52	O
patients	O
had	O
complete	O
relief	O
of	O
prostatism	O
and	O
21	O
had	O
only	O
mild	O
signs	O
and	O
symptoms	O
.	O

Seventy	O
patients	O
were	O
experiencing	O
no	O
bone	S-Organ
pain	O
and	O
an	O
additional	O
six	O
had	O
only	O
mild	O
pain	O
.	O

Prostatic	S-Organ
size	O
,	O
evaluated	O
by	O
rectal	O
examination	O
and	O
transabdominal	S-Organism_subdivision
ultrasonography	O
,	O
reverted	O
to	O
normal	O
in	O
26	O
.	O
4	O
%	O
of	O
patients	O
(	O
complete	O
remission	O
)	O
and	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
in	O
an	O
additional	O
17	O
.	O
6	O
%	O
(	O
partial	O
remission	O
)	O
,	O
the	O
overall	O
rate	O
of	O
complete	O
plus	O
partial	O
regression	O
of	O
prostatic	S-Organ
enlargement	O
being	O
44	O
%	O
.	O

Scans	O
showed	O
a	O
major	O
improvement	O
of	O
bone	B-Cancer
lesions	E-Cancer
in	O
14	O
.	O
8	O
%	O
of	O
cases	O
.	O

This	O
response	O
increased	O
to	O
37	O
%	O
after	O
more	O
than	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O

Prostatic	S-Organ
acid	O
phosphatase	O
levels	O
were	O
decreased	O
by	O
more	O
than	O
50	O
%	O
in	O
61	O
%	O
of	O
the	O
patients	O
,	O
but	O
this	O
test	O
appears	O
to	O
be	O
a	O
less	O
valid	O
marker	O
than	O
the	O
lipid	O
-	O
associated	O
sialic	O
acid	O
(	O
LASA	O
)	O
.	O

The	O
increase	O
in	O
LASA	O
before	O
treatment	O
and	O
a	O
reduction	O
after	O
treatment	O
can	O
frequently	O
be	O
correlated	O
with	O
the	O
objective	O
volume	O
of	O
the	O
neoplasms	S-Cancer
.	O

No	O
flare	O
-	O
up	O
of	O
the	O
disease	O
was	O
encountered	O
,	O
and	O
there	O
were	O
no	O
side	O
effects	O
except	O
for	O
impotence	O
.	O

Statistical	O
analyses	O
of	O
results	O
by	O
the	O
method	O
of	O
Lee	O
and	O
Wesley	O
indicated	O
that	O
the	O
incidence	O
of	O
complete	O
and	O
partial	O
regression	O
(	O
CR	O
and	O
PR	O
)	O
observed	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
was	O
not	O
significantly	O
different	O
from	O
that	O
recorded	O
in	O
previous	O
studies	O
for	O
another	O
LH	O
-	O
RH	O
analog	O
,	O
Buserelin	O
.	O

However	O
,	O
CR	O
and	O
PR	O
obtained	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
44	O
%	O
)	O
were	O
significantly	O
higher	O
than	O
with	O
subcapsular	O
orchiectomy	O
(	O
22	O
%	O
)	O
.	O

Hormonal	O
effects	O
and	O
some	O
other	O
actions	O
of	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
were	O
compared	O
and	O
contrasted	O
with	O
those	O
produced	O
by	O
castration	O
,	O
estrogens	O
,	O
antiandrogens	O
,	O
and	O
progestogens	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Multi	O
-	O
step	O
neoplastic	S-Cancer
transformation	O
of	O
normal	O
human	O
fibroblasts	S-Cell
by	O
Co	O
-	O
60	O
gamma	O
rays	O
and	O
Ha	O
-	O
ras	O
oncogenes	O
.	O

As	O
reported	O
previously	O
(	O
Namba	O
et	O
al	O
.	O
,	O
1985	O
;	O
Namba	O
,	O
1985	O
)	O
,	O
normal	O
human	O
fibroblasts	S-Cell
were	O
transformed	O
into	O
immortal	B-Cell
cells	E-Cell
with	O
abnormal	O
karyotypes	O
by	O
Co	O
-	O
60	O
gamma	O
-	O
ray	O
irradiation	O
.	O

These	O
immortally	O
transformed	O
cells	S-Cell
(	O
KMST	B-Cell
-	I-Cell
6	E-Cell
)	O
showed	O
no	O
clonability	O
in	O
soft	O
agar	O
and	O
were	O
not	O
tumorigenic	O
.	O

However	O
,	O
by	O
treatment	O
with	O
Ha	O
-	O
ras	O
oncogenes	O
derived	O
from	O
a	O
human	O
lung	B-Cancer
carcinoma	E-Cancer
or	O
Harvey	O
murine	O
sarcoma	O
virus	O
,	O
the	O
KMST	B-Cell
-	I-Cell
6	I-Cell
cells	E-Cell
acquired	O
elevated	O
clonability	O
in	O
soft	O
agar	O
and	O
transplantability	O
in	O
nude	O
mice	O
.	O

All	O
the	O
tumors	S-Cancer
produced	O
grew	O
progressively	O
without	O
showing	O
regression	O
and	O
killed	O
the	O
mice	O
.	O

The	O
tumors	S-Cancer
were	O
also	O
serially	O
transplantable	O
into	O
other	O
mice	O
.	O

The	O
Ha	O
-	O
ras	O
oncogene	O
alone	O
did	O
not	O
convert	O
normal	O
human	O
fibroblasts	S-Cell
into	O
either	O
immortal	S-Cell
or	O
tumorigenic	B-Cell
cells	E-Cell
.	O

Our	O
current	O
data	O
suggest	O
that	O
gamma	O
rays	O
worked	O
as	O
an	O
initiator	O
of	O
carcinogenesis	O
in	O
normal	O
human	O
cells	S-Cell
,	O
giving	O
rise	O
to	O
chromosome	S-Cellular_component
aberrations	O
and	O
immortality	O
,	O
and	O
the	O
Ha	O
-	O
ras	O
oncogene	O
played	O
a	O
role	O
in	O
the	O
progression	O
of	O
the	O
immortally	O
transformed	O
cell	S-Cell
population	O
to	O
a	O
neoplastic	S-Cancer
one	O
showing	O
enhanced	O
colony	S-Cell
formation	O
in	O
soft	O
agar	O
and	O
tumorigenicity	O
in	O
nude	O
mice	O
.	O

Cigarette	O
smoking	O
and	O
alveolar	B-Organ
bone	E-Organ
height	O
in	O
subjects	O
with	O
a	O
high	O
standard	O
of	O
oral	S-Organism_subdivision
hygiene	O
.	O

Smokers	O
and	O
non	O
-	O
smokers	O
were	O
compared	O
with	O
respect	O
to	O
alveolar	B-Organ
bone	E-Organ
height	O
.	O

The	O
study	O
covered	O
235	O
subjects	O
aged	O
21	O
-	O
60	O
years	O
,	O
72	O
of	O
whom	O
were	O
smokers	O
.	O

Oral	S-Organism_subdivision
hygiene	O
status	O
and	O
dental	S-Organ
care	O
habits	O
were	O
above	O
average	O
and	O
of	O
equal	O
standard	O
in	O
both	O
groups	O
(	O
PlI	O
=	O
0	O
.	O
9	O
)	O
.	O

Alveolar	B-Organ
bone	E-Organ
height	O
was	O
assessed	O
on	O
radiographs	O
and	O
expressed	O
as	O
%	O
of	O
the	O
root	S-Multi-tissue_structure
length	O
.	O

Alveolar	B-Organ
bone	E-Organ
height	O
was	O
significantly	O
reduced	O
in	O
smokers	O
as	O
compared	O
to	O
non	O
-	O
smokers	O
,	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
being	O
77	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
82	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
6	O
%	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Regression	O
analysis	O
suggested	O
that	O
periodontal	S-Organism_subdivision
breakdown	O
judged	O
from	O
loss	O
of	O
alveolar	B-Organ
bone	E-Organ
over	O
time	O
was	O
more	O
accelerated	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
.	O

The	O
lower	B-Organ
bone	E-Organ
height	O
in	O
smokers	O
remained	O
when	O
age	O
and	O
oral	S-Organism_subdivision
hygiene	O
were	O
allowed	O
for	O
.	O

It	O
is	O
concluded	O
that	O
smoking	O
is	O
a	O
risk	O
factor	O
for	O
periodontal	S-Organism_subdivision
health	O
.	O

Combined	O
aortic	S-Multi-tissue_structure
,	O
mitral	S-Multi-tissue_structure
and	O
tricuspid	S-Multi-tissue_structure
surgery	O
:	O
results	O
in	O
78	O
patients	O
.	O

Between	O
1968	O
and	O
1984	O
,	O
78	O
patients	O
(	O
mean	O
age	O
43	O
,	O
range	O
14	O
to	O
65	O
years	O
)	O
underwent	O
combined	O
aortic	S-Multi-tissue_structure
,	O
mitral	S-Multi-tissue_structure
and	O
tricuspid	S-Multi-tissue_structure
surgery	O
(	O
22	O
triple	B-Multi-tissue_structure
valve	E-Multi-tissue_structure
replacements	O
,	O
56	O
aortic	B-Multi-tissue_structure
valve	E-Multi-tissue_structure
replacements	O
with	O
tricuspid	S-Multi-tissue_structure
conservative	O
surgery	O
and	O
mitral	B-Multi-tissue_structure
valve	E-Multi-tissue_structure
replacement	O
(	O
N	O
=	O
48	O
)	O
,	O
or	O
commissuroplasty	O
(	O
N	O
=	O
8	O
)	O
.	O

Pre	O
-	O
operative	O
consequences	O
of	O
valvular	S-Multi-tissue_structure
disease	O
(	O
mainly	O
mixed	O
valve	S-Multi-tissue_structure
disease	O
)	O
were	O
severe	O
as	O
assessed	O
by	O
functional	O
class	O
(	O
72	O
pts	O
in	O
III	O
or	O
IV	O
NYHA	O
)	O
,	O
cardiomegaly	O
(	O
CTR	O
:	O
62	O
+	O
/	O
-	O
6	O
%	O
)	O
,	O
increase	O
of	O
mean	O
pulmonary	B-Multi-tissue_structure
arterial	E-Multi-tissue_structure
and	O
wedge	O
pressures	O
(	O
respectively	O
30	O
+	O
/	O
-	O
12	O
and	O
19	O
+	O
/	O
-	O
6	O
mmHg	O
)	O
decrease	O
in	O
cardiac	S-Organ
index	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
l	O
min	O
-	O
1	O
m	O
-	O
2	O
)	O
,	O
LV	S-Multi-tissue_structure
dilatation	O
(	O
LV	S-Multi-tissue_structure
end	O
diastolic	O
volume	O
:	O
184	O
+	O
/	O
-	O
86	O
ml	O
m	O
-	O
2	O
)	O
and	O
impairment	O
of	O
LV	S-Multi-tissue_structure
systolic	O
function	O
(	O
LV	S-Multi-tissue_structure
ejection	O
fraction	O
:	O
50	O
+	O
/	O
-	O
12	O
%	O
)	O
.	O

Operative	O
mortality	O
rate	O
was	O
11	O
.	O
5	O
%	O
.	O

The	O
69	O
survivors	O
were	O
all	O
followed	O
up	O
,	O
for	O
a	O
mean	O
of	O
56	O
months	O
(	O
2	O
to	O
207	O
)	O
.	O

16	O
late	O
deaths	O
occurred	O
.	O

Actuarial	O
survival	O
rate	O
at	O
10	O
years	O
was	O
58	O
.	O
4	O
%	O
,	O
and	O
greatly	O
influenced	O
by	O
pre	O
-	O
operative	O
NYHA	O
class	O
.	O

Linearized	O
rates	O
of	O
thromboembolic	O
events	O
,	O
valve	S-Multi-tissue_structure
thrombosis	O
and	O
haemorrhage	O
were	O
respectively	O
6	O
.	O
4	O
,	O
1	O
.	O
5	O
and	O
1	O
.	O
2	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
.	O

Those	O
of	O
infective	O
endocarditis	O
,	O
periprosthetic	O
leak	O
,	O
reoperation	O
and	O
valve	S-Multi-tissue_structure
failure	O
were	O
0	O
.	O
6	O
,	O
3	O
.	O
3	O
and	O
4	O
.	O
9	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
respectively	O
.	O

At	O
9	O
years	O
,	O
42	O
%	O
of	O
the	O
patients	O
were	O
in	O
NYHA	O
class	O
I	O
or	O
II	O
and	O
free	O
from	O
complications	O
.	O

Conjunctival	S-Multi-tissue_structure
hypoxia	O
in	O
diabetes	O
mellitus	O
.	O

A	O
frequently	O
cited	O
theory	O
for	O
the	O
pathogenesis	O
of	O
neovascularization	O
in	O
diabetic	O
retinopathy	O
is	O
that	O
retinal	S-Multi-tissue_structure
hypoxia	O
and	O
/	O
or	O
ischemia	O
release	O
a	O
factor	O
which	O
stimulates	O
neovascularization	O
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
there	O
is	O
no	O
direct	O
in	O
vivo	O
evidence	O
in	O
the	O
human	O
proving	O
this	O
theory	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
diabetic	O
subjects	O
were	O
studied	O
to	O
see	O
whether	O
worsening	O
retinopathy	O
was	O
associated	O
with	O
changes	O
in	O
conjunctival	S-Multi-tissue_structure
oxygen	O
tension	O
(	O
pO2	O
)	O
.	O

Diabetics	O
without	O
retinopathy	O
had	O
a	O
conjunctival	S-Multi-tissue_structure
pO2	O
which	O
was	O
similar	O
to	O
an	O
age	O
-	O
matched	O
normal	O
population	O
.	O

Diabetics	O
with	O
only	O
background	O
retinopathy	O
had	O
a	O
significantly	O
lower	O
conjunctival	S-Multi-tissue_structure
pO2	O
than	O
those	O
without	O
retinopathy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Diabetics	O
with	O
proliferative	O
retinopathy	O
showed	O
a	O
conjunctival	S-Multi-tissue_structure
pO2	O
that	O
was	O
significantly	O
lower	O
than	O
either	O
of	O
the	O
first	O
two	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
value	O
of	O
all	O
was	O
found	O
in	O
patients	O
with	O
rubeosis	O
iridis	O
.	O

Duration	O
of	O
diabetes	O
alone	O
did	O
not	O
correlate	O
significantly	O
to	O
conjunctival	S-Multi-tissue_structure
pO2	O
.	O

These	O
findings	O
support	O
the	O
hypoxic	O
theory	O
of	O
diabetic	O
neovascular	O
retinopathy	O
.	O

New	O
functions	O
of	O
epidermal	O
growth	O
factor	O
:	O
stimulation	O
of	O
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	O
and	O
matrix	S-Cellular_component
dependent	O
proliferation	O
.	O

The	O
proliferative	O
response	O
of	O
bovine	O
retinal	B-Cell
capillary	I-Cell
endothelial	I-Cell
cells	E-Cell
to	O
EGF	O
is	O
dependent	O
upon	O
attaching	O
the	O
cells	S-Cell
to	O
a	O
matrix	S-Cellular_component
of	O
fibronectin	O
.	O

Bovine	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
are	O
also	O
stimulated	O
to	O
actively	O
migrate	O
when	O
exposed	O
to	O
EGF	O
in	O
vitro	O
.	O

These	O
activities	O
provide	O
an	O
explanation	O
for	O
the	O
angiogenic	O
properties	O
of	O
EGF	O
in	O
vivo	O
.	O

Capillary	B-Cell
cell	E-Cell
migration	O
and	O
proliferation	O
are	O
proposed	O
as	O
sensitive	O
quantifiable	O
bioassays	O
to	O
explore	O
the	O
functional	O
domains	O
of	O
the	O
EGF	O
molecule	O
.	O

Studies	O
on	O
the	O
inactivation	O
of	O
these	O
properties	O
of	O
EGF	O
by	O
specific	O
cleavage	O
of	O
the	O
molecule	O
with	O
CNBr	O
or	O
proteases	O
suggest	O
that	O
an	O
intact	O
loop	O
composed	O
in	O
part	O
by	O
amino	O
acid	O
residues	O
20	O
to	O
31	O
is	O
essential	O
for	O
at	O
least	O
some	O
functions	O
.	O

[	O
Histophysiology	O
and	O
histopathology	O
of	O
the	O
adrenals	S-Organ
in	O
experimental	O
hypokinesia	O
]	O
.	O

In	O
experiments	O
on	O
male	O
rats	O
in	O
the	O
course	O
of	O
3	O
-	O
month	O
hypokinesia	O
phasic	O
changes	O
were	O
observed	O
in	O
the	O
relative	O
adrenal	B-Organ
gland	E-Organ
weight	O
,	O
in	O
the	O
volume	O
of	O
the	O
cell	B-Cellular_component
nuclei	E-Cellular_component
of	O
the	O
glomerular	S-Multi-tissue_structure
,	O
fasicular	B-Multi-tissue_structure
zones	E-Multi-tissue_structure
and	O
the	O
medulla	S-Multi-tissue_structure
,	O
in	O
the	O
activity	O
of	O
the	O
succinic	O
dehydrogenase	O
,	O
alkaline	O
and	O
acid	O
phosphatases	O
,	O
in	O
the	O
RNA	O
and	O
catecholamine	O
content	O
.	O

These	O
changes	O
are	O
associated	O
with	O
variations	O
in	O
the	O
secretion	O
and	O
biosynthesis	O
of	O
the	O
hormones	O
of	O
the	O
cortical	S-Multi-tissue_structure
and	O
the	O
medullary	B-Multi-tissue_structure
layer	E-Multi-tissue_structure
of	O
the	O
adrenal	B-Organ
glands	E-Organ
during	O
the	O
hypokinetic	O
stress	O
development	O
.	O

Dynorphin	O
is	O
contained	O
within	O
hippocampal	B-Tissue
mossy	I-Tissue
fibers	E-Tissue
:	O
immunochemical	O
alterations	O
after	O
kainic	O
acid	O
administration	O
and	O
colchicine	O
-	O
induced	O
neurotoxicity	O
.	O

Antisera	S-Organism_substance
raised	O
against	O
synthetic	O
dynorphin	O
or	O
[	O
Leu5	O
]	O
enkephalin	O
demonstrate	O
immunostaining	O
in	O
hippocampal	B-Tissue
mossy	I-Tissue
fibers	E-Tissue
and	O
in	O
dentate	B-Cell
granule	I-Cell
cells	E-Cell
.	O

However	O
,	O
dynorphin	O
immunoreactivity	O
(	O
ir	O
)	O
appears	O
to	O
be	O
denser	O
in	O
immunocytochemical	O
preparations	O
and	O
is	O
quantitatively	O
greater	O
by	O
radioimmunoassay	O
than	O
enkephalin	O
-	O
ir	O
.	O

Immunostaining	O
with	O
dynorphin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
dynorphin	O
-	O
17	O
whereas	O
immunostaining	O
with	O
enkephalin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
[	O
Leu5	O
]	O
enkephalin	O
,	O
dynorphin	O
-	O
17	O
,	O
dynorphin	O
-	O
(	O
1	O
-	O
13	O
)	O
,	O
or	O
alpha	O
-	O
neo	O
-	O
endorphin	O
.	O

Intrahippocampal	S-Immaterial_anatomical_entity
colchicine	O
injections	O
,	O
which	O
selectively	O
destroy	O
dentate	B-Cell
granule	I-Cell
cells	E-Cell
,	O
significantly	O
decrease	O
the	O
dynorphin	O
-	O
ir	O
and	O
enkephalin	O
-	O
ir	O
levels	O
in	O
rat	O
hippocampus	S-Multi-tissue_structure
.	O

Intraventricularly	S-Immaterial_anatomical_entity
administered	O
kainic	O
acid	O
,	O
which	O
selectively	O
destroys	O
CA3	B-Cell
-	I-Cell
4	I-Cell
pyramidal	I-Cell
cells	E-Cell
,	O
results	O
in	O
an	O
increase	O
of	O
enkephalin	O
immunostaining	O
in	O
mossy	B-Tissue
fibers	E-Tissue
and	O
a	O
significant	O
increase	O
in	O
enkephalin	O
-	O
ir	O
by	O
radioimmunoassay	O
in	O
whole	O
hippocampus	S-Multi-tissue_structure
.	O

The	O
enkephalin	B-Cell
-	I-Cell
ir	I-Cell
cells	E-Cell
and	O
fibers	S-Tissue
in	O
entorhinal	S-Multi-tissue_structure
/	O
perirhinal	B-Multi-tissue_structure
cortex	E-Multi-tissue_structure
,	O
which	O
innervate	O
rat	O
hippocampus	S-Multi-tissue_structure
and	O
dentate	B-Multi-tissue_structure
gyrus	E-Multi-tissue_structure
,	O
do	O
not	O
contain	O
dynorphin	O
-	O
ir	O
.	O

Angiogenesis	O
:	O
initiation	O
and	O
control	O
.	O

From	O
in	O
vivo	O
experiments	O
using	O
new	O
methods	O
such	O
as	O
the	O
rabbit	O
cornea	S-Multi-tissue_structure
,	O
it	O
is	O
now	O
becoming	O
clear	O
that	O
the	O
growth	O
of	O
a	O
capillary	S-Tissue
involves	O
an	O
ordered	O
sequence	O
of	O
events	O
that	O
includes	O
lysis	O
of	O
the	O
basement	B-Cellular_component
membrane	E-Cellular_component
of	O
a	O
parent	O
venule	S-Multi-tissue_structure
,	O
directional	O
migration	O
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
toward	O
the	O
angiogenic	O
stimulus	O
,	O
lumen	S-Immaterial_anatomical_entity
formation	O
,	O
development	O
of	O
branches	S-Tissue
,	O
and	O
anastomosis	O
of	O
the	O
tip	O
of	O
one	O
tube	S-Tissue
with	O
another	O
to	O
form	O
a	O
loop	O
.	O

It	O
is	O
also	O
clear	O
that	O
diffusible	O
angiogenic	O
stimuli	O
can	O
be	O
released	O
not	O
only	O
from	O
most	O
solid	B-Cancer
tumors	E-Cancer
,	O
but	O
also	O
from	O
at	O
least	O
three	O
non	B-Cell
-	I-Cell
neoplastic	I-Cell
cells	E-Cell
.	O

These	O
include	O
activated	O
macrophages	S-Cell
,	O
sensitized	O
lymphocytes	S-Cell
,	O
and	O
adipocytes	S-Cell
.	O

Other	O
normal	O
tissues	S-Tissue
can	O
also	O
stimulate	O
angiogenesis	O
,	O
but	O
the	O
type	O
of	O
cell	S-Cell
giving	O
rise	O
to	O
the	O
angiogenic	O
stimulus	O
is	O
unknown	O
,	O
and	O
the	O
period	O
of	O
angiogenic	O
stimulation	O
is	O
brief	O
.	O

With	O
the	O
recent	O
ability	O
to	O
clone	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
and	O
to	O
carry	O
them	O
in	O
long	O
-	O
term	O
culture	O
,	O
it	O
has	O
been	O
possible	O
to	O
further	O
delineate	O
the	O
mechanism	O
of	O
capillary	S-Tissue
growth	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
mast	B-Cell
cell	E-Cell
seems	O
to	O
behave	O
as	O
a	O
helper	B-Cell
cell	E-Cell
for	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
in	O
some	O
way	O
speeding	O
up	O
their	O
rate	O
of	O
directional	O
migration	O
.	O

At	O
this	O
writing	O
,	O
heparin	O
appears	O
to	O
be	O
the	O
principal	O
mast	B-Cell
cell	E-Cell
factor	O
responsible	O
for	O
this	O
effect	O
on	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

One	O
theoretical	O
possibility	O
is	O
that	O
mast	B-Cell
cells	E-Cell
may	O
prepare	O
the	O
matrix	S-Cellular_component
,	O
perhaps	O
by	O
slow	O
release	O
of	O
heparin	O
,	O
so	O
that	O
capillary	B-Tissue
sprouts	E-Tissue
can	O
more	O
easily	O
move	O
through	O
it	O
toward	O
their	O
angiogenic	O
target	O
.	O

While	O
the	O
study	O
of	O
angiogenesis	O
as	O
a	O
phenomenon	O
is	O
still	O
in	O
an	O
early	O
phase	O
,	O
it	O
has	O
become	O
possible	O
,	O
by	O
using	O
a	O
combination	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
techniques	O
,	O
to	O
more	O
thoroughly	O
understand	O
the	O
initiation	O
and	O
control	O
of	O
capillary	S-Tissue
growth	O
.	O

Protection	O
from	O
experimental	O
ocular	S-Organ
herpetic	O
keratitis	O
by	O
a	O
heat	O
-	O
killed	O
virus	O
vaccine	O
.	O

New	O
Zealand	O
white	O
rabbits	O
were	O
given	O
limbal	S-Multi-tissue_structure
inoculations	O
of	O
a	O
heat	O
-	O
killed	O
suspension	O
of	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
in	O
a	O
lysate	O
of	O
human	O
embryonic	B-Cell
kidney	I-Cell
cells	E-Cell
.	O

At	O
intervals	O
of	O
four	O
to	O
14	O
days	O
,	O
the	O
animals	O
were	O
challenged	O
by	O
intrastromal	S-Immaterial_anatomical_entity
inoculation	O
with	O
10	O
,	O
000	O
plaque	O
-	O
forming	O
units	O
of	O
viable	O
HSV	O
.	O

Epithelial	S-Tissue
keratitis	O
,	O
disciform	B-Pathological_formation
edema	E-Pathological_formation
,	O
and	O
necrotizing	O
keratitis	O
with	O
neovascularization	O
of	O
the	O
cornea	S-Multi-tissue_structure
developed	O
in	O
control	O
animals	O
.	O

Epithelial	S-Tissue
keratitis	O
and	O
corneal	B-Pathological_formation
edema	E-Pathological_formation
also	O
developed	O
in	O
the	O
immunized	O
animals	O
during	O
the	O
first	O
week	O
after	O
virus	O
challenge	O
,	O
but	O
these	O
symptoms	O
rapidly	O
resolved	O
during	O
the	O
following	O
weeks	O
.	O

The	O
absence	O
of	O
iritis	O
,	O
neovascularization	O
,	O
and	O
necrotizing	O
keratitis	O
in	O
the	O
corneas	S-Multi-tissue_structure
of	O
the	O
immunized	O
animals	O
was	O
particularly	O
striking	O
.	O

Effects	O
of	O
growth	O
temperature	O
,	O
47	O
-	O
megadalton	O
plasmid	S-Cellular_component
,	O
and	O
calcium	O
deficiency	O
on	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
protein	O
porin	O
and	O
lipopolysaccharide	O
composition	O
of	O
Yersinia	O
pestis	O
EV76	O
.	O

The	O
expression	O
of	O
several	O
virulence	O
determinants	O
of	O
Yersinia	O
pestis	O
is	O
known	O
to	O
be	O
dependent	O
on	O
the	O
in	O
vitro	O
growth	O
temperature	O
.	O

One	O
of	O
these	O
,	O
calcium	O
dependence	O
,	O
is	O
associated	O
with	O
the	O
presence	O
of	O
a	O
47	O
-	O
megadalton	O
plasmid	S-Cellular_component
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
incubation	O
temperature	O
,	O
calcium	O
in	O
the	O
growth	O
medium	O
,	O
the	O
presence	O
of	O
the	O
47	O
-	O
megadalton	O
plasmid	S-Cellular_component
on	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
protein	O
,	O
and	O
the	O
lipopolysaccharide	O
composition	O
of	O
Y	O
.	O
pestis	O
EV76	O
.	O

When	O
cells	S-Cell
were	O
grown	O
at	O
37	O
degrees	O
C	O
as	O
opposed	O
to	O
26	O
degrees	O
C	O
,	O
a	O
change	O
in	O
lipopolysaccharide	O
composition	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
an	O
outer	B-Cellular_component
membrane	E-Cellular_component
protein	O
(	O
protein	O
E	O
)	O
were	O
observed	O
.	O

The	O
lipopolysaccharide	O
obtained	O
from	O
cells	S-Cell
incubated	O
at	O
37	O
degrees	O
C	O
had	O
a	O
lower	O
proportion	O
of	O
2	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
,	O
a	O
lower	O
phosphate	O
to	O
2	O
-	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
ratio	O
,	O
and	O
an	O
increased	O
gel	O
mobility	O
upon	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
when	O
compared	O
with	O
lipopolysaccharide	O
obtained	O
from	O
cells	S-Cell
grown	O
at	O
26	O
degrees	O
C	O
.	O

Because	O
of	O
its	O
growth	O
temperature	O
-	O
related	O
abundance	O
,	O
we	O
investigated	O
the	O
nature	O
of	O
protein	O
E	O
.	O

This	O
protein	O
had	O
physical	O
properties	O
similar	O
to	O
those	O
of	O
other	O
enterobacterial	O
porins	O
,	O
including	O
apparent	O
formation	O
of	O
an	O
oligomer	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
when	O
solubilized	O
at	O
low	O
temperature	O
,	O
acidic	O
isoelectric	O
point	O
,	O
and	O
strong	O
noncovalent	O
association	O
with	O
the	O
peptidoglycan	O
.	O

Protein	O
E	O
was	O
purified	O
and	O
shown	O
to	O
form	O
an	O
aqueous	O
channel	O
in	O
planar	O
lipid	B-Cellular_component
membranes	E-Cellular_component
with	O
a	O
conductance	O
of	O
1	O
.	O
1	O
nS	O
in	O
1	O
M	O
KCl	O
.	O

In	O
addition	O
to	O
growth	O
temperature	O
-	O
related	O
alterations	O
in	O
the	O
lipopolysaccharide	O
and	O
porin	O
components	O
of	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
,	O
the	O
amount	O
of	O
three	O
spots	O
in	O
two	O
-	O
dimensional	O
polyacrylamide	O
gels	O
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
temperature	O
or	O
the	O
presence	O
of	O
calcium	O
during	O
growth	O
.	O

One	O
of	O
these	O
spots	O
was	O
shown	O
to	O
contain	O
residual	O
unmodified	O
portions	O
of	O
two	O
major	O
heat	O
-	O
modifiable	O
proteins	O
which	O
failed	O
to	O
shift	O
to	O
their	O
heat	O
-	O
modified	O
positions	O
on	O
gels	O
,	O
despite	O
solubilization	O
at	O
100	O
degrees	O
C	O
for	O
10	O
min	O
before	O
electrophoresis	O
.	O

The	O
other	O
two	O
spots	O
were	O
the	O
heat	O
-	O
modified	O
and	O
unmodified	O
forms	O
of	O
another	O
outer	B-Cellular_component
membrane	E-Cellular_component
protein	O
(	O
J	O
)	O
which	O
did	O
not	O
appear	O
in	O
the	O
isoelectric	O
focusing	O
gel	O
of	O
cells	S-Cell
grown	O
at	O
37	O
degrees	O
C	O
.	O

It	O
is	O
proposed	O
that	O
the	O
appearance	O
of	O
these	O
spots	O
in	O
two	O
-	O
dimensional	O
analyses	O
is	O
related	O
to	O
the	O
lipopolysaccharide	O
composition	O
of	O
the	O
cells	S-Cell
from	O
which	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
is	O
derived	O
and	O
reflects	O
lipopolysaccharide	O
-	O
protein	O
interactions	O
or	O
calcium	O
-	O
protein	O
interactions	O
.	O

Protein	O
kinase	O
activities	O
in	O
immune	O
complexes	O
of	O
simian	O
virus	O
40	O
large	O
T	O
-	O
antigen	O
and	O
transformation	O
-	O
associated	O
cellular	S-Cell
p53	O
protein	O
.	O

Immune	O
complex	O
kinase	O
assays	O
in	O
the	O
simian	O
virus	O
40	O
system	O
were	O
performed	O
by	O
incubation	O
of	O
immunoprecipitates	O
containing	O
tumor	S-Cancer
antigens	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
,	O
followed	O
by	O
analysis	O
of	O
any	O
phosphoacceptor	O
proteins	O
.	O

These	O
assays	O
yielded	O
mainly	O
the	O
viral	O
large	O
T	O
-	O
antigen	O
and	O
,	O
in	O
particular	O
,	O
the	O
associated	O
cellular	S-Cell
p53	O
as	O
endogenous	O
substrates	O
.	O

The	O
nature	O
of	O
these	O
substrates	O
was	O
confirmed	O
by	O
proteolysis	O
techniques	O
.	O

Under	O
specific	O
conditions	O
,	O
casein	O
could	O
be	O
used	O
as	O
an	O
exogenous	O
substrate	O
as	O
well	O
.	O

The	O
kinase	O
reactions	O
showed	O
preference	O
for	O
ATP	O
and	O
MgCl2	O
instead	O
of	O
GTP	O
or	O
MnCl2	O
.	O

Both	O
phosphoserine	O
and	O
phosphothreonine	O
,	O
but	O
in	O
no	O
case	O
phosphotyrosine	O
,	O
were	O
detected	O
after	O
an	O
immune	O
complex	O
kinase	O
reaction	O
.	O

Apparently	O
,	O
several	O
in	O
vivo	O
phosphorylation	O
sites	O
were	O
recognized	O
in	O
vitro	O
in	O
both	O
large	O
T	O
-	O
antigen	O
and	O
p53	O
,	O
but	O
the	O
presence	O
of	O
some	O
artifactual	O
sites	O
could	O
not	O
be	O
completely	O
excluded	O
.	O

Although	O
contaminating	O
kinases	O
were	O
detectable	O
in	O
the	O
immune	O
complexes	O
,	O
at	O
least	O
the	O
p53	O
molecules	O
were	O
phosphorylated	O
in	O
vitro	O
in	O
a	O
more	O
specific	O
way	O
.	O

This	O
followed	O
from	O
several	O
characteristics	O
of	O
the	O
immune	O
complex	O
kinase	O
reactions	O
and	O
especially	O
from	O
the	O
strong	O
inhibition	O
of	O
p53	O
phosphorylation	O
by	O
two	O
anti	O
-	O
large	O
-	O
T	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
shown	O
that	O
large	O
T	O
-	O
antigen	O
showed	O
associated	O
kinase	O
activity	O
,	O
although	O
none	O
of	O
our	O
results	O
could	O
unambiguously	O
demonstrate	O
an	O
intrinsic	O
kinase	O
activity	O
of	O
this	O
protein	O
.	O

Finally	O
,	O
anti	O
-	O
p53	O
monoclonal	O
antibodies	O
only	O
slightly	O
affected	O
in	O
vitro	O
phosphorylation	O
reactions	O
,	O
whereas	O
a	O
p53	O
molecule	O
from	O
a	O
simian	O
virus	O
40	O
-	O
free	O
,	O
chemically	O
transformed	O
human	O
cell	B-Cell
line	E-Cell
was	O
not	O
phosphorylated	O
in	O
vitro	O
under	O
any	O
condition	O
tested	O
.	O

Thus	O
,	O
it	O
is	O
highly	O
unlikely	O
that	O
the	O
p53	O
molecule	O
per	O
se	O
carries	O
intrinsic	O
or	O
even	O
associated	O
kinase	O
activities	O
.	O

Preparation	O
and	O
physicochemical	O
and	O
immunological	O
characterization	O
of	O
polysaccharide	O
-	O
outer	B-Cellular_component
membrane	E-Cellular_component
protein	O
complexes	O
of	O
Neisseria	O
meningitidis	O
.	O

A	O
crude	O
complex	O
containing	O
group	O
C	O
polysaccharide	O
,	O
outer	B-Cellular_component
membrane	E-Cellular_component
proteins	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
isolated	O
from	O
the	O
cell	S-Cell
-	O
free	O
culture	O
liquid	O
of	O
Neisseria	O
meningitidis	O
serogroup	O
C	O
,	O
serotype	O
2a	O
.	O

Group	O
C	O
polysaccharide	O
and	O
LPS	O
were	O
removed	O
from	O
this	O
complex	O
,	O
resulting	O
in	O
an	O
outer	B-Cellular_component
membrane	E-Cellular_component
complex	O
and	O
a	O
purified	O
complex	O
,	O
respectively	O
.	O

Analysis	O
by	O
electron	O
microscopy	O
showed	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
origin	O
of	O
the	O
crude	O
complex	O
and	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
complex	O
,	O
whereas	O
such	O
a	O
structure	O
was	O
absent	O
in	O
the	O
purified	O
complex	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
patterns	O
of	O
the	O
three	O
complexes	O
were	O
identical	O
.	O

Pyrolysis	O
-	O
mass	O
spectrometry	O
data	O
correlated	O
well	O
with	O
those	O
obtained	O
by	O
the	O
biochemical	O
assays	O
and	O
suggested	O
a	O
low	O
LPS	O
content	O
in	O
the	O
purified	O
complex	O
and	O
a	O
low	O
polysaccharide	O
content	O
in	O
the	O
outer	B-Cellular_component
membrane	E-Cellular_component
complex	O
.	O

The	O
purified	O
complex	O
was	O
shown	O
to	O
be	O
nonpyrogenic	O
and	O
could	O
be	O
prepared	O
with	O
the	O
same	O
yield	O
as	O
that	O
of	O
purified	O
polysaccharide	O
.	O

The	O
immunogenic	O
activities	O
of	O
the	O
complexes	O
were	O
studied	O
in	O
mice	O
.	O

The	O
antibodies	O
were	O
measured	O
by	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
and	O
the	O
bactericidal	O
antibody	O
assay	O
.	O

All	O
complexes	O
induced	O
immunoglobulin	O
G	O
antibodies	O
to	O
group	O
C	O
polysaccharide	O
as	O
well	O
as	O
to	O
the	O
serotype	O
antigen	O
,	O
although	O
the	O
removal	O
of	O
polysaccharide	O
and	O
LPS	O
resulted	O
in	O
a	O
reduction	O
of	O
the	O
immunogenic	O
activities	O
of	O
outer	B-Cellular_component
membrane	E-Cellular_component
complex	O
and	O
purified	O
complex	O
,	O
respectively	O
.	O

A	O
second	O
dose	O
of	O
all	O
complexes	O
produced	O
a	O
clear	O
booster	O
effect	O
of	O
both	O
antibody	O
responses	O
.	O

The	O
antibodies	O
were	O
bactericidal	O
.	O

Differential	O
reactivity	O
of	O
the	O
functional	O
sulfhydryl	O
groups	O
of	O
cysteine	O
-	O
32	O
and	O
cysteine	O
-	O
35	O
present	O
in	O
the	O
reduced	O
form	O
of	O
thioredoxin	O
from	O
Escherichia	O
coli	O
.	O

Only	O
one	O
of	O
the	O
sulfhydryl	O
groups	O
from	O
Cys	O
-	O
32	O
and	O
Cys	O
-	O
35	O
in	O
the	O
active	O
center	O
of	O
native	O
Escherichia	O
coli	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
was	O
alkylated	O
by	O
excess	O
iodoacetic	O
acid	O
at	O
pH	O
values	O
below	O
8	O
.	O
0	O
.	O

Both	O
groups	O
reacted	O
in	O
the	O
protein	O
denatured	O
with	O
4	O
.	O
5	O
M	O
guanidine	O
hydrochloride	O
.	O

The	O
second	O
order	O
rate	O
of	O
alkylation	O
of	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
with	O
1	O
eq	O
of	O
iodoacetic	O
acid	O
was	O
pH	O
-	O
dependent	O
and	O
showed	O
independent	O
initial	O
reactions	O
of	O
one	O
thiolate	O
ion	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
and	O
a	O
second	O
with	O
a	O
pK	O
value	O
close	O
to	O
9	O
.	O
0	O
.	O

The	O
same	O
pH	O
dependence	O
was	O
observed	O
for	O
alkylation	O
with	O
iodoacetamide	O
but	O
the	O
apparent	O
rate	O
constant	O
,	O
107	O
M	O
-	O
1	O
S	O
-	O
1	O
at	O
pH	O
7	O
.	O
2	O
,	O
was	O
about	O
20	O
-	O
fold	O
higher	O
than	O
the	O
corresponding	O
rate	O
with	O
iodoacetate	O
.	O

The	O
sulfhydryl	O
group	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
was	O
shown	O
to	O
belong	O
to	O
Cys	O
-	O
32	O
by	O
labeling	O
thioredoxin	O
with	O
[	O
14C	O
]	O
iodoacetic	O
acid	O
followed	O
by	O
complete	O
alkylation	O
with	O
[	O
3H	O
]	O
iodoacetate	O
and	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptides	O
from	O
the	O
active	O
center	O
.	O

The	O
abnormally	O
low	O
pK	O
value	O
of	O
Cys	O
-	O
32	O
is	O
suggested	O
to	O
arise	O
by	O
electrostatic	O
influence	O
from	O
a	O
positive	O
charge	O
on	O
the	O
amino	O
group	O
of	O
Lys	O
-	O
36	O
.	O

A	O
mechanism	O
of	O
action	O
for	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
as	O
a	O
protein	O
disulfide	O
reductase	O
has	O
been	O
formulated	O
.	O

This	O
is	O
based	O
on	O
an	O
initial	O
nucleophilic	O
attack	O
by	O
the	O
thiolate	O
of	O
Cys	O
-	O
32	O
with	O
the	O
formation	O
of	O
an	O
unstable	O
transient	O
mixed	O
disulfide	O
involving	O
Cys	O
-	O
32	O
and	O
one	O
of	O
the	O
sulfurs	O
in	O
the	O
substrate	O
.	O

This	O
is	O
followed	O
by	O
a	O
conformational	O
change	O
and	O
a	O
nucleophilic	O
attack	O
of	O
Cys	O
-	O
35	O
to	O
give	O
the	O
14	O
-	O
membered	O
disulfide	O
ring	O
in	O
thioredoxin	O
-	O
S2	O
and	O
the	O
dithiol	O
of	O
the	O
substrate	O
.	O

Molecular	O
mediators	O
of	O
interactions	O
with	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
components	E-Cellular_component
in	O
metastasis	O
and	O
angiogenesis	O
.	O

Metastasis	O
and	O
tumor	S-Cancer
angiogenesis	O
are	O
invasive	O
phenomena	O
and	O
share	O
many	O
common	O
properties	O
at	O
the	O
physiological	O
level	O
and	O
some	O
similarities	O
at	O
the	O
molecular	O
level	O
.	O

Each	O
consists	O
of	O
repetitive	O
cycles	O
of	O
interaction	O
with	O
adjacent	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
components	E-Cellular_component
by	O
mediating	O
cellular	S-Cell
adhesion	O
,	O
matrix	S-Cellular_component
dissolution	O
,	O
and	O
cellular	S-Cell
motility	O
to	O
achieve	O
metastasis	O
of	O
cancer	B-Cell
cells	E-Cell
or	O
neovascularization	O
of	O
tumors	S-Cancer
.	O

Molecular	O
factors	O
which	O
implement	O
this	O
triad	O
of	O
events	O
are	O
reviewed	O
,	O
as	O
are	O
several	O
signal	O
transduction	O
components	O
which	O
may	O
regulate	O
them	O
.	O

Some	O
potentially	O
promising	O
prognostic	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
modalities	O
for	O
tumor	S-Cancer
angiogenesis	O
and	O
metastatic	B-Cancer
disease	E-Cancer
are	O
also	O
discussed	O
.	O

Suppressed	O
transformation	O
and	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
by	O
emodin	O
.	O

The	O
amplification	O
and	O
overexpression	O
of	O
the	O
HER	O
-	O
2	O
/	O
neu	O
proto	O
-	O
oncogene	O
,	O
which	O
encodes	O
the	O
tyrosine	O
kinase	O
receptor	O
p185neu	O
,	O
have	O
been	O
observed	O
frequently	O
in	O
tumors	S-Cancer
from	O
human	O
breast	B-Cancer
cancer	E-Cancer
patients	O
and	O
are	O
correlated	O
with	O
poor	O
prognosis	O
.	O

To	O
explore	O
the	O
potential	O
of	O
chemotherapy	O
directed	O
at	O
the	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
we	O
have	O
found	O
that	O
emodin	O
(	O
3	O
-	O
methyl	O
-	O
1	O
,	O
6	O
,	O
8	O
-	O
trihydroxyanthraquinone	O
)	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
suppresses	O
autophosphorylation	O
and	O
transphosphorylation	O
activities	O
of	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
,	O
resulting	O
in	O
tyrosine	O
hypophosphorylation	O
of	O
p185neu	O
in	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Emodin	O
,	O
at	O
a	O
40	O
-	O
microM	O
concentration	O
,	O
which	O
repressed	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
efficiently	O
inhibited	O
both	O
anchorage	O
-	O
dependent	O
and	O
anchorage	O
-	O
independent	O
growth	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

However	O
,	O
the	O
inhibition	O
was	O
much	O
less	O
effective	O
for	O
those	O
cells	S-Cell
expressing	O
basal	O
levels	O
of	O
p185neu	O
under	O
the	O
same	O
conditions	O
.	O

Emodin	O
also	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
by	O
exhibiting	O
a	O
morphological	O
maturation	O
property	O
of	O
large	O
lacy	O
nuclei	S-Cellular_component
surrounded	O
by	O
sizable	O
flat	B-Organism_substance
cytoplasm	E-Organism_substance
and	O
by	O
showing	O
a	O
measurable	O
production	O
of	O
large	O
lipid	O
droplets	O
,	O
which	O
is	O
a	O
marker	O
of	O
mature	B-Cell
breast	I-Cell
cells	E-Cell
.	O

Therefore	O
,	O
our	O
results	O
indicate	O
that	O
emodin	O
inhibits	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
activity	O
and	O
preferentially	O
suppresses	O
growth	O
and	O
induces	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	B-Cell
cells	E-Cell
.	O

These	O
results	O
may	O
have	O
chemotherapeutic	O
implications	O
for	O
using	O
emodin	O
to	O
target	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	B-Cell
cells	E-Cell
.	O

Identification	O
of	O
NAB1	O
,	O
a	O
repressor	O
of	O
NGFI	O
-	O
A	O
-	O
and	O
Krox20	O
-	O
mediated	O
transcription	O
.	O

NGFI	O
-	O
A	O
(	O
also	O
called	O
Egr1	O
,	O
Zif268	O
,	O
or	O
Krox24	O
)	O
and	O
the	O
closely	O
related	O
proteins	O
Krox20	O
,	O
NGFI	O
-	O
C	O
,	O
and	O
Egr3	O
are	O
zinc	O
-	O
finger	O
transcription	O
factors	O
encoded	O
by	O
immediate	O
-	O
early	O
genes	O
which	O
are	O
induced	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	S-Immaterial_anatomical_entity
stimuli	O
.	O

NGFI	O
-	O
A	O
has	O
been	O
implicated	O
in	O
cell	S-Cell
proliferation	O
,	O
macrophage	S-Cell
differentiation	O
,	O
synaptic	S-Cellular_component
activation	O
,	O
and	O
long	O
-	O
term	O
potentiation	O
,	O
whereas	O
Krox20	O
is	O
critical	O
for	O
proper	O
hindbrain	S-Multi-tissue_structure
segmentation	O
and	O
peripheral	B-Multi-tissue_structure
nerve	E-Multi-tissue_structure
myelination	O
.	O

In	O
previous	O
work	O
,	O
a	O
structure	O
/	O
function	O
analysis	O
of	O
NGFI	O
-	O
A	O
revealed	O
a	O
34	O
-	O
aa	O
inhibitory	O
domain	O
that	O
was	O
hypothesized	O
to	O
be	O
the	O
target	O
of	O
a	O
cellular	S-Cell
factor	O
that	O
represses	O
NGFI	O
-	O
A	O
transcriptional	O
activity	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
clone	O
which	O
encodes	O
a	O
protein	O
that	O
interacts	O
with	O
this	O
inhibitory	O
domain	O
and	O
inhibits	O
the	O
ability	O
of	O
NGFI	O
-	O
A	O
to	O
activate	O
transcription	O
.	O

This	O
NGFI	O
-	O
A	O
-	O
binding	O
protein	O
,	O
NAB1	O
,	O
is	O
a	O
570	O
-	O
aa	O
nuclear	S-Cellular_component
protein	O
that	O
bears	O
no	O
obvious	O
sequence	O
homology	O
to	O
known	O
proteins	O
.	O

NAB1	O
also	O
represses	O
Krox20	O
activity	O
,	O
but	O
it	O
does	O
not	O
influence	O
Egr3	O
or	O
NGFI	O
-	O
G	O
,	O
thus	O
providing	O
a	O
mechanism	O
for	O
the	O
differential	O
regulation	O
of	O
this	O
family	O
of	O
immediate	O
-	O
early	O
transcription	O
factors	O
.	O

Metastatic	B-Cell
NIH	I-Cell
3T3	I-Cell
x	I-Cell
LTA	I-Cell
cell	I-Cell
hybrids	E-Cell
express	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

We	O
previously	O
reported	O
that	O
the	O
murine	O
fibroblast	B-Cell
cell	I-Cell
line	I-Cell
LTA	E-Cell
is	O
tumorigenic	O
but	O
non	O
-	O
metastatic	O
,	O
and	O
is	O
non	O
-	O
responsive	O
to	O
a	O
transfected	O
H	O
-	O
ras	O
oncogene	O
.	O

In	O
contrast	O
,	O
NIH	B-Cell
3T3	I-Cell
cells	E-Cell
are	O
non	O
-	O
tumorigenic	O
but	O
are	O
ras	O
-	O
responsive	O
and	O
become	O
metastatic	O
when	O
transfected	O
with	O
ras	O
.	O

Somatic	B-Cell
cell	I-Cell
hybrids	E-Cell
between	O
LTA	S-Cell
and	O
NIH	B-Cell
3T3	I-Cell
cells	E-Cell
are	O
tumorigenic	O
,	O
metastatic	O
and	O
ras	O
-	O
responsive	O
.	O

Here	O
we	O
examined	O
expression	O
of	O
type	O
IV	O
collagenases	O
in	O
parental	O
LTA	S-Cell
and	O
NIH	B-Cell
3T3	I-Cell
cells	E-Cell
(	O
with	O
and	O
without	O
ras	O
)	O
and	O
four	O
metastatic	B-Cell
LTA	I-Cell
x	I-Cell
NIH	I-Cell
3T3	I-Cell
hybrids	E-Cell
(	O
also	O
with	O
and	O
without	O
ras	O
)	O
.	O

Parental	O
NIH	B-Cell
3T3	I-Cell
-	I-Cell
derived	I-Cell
cells	E-Cell
had	O
both	O
72	O
kDa	O
and	O
92	O
kDa	O
gelatinase	O
activities	O
,	O
and	O
LTA	S-Cell
-	O
derived	O
cells	S-Cell
had	O
either	O
aberrantly	O
sized	O
approximately	O
90	O
kDa	O
activity	O
alone	O
or	O
neither	O
enzyme	O
activity	O
.	O

All	O
four	O
metastatic	B-Cell
hybrids	E-Cell
expressed	O
60	O
-	O
72	O
kDa	O
gelatinase	O
activity	O
,	O
while	O
three	O
of	O
them	O
also	O
had	O
92	O
kDa	O
activity	O
and	O
one	O
had	O
only	O
minimal	O
92	O
kDa	O
activity	O
.	O

Thus	O
the	O
metastatic	O
phenotype	O
of	O
the	O
hybrids	S-Cell
was	O
associated	O
with	O
expression	O
of	O
72	O
kDa	O
gelatinase	O
.	O

Levels	O
of	O
RNA	O
for	O
tissue	S-Tissue
inhibitors	O
of	O
metalloproteinases	O
(	O
TIMP	O
-	O
1	O
,	O
TIMP	O
-	O
2	O
)	O
were	O
relatively	O
constant	O
,	O
suggesting	O
independent	O
regulation	O
of	O
type	O
IV	O
collagenases	O
and	O
their	O
inhibitors	O
.	O

Southern	O
blotting	O
and	O
probing	O
with	O
PCR	O
-	O
synthesized	O
cDNA	O
fragments	O
of	O
the	O
mouse	O
72	O
kDa	O
type	O
IV	O
collagenase	O
gene	O
showed	O
that	O
this	O
gene	O
was	O
present	O
in	O
all	O
cells	S-Cell
although	O
the	O
structure	O
of	O
this	O
gene	O
in	O
one	O
of	O
the	O
three	O
LTA	B-Cell
cell	I-Cell
lines	E-Cell
differed	O
from	O
that	O
of	O
the	O
other	O
cells	S-Cell
.	O

Our	O
results	O
suggest	O
that	O
a	O
key	O
change	O
in	O
the	O
metastatic	B-Cell
hybrids	E-Cell
,	O
relative	O
to	O
non	B-Cell
-	I-Cell
metastatic	I-Cell
parental	I-Cell
LTA	I-Cell
cells	E-Cell
,	O
is	O
induction	O
of	O
expression	O
of	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

Neoplastic	S-Cancer
progression	O
of	O
human	O
colorectal	B-Cancer
cancer	E-Cancer
is	O
associated	O
with	O
overexpression	O
of	O
the	O
stromelysin	O
-	O
3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
genes	O
.	O

The	O
interaction	O
of	O
neoplastic	B-Cell
cells	E-Cell
with	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
is	O
a	O
critical	O
event	O
for	O
the	O
initiation	O
of	O
cancer	S-Cancer
invasion	O
and	O
metastasis	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
potential	O
implication	O
of	O
stromelysin	O
-	O
3	O
(	O
ST3	O
)	O
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
matrix	O
-	O
degrading	O
metalloproteinase	O
family	O
,	O
and	O
of	O
BM	O
-	O
40	O
/	O
SPARC	O
,	O
a	O
glycoprotein	O
associated	O
with	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
,	O
during	O
the	O
progression	O
of	O
human	O
colorectal	B-Cancer
cancers	E-Cancer
.	O

We	O
analyzed	O
the	O
relative	O
abundance	O
of	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
by	O
Northern	O
blot	O
,	O
and	O
their	O
distribution	O
by	O
in	O
situ	O
hybridization	O
,	O
in	O
normal	O
mucosa	S-Multi-tissue_structure
,	O
benign	B-Pathological_formation
adenomas	E-Pathological_formation
,	O
and	O
primary	B-Cancer
colorectal	I-Cancer
adenocarcinomas	E-Cancer
and	O
their	O
liver	B-Cancer
metastases	E-Cancer
.	O

The	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
were	O
overexpressed	O
in	O
primary	B-Cancer
colorectal	I-Cancer
cancers	E-Cancer
and	O
their	O
liver	B-Cancer
metastases	E-Cancer
compared	O
to	O
non	B-Multi-tissue_structure
-	I-Multi-tissue_structure
neoplastic	I-Multi-tissue_structure
mucosa	E-Multi-tissue_structure
.	O

These	O
transcripts	O
were	O
localized	O
in	O
stromal	B-Cell
fibroblasts	E-Cell
adjacent	O
to	O
the	O
neoplastic	B-Cancer
foci	E-Cancer
.	O

Overexpression	O
of	O
ST3	O
correlated	O
with	O
the	O
progression	O
of	O
human	O
colorectal	B-Cancer
tumors	E-Cancer
toward	O
local	O
invasion	O
and	O
liver	S-Organ
metastasis	O
.	O

Induction	O
of	O
these	O
genes	O
also	O
occurred	O
in	O
diverticulitis	O
and	O
digestive	O
neoplasms	S-Cancer
such	O
as	O
gastric	S-Cancer
and	O
esophageal	B-Cancer
carcinomas	E-Cancer
.	O

Childhood	O
conscientiousness	O
and	O
longevity	O
:	O
health	O
behaviors	O
and	O
cause	O
of	O
death	O
.	O

Previous	O
research	O
showed	O
that	O
conscientiousness	O
(	O
social	O
dependability	O
)	O
in	O
childhood	O
predicted	O
longevity	O
in	O
an	O
archival	O
prospective	O
cohort	O
study	O
of	O
bright	O
children	O
first	O
studied	O
by	O
Terman	O
in	O
the	O
1920s	O
(	O
H	O
.	O
S	O
.	O
Friedman	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Possible	O
behavioral	O
mechanisms	O
for	O
this	O
robust	O
association	O
are	O
now	O
examined	O
by	O
gathering	O
cause	O
of	O
death	O
information	O
and	O
by	O
considering	O
the	O
possible	O
mediating	O
influences	O
of	O
drinking	O
alcohol	O
,	O
smoking	O
,	O
and	O
overeating	O
.	O

Survival	O
analyses	O
(	O
N	O
=	O
1	O
,	O
215	O
)	O
suggest	O
that	O
the	O
protective	O
effect	O
of	O
conscientiousness	O
is	O
not	O
primarily	O
due	O
to	O
accident	O
avoidance	O
and	O
cannot	O
be	O
mostly	O
explained	O
by	O
abstinence	O
from	O
unhealthy	O
substance	O
intake	O
.	O

Conscientiousness	O
may	O
have	O
more	O
wide	O
-	O
ranging	O
effects	O
on	O
health	O
-	O
relevant	O
activities	O
.	O

Down	O
-	O
regulation	O
of	O
collagen	O
XII	O
in	O
transformed	O
mesenchymal	B-Cell
cells	E-Cell
.	O

Collagen	O
XII	O
is	O
a	O
complex	O
multidomain	O
protein	O
associated	O
with	O
the	O
surface	S-Cellular_component
of	O
interstitial	S-Immaterial_anatomical_entity
collagen	O
fibrils	S-Cellular_component
.	O

This	O
protein	O
is	O
produced	O
in	O
large	O
amounts	O
by	O
fibroblasts	S-Cell
cultivated	O
in	O
vitro	O
.	O

However	O
,	O
it	O
is	O
completely	O
absent	O
from	O
cells	S-Cell
transformed	O
by	O
the	O
oncogene	O
v	O
-	O
myc	O
or	O
v	O
-	O
src	O
and	O
from	O
cells	S-Cell
derived	O
from	O
a	O
methylcholanthrene	O
-	O
induced	O
fibrosarcoma	S-Cancer
.	O

Since	O
all	O
these	O
cells	S-Cell
lack	O
any	O
mRNA	O
for	O
collagen	O
,	O
XII	O
,	O
it	O
seems	O
likely	O
that	O
the	O
synthesis	O
is	O
blocked	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
of	O
Rous	O
sarcoma	O
virus	O
demonstrated	O
that	O
a	O
single	O
oncogene	O
product	O
is	O
sufficient	O
to	O
inhibit	O
the	O
synthesis	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
collagen	O
XII	O
might	O
have	O
profound	O
effects	O
on	O
the	O
stability	O
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
of	O
transformed	O
cells	S-Cell
.	O

Comparative	O
NMR	O
study	O
of	O
a	O
differentiated	O
rat	O
hepatoma	S-Cancer
and	O
its	O
dedifferentiated	O
subclone	S-Cell
cultured	O
as	O
spheroids	S-Cell
and	O
as	O
implanted	O
tumors	S-Cancer
.	O

H4IIEC3	S-Cell
(	O
H4	S-Cell
)	O
,	O
a	O
differentiated	O
rat	O
hepatoma	B-Cell
line	E-Cell
and	O
H5	S-Cell
,	O
its	O
dedifferentiated	O
subclone	S-Cell
,	O
were	O
investigated	O
as	O
proliferating	O
spheroids	S-Cell
and	O
as	O
implanted	O
subcutaneous	B-Cancer
tumors	E-Cancer
in	O
juvenile	O
rats	O
.	O

H4	B-Cell
cells	E-Cell
formed	O
tight	O
,	O
round	O
spheroids	S-Cell
whereas	O
H5	B-Cell
cells	E-Cell
formed	O
loose	O
,	O
grape	B-Cell
-	I-Cell
like	I-Cell
structures	E-Cell
.	O

31P	O
MR	O
spectra	O
showed	O
that	O
phosphocreatine	O
was	O
present	O
in	O
H5	B-Cell
spheroids	E-Cell
but	O
not	O
in	O
H4	B-Cell
spheroids	E-Cell
or	O
tumors	S-Cancer
.	O

[	O
13C	O
]	O
Lactate	O
production	O
from	O
[	O
13C	O
]	O
glucose	O
,	O
with	O
no	O
detectable	O
uptake	O
of	O
[	O
13C	O
]	O
alanine	O
,	O
indicated	O
that	O
energy	O
production	O
in	O
H5	B-Cell
spheroids	E-Cell
was	O
primarily	O
via	O
glycolysis	O
.	O

No	O
[	O
13C	O
]	O
glucose	O
utilization	O
was	O
detected	O
in	O
H4	B-Cell
spheroids	E-Cell
,	O
but	O
uptake	O
of	O
alanine	O
and	O
accumulation	O
of	O
labeled	O
lactate	O
,	O
glutamate	O
and	O
glutamine	O
indicated	O
oxidation	O
via	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
.	O

Tumors	S-Cancer
of	O
H4	B-Cell
cells	E-Cell
were	O
well	O
perfused	O
,	O
unlike	O
tumors	S-Cancer
of	O
H5	B-Cell
cells	E-Cell
which	O
were	O
highly	O
necrotic	O
.	O

Following	O
i	B-Immaterial_anatomical_entity
.	I-Immaterial_anatomical_entity
v	I-Immaterial_anatomical_entity
.	E-Immaterial_anatomical_entity
infusion	O
with	O
[	O
13C	O
]	O
alanine	O
,	O
[	O
13C	O
]	O
lactate	O
and	O
glutamate	O
,	O
evidence	O
of	O
oxidation	O
via	O
the	O
TCA	O
cycle	O
,	O
were	O
observed	O
in	O
H4	B-Cancer
tumors	E-Cancer
.	O

Thus	O
the	O
results	O
obtained	O
by	O
31P	O
and	O
13C	O
MRS	O
correlated	O
with	O
the	O
differentiation	O
state	O
of	O
H4	S-Cell
and	O
H5	B-Cell
spheroids	E-Cell
and	O
tumors	S-Cancer
.	O

[	O
The	O
erbB	O
gene	O
family	O
:	O
significance	O
for	O
tumor	S-Cancer
development	O
,	O
prognosis	O
and	O
new	O
therapeutic	O
modalities	O
]	O
.	O

RNA	O
and	O
DNA	O
viruses	O
can	O
be	O
transforming	O
and	O
tumourigenic	O
agents	O
.	O

The	O
transformation	O
is	O
a	O
consequence	O
of	O
the	O
ability	O
of	O
viruses	O
to	O
integrate	O
into	O
the	O
host	O
cell	S-Cell
'	O
s	O
DNA	O
and	O
to	O
produce	O
transforming	O
proteins	O
.	O

These	O
proteins	O
are	O
mainly	O
produced	O
by	O
specific	O
integral	O
parts	O
of	O
the	O
viral	O
genome	O
,	O
the	O
oncogenes	O
.	O

Comparison	O
between	O
RNA	O
/	O
DNA	O
sequence	O
of	O
viral	O
oncogenes	O
and	O
normal	O
human	O
genome	O
of	O
non	O
-	O
transformed	O
cells	S-Cell
revealed	O
high	O
sequence	O
similarities	O
in	O
specific	O
genomic	O
areas	O
,	O
which	O
were	O
named	O
cellular	S-Cell
proto	O
-	O
oncogens	O
.	O

They	O
are	O
important	O
components	O
of	O
the	O
growth	O
regulatory	O
pathways	O
in	O
normal	O
cells	S-Cell
.	O

The	O
accumulation	O
of	O
genetic	O
alterations	O
of	O
some	O
proto	O
-	O
oncogens	O
,	O
like	O
the	O
erbB	O
-	O
family	O
,	O
may	O
be	O
part	O
of	O
the	O
mechanism	O
,	O
by	O
which	O
malignant	B-Cell
cells	E-Cell
can	O
acquire	O
a	O
selective	O
growth	O
advantage	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
R	O
,	O
c	O
-	O
erbB1	O
)	O
,	O
Her	O
-	O
2	O
/	O
neu	O
(	O
c	O
-	O
erbB2	O
)	O
,	O
and	O
c	O
-	O
erbB3	O
are	O
members	O
of	O
the	O
erbB	O
-	O
family	O
.	O

The	O
detection	O
of	O
increased	O
abundance	O
of	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
proteins	O
in	O
human	O
tumours	S-Cancer
can	O
provide	O
additional	O
information	O
on	O
the	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
for	O
patients	O
with	O
breast	S-Cancer
,	O
ovarian	S-Cancer
,	O
endometrial	S-Cancer
or	O
cervical	B-Cancer
cancer	E-Cancer
.	O

Molecular	O
and	O
cell	S-Cell
-	O
physiological	O
analyses	O
have	O
improved	O
the	O
understanding	O
of	O
tumour	S-Cancer
biology	O
and	O
provide	O
the	O
opportunity	O
for	O
new	O
therapeutic	O
approaches	O
.	O

Monoclonal	O
antibody	O
targeted	O
therapy	O
directed	O
against	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
,	O
the	O
use	O
of	O
anti	O
-	O
sense	O
oligonucleotides	O
and	O
oligodeoxynucleotides	O
,	O
and	O
the	O
application	O
of	O
tyrosine	O
kinase	O
and	O
protein	O
C	O
-	O
kinase	O
inhibitors	O
are	O
currently	O
being	O
investigated	O
.	O

Human	O
cytomegalovirus	O
elevates	O
levels	O
of	O
the	O
cellular	S-Cell
protein	O
p53	O
in	O
infected	O
fibroblasts	S-Cell
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
like	O
other	O
DNA	O
tumor	S-Cancer
viruses	O
,	O
induces	O
morphological	O
transformation	O
of	O
cells	S-Cell
in	O
vitro	O
and	O
stimulates	O
host	O
cell	S-Cell
macromolecular	O
synthesis	O
in	O
infected	O
cells	S-Cell
.	O

Since	O
other	O
DNA	O
tumor	S-Cancer
viruses	O
,	O
such	O
as	O
simian	O
virus	O
40	O
and	O
adenovirus	O
,	O
have	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
cellular	S-Cell
protein	O
p53	O
,	O
we	O
investigated	O
whether	O
infection	O
of	O
cells	S-Cell
by	O
HCMV	O
would	O
modulate	O
cellular	S-Cell
p53	O
levels	O
.	O

Our	O
results	O
indicate	O
that	O
HCMV	O
elevates	O
cellular	S-Cell
p53	O
levels	O
on	O
the	O
order	O
of	O
10	O
-	O
to	O
20	O
-	O
fold	O
in	O
infected	O
fibroblasts	S-Cell
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
active	O
virus	O
and	O
was	O
prevented	O
by	O
neutralizing	O
antibody	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
determined	O
not	O
to	O
be	O
due	O
to	O
virus	O
-	O
receptor	O
interactions	O
or	O
HCMV	O
late	O
events	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
commenced	O
at	O
immediate	O
-	O
early	O
times	O
of	O
the	O
HCMV	O
multiplication	O
cycle	O
(	O
6	O
h	O
postinfection	O
)	O
and	O
reached	O
maximal	O
levels	O
by	O
24	O
h	O
postinfection	O
,	O
before	O
most	O
of	O
the	O
HCMV	O
DNA	O
synthesis	O
was	O
initiated	O
.	O

HCMV	O
immediate	O
-	O
early	O
proteins	O
were	O
clearly	O
shown	O
to	O
be	O
responsible	O
for	O
elevating	O
p53	O
levels	O
in	O
infected	O
fibroblasts	S-Cell
;	O
expression	O
of	O
HCMV	O
immediate	O
-	O
early	O
region	O
1	O
and	O
2	O
proteins	O
resulted	O
in	O
elevation	O
of	O
p53	O
levels	O
in	O
transfected	O
human	O
fibroblasts	S-Cell
.	O

This	O
is	O
the	O
first	O
report	O
of	O
increased	O
p53	O
levels	O
caused	O
by	O
HCMV	O
in	O
infected	O
fibroblasts	S-Cell
.	O

Comparison	O
of	O
image	O
(	O
CAS	O
200	O
)	O
and	O
flow	O
cytometry	O
determined	O
DNA	O
content	O
of	O
paraffin	O
-	O
embedded	O
Hodgkin	B-Tissue
'	I-Tissue
s	I-Tissue
disease	I-Tissue
tissue	E-Tissue
.	O

To	O
assess	O
the	O
reliability	O
of	O
DNA	O
estimation	O
using	O
image	O
cytometry	O
,	O
deparaffinized	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
from	O
70	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
were	O
examined	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
with	O
those	O
from	O
flow	O
cytometry	O
.	O

Image	O
analysis	O
without	O
discriminating	O
between	O
the	O
various	O
cell	S-Cell
types	O
,	O
as	O
found	O
in	O
Hodgkin	O
'	O
s	O
disease	O
,	O
revealed	O
no	O
separate	O
aneuploid	O
peak	O
.	O

Selecting	O
on	O
morphologically	O
defined	O
nuclear	S-Cellular_component
types	O
DNA	O
aneuploidy	O
was	O
detected	O
in	O
20	O
%	O
of	O
the	O
cases	O
(	O
14	O
/	O
70	O
)	O
.	O

The	O
aneuploid	O
populations	O
were	O
limited	O
to	O
the	O
population	O
of	O
nuclei	S-Cellular_component
defined	O
as	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
-	O
like	O
or	O
medium	O
-	O
sized	O
lymphocytes	S-Cell
.	O

Benign	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
DNA	O
aneuploidy	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
controls	O
.	O

Comparison	O
of	O
DNA	O
histograms	O
obtained	O
by	O
image	O
and	O
flow	O
cytometry	O
showed	O
aneuploid	O
peaks	O
using	O
image	O
cytometry	O
in	O
4	O
of	O
30	O
diploid	O
and	O
10	O
of	O
40	O
aneuploid	O
flow	O
histograms	O
.	O

In	O
conclusion	O
,	O
image	O
analysis	O
using	O
the	O
CAS	O
200	O
system	O
as	O
compared	O
to	O
flow	O
cytometry	O
is	O
more	O
time	O
-	O
consuming	O
and	O
less	O
sensitive	O
to	O
assess	O
ploidy	O
status	O
,	O
although	O
it	O
may	O
provide	O
extra	O
information	O
in	O
some	O
selected	O
cases	O
.	O

Evidence	O
is	O
obtained	O
that	O
DNA	O
aneuploidy	O
in	O
Hodgkin	O
'	O
s	O
disease	O
is	O
preferentially	O
expressed	O
by	O
cells	S-Cell
with	O
the	O
RS	O
/	O
H	O
-	O
like	O
and	O
medium	O
-	O
sized	O
lymphocyte	S-Cell
morphology	O
.	O

Imaging	O
techniques	O
for	O
the	O
assessment	O
of	O
body	S-Organism_subdivision
composition	O
.	O

Three	O
imaging	O
methods	O
,	O
ultrasound	O
imaging	O
(	O
UI	O
)	O
,	O
computer	O
-	O
assisted	O
axial	O
tomography	O
(	O
CAT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
are	O
widely	O
used	O
in	O
medicine	O
.	O

Their	O
application	O
to	O
the	O
assessment	O
of	O
body	S-Organism_subdivision
composition	O
in	O
nutrition	O
research	O
is	O
still	O
being	O
explored	O
and	O
developed	O
.	O

Ultrasound	O
imaging	O
yields	O
poor	O
image	O
quality	O
but	O
,	O
because	O
it	O
is	O
cheap	O
and	O
safe	O
,	O
deserves	O
further	O
exploration	O
.	O

Both	O
CAT	O
and	O
MRI	O
can	O
produce	O
images	O
with	O
good	O
discrimination	O
among	O
bone	S-Organ
,	O
muscle	S-Organ
and	O
adipose	B-Tissue
tissue	E-Tissue
.	O

Movement	O
artifacts	O
tend	O
to	O
be	O
more	O
serious	O
in	O
MRI	O
than	O
in	O
CAT	O
due	O
to	O
the	O
longer	O
imaging	O
time	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
X	O
-	O
ray	O
exposure	O
in	O
CAT	O
is	O
likely	O
to	O
limit	O
its	O
use	O
in	O
human	O
nutrition	O
research	O
.	O

Repeated	O
measurements	O
of	O
tissue	S-Tissue
volumes	O
by	O
CAT	O
and	O
MRI	O
give	O
similar	O
CV	O
.	O

In	O
both	O
CAT	O
and	O
MRI	O
,	O
intra	O
-	O
abdominal	B-Tissue
adipose	I-Tissue
tissue	E-Tissue
presents	O
greater	O
problems	O
of	O
measurement	O
than	O
subcutaneous	B-Tissue
adipose	I-Tissue
tissue	E-Tissue
.	O

Validation	O
studies	O
with	O
77	O
-	O
kg	O
pigs	O
of	O
MRI	O
,	O
using	O
13	O
slices	O
,	O
predicted	O
total	O
body	S-Organism_subdivision
lipid	O
with	O
residual	O
standard	O
deviation	O
of	O
1	O
.	O
9	O
%	O
.	O

In	O
validating	O
any	O
of	O
these	O
methods	O
,	O
account	O
should	O
be	O
take	O
of	O
the	O
extent	O
to	O
which	O
the	O
information	O
they	O
give	O
can	O
augment	O
that	O
given	O
by	O
more	O
simple	O
measures	O
like	O
age	O
and	O
weight	O
.	O

H	O
-	O
ras	O
mutations	O
in	O
human	O
pituitary	B-Cancer
carcinoma	I-Cancer
metastases	E-Cancer
.	O

Molecular	O
mechanisms	O
of	O
pituitary	S-Organ
tumorigenesis	O
were	O
studied	O
using	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
with	O
DNA	O
sequencing	O
to	O
identify	O
potential	O
mutations	O
in	O
the	O
ras	O
protooncogenes	O
and	O
the	O
tumor	S-Cancer
suppressor	O
gene	O
p53	O
in	O
invasive	B-Cancer
pituitary	I-Cancer
adenomas	E-Cancer
and	O
carcinomas	S-Cancer
.	O

Sequencing	O
of	O
exons	O
5	O
through	O
8	O
of	O
the	O
p53	O
gene	O
revealed	O
no	O
mutations	O
,	O
nor	O
were	O
mutations	O
detected	O
in	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
protooncogenes	O
in	O
four	O
of	O
the	O
carcinomas	S-Cancer
and	O
their	O
respective	O
metastatic	B-Cancer
deposits	E-Cancer
.	O

Point	O
mutations	O
of	O
H	O
-	O
ras	O
however	O
,	O
were	O
identified	O
in	O
three	O
distant	O
metastatic	B-Cancer
pituitary	I-Cancer
tumor	I-Cancer
secondaries	E-Cancer
,	O
but	O
not	O
in	O
their	O
respective	O
primary	B-Cancer
pituitary	I-Cancer
carcinomas	E-Cancer
,	O
or	O
in	O
six	O
invasive	B-Cancer
adenomas	E-Cancer
.	O

Two	O
of	O
the	O
mutations	O
included	O
a	O
G	O
to	O
C	O
substitution	O
at	O
codon	O
12	O
,	O
and	O
a	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
18	O
,	O
resulting	O
in	O
a	O
glycine	O
to	O
arginine	O
,	O
and	O
an	O
alanine	O
to	O
threonine	O
change	O
at	O
these	O
amino	O
acids	O
,	O
respectively	O
.	O

A	O
third	O
mutation	O
involved	O
a	O
single	O
base	O
pair	O
(	O
adenine	O
)	O
deletion	O
in	O
codon	O
3	O
of	O
H	O
-	O
ras	O
which	O
causes	O
a	O
frame	O
shift	O
,	O
resulting	O
in	O
a	O
termination	O
signal	O
at	O
codon	O
19	O
.	O

These	O
results	O
suggest	O
that	O
point	O
mutations	O
in	O
p53	O
and	O
ras	O
are	O
not	O
associated	O
with	O
pituitary	S-Organ
tumorigenesis	O
,	O
however	O
,	O
point	O
mutations	O
of	O
the	O
H	O
-	O
ras	O
gene	O
may	O
be	O
important	O
in	O
the	O
formation	O
and	O
or	O
growth	O
of	O
pituitary	B-Cancer
metastases	E-Cancer
.	O

This	O
observed	O
genomic	O
instability	O
will	O
be	O
of	O
value	O
in	O
predicting	O
the	O
potential	O
metastatic	O
behavior	O
of	O
these	O
aggressive	O
pituitary	B-Cancer
tumors	E-Cancer
.	O

Overexpression	O
of	O
Glut	O
-	O
1	O
glucose	O
transporter	O
in	O
human	O
breast	B-Cancer
cancer	E-Cancer
.	O

An	O
immunohistochemical	O
study	O
.	O

BACKGROUND	O
:	O
Breast	B-Cancer
cancers	E-Cancer
have	O
higher	O
than	O
normal	O
glucose	O
metabolism	O
,	O
but	O
the	O
mechanism	O
of	O
glucose	O
entry	O
into	O
these	O
tumors	S-Cancer
is	O
not	O
well	O
understood	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
five	O
facilitative	O
glucose	O
transporters	O
,	O
Glut	O
-	O
1	O
(	O
erythrocyte	S-Cell
type	O
)	O
,	O
Glut	O
-	O
2	O
(	O
liver	S-Organ
type	O
)	O
,	O
Glut	O
-	O
3	O
(	O
brain	S-Organ
type	O
)	O
,	O
Glut	O
-	O
4	O
(	O
muscle	S-Organ
/	O
fat	S-Tissue
type	O
)	O
,	O
and	O
Glut	O
-	O
5	O
(	O
small	B-Organ
intestine	E-Organ
type	O
)	O
,	O
was	O
studied	O
by	O
immunohistochemistry	O
of	O
paraffin	B-Cancer
sections	E-Cancer
from	O
12	O
primary	B-Cancer
human	I-Cancer
breast	I-Cancer
cancers	E-Cancer
and	O
8	O
lymph	B-Cancer
node	I-Cancer
metastases	E-Cancer
from	O
2	O
patients	O
.	O

Rat	O
tissues	S-Tissue
known	O
to	O
express	O
these	O
glucose	O
transporters	O
were	O
used	O
as	O
controls	O
.	O

RESULTS	O
:	O
All	O
the	O
primary	B-Cancer
breast	I-Cancer
cancers	E-Cancer
and	O
the	O
lymph	B-Cancer
node	I-Cancer
metastases	E-Cancer
were	O
positive	O
for	O
Glut	O
-	O
1	O
.	O

This	O
transporter	O
was	O
expressed	O
on	O
the	O
cell	B-Cellular_component
membrane	E-Cellular_component
and	O
in	O
the	O
cytoplasm	S-Organism_substance
of	O
the	O
tumor	B-Cell
cells	E-Cell
,	O
but	O
exhibited	O
marked	O
intratumoral	S-Cancer
and	O
intertumoral	S-Cancer
variability	O
in	O
the	O
proportions	O
of	O
positive	O
cells	S-Cell
and	O
the	O
intensity	O
of	O
staining	O
.	O

Staining	O
of	O
the	O
normal	O
mammary	B-Tissue
epithelium	E-Tissue
,	O
if	O
present	O
,	O
was	O
much	O
lower	O
than	O
observed	O
in	O
tumor	B-Cell
cells	E-Cell
from	O
the	O
same	O
patient	O
.	O

Glut	O
-	O
2	O
was	O
expressed	O
in	O
all	O
of	O
the	O
tumors	S-Cancer
,	O
but	O
the	O
intensity	O
of	O
staining	O
was	O
not	O
consistently	O
stronger	O
than	O
that	O
seen	O
in	O
healthy	B-Tissue
breast	E-Tissue
.	O

Clusters	O
of	O
Glut	O
-	O
4	O
-	O
positive	O
granule	O
were	O
observed	O
in	O
cells	S-Cell
in	O
six	O
of	O
the	O
tumors	S-Cancer
.	O

None	O
of	O
the	O
tumors	S-Cancer
or	O
the	O
healthy	B-Tissue
breast	E-Tissue
in	O
the	O
tissues	S-Tissue
studied	O
expressed	O
Glut	O
-	O
3	O
or	O
Glut	O
-	O
5	O
.	O

CONCLUSIONS	O
:	O
Higher	O
expression	O
of	O
the	O
glucose	O
transporter	O
Glut	O
-	O
1	O
by	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
compared	O
with	O
the	O
healthy	B-Tissue
breast	I-Tissue
tissue	E-Tissue
is	O
common	O
.	O

Increased	O
glucose	O
transporter	O
protein	O
expression	O
may	O
contribute	O
to	O
the	O
increased	O
uptake	O
of	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
FDG	O
)	O
by	O
these	O
tumors	S-Cancer
observed	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
.	O

High	O
density	O
of	O
somatostatin	O
receptors	O
in	O
veins	S-Multi-tissue_structure
surrounding	O
human	O
cancer	B-Tissue
tissue	E-Tissue
:	O
role	O
in	O
tumor	S-Cancer
-	O
host	O
interaction	O
?	O

Somatostatin	O
receptors	O
were	O
detected	O
in	O
peritumoral	B-Multi-tissue_structure
veins	E-Multi-tissue_structure
of	O
various	O
human	O
cancer	B-Tissue
tissue	I-Tissue
specimens	E-Tissue
.	O

Vascular	S-Tissue
and	O
neoplastic	B-Tissue
tissue	E-Tissue
from	O
14	O
colonic	B-Cancer
adenocarcinomas	E-Cancer
,	O
13	O
carcinoids	S-Cancer
,	O
6	O
renal	B-Cancer
-	I-Cancer
cell	I-Cancer
carcinomas	E-Cancer
and	O
7	O
malignant	B-Cancer
lymphomas	E-Cancer
were	O
analyzed	O
for	O
somatostatin	O
receptors	O
by	O
use	O
of	O
quantitative	O
receptor	O
autoradiography	O
.	O

In	O
colonic	B-Cancer
carcinoma	I-Cancer
specimens	E-Cancer
,	O
the	O
peritumoral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
expressed	O
a	O
high	O
density	O
of	O
somatostatin	O
receptors	O
,	O
whereas	O
the	O
neoplastic	B-Tissue
tissue	E-Tissue
itself	O
was	O
receptor	O
-	O
negative	O
in	O
many	O
cases	O
.	O

In	O
contrast	O
,	O
the	O
incidence	O
and	O
density	O
of	O
somatostatin	O
receptors	O
in	O
peritumoral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
was	O
low	O
in	O
well	O
-	O
differentiated	O
gastrointestinal	S-Cancer
and	O
bronchial	B-Cancer
carcinoids	E-Cancer
,	O
in	O
contrast	O
to	O
the	O
high	O
density	O
of	O
such	O
receptors	O
in	O
the	O
carcinoid	B-Tissue
tumor	I-Tissue
tissue	E-Tissue
.	O

Autochthonous	O
vessels	S-Multi-tissue_structure
surrounding	O
other	O
tumors	S-Cancer
such	O
as	O
renal	B-Cancer
-	I-Cancer
cell	I-Cancer
carcinomas	E-Cancer
or	O
malignant	B-Cancer
lymphomas	E-Cancer
also	O
frequently	O
expressed	O
somatostatin	O
receptors	O
.	O

In	O
all	O
cases	O
,	O
the	O
somatostatin	O
receptors	O
were	O
localized	O
in	O
veins	S-Multi-tissue_structure
,	O
particularly	O
in	O
the	O
smooth	B-Tissue
-	I-Tissue
muscle	I-Tissue
cell	I-Tissue
layer	E-Tissue
.	O

They	O
exhibited	O
specific	O
and	O
high	O
-	O
affinity	O
binding	O
of	O
somatostatin	O
-	O
14	O
,	O
somatostatin	O
-	O
28	O
and	O
octreotide	O
,	O
suggesting	O
a	O
preferential	O
expression	O
of	O
the	O
SSTR2	O
receptor	O
subtype	O
.	O

Since	O
the	O
vessels	S-Multi-tissue_structure
of	O
normal	O
non	B-Tissue
-	I-Tissue
neoplastic	I-Tissue
human	I-Tissue
tissues	E-Tissue
,	O
e	O
.	O
g	O
.	O
of	O
intestine	S-Organ
or	O
lymphatic	B-Organ
organs	E-Organ
,	O
have	O
few	O
somatostatin	O
receptors	O
,	O
the	O
increased	O
somatostatin	O
receptor	O
expression	O
in	O
peritumoral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
observed	O
in	O
this	O
study	O
may	O
be	O
linked	O
to	O
the	O
neoplastic	S-Cancer
process	O
itself	O
.	O

The	O
results	O
suggest	O
that	O
somatostatin	O
and	O
somatostatin	O
receptors	O
may	O
play	O
a	O
regulatory	O
role	O
for	O
hemodynamic	O
tumor	S-Cancer
-	O
host	O
interactions	O
,	O
possibly	O
involving	O
tumor	B-Tissue
stroma	E-Tissue
generation	O
,	O
tumor	S-Cancer
environment	O
,	O
angiogenesis	O
and	O
,	O
particularly	O
,	O
vascular	S-Multi-tissue_structure
drainage	O
of	O
poorly	O
differentiated	O
neoplasms	S-Cancer
.	O

Toward	O
a	O
theory	O
regarding	O
the	O
pathogenesis	O
of	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
:	O
what	O
we	O
do	O
and	O
do	O
not	O
know	O
about	O
cytokine	O
regulation	O
.	O

OBJECTIVES	O
:	O

The	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
is	O
the	O
massive	O
inflammatory	O
reaction	O
resulting	O
from	O
systemic	O
mediator	O
release	O
that	O
may	O
lead	O
to	O
multiple	O
organ	S-Organ
dysfunction	O
.	O

The	O
objective	O
of	O
this	O
review	O
article	O
is	O
to	O
analyze	O
the	O
roles	O
of	O
cytokines	O
,	O
cytokine	O
production	O
,	O
and	O
the	O
relationship	O
of	O
cytokine	O
production	O
to	O
the	O
development	O
of	O
SIRS	O
.	O

DATA	O
SOURCES	O
:	O

Previous	O
research	O
and	O
clinical	O
studies	O
related	O
to	O
cytokines	O
and	O
their	O
relationship	O
to	O
SIRS	O
.	O

STUDY	O
SELECTION	O
:	O

From	O
the	O
studies	O
reviewed	O
,	O
three	O
critical	O
questions	O
are	O
addressed	O
.	O

First	O
,	O
what	O
is	O
the	O
definition	O
of	O
increased	O
cytokine	O
concentrations	O
?	O

Second	O
,	O
what	O
other	O
systemic	O
illnesses	O
besides	O
sepsis	O
can	O
alter	O
cytokine	O
concentrations	O
?	O

Third	O
,	O
what	O
are	O
the	O
right	O
cytokines	O
to	O
measure	O
?	O

DATA	O
SYNTHESIS	O
:	O

This	O
article	O
postulates	O
a	O
three	O
-	O
stage	O
development	O
of	O
SIRS	O
,	O
in	O
which	O
stage	O
1	O
is	O
a	O
local	O
production	O
of	O
cytokines	O
in	O
response	O
to	O
an	O
injury	O
or	O
infection	O
.	O

Stage	O
2	O
is	O
the	O
protective	O
release	O
of	O
a	O
small	O
amount	O
of	O
cytokines	O
into	O
the	O
body	S-Organism_subdivision
'	O
s	O
circulation	O
.	O

Stage	O
3	O
is	O
the	O
massive	O
systemic	O
reaction	O
where	O
cytokines	O
turn	O
destructive	O
by	O
compromising	O
the	O
integrity	O
of	O
the	O
capillary	B-Tissue
walls	E-Tissue
and	O
flooding	O
end	O
organs	S-Organ
.	O

CONCLUSIONS	O
:	O

While	O
cytokines	O
are	O
generally	O
viewed	O
as	O
a	O
destructive	O
development	O
in	O
the	O
patient	O
that	O
generally	O
leads	O
to	O
multiple	O
organ	S-Organ
dysfunction	O
,	O
cytokines	O
also	O
protect	O
the	O
body	S-Organism_subdivision
when	O
localized	O
.	O

It	O
will	O
be	O
necessary	O
to	O
study	O
the	O
positive	O
effects	O
of	O
cytokines	O
while	O
also	O
studying	O
their	O
role	O
in	O
causing	O
SIRS	O
.	O

It	O
will	O
also	O
be	O
important	O
to	O
investigate	O
the	O
relationship	O
between	O
cytokines	O
and	O
their	O
blockers	O
in	O
SIRS	O
.	O

Syndecan	O
-	O
1	O
expression	O
in	O
mammary	B-Cell
epithelial	I-Cell
tumor	I-Cell
cells	E-Cell
is	O
E	O
-	O
cadherin	O
-	O
dependent	O
.	O

E	O
-	O
cadherin	O
is	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
cell	S-Cell
-	O
cell	S-Cell
adhesion	O
molecule	O
,	O
which	O
is	O
mainly	O
expressed	O
in	O
epithelial	B-Cell
cells	E-Cell
.	O

Recent	O
studies	O
have	O
shown	O
that	O
E	O
-	O
cadherin	O
has	O
an	O
important	O
role	O
as	O
an	O
invasion	O
suppressor	O
molecule	O
in	O
epithelial	B-Cell
tumor	I-Cell
cells	E-Cell
.	O

Syndecan	O
-	O
1	O
is	O
a	O
cell	B-Cellular_component
surface	E-Cellular_component
proteoglycan	O
that	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
cellular	S-Cell
functions	O
including	O
cell	S-Cell
-	O
cell	S-Cell
adhesion	O
,	O
cell	S-Cell
-	O
matrix	S-Cellular_component
anchorage	O
and	O
growth	O
factor	O
presentation	O
for	O
signalling	O
receptors	O
.	O

Its	O
suppression	O
has	O
also	O
been	O
shown	O
to	O
be	O
associated	O
with	O
malignant	O
transformation	O
of	O
epithelial	B-Cell
cells	E-Cell
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
coordinated	O
regulation	O
of	O
cell	S-Cell
-	O
cell	S-Cell
and	O
cell	S-Cell
-	O
matrix	S-Cellular_component
interactions	O
during	O
malignant	O
transformation	O
,	O
we	O
have	O
studied	O
the	O
expression	O
of	O
syndecan	O
-	O
1	O
in	O
malignant	B-Cell
mammary	I-Cell
tumor	I-Cell
cells	E-Cell
genetically	O
manipulated	O
for	O
E	O
-	O
cadherin	O
expression	O
.	O

In	O
invasive	O
NM	B-Cell
-	I-Cell
e	I-Cell
-	I-Cell
ras	I-Cell
-	I-Cell
MAC1	I-Cell
cells	E-Cell
,	O
where	O
E	O
-	O
cadherin	O
was	O
partially	O
downregulated	O
by	O
specific	O
antisense	O
RNA	O
,	O
syndecan	O
-	O
1	O
expression	O
was	O
suppressed	O
.	O

Furthermore	O
,	O
transfection	O
of	O
E	O
-	O
cadherin	O
cDNA	O
into	O
invasive	O
NM	B-Cell
-	I-Cell
f	I-Cell
-	I-Cell
ras	I-Cell
-	I-Cell
TD	I-Cell
cells	E-Cell
resulted	O
in	O
the	O
upregulation	O
of	O
syndecan	O
-	O
1	O
expression	O
in	O
association	O
with	O
decreased	O
invasiveness	O
.	O

In	O
both	O
cases	O
,	O
regulation	O
of	O
syndecan	O
-	O
1	O
occurred	O
post	O
-	O
transcriptionally	O
,	O
since	O
syndecan	O
-	O
1	O
mRNA	O
levels	O
remained	O
unchanged	O
.	O

Instead	O
,	O
a	O
translational	O
regulation	O
is	O
suggested	O
,	O
since	O
syndecan	O
-	O
1	O
core	O
protein	O
synthesis	O
was	O
E	O
-	O
cadherin	O
dependent	O
.	O

Another	O
cell	S-Cell
adhesion	O
protein	O
,	O
beta	O
1	O
-	O
integrin	O
was	O
not	O
affected	O
by	O
E	O
-	O
cadherin	O
expression	O
.	O

The	O
data	O
provide	O
an	O
example	O
of	O
coordinated	O
changes	O
in	O
the	O
expression	O
of	O
two	O
cell	S-Cell
adhesion	O
molecules	O
,	O
syndecan	O
-	O
1	O
and	O
E	O
-	O
cadherin	O
during	O
epithelial	B-Cell
cell	E-Cell
transformation	O
.	O

Metastasis	O
-	O
associated	O
5T4	O
antigen	O
disrupts	O
cell	B-Cellular_component
-	I-Cellular_component
cell	I-Cellular_component
contacts	E-Cellular_component
and	O
induces	O
cellular	S-Cell
motility	O
in	O
epithelial	B-Cell
cells	E-Cell
.	O

The	O
5T4	O
antigen	O
is	O
defined	O
by	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
specific	O
for	O
human	O
trophoblast	S-Cell
.	O

It	O
is	O
also	O
expressed	O
by	O
many	O
types	O
of	O
tumour	B-Cell
cell	E-Cell
and	O
has	O
been	O
associated	O
with	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
in	O
a	O
number	O
of	O
cancers	S-Cancer
.	O

This	O
pattern	O
of	O
expression	O
is	O
consistent	O
with	O
a	O
mechanistic	O
involvement	O
of	O
5T4	O
molecules	O
in	O
the	O
spread	O
of	O
cancer	B-Cell
cells	E-Cell
.	O

The	O
5T4	O
antigen	O
is	O
a	O
transmembrane	S-Cellular_component
glycoprotein	O
with	O
a	O
310	O
amino	O
acid	O
extracellular	S-Immaterial_anatomical_entity
domain	O
and	O
a	O
44	O
amino	O
acid	O
cytoplasmic	S-Organism_substance
domain	O
.	O

Transfection	O
of	O
full	O
-	O
length	O
5T4	O
cDNA	O
into	O
epithelial	B-Cell
cells	E-Cell
alters	O
cell	B-Cellular_component
-	I-Cellular_component
cell	I-Cellular_component
contacts	E-Cellular_component
and	O
cellular	S-Cell
motility	O
.	O

Thus	O
,	O
in	O
5T4	O
-	O
transfected	O
CL	B-Cell
-	I-Cell
S1	I-Cell
murine	I-Cell
mammary	I-Cell
cells	E-Cell
,	O
5T4	O
expression	O
is	O
associated	O
with	O
dendritic	S-Cell
morphology	O
,	O
accompanied	O
by	O
abrogation	O
of	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
and	O
increased	O
motility	O
.	O

In	O
transfected	O
MDCK	B-Cell
canine	I-Cell
kidney	I-Cell
epithelial	I-Cell
cells	E-Cell
,	O
5T4	O
over	O
-	O
expression	O
also	O
results	O
in	O
increased	O
motility	O
,	O
but	O
disruption	O
of	O
cell	B-Cellular_component
-	I-Cellular_component
cell	I-Cellular_component
contacts	E-Cellular_component
,	O
either	O
by	O
culturing	O
cells	S-Cell
in	O
low	O
calcium	O
medium	O
or	O
by	O
addition	O
of	O
HGF	O
/	O
SF	O
,	O
is	O
needed	O
.	O

The	O
effects	O
of	O
5T4	O
expression	O
on	O
morphology	O
and	O
motility	O
are	O
separable	O
since	O
cells	S-Cell
transfected	O
with	O
a	O
truncated	O
form	O
of	O
5T4	O
cDNA	O
in	O
which	O
the	O
cytoplasmic	S-Organism_substance
domain	O
is	O
deleted	O
reveal	O
that	O
the	O
latter	O
is	O
necessary	O
to	O
abrogate	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
but	O
does	O
not	O
influence	O
the	O
effects	O
on	O
motility	O
.	O

Thus	O
,	O
5T4	O
molecules	O
can	O
deliver	O
signals	O
through	O
both	O
the	O
extracellular	S-Immaterial_anatomical_entity
and	O
intracellular	S-Immaterial_anatomical_entity
domains	O
,	O
and	O
the	O
resultant	O
effects	O
are	O
consistent	O
with	O
a	O
role	O
for	O
5T4	O
molecules	O
in	O
invasion	O
processes	O
.	O

Defective	O
biliary	O
copper	O
excretion	O
in	O
Wilson	O
'	O
s	O
disease	O
:	O
the	O
role	O
of	O
caeruloplasmin	O
.	O

Previous	O
studies	O
have	O
failed	O
to	O
explain	O
the	O
link	O
between	O
copper	O
accumulation	O
and	O
abnormal	O
caeruloplasmin	O
expression	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
despite	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Wilson	O
'	O
s	O
disease	O
,	O
which	O
predicts	O
a	O
defective	O
copper	O
transport	O
protein	O
,	O
the	O
localization	O
of	O
this	O
putative	O
protein	O
and	O
its	O
relationship	O
to	O
the	O
pathway	O
involved	O
in	O
copper	O
excretion	O
and	O
to	O
caeruloplasmin	O
remain	O
unknown	O
.	O

We	O
now	O
present	O
evidence	O
that	O
caeruloplasmin	O
,	O
the	O
major	O
plasma	S-Organism_substance
copper	O
-	O
carrying	O
protein	O
,	O
is	O
present	O
in	O
the	O
liver	S-Organ
in	O
Wilson	O
'	O
s	O
disease	O
,	O
and	O
thus	O
that	O
reduced	O
circulating	O
levels	O
of	O
the	O
protein	O
result	O
from	O
a	O
post	O
-	O
translational	O
defect	O
in	O
the	O
secretory	O
pathway	O
.	O

We	O
have	O
also	O
identified	O
a	O
novel	O
form	O
of	O
caeruloplasmin	O
,	O
molecular	O
weight	O
125	O
kD	O
,	O
which	O
we	O
propose	O
may	O
act	O
as	O
the	O
carrier	O
for	O
excretory	O
copper	O
into	O
bile	S-Organism_substance
,	O
since	O
it	O
is	O
normally	O
present	O
in	O
both	O
liver	S-Organ
and	O
bile	S-Organism_substance
,	O
although	O
largely	O
absent	O
from	O
serum	S-Organism_substance
,	O
and	O
undetectable	O
in	O
bile	S-Organism_substance
from	O
Wilson	O
'	O
s	O
disease	O
patients	O
.	O

The	O
presence	O
of	O
this	O
form	O
of	O
caeruloplasmin	O
in	O
Wilson	O
'	O
s	O
disease	O
liver	S-Organ
suggests	O
that	O
a	O
related	O
post	O
-	O
translational	O
defect	O
may	O
also	O
be	O
responsible	O
for	O
its	O
absence	O
from	O
bile	S-Organism_substance
in	O
Wilson	O
'	O
s	O
disease	O
.	O

This	O
study	O
thus	O
provides	O
the	O
first	O
plausible	O
explanation	O
of	O
a	O
link	O
between	O
the	O
defective	O
copper	O
excretion	O
and	O
the	O
reduced	O
plasma	S-Organism_substance
caeruloplasmin	O
,	O
which	O
characterize	O
Wilson	O
'	O
s	O
disease	O
.	O

[	O
Effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
hematogenous	O
metastasis	O
of	O
cancer	S-Cancer
]	O
.	O

The	O
experimental	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
were	O
performed	O
to	O
investigate	O
the	O
effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
adhesion	O
of	O
cancer	B-Cell
cells	E-Cell
to	O
endothelial	B-Cell
cells	E-Cell
.	O

Certain	O
carcinostatic	O
agents	O
induce	O
the	O
expression	O
of	O
E	O
-	O
selectin	O
on	O
endothelial	B-Cell
cells	E-Cell
and	O
enhance	O
the	O
expression	O
of	O
carbohydrate	O
ligands	O
on	O
cancer	B-Cell
cells	E-Cell
.	O

Consequently	O
,	O
increased	O
adhesion	O
of	O
cancer	B-Cell
cells	E-Cell
to	O
endothelial	B-Cell
cells	E-Cell
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

In	O
the	O
trans	B-Immaterial_anatomical_entity
-	I-Immaterial_anatomical_entity
splenic	E-Immaterial_anatomical_entity
hepatic	S-Organ
metastasis	O
model	O
using	O
nude	O
mice	O
,	O
the	O
augmentation	O
of	O
cancer	S-Cancer
metastasis	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

From	O
the	O
above	O
,	O
we	O
concluded	O
that	O
carcinostatic	O
agents	O
may	O
increase	O
the	O
metastatic	O
ability	O
of	O
cancer	B-Cell
cells	E-Cell
in	O
patients	O
with	O
cancer	S-Cancer
.	O

Changes	O
in	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
levels	O
in	O
non	B-Cancer
-	I-Cancer
small	I-Cancer
cell	I-Cancer
lung	I-Cancer
cancer	E-Cancer
.	O

Increased	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
levels	O
are	O
increased	O
in	O
a	O
number	O
of	O
malignancies	S-Cancer
and	O
have	O
been	O
correlated	O
with	O
decreased	O
disease	O
-	O
free	O
interval	O
and	O
decreased	O
overall	O
survival	O
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
components	O
of	O
this	O
plasminogen	O
activating	O
system	O
in	O
patients	O
with	O
Non	B-Cancer
-	I-Cancer
Small	I-Cancer
Cell	I-Cancer
Lung	I-Cancer
Cancer	E-Cancer
(	O
NSCLC	S-Cancer
)	O
.	O

Levels	O
of	O
uPA	O
,	O
urokinase	O
-	O
plasminogen	O
activator	O
receptor	O
(	O
uPAR	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
were	O
measured	O
semiquantitatively	O
in	O
paraffin	B-Cancer
sections	E-Cancer
of	O
tumours	S-Cancer
from	O
147	O
patients	O
with	O
NSCLC	S-Cancer
.	O

Immunohistochemically	O
stained	O
sections	S-Cancer
of	O
tumour	S-Cancer
were	O
allocated	O
a	O
score	O
for	O
stain	O
intensity	O
and	O
results	O
correlated	O
to	O
:	O
survival	O
;	O
tumour	S-Cancer
stage	O
(	O
T	O
)	O
;	O
nodal	S-Multi-tissue_structure
stage	O
(	O
N	O
)	O
;	O
stage	O
grouping	O
(	O
I	O
to	O
IIIb	O
)	O
,	O
survival	O
status	O
and	O
sex	O
.	O

Increased	O
levels	O
of	O
PAI	O
-	O
1	O
were	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
squamous	B-Cancer
cell	I-Cancer
carcinoma	E-Cancer
(	O
SCC	S-Cancer
)	O
X2	O
=	O
5	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
017	O
(	O
n	O
=	O
74	O
)	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
N	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
presence	O
of	O
nodal	B-Cancer
metastases	E-Cancer
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
stage	O
grouping	O
(	O
p	O
=	O
<	O
0	O
.	O
01	O
)	O
and	O
extent	O
of	O
disease	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
and	O
the	O
SCC	S-Cancer
subgroup	O
,	O
but	O
not	O
adenocarcinoma	S-Cancer
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
T	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
,	O
and	O
survival	O
status	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
SCC	S-Cancer
subgroup	O
alone	O
.	O

uPA	O
and	O
uPAR	O
levels	O
were	O
not	O
significantly	O
associated	O
with	O
tumour	S-Cancer
staging	O
or	O
survival	O
.	O

We	O
conclude	O
that	O
increased	O
PAI	O
-	O
1	O
antigen	O
levels	O
may	O
be	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
patients	O
with	O
SCC	S-Cancer
.	O

Conservative	O
treatment	O
of	O
endometriosis	O
:	O
the	O
effects	O
of	O
limited	O
surgery	O
and	O
hormonal	O
pseudopregnancy	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
limited	O
surgery	O
or	O
hormonal	O
pseudopregnancy	O
,	O
or	O
a	O
combination	O
of	O
these	O
two	O
,	O
upon	O
fertility	O
and	O
the	O
need	O
for	O
subsequent	O
surgery	O
with	O
respect	O
to	O
the	O
extent	O
of	O
the	O
disease	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
in	O
patients	O
with	O
endometriosis	O
externa	O
.	O

Of	O
the	O
61	O
patients	O
who	O
desired	O
to	O
enhance	O
or	O
preserve	O
reproductive	O
capacity	O
,	O
20	O
patients	O
became	O
pregnant	O
,	O
for	O
a	O
pregnancy	O
rate	O
of	O
33	O
%	O
.	O

The	O
pregnancy	O
rate	O
in	O
all	O
categories	O
,	O
that	O
is	O
,	O
those	O
patients	O
treated	O
with	O
pseudopregnancy	O
,	O
conservative	O
surgery	O
,	O
and	O
combined	O
pseudopregnancy	O
and	O
surgery	O
,	O
was	O
found	O
to	O
be	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
.	O

In	O
such	O
patients	O
,	O
conservative	O
surgery	O
alone	O
seemed	O
to	O
give	O
the	O
best	O
results	O
in	O
the	O
achievement	O
of	O
pregnancy	O
.	O

There	O
seemed	O
to	O
be	O
little	O
difference	O
between	O
pseudopregnancy	O
alone	O
and	O
conservative	O
surgery	O
in	O
regard	O
to	O
the	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
,	O
although	O
there	O
seemed	O
to	O
be	O
a	O
significantly	O
greater	O
chance	O
for	O
the	O
need	O
for	O
subsequent	O
surgery	O
in	O
patients	O
receiving	O
a	O
combination	O
of	O
the	O
two	O
forms	O
of	O
therapy	O
.	O

The	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
in	O
80	O
patients	O
increased	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
present	O
,	O
despite	O
the	O
form	O
of	O
therapy	O
used	O
.	O

Fifty	O
-	O
nine	O
other	O
patients	O
with	O
endometriosis	O
,	O
who	O
did	O
not	O
desire	O
to	O
preserve	O
fertility	O
and	O
presented	O
for	O
relief	O
of	O
other	O
symptoms	O
,	O
underwent	O
initial	O
"	O
radical	O
"	O
therapy	O
.	O

Forty	O
-	O
six	O
patients	O
underwent	O
complete	O
operation	O
,	O
including	O
removal	O
of	O
uterus	S-Organ
,	O
tubes	S-Multi-tissue_structure
and	O
ovaries	S-Organ
,	O
and	O
none	O
required	O
subsequent	O
reoperation	O
.	O

Of	O
the	O
13	O
remaining	O
patients	O
,	O
who	O
underwent	O
incomplete	O
surgical	O
removal	O
,	O
leaving	O
one	O
or	O
both	O
ovaries	S-Organ
in	O
situ	O
,	O
11	O
required	O
subsequent	O
reoperation	O
for	O
recurrent	O
pelvic	O
endometriosis	O
.	O

Lack	O
of	O
developmental	O
and	O
reproductive	O
toxicity	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
in	O
ring	O
-	O
necked	O
pheasants	O
.	O

Mono	O
-	O
ortho	O
PCBs	O
are	O
global	O
contaminants	O
of	O
wildlife	O
with	O
the	O
potential	O
to	O
produce	O
toxicity	O
by	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
-	O
mediated	O
mechanism	O
.	O

To	O
determine	O
the	O
potency	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
for	O
producing	O
reproductive	O
and	O
developmental	O
toxicity	O
,	O
adult	O
ring	O
-	O
necked	S-Organism_subdivision
pheasant	O
hens	O
(	O
Phasianus	O
colchicus	O
)	O
were	O
orally	S-Organism_subdivision
dosed	O
with	O
0	O
,	O
0	O
.	O
06	O
,	O
0	O
.	O
6	O
,	O
or	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
/	O
week	O
for	O
10	O
weeks	O
to	O
achieve	O
cumulative	O
doses	O
of	O
0	O
,	O
0	O
.	O
6	O
,	O
6	O
,	O
or	O
60	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
after	O
which	O
hens	O
were	O
bred	O
with	O
untreated	O
roosters	O
once	O
per	O
week	O
for	O
8	O
weeks	O
.	O

Except	O
at	O
week	O
6	O
of	O
the	O
egg	S-Developing_anatomical_structure
-	O
laying	O
period	O
when	O
cumulative	O
egg	S-Developing_anatomical_structure
production	O
in	O
the	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
group	O
was	O
greater	O
than	O
controls	O
,	O
fertilized	O
egg	S-Developing_anatomical_structure
production	O
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Embryo	S-Developing_anatomical_structure
mortality	O
and	O
chick	O
mortality	O
were	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Total	O
body	S-Organism_subdivision
and	O
heart	S-Organ
weights	O
of	O
all	O
chicks	O
1	O
day	O
posthatch	O
(	O
dph	O
)	O
were	O
not	O
different	O
between	O
groups	O
,	O
however	O
,	O
liver	S-Organ
weights	O
of	O
chicks	O
from	O
the	O
60	O
mg	O
/	O
kg	O
treatment	O
group	O
were	O
greater	O
than	O
controls	O
at	O
1	O
dph	O
.	O

The	O
first	O
chick	O
to	O
hatch	O
from	O
each	O
hen	O
was	O
reared	O
to	O
21	O
dph	O
and	O
among	O
these	O
birds	O
,	O
the	O
total	O
body	S-Organism_subdivision
,	O
liver	S-Organ
,	O
and	O
heart	S-Organ
weights	O
were	O
not	O
different	O
between	O
groups	O
.	O

There	O
were	O
no	O
dose	O
-	O
related	O
malformations	O
of	O
the	O
beak	S-Organism_subdivision
or	O
limbs	S-Organism_subdivision
,	O
and	O
no	O
signs	O
of	O
subcutaneous	B-Pathological_formation
edema	E-Pathological_formation
,	O
ascites	S-Organism_substance
,	O
or	O
pericardial	B-Pathological_formation
edema	E-Pathological_formation
in	O
chicks	O
at	O
1	O
or	O
21	O
dph	O
.	O

Hepatic	S-Organ
microsomal	O
monooxygenase	O
activities	O
[	O
ethoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
EROD	O
)	O
,	O
benzyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
BROD	O
)	O
,	O
and	O
methyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
MROD	O
)	O
]	O
were	O
significantly	O
elevated	O
in	O
chicks	O
at	O
1	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
105	O
dose	O
of	O
6	O
mg	O
/	O
kg	O
and	O
in	O
chicks	O
at	O
21	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
dose	O
of	O
60	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
a	O
cumulative	O
PCB	O
105	O
dose	O
up	O
to	O
60	O
mg	O
/	O
kg	O
hen	O
does	O
not	O
decrease	O
the	O
production	O
of	O
fertilized	O
eggs	S-Developing_anatomical_structure
or	O
increase	O
embryo	S-Developing_anatomical_structure
or	O
chick	O
mortality	O
in	O
ring	O
-	O
necked	O
pheasants	O
,	O
but	O
does	O
increase	O
chick	O
hepatic	S-Organ
monooxygenase	O
activity	O
.	O

Detection	O
of	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
the	O
pulsatility	O
of	O
a	O
continuous	O
flow	O
artificial	O
heart	O
:	O
in	O
vivo	O
evaluation	O
.	O

Our	O
novel	O
control	O
strategy	O
for	O
a	O
continuous	O
flow	O
artificial	O
heart	O
by	O
detecting	O
the	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
pump	O
pulsatility	O
was	O
evaluated	O
in	O
acute	O
animal	O
experiments	O
using	O
beagle	O
dogs	O
and	O
our	O
mixed	O
flow	O
pump	O
.	O

The	O
pump	O
was	O
installed	O
as	O
a	O
left	B-Multi-tissue_structure
ventricular	E-Multi-tissue_structure
(	O
LV	S-Multi-tissue_structure
)	O
bypass	O
through	O
a	O
left	O
thoracotomy	O
.	O

To	O
change	O
LV	S-Multi-tissue_structure
contractility	O
,	O
the	O
left	B-Multi-tissue_structure
coronary	I-Multi-tissue_structure
arteries	E-Multi-tissue_structure
were	O
occluded	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
120	O
min	O
reperfusion	O
.	O

To	O
change	O
LV	S-Multi-tissue_structure
end	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
,	O
dextran	O
solution	O
was	O
rapidly	O
infused	O
.	O

To	O
estimate	O
the	O
pump	O
pulsatility	O
without	O
any	O
specific	O
sensor	O
,	O
we	O
calculated	O
the	O
index	O
of	O
current	O
amplitude	O
(	O
ICA	O
)	O
,	O
which	O
was	O
obtained	O
from	O
the	O
amplitude	O
of	O
the	O
motor	O
current	O
waveform	O
divided	O
by	O
the	O
simultaneous	O
mean	O
value	O
.	O

To	O
investigate	O
the	O
basic	O
characteristics	O
of	O
the	O
ICA	O
,	O
the	O
pump	O
speed	O
was	O
changed	O
temporarily	O
from	O
2	O
,	O
300	O
rpm	O
to	O
5	O
,	O
000	O
rpm	O
.	O

In	O
92	O
%	O
of	O
all	O
measurements	O
,	O
the	O
ICA	O
plotted	O
against	O
the	O
pump	O
speed	O
had	O
a	O
peak	O
point	O
(	O
t	O
-	O
point	O
)	O
that	O
corresponded	O
highly	O
with	O
the	O
turning	O
point	O
from	O
partial	O
to	O
total	O
assistance	O
.	O

The	O
ICA	O
also	O
had	O
a	O
trough	O
(	O
s	O
-	O
point	O
)	O
that	O
corresponded	O
with	O
the	O
beginning	O
of	O
severe	O
sucking	O
in	O
most	O
cases	O
.	O

Only	O
preload	O
significantly	O
influenced	O
pump	O
flow	O
rate	O
at	O
the	O
t	O
-	O
point	O
from	O
among	O
preload	O
(	O
LVEDP	O
)	O
,	O
afterload	O
(	O
SAoP	O
)	O
,	O
and	O
contractility	O
(	O
max	O
LV	S-Multi-tissue_structure
dP	O
/	O
dt	O
)	O
,	O
by	O
which	O
we	O
can	O
simulate	O
Starling	O
'	O
s	O
law	O
of	O
the	O
natural	O
heart	S-Organ
.	O

We	O
concluded	O
that	O
a	O
continuous	O
flow	O
artificial	O
heart	O
could	O
be	O
well	O
controlled	O
by	O
detecting	O
the	O
t	O
-	O
point	O
and	O
s	O
-	O
point	O
.	O

Potential	O
roles	O
for	O
focal	O
adhesion	O
kinase	O
in	O
development	O
.	O

Focal	O
adhesion	O
kinase	O
(	O
pp125FAK	O
or	O
FAK	O
)	O
is	O
a	O
protein	O
tyrosine	O
kinase	O
which	O
is	O
associated	O
with	O
intracellular	S-Immaterial_anatomical_entity
signalling	O
cascades	O
which	O
are	O
initiated	O
when	O
the	O
integrin	O
family	O
of	O
cell	O
adhesion	O
molecules	O
engage	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
molecules	O
.	O

In	O
cultured	O
cells	S-Cell
,	O
this	O
molecule	O
is	O
physically	O
associated	O
with	O
focal	B-Cellular_component
adhesions	E-Cellular_component
,	O
which	O
are	O
well	O
-	O
defined	O
regions	O
of	O
intimate	O
cell	S-Cell
-	O
to	O
-	O
substratum	O
adhesion	O
.	O

In	O
this	O
location	O
,	O
it	O
interacts	O
with	O
other	O
proteins	O
of	O
the	O
focal	B-Cellular_component
adhesion	E-Cellular_component
to	O
activate	O
intracellular	S-Immaterial_anatomical_entity
signalling	O
events	O
associated	O
with	O
cell	S-Cell
adhesion	O
.	O

The	O
in	O
vitro	O
expression	O
of	O
FAK	O
and	O
its	O
level	O
of	O
phosphorylation	O
appear	O
to	O
be	O
related	O
to	O
several	O
physiological	O
phenomena	O
,	O
including	O
cell	S-Cell
spreading	O
,	O
cell	S-Cell
differentiation	O
,	O
cell	S-Cell
locomotion	O
and	O
cell	S-Cell
death	O
.	O

Because	O
these	O
phenomena	O
are	O
all	O
of	O
critical	O
importance	O
during	O
morphogenesis	O
,	O
and	O
because	O
FAK	O
is	O
expressed	O
in	O
embryonic	B-Cell
cells	E-Cell
,	O
evidence	O
has	O
been	O
accumulating	O
to	O
indicate	O
that	O
FAK	O
may	O
be	O
an	O
important	O
modulator	O
of	O
developmental	O
processes	O
.	O

In	O
this	O
review	O
,	O
this	O
evidence	O
is	O
surveyed	O
together	O
with	O
evidence	O
from	O
analogous	O
situations	O
,	O
such	O
as	O
tumour	B-Cell
cell	E-Cell
migration	O
and	O
invasiveness	O
.	O

Although	O
evidence	O
suggesting	O
a	O
role	O
for	O
FAK	O
in	O
morphogenesis	O
is	O
accumulating	O
,	O
current	O
uncertainties	O
regarding	O
its	O
cytoplasmic	S-Organism_substance
location	O
and	O
its	O
molecular	O
interactions	O
in	O
vivo	O
make	O
it	O
difficult	O
to	O
reach	O
definitive	O
conclusions	O
regarding	O
the	O
significance	O
of	O
its	O
contributions	O
to	O
developmental	O
processes	O
.	O

